lamivudine has been researched along with Chronic Hepatitis B in 2102 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (3.00) | 18.2507 |
| 2000's | 1273 (60.56) | 29.6817 |
| 2010's | 727 (34.59) | 24.3611 |
| 2020's | 39 (1.86) | 2.80 |
| Authors | Studies |
|---|---|
| Brunelle, MN; Holy, A; Lucifora, J; Neyts, J; Trepo, C; Villet, S; Zoulim, F | 1 |
| Asif, G; Butler, SD; Chu, CK; Cote, PJ; George, AL; Gerin, JL; Hurwitz, SJ; Menne, S; Narayanasamy, J; Schinazi, RF; Tennant, BC | 1 |
| Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
| Butler, SD; Cote, PJ; George, AL; Gerin, JL; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S; Zhu, Y | 1 |
| Avila, C; Evans, TG; Karwowska, S; Lam, E; Limoli, K; Lin, K | 1 |
| Bai, L; Ise, RM; Liu, H; Ran, J; Shang, J; Tang, H; Tu, Y; Zhou, J | 1 |
| Cao, WK; Tao, S; Wang, CY; Wang, HW; Zhang, H | 1 |
| Chen, WC; Cheng, JS; Kao, SS; Li, YD; Li, YR; Lin, HS; Lu, CM; Sun, WC; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, HM; Yin, CH | 1 |
| Anderson, M; Badal-Faesen, S; Bhattacharya, D; Chinula, L; Cloherty, G; Gaseitsiwe, S; Hawkins, C; Holzmayer, V; Kang, M; Kuhns, M; Lama, J; Matining, R; Mulinda, N; Murphy, R; Peters, M; Samaneka, W; Sugandhavesa, P; Thio, C | 1 |
| Casian, M; Chiriac, D; Grancea, C; Ianache, I; Oprea, C; Ruta, S; Sultana, C | 1 |
| Bhat, R; Jayaram, B; Kiruthika, S; Vivekanandan, P | 1 |
| Araujo, NM; Araújo, ORC; da Motta de Mello, V; de Almeida Ribeiro, CR; de Paula, VS; Lewis-Ximenez, LL; Martinelli, KG; Spitz, N | 1 |
| El Messaoudi, S; Gonçalves, A; Guedj, J; Lemenuel-Diot, A | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Bian, CR; Dong, RM; Gao, Y; Li, BA; Li, JJ; Li, JY; Men, SQ; Song, LJ; Song, YW; Xu, TT; Yuan, WW; Zhang, L; Zhao, J; Zhao, LL | 1 |
| Arai, K; Hayakawa, N; Honda, M; Horii, R; Kagaya, T; Kaneko, S; Kawaguchi, K; Komura, T; Mizukoshi, E; Nio, K; Nishikawa, M; Orita, N; Sakai, Y; Shimakami, T; Shimode, T; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Kimura, A; Mizokami, M; Murata, K; Noguchi, M; Sugiyama, M; Suizu, F; Tsukuda, S; Watashi, K | 1 |
| Li, DM; Li, J; Sun, CH; Sun, FY; Yu, H; Zhang, J | 1 |
| Abd-Elsalam, S; Abdo, S; Awad, P; El Agawy, W; El-Damasy, DA; Elkadeem, M; Ghanem, AIM; Khattab, RA; Mohamed, AA; Said, E | 1 |
| Zhang, D; Zhang, Q; Zhu, F | 1 |
| Feng, Q; Jiang, C; Li, G; Lin, J; Wen, L | 1 |
| Babudieri, S; Bagella, P; Bandiera, F; Calvisi, DF; Fiore, V; Garrucciu, G; Madeddu, G; Mannu, F; Melis, M; Muredda, AA; Ortu, S; Zaru, S | 1 |
| Chen, C; Chen, M; Hang, S; Liu, L; Shen, H; Xue, Y; Ye, C; Zhang, H; Zhu, Z | 1 |
| Bajin, İY; Demir, H; Özen, H; Saltık-Temizel, İN; Yüce, A | 1 |
| Cai, D; Colonno, R; Guo, H; Hou, J; Huang, Q; Liu, S; Mercier, A; Sun, J; Wu, Y; Zhou, B; Zong, Y | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Ahn, SH; Cho, ES; Dezhbord, M; Kim, DH; Kim, KH; Koo, JE; Lee, AR; Lee, HC; Lee, JH; Park, ES; Park, S; Park, YK | 1 |
| Chiang, BL; Lai, HS; Lee, CY; Tsai, MK; Yang, CY; Yang, YW | 1 |
| Ahn, SH; Bae, SH; Heo, J; Jang, JY; Kim, CW; Kim, DJ; Kim, IH; Park, JY; Tak, WY; Woo, HY | 1 |
| Astbury, S; Costa Nunes Soares, MM; Irving, WL; Jalal, P; Jardim, ACG; King, B; McClure, CP; Peprah, E; Sabeer, FT; Saeed, CH; Shimizu, JF; Tarr, AW | 1 |
| Jang, BK | 1 |
| Chan, A; Cheung, TT; Chu, KW; Dai, WC; Fung, J; Lo, CM; Ma, KW; Mak, LY; Seto, WK; She, WH; Sin, SL; Wong, T; Yuen, MF | 1 |
| Chien, RN; Chu, YD; Huang, YH; Ke, PY; Liang, KH; Lin, CL; Lin, KH; Lin, YH; Yeh, CT | 1 |
| Chen, J; Liao, H; Liu, Y; Lu, F; Wang, J; Xu, D | 1 |
| Dong, Y; Gao, X; Li, M; Zhao, P; Zhu, S | 1 |
| Chen, RJ; Fan, ZP; Huang, BX; Liu, XG; Liu, Y; Luo, D; Si, LL; Wang, FS; Wang, J; Xu, DP | 1 |
| Wang, L; Xie, B; Xu, L; Ye, Z; Zheng, Q | 1 |
| Chen, G; Chen, H; Dai, E; Dou, X; Guo, Y; Han, T; Jia, J; Jiang, J; Ning, Q; Shang, J; Shen, Y; Sheng, J; Su, Z; Tan, D; Tang, H; Wei, Z; Ye, Y; Yuan, J; Zhang, M; Zhang, S; Zhou, X; Zhu, S | 1 |
| Asaftei, SD; Biasin, E; Calvo, PL; Carpino, A; Catalano, S; Cisarò, F; Dell'Olio, D; Fagioli, F; Opramolla, A; Peruzzi, L; Pinon, M; Pizzol, A; Quarello, P; Rigazio, C | 1 |
| Chen, G; Chen, S; Chen, Y; Cheng, J; Ding, H; Jia, J; Jiang, W; Kong, Y; Ma, A; Ma, H; Meng, T; Ou, X; Piao, H; Shi, Y; Sun, Y; Wang, B; Wu, X; Xie, W; Xu, M; Xu, X; Xu, Y; You, H; Zhou, J | 1 |
| Chen, R; Li, L; Li, X; Li, Y; Liao, H; Liu, W; Liu, Y; Si, L; Wang, J; Xu, D; Yao, Z; Zhao, J | 1 |
| Bansal, S; Daniel, JF; Kansu, A; Kelly, D; Martin, C; Mieli-Vergani, G; Tizzard, S; Vergani, D; Wirth, S; Zhou, J | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| de Carvalho Santana, R; de Lourdes Candolo Martinelli, A; Dessordi, R; Guimarães, MP; Navarro, AM; Romão, EA; Watanabe, LM | 1 |
| Chu, SV; Le, NT; Nguyen, ATV; Nguyen, HM; Phung, TTB; Truong, PT; Vu, ST; Vu, VTT | 1 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Capobianchi, MR; D'Offizi, G; Menzo, S; Piselli, P; Solmone, M; Vincenti, D | 1 |
| Bedir, A; Celikbilek, M; Das, YK; Kader, C; Karaca, E; Ozaras, R; Sunbul, M; Yarim, M | 1 |
| Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Myoung, SM; Park, JY | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Allweiss, L; Beninati, C; Dandri, M; Giersch, K; Kah, J; Lohse, AW; Lütgehetmann, M; Petersen, J; Pollicino, T; Raffa, G; Urban, S; Volz, T | 1 |
| Liu, CJ; Su, TH | 1 |
| Dos Santos, MIMA; Pacheco, SR; Paraná, R; Reis, MG; Schinoni, MI; Silva, LK; Stocker, A | 1 |
| Hu, C; Huang, H; Li, Y; Liu, J; Yang, D; Yuan, G; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Gane, EJ | 1 |
| Erdem Eralp, E; Kalyoncu, D; Urganci, N | 1 |
| Ahn, JS; Jeon, HJ; Jung, SW; Kim, HR; Lee, JH; Noh, JH; Park, NH; Shin, JW; Yang, Y | 1 |
| Chen, CY; Hsu, YC; Lee, TY; Lia, HC; Yang, SS | 1 |
| Chan, A; Cheung, TT; Chok, K; Dai, WC; Fung, J; Lai, CL; Lo, CM; Man, K; Ng, K; Seto, WK; Sin, SL; Wong, T; Yuen, MF | 1 |
| Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G | 1 |
| Ahir, BK; Li, LQ; Wu, GB; Zhang, CY; Zhong, JH | 1 |
| Cathcart, AL; Delaney, WE; Kitrinos, KM; Liu, Y | 1 |
| Du, WX; Wu, L; Ye, ZR | 1 |
| Lee, JH; Lee, YB | 1 |
| Byun, KS; Heo, J; Kim, BH; Kim, D; Kim, DJ; Kim, TH; Kweon, YO; Lee, HJ; Lee, KS; Lee, MS; Lee, YS; Lim, YS; Paik, SW; Suh, DJ; Um, SH; Yu, K | 1 |
| Adinolfi, LE; Boemio, A; Capoluongo, N; Coppola, N; D'Amore, C; Esposito, M; Guastafierro, S; Macera, M; Marrone, A; Mastrullo, L; Minichini, C; Onorato, L; Pisaturo, M; Rinaldi, L; Sagnelli, E; Siniscalchi, I | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Blanco, MÁ; Bonet, ML; Calleja, JL; Casado, MÁ; Fraga, E; Fuentes, J; García-Buey, ML; González, JM; Jorquera, F; Molina, E; Pascasio, JM; Pons, JA; Prieto, M; Rodríguez, M; Salmerón, J; Sánchez-Antolín, G | 1 |
| Choi, J; Lim, YS | 1 |
| Lee, JH; Nam, JY | 1 |
| Choe, BH; Choe, JY; Kang, B; Kim, JE; Ko, JS; Lee, KJ; Yang, HR | 1 |
| Ahn, SH; Hur, SS; Kang, HS; Kim, DH; Kim, KH; Kwon, SY; Lee, AR; Lee, JH; Park, ES; Park, S; Park, YK; Sim, S | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 2 |
| Becht, E; Bertoletti, A; Cheng, Y; Foster, GR; Gill, US; Hansi, NK; Kao, JH; Kennedy, PT; Kunasegaran, K; Le Bert, N; Lim, SG; Newell, EW; Rivino, L; Su, TH; Tan, DZ; Tseng, TC | 1 |
| Chung, WJ; Heo, J; Hwang, JS; Jang, BK; Kim, BS; Kim, SJ; Kweon, YO; Lee, CH; Lee, HJ; Park, SY; Suh, JI; Tak, WY; Woo, HY | 1 |
| Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W | 1 |
| Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Nishida, N; Nishijima, N; Osaki, Y; Sakurai, T; Takita, M; Ueshima, K; Watanabe, T | 1 |
| Chang, JY; Choe, BH; Choe, JY; Jeong, IS; Kim, JW; Kim, JY; Kim, KM; Ko, JS; Lee, KJ; Moon, JS; Yang, HR | 1 |
| Chen, D; Dong, Y; Gan, Y; Liu, W; Tang, H; Wang, F; Wang, L; Xu, Z; Zhang, H; Zhao, P; Zhu, S | 1 |
| Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT | 1 |
| Li, W; Li, Y; Liu, Y; Wang, L; Yu, S | 1 |
| Long, L; Su, J; Zou, K | 1 |
| Chen, D; Guo, X; Li, Q; Liu, K; Ouyang, Y; Wang, Y; Wei, F; Wu, J; Zhang, Y | 1 |
| Huang, AL; Huang, C; Shi, XF; Yang, XH; Yang, YL | 1 |
| Chen, YM; Deng, H; Gao, ZL; Lin, CS; Mei, YY; Peng, L; Xie, C; Xie, DY; Xu, WX; Zhang, Q; Zhao, ZX; Zhu, X | 1 |
| Asci, Z; Demir, LS; Demir, NA; Kolgelier, S; Ozcimen, S; Sumer, S; Ural, O | 1 |
| Bao, L; Li, WT; Li, Y; Wang, Y; Xu, J; Yang, L; Zhao, ZH | 1 |
| Caviglia, GP; Ngatchou, D; Olivero, A; Saracco, GM; Smedile, A | 1 |
| Chen, J; Liu, J; Liu, T; Pan, M; Zhang, Q; Zhou, YH | 1 |
| Alam, S; Khanna, R; Lal, BB; Sood, V | 1 |
| Alam, S; Khanna, R; Lal, BB; Rawat, D; Sood, V; Verma, S | 1 |
| Balkan, A; Gülşen, MT; Karaoğlan, İ; Namıduru, M; Şahin, A | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY | 1 |
| Alavian, SM; Fesharaki, MG; Jalilianhasanpour, R; Khalighinejad, P | 1 |
| Della Pepa, R; Di Perna, M; Giordano, A; Giordano, C; Lucignano, M; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, C; Trastulli, F; Zacheo, I | 1 |
| Bair, MJ; Chen, CJ; Chen, MJ; Chu, CH; Lin, CC; Lin, ZY; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Ahn, SH; Bae, SH; Cheong, JY; Han, KH; Jang, BK; Jeong, SW; Kim, BI; Kim, DJ; Kim, JK; Kim, MY; Kim, SG; Kim, TY; Kwon, JH; Kwon, SY; Lee, HW; Lee, JW; Myoung, S; Park, JY; Seo, YS; Tak, WY; Yim, HJ; Yoon, KT | 1 |
| Berg, T; Brodzinski, A; Fülöp, B; Jung, MC; Koukoulioti, E; Mihm, U; Sarrazin, C; Schlosser, B; Schott, E; van Bömmel, F | 1 |
| Fujii, T; Honda, H; Iwaki, T; Kawamura, N; Kira, JI; Takase, KI; Uchiumi, T; Urata, M; Yamasaki, R | 1 |
| Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N | 1 |
| Akita, T; Kumada, T; Kurisu, A; Miyake, N; Ohisa, M; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Aydın, N; Kırdar, S; Sayan, M; Yaşa, MH | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J | 1 |
| Jiang, X; Luo, A; Ren, H | 1 |
| Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF | 1 |
| Chan, TM; Choy, BY; Fung, JYY; Ma, MKM; Seto, WK; Tang, C; Yap, DYH | 1 |
| Chen, Z; He, T; Pan, G; Qin, B; Tu, C; Xu, W | 1 |
| Agarwal, K; Bruce, M; Byrne, R; Carey, I; Childs, K; Joshi, D; Taylor, C | 1 |
| Bhattacharya, D; Bickel, M; Knecht, G; Lassmann, B; Lewis, MJ; Phan, T; Yang, OO | 1 |
| Fung, J; Huang, FY; Lai, CL; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Farnik, H; Herrmann, E; Hofmann, WP; Kronenberger, B; Peveling-Oberhag, J; Sarrazin, C; Susser, S; Zeuzem, S | 1 |
| Bao, W; Chan, HL; Gane, EJ; Hou, J; Jia, J; Liaw, YF; Naoumov, NV; Niu, J; Papatheodoridis, G; Thongsawat, S; Trylesinski, A; Wan, M; Wang, Y | 1 |
| Bensadoun, P; Chevaliez, S; Pawlotsky, JM; Rodriguez, C | 1 |
| Amarapurkar, DN; Patel, N | 1 |
| Chen, FW; Coyle, L; Jones, BE; Pattullo, V | 1 |
| Han, GR; Ji, Y; Jiang, HX; Wang, CM | 1 |
| Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M | 1 |
| Arai, M; Chiba, T; Fujiwara, K; Imazeki, F; Kamezaki, H; Kanai, F; Kanda, T; Maruyama, H; Nakamoto, S; Nomura, F; Wu, S; Yokosuka, O | 1 |
| Guclu, E; Karabay, O | 1 |
| Chen, CW; Gu, EL; Ji, YY; Li, J; Ma, XY; Pang, HY; Wang, H; Wu, SM; Xie, Q; Xu, XW; Yao, GB | 1 |
| Gan, WQ; Ke, WM; Lai, J; Mai, L; Yan, Y; Zheng, YB | 1 |
| Agarwal, J; Krishnani, N; Poddar, U; Yachha, SK | 1 |
| Arai, M; Goto, N; Imazeki, F; Kamezaki, H; Kanda, T; Kato, K; Kimura, M; Mikami, S; Miyauchi, T; Nakamoto, S; Shinozaki, M; Sugiura, N; Wu, S; Yokosuka, O | 1 |
| Deng, H; Gao, Z; Huang, Z; Lin, C; Peng, L; Zhao, Q; Zhao, Z; Zheng, Y | 1 |
| Acalovschi, M; Arama, V; Bjork, S; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Marcellin, P; Mauss, S; Morais, E; Sieklucki, J; Simon, K; Usluer, G; Zarski, JP; Zeuzem, S | 1 |
| Liu, D; Liu, X; Ma, J; Ma, N; Wang, Y; Yu, F; Yuan, S; Zhang, X | 1 |
| Alteri, C; Andreoni, M; Angelico, M; Cento, V; De Sanctis, GM; Gubertini, G; Micheli, V; Parruti, G; Perno, CF; Pollicita, M; Romano, S; Salpini, R; Sarrecchia, C; Svicher, V; Visca, M | 1 |
| Ahn, SH; Baartarkhuu, O; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, JK; Kim, KS; Kim, SU; Park, JY; Park, MS | 1 |
| Alvarez Estévez, M; Chueca-Porcuna, N; García-García, F; Guillot-Suay, V; Peña-Monje, A | 1 |
| Cao, ZH; Chen, XY; Liu, YL; Ma, LN; Zhang, HW | 1 |
| Deng, XL; Guo, JJ; Li, QL | 1 |
| Huang, XX; Lou, GQ; Shi, JP; Wang, J; Wu, J; Zhu, MF | 1 |
| Hao, CQ; Liu, JF; Wang, M; Zhang, L | 1 |
| Chan, AC; Chan, SC; Cheung, C; Cheung, TT; Chok, KS; Fan, ST; Fung, J; Lai, CL; Lo, CM; Seto, WK; Sharr, W; Yuen, MF | 1 |
| Dong, X; Meng, H; Tian, W; Wang, G; Wei, G; Wu, X; Yuchi, J | 1 |
| Gluud, C; Liu, JP; Luo, H; Xia, Y | 1 |
| Lee, D; Lee, HC; Lee, JY; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 2 |
| Ahn, SH; Choi, A; Chon, CY; Chon, YE; Han, KH; Kim, DY; Kim, SU; Park, JY | 1 |
| Chen, Q; He, LL; Wang, JC | 1 |
| Hung, HH; Sheen, IJ; Su, CW; Wu, CH; Wu, CY; Wu, JC | 1 |
| Terrault, N | 1 |
| Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F | 1 |
| Chan, HL; Chan, HY; Chim, AM; Lo, AO; Tse, CH; Wong, GL; Wong, VW | 1 |
| Fang, J; Li, D; Li, W; Tan, Z | 1 |
| Fan, J; Lu, H; Shen, C; Wang, Y; Yu, W; Zhao, C | 1 |
| Kao, JH; Lin, CL | 1 |
| Fung, J; Huang, FY; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Chan, HL; Chen, DS; Chuang, WL; Dai, CY; Huang, JF; Kao, JH; Liu, CJ; Tseng, TC; Wong, GL; Wong, VW; Yu, ML | 1 |
| Bojovic, K; Delic, D; Jevtovic, D; Korac, M; Lazarevic, I; Milosevic, I; Pavlovic, IP | 1 |
| Cortes, CP; Otto-Knapp, R; Saavedra, F; Weitzel, T; Wolff, M | 1 |
| Bose, PD; Das, BC; Goel, V; Gondal, R; Hazam, RK; Kar, P; Sarma, MP | 1 |
| Chen, H; Fan, C; Gong, Z; Wang, L | 1 |
| Horváth, G | 1 |
| Chang, KC; Chiu, KW; Chou, YP; Hsu, YC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC | 1 |
| Byun, KS; Cho, M; Chon, CY; Koh, KC; Kweon, YO; Lee, HC; Lee, YS; Suh, DJ; Tak, WY | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Šperl, J | 1 |
| Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Balci, E; Hascuhadar, M; Oksuzoglu, B; Turker, K; Uyeturk, U | 1 |
| Arzumanyan, A; Clayton, MM; Feitelson, MA; Goldmann, S; Li, J; Liu, B; Ren, Q; Schinazi, RF; Wang, Z; Wu, G; Zhang, F; Zhang, Y | 1 |
| Chen, L; Deng, YD; Mao, XR; Yuan, H; Yue, W | 1 |
| Guo, JJ; He, S; Li, QL; Zhang, Y | 1 |
| Alp, A; Aydoğan, S; Balaban, Y; Ergünay, K; Hasçelik, G; Simşek, H; Tatar, G; Us, D | 1 |
| Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST; Seo, SY; Sohn, JY | 1 |
| Chao, DC; Hu, KQ | 1 |
| He, X; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Zeng, WZ; Zhang, Y; Zhou, DJ | 1 |
| Chen, H; Ding, Y; Li, X; Liu, B; Sun, Y; Zhang, H; Zhang, Q | 1 |
| Cai, FJ; Ding, JG; Du, QW; Fu, RQ; Hong, L; Sun, QF; Wu, YH; Zhou, QQ | 1 |
| Ji, YJ; Li, FF; Qin, CY; Ren, WH; Zhu, YH | 1 |
| Bailly, F; Chevallier, P; Egounlety, R; Koffi, J; Lebosse, F; Lussier, V; Pradat, P; Si-Ahmed, SN; Zoulim, F | 1 |
| Abraham, P; Eapen, CE; Ismail, AM; Kannangai, R; Ramachandran, J; Samuel, P | 1 |
| Abaci, N; Arikan, M; Badur, S; Bozkaya, E; Cakiris, A; Gumus, E; Kaymakoglu, S; Kursun, O; Mese, S; Onel, D; Ustek, D; Yenen, OS | 1 |
| McMahon, B; Soriano, V | 1 |
| Savaj, S | 1 |
| Ahmed, H; Hussain, SA; Kashif, W; Khan, N; Subhan, A; Yaqub, S | 1 |
| Alegría-Motte, C; Gómez García, M; González-Artacho, C; Rodríguez Sicilia, MJ | 1 |
| Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Hu, H; Hu, P; Liu, J; Peng, H; Ren, H; Tang, H; Tong, S; Yang, M; Yin, W | 1 |
| Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH | 1 |
| An, J; Chung, YH; Kim, GA; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Abrão, PR; Caseiro, MM; Cicero, M; Diaz, RS; do Carmo, EP; Komninakis, SV; Mantovani, N; Santana, LC; Silveira, C | 1 |
| Ding, XC; Liu, SW; Liu, XY; Ma, LN; Xu, CQ; Yan, X | 1 |
| Alagozlu, H; Coskun, M; Koksal, B; Ozdemir, O; Yilmaz, A | 1 |
| Giagnorio, MG; Giannattasio, A; Iorio, R; Spagnuolo, MI; Tufano, M | 1 |
| Li, Y; Qiao, B; Wang, M; Yuan, L | 1 |
| Chen, RC; Dai, XH; Fan, XG; Huang, Y; Huang, ZB; Li, N; Li, WT; Yi, PP; Zhang, BX; Zhao, SS; Zhou, RR | 1 |
| Cholongitas, E; Papatheodoridis, G; Pipili, C | 1 |
| Ding, H; Li, T; Liu, B; Yan, C; Yan, L; Yang, J; Zhao, C; Zhuang, H | 1 |
| Ahn, SH; Hahn, KY; Han, KH; Kim, BK; Kim, DY; Kim, HC; Kim, JK; Kim, SU; Park, JY; Park, YH; Shin, SH | 1 |
| Anan, A; Irie, M; Iwata, K; Kawashima, M; Morihara, D; Sakisaka, S; Serrano-Luna, J; Shakado, S; Shibayama, M; Sohda, T; Takeyama, Y; Tanaka, T; Ueda, S; Yamauchi, E | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY | 1 |
| Arama, V; Bjork, S; Bludzin, W; Habersetzer, F; Jinga, M; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Morais, E; Niederau, C; Simon, K; Ulusoy, S; Vermehren, J; Zarski, JP; Zeuzem, S | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Alkan, E; Ataseven, H; Basar, O; Baykal, O; Biyik, M; Coban, S; Demir, M; Etgul, S; Gokturk, S; Gulsen, MT; Guner, R; Ibis, M; Karaca, C; Kockar, C; Koklu, H; Koklu, N; Koklu, S; Kucukazman, M; Poyrazoglu, OK; Purnak, T; Simsek, H; Tatar, G; Tuna, Y; Yilmaz, B; Yuksel, O | 1 |
| Chen, XL; Li, M; Zhang, XL | 1 |
| Caruntu, FA; Corsa, A; Dinh, P; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Subramanian, GM | 1 |
| Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q | 1 |
| Deng, YR; Jin, QL; Lian, ZX; Matsuzaki, K; Moritoki, Y; Murata, M; Niu, JQ; Tsuneyama, K; Yamaguchi, T; Yoshida, K | 1 |
| Buti, M | 3 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Esteban, R; Pérez-Cameo, C; Pons, M | 1 |
| Cho, Y; Cho, YY; Choi, WM; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Hsu, PI; Lai, KH; Lin, HS; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, HM; Yu, HC | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, H; Park, JY | 1 |
| Choe, WH; Choi, YJ; Kim, JH; Ko, SY; Kwon, SY; Moon, HW | 1 |
| Chang, K; Chen, M; Deng, S; Jia, S; Jiang, W; Li, F; Shang, Y; Wang, F; Yang, S; Zhang, K | 1 |
| Li, YC | 1 |
| Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL | 1 |
| Jie, YS; Ke, WM; Lai, J; Sun, HX; Zhang, K | 1 |
| Cai, SH; Jiang, YG; Lv, FF; Peng, J; Zhang, YH | 1 |
| Bielawski, KP; Dreczewski, M; Rybicka, M; Smiatacz, T; Stalke, P; Stracewska, E; Wróblewska, A | 1 |
| Ahn, SH; Choi, IS; Han, KH; Han, KJ; Hwang, JS; Jang, JY; Kang, W; Kim, DY; Kim, JK; Lee, CK; Lee, HJ; Lee, HW; Lee, KS; Paik, YH; Sohn, JH | 1 |
| Chanson, P; Pariente, A | 1 |
| Han, S; Heo, NY; Lee, HC; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Chang, JY; Chen, CH; Chien, RN; Hu, TH; Hung, CH; Lee, CM; Lin, CL; Lu, SN; Tseng, PL; Wang, JH | 1 |
| Chen, L; Li, X; Liu, L; Liu, Y; Wang, Y; Xin, S; Xu, D; Xu, Z | 1 |
| Chen, H; Chen, J; Jiang, L; Li, D; Lin, J; Ou, Q; Su, M; Wang, W; Yang, B; Zeng, Y | 1 |
| Atmaca, S; Mese, S; Ozbek, E; Ozekinci, T | 1 |
| Fabrizi, F; Mangano, S; Martin, P; Messa, P; Stellato, T | 1 |
| Cho, HC; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sohn, W; Yoo, BC | 1 |
| Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH | 1 |
| Doss, W; El Din, SS; Hassan, K; Maklad, S; Zeid, AA | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Cai, HD; Gao, XH; Li, YQ; Lu, XZ; Ma, XY; Sun, AM; Xu, DZ; Yu, HY; Zhang, LY; Zhao, LF | 1 |
| Hu, P; Shi, XF; Wang, ZY; Yang, CX; Zhang, DZ; Zhou, Z | 1 |
| Shouval, D | 2 |
| Chatterjee, U; Davison, S; Glass, A; Greenup, AJ; Holdaway, S; Jackson, K; Levy, MT; Locarnini, SA; Nguyen, V; Samarasinghe, D; Strasser, SI; Tan, PK | 1 |
| Sarkar, M; Terrault, NA | 1 |
| Hu, H; Hu, P; Liu, F; Ren, H; Wang, X; Wei, F; Zhang, D | 1 |
| Choe, BH; Choe, HJ | 1 |
| Jang, JY; Kim, BH; Kim, JW; Lee, CK; Shim, JJ | 1 |
| Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P | 1 |
| Frolov, VM; Kozlov, VK; Oyungerel, M; Romantsov, MG; Shul'diakov, AA; Sologub, TV; Stel'makh, VV; Tuan, NKh | 1 |
| Abe, H; Chayama, K; Chen, CL; Chen, DS; Hu, JT; Huang, YW; Kao, JH; Takahashi, S; Tsuge, M; Wang, TC; Yang, SS | 1 |
| Flisiak, R; Jaroszewicz, J; Kowalczuk, O; Lapiński, TW; Nikliński, J; Parfieniuk-Kowerda, A; Trzos, A | 1 |
| Błudzin, W; Dziambor, A; Goryszewski, D; Kolasa, K; Lescrauwaet, B; Postawa-Kłosińska, B; Sieklucki, J; Simon, K | 1 |
| Dong, J; Jia, J; Li, M; Li, T; Liu, D; Liu, W; Liu, X; Ma, N; Yu, F; Zhang, X | 1 |
| Chen, G; Hu, XY; Luo, JX; Wang, YY; Yang, F; Zhang, Y; Zhong, S; Zhou, TY | 1 |
| Jeon, CH; Lee, AJ; Lee, CH | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Al Awaidy, S; Al Baqlani, SA; Al Naamani, K; Bock, CT; Busaidy, SA; Pauli, G; Ratsch, BA; Sy, BT | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Kim, JH; Kim, KH; Park, ES; Park, YK | 1 |
| Chen, EQ; Tang, H | 1 |
| Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B | 1 |
| Li, DC; Lin, CS; Liu, J; Lu, LR; Xu, Z; Zhang, GL | 1 |
| Lei, Y; Liu, JY; Xu, H; Zeng, T; Zhong, S; Zhou, Z | 1 |
| Chen, L; Li, X; Liu, Y; Wang, Y; Xin, S; Xu, D; Zhang, XX; Zhao, P | 1 |
| Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, HJ; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ | 1 |
| Ji, Y; Jiang, Q; Ju, LL; Tang, X; Wu, KH; Yang, YF; Yu, MM | 1 |
| Dinçkan, A; Ersoy, F; Koçak, H; Ruhi, Ç; Süleymanlar, G; Süleymanlar, İ | 1 |
| Bunce, PE; Gold, WL; Shafran, DM | 1 |
| Cheng, YC; Fan, J; Guo, X; Wang, Y; Xiong, H | 1 |
| Berg, T; van Bömmel, F | 1 |
| Gerlich, WH | 1 |
| Locarnini, S; Warner, N | 2 |
| Geipel, A; Glebe, D | 1 |
| Beggel, B; Kaiser, R; Neumann-Fraune, M; Obermeier, M | 1 |
| Chouta, A; Dalekos, GN; Drakoulis, C; Gogos, C; Hatzis, G; Ilias, A; Karamanolis, D; Ketikoglou, I; Manesis, E; Manolakopoulos, S; Mela, M; Mimidis, K; Nikolopoulou, G; Papatheodoridis, GV; Raptopoulou-Gigi, M; Touloumi, G; Vafiadis-Zouboulis, I | 1 |
| Cheng, X; Dong, X; Hu, Q; Sun, P; Zheng, Q | 1 |
| Fan, WH; Hu, JJ; Li, CZ; Liang, XS; Liu, YY; Xu, H; Xue, JY; Yin, W | 1 |
| Bárcena, R | 1 |
| Akuta, N; Arase, Y; Fukushima, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N | 1 |
| Hwang, JH; Jang, ES; Jeong, SH; Kim, JW; Kim, N; Lee, DH; Lee, SS; Min, BY; Park, YS; Seong, MH; Shin, CM; Sohn, HR; Song, JC | 1 |
| Bao, S; Cai, W; Guo, Q; Lin, L; Liu, Y; Wang, H; Wu, S; Xie, Q; Xu, B; Xu, G; Zhou, X; Zhuang, Y | 1 |
| Do, ST; Garcia, RT; Lutchman, GA; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, NH; Nguyen, TT; Tran, P; Trinh, HN | 1 |
| Liu, X; Pan, CQ; Pang, Q; Tian, R; Yan, M; Zhang, H | 1 |
| Zhang, H; Zhu, S | 1 |
| Berkley, EM; Dunkelberg, JC; Leslie, KK; Thiel, KW | 1 |
| Calise, F; Cuomo, O; DiCostanzo, G; Lanza, AG; Perrella, A; Pisaniello, D | 1 |
| Byoun, YS; Chung, SM; Jang, ES; Jeong, SH; Kim, HS; Kim, JW | 1 |
| Bansal, S; Bruce, M; Carey, I; D'Antiga, L; Horner, M; Mieli-Vergani, G; Vergani, D; Zen, Y | 1 |
| Fen, L | 1 |
| Abdelkader, NA; F, IM; Ismail, SA; Montasser, MF | 1 |
| Choi, K; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, J; Kim, SG; Kim, YS; Lee, SH | 1 |
| Cho, YK; Cui, XJ; Jeong, SU; Song, BC | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| An, Y; Cai, B; Li, L; Li, Y; Liao, Y; Wang, L; Zhang, J; Zhang, Q | 1 |
| Ahn, DG; Baek, EK; Cho, HJ; Chung, HW; Kim, HJ; Kwon, JC; Lee, H; Lee, JJ; Ze, E | 1 |
| Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Moon, HW | 1 |
| Chen, C; Chen, S; Chen, X; Cheng, J; Dou, X; Hou, J; Jia, J; Jiang, J; Li, T; Liang, X; Long, H; Ma, H; Ning, Q; Niu, J; Ren, H; Sheng, J; Shi, G; Shi, J; Sun, J; Sun, Y; Tan, D; Tang, H; Wan, M; Wang, H; Xie, Q; Yu, Y; Zhuang, H | 1 |
| Connell, J; Coughlan, S; Eogan, M; Ferguson, W; Jackson, V; Kelleher, TB; Lambert, JS; Lawless, M; Nusgen, U | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Chang, ML; Jeng, WJ; Liaw, YF | 1 |
| Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y | 1 |
| Ozdogan, OC; Yegin, EG | 1 |
| Fan, J; Guo, X; Wang, Y; Xiong, H; Zhang, Y | 1 |
| Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B | 1 |
| Chen, J; Chen, ZH; Dong, M; Li, X; Lin, Q; Lin, ZX; Ma, XK; Ruan, DY; Wang, TT; Wei, L; Wen, JY; Wu, DH; Wu, XY; Xing, YF; Zhong, X | 1 |
| Angarano, G; Bellacosa, C; Coladonato, L; Fasano, M; Grattagliano, V; Lapadula, G; Leone, A; Maggi, P; Montinaro, V; Santantonio, T; Volpe, A | 1 |
| Barreiro, P; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Gao, T; Hu, P; Li, H; Li, ST; Tang, WL; Wang, H; Xie, Q; Zhao, GD; Zhou, HJ | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Jiang, ZP; Zhou, TB | 1 |
| Ahn, SH; Chan, HL; Heo, J; Horban, A; Kim, BH; Kweon, YO; Lee, KS; Llamoso, C; Wongcharatrawee, S | 1 |
| Chen, J; Chen, X; Lin, J; Ou, Q; Shang, H; Su, M; Wu, S; Wu, Y; Yang, B; Zeng, Y | 1 |
| Chen, CW; Gu, EL; Ji, YY; Li, J; Ma, XY; Pan, HY; Wang, H; Wang, JL; Wang, YE; Wu, SM; Xie, Q; Xu, XW; Yao, GB; Yu, YQ; Zhang, WH | 1 |
| Andrade, JR; Barros, LM; Bertolini, DA; Carrilho, FJ; Conde, SR; de Araújo, LV; Ferreira, AC; Ferreira, AS; Galvan, J; Gomes-Gouvêa, MS; Kliemann, DA; Kunyoshi, AS; Leite, AG; Lyra, AC; Mendes-Corrêa, MC; Nastri, AC; Oikawa, MK; Piccoli, LZ; Pinho, JR; Rezende, RE; Soares, MC; Teixeira, R | 1 |
| Ogunrin, AO; Ola, SO; Udo, UA | 1 |
| Jia, J; Wu, X; You, H | 1 |
| Buti, M; Casafont, F; Casillas, R; Castells, L; Esteban, R; González, A; Herrero, JI; Homs, M; Mas, A; Miras, M; Prieto, M; Rodríguez-Frías, F; Tabernero, D | 1 |
| Chakrabarti, S; Chakravarty, R; Guha, SK; Pal, A; Saha, B; Saha, D; Sarkar, N | 1 |
| Dai, M; Li, YM; Wang, FL; Xiao, GM; Yang, HZ; Zhang, JS | 1 |
| Ahishali, E; Doganay, L; Enc, FY; Erdem, E; Gonen, C; Gunduz, F; Ozdogan, O; Sokmen, M; Tuncer, I; Yegin, EG | 1 |
| Ha, FS; Han, T; Liu, H; Liu, L; Nie, CY; Zhang, Q | 1 |
| Chen, L; Gan, JH; Ge, GH; Niu, ZL; Tan, YW; Yang, LJ; Ye, Y; Yu, XJ; Zhang, DJ; Zhao, W; Zhao, Y | 1 |
| Armendáriz-Borunda, J; Bobadilla-Morales, L; Bueno-Topete, M; Fernández-Galindo, DA; Gómez-Quiróz, P; Sánchez-Ávila, F; Sánchez-Orozco, LV | 1 |
| Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W | 1 |
| Caccuri, F; Caruso, A; Castelli, F; De Francesco, MA; Gargiulo, F; Giagulli, C; Spinetti, A; Zaltron, S | 1 |
| Gao, H; Li, X; Lin, M; Lin, T; Pan, C; Wang, X; Zhou, R | 1 |
| Ouyang, R; Ye, X | 1 |
| Kim, CW | 1 |
| Huang, HJ; Li, MW; Pan, HY; Xie, YJ; Yang, DH; Zhao, NF | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Itoh, A; Katano, Y; Kuzuya, T; Luo, F; Nakano, I | 1 |
| Heathcote, EJ; Ho, EY; Lau, GK; Rousseau, F; Yau, T | 1 |
| Janssen, HL; van Campenhout, MJ | 1 |
| Ari, A; Avci, M; Bal, F; Biçer, KÇ; Genç, VE; Özsu Caymaz, S | 1 |
| Hu, TT; Huang, S; Liu, WW; Wang, AZ; Xie, FY; Zhong, Q | 1 |
| Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW | 1 |
| Bae, WK; Ha, SY; Jung, SK; Jwa, YJ; Kim, JW; Kim, KA; Kim, NH; Kim, YD; Lee, BH; Lee, HK; Lee, JS; Paik, WH | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Ahn, SH; Choi, SH; Chon, YE; Han, KH; Hong, SP; Jin, B; Kim, DY; Kim, KH; Kim, ND; Kim, S; Nam, CM; Park, JH; Park, JY | 1 |
| Chen, L; Huang, Y; Mao, R; Qi, X; Qin, Y; Wang, J; Zhang, J | 1 |
| Chen, L; Gong, L; Gong, QM; Han, Y; Hao, P; Li, XH; Liu, F; Sheng, J; Yu, DM; Zhang, XX | 1 |
| Enomoto, M; Hayashi, T; Jomura, H; Kawada, N; Kohmoto, MT; Kozuka, R; Morikawa, H; Murakami, Y; Nishiguchi, S; Shiomi, S; Tamori, A | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Abreu, RM; Baldassare, RM; Carrilho, FJ; Kim, V; Nakagawa, DM; Ono, SK | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Cui, X; Dai, J; Huang, M; Jiang, X; Li, J; Ning, H; Su, F; Yang, S | 1 |
| Allegra, S; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Pensi, D; Simiele, M | 1 |
| Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF | 1 |
| Casazza, G; Colombo, M; de Franchis, R; Facchetti, F; Fraquelli, M; Iavarone, M; Invernizzi, F; Jovani, M; Lampertico, P; Loglio, A; Mangia, G; Primignani, M; Viganò, M | 1 |
| Chen, G; Chen, X; Jiang, D; Yang, G; Yang, J; Zhang, H | 1 |
| Merza, MA; Mustafa, NH; Queiky, F; Saadat, S; Sali, S; Yadegarynia, D | 1 |
| Chan, HL; Ding, CM; Luan, J; Sung, JJ | 1 |
| Cheong, JY; Cho, SW; Hwang, JA; Hwang, JC; Kim, KB; Kim, SS; Lim, SG; Yang, MJ | 1 |
| Boettler, T; Thimme, R | 1 |
| Cai, S; Jiang, Y; Lv, F; Peng, J; Yu, T; Zhang, Y | 1 |
| El Agheb, MO; Grange, JD | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY | 1 |
| Cao, F; Chen, T; He, Y; Jin, L; Liu, J; Qi, C; Wang, J; Yan, T; Yang, Y; Zhang, S; Zhao, Y | 1 |
| Chen, CR; Chen, L; Huang, HJ; Pan, HY; Tong, YX; Yan, J; Yang, DH | 1 |
| Chang, YS; Huang, MH; Li, TC; Peng, WH; Tsai, DS | 1 |
| Ahn, SH; Chong, Y; Kang, HS; Kim, BK; Kim, DH; Kim, KH; Lee, AR; Park, ES; Park, S; Park, YK; Rhee, JK; Shin, GC; Yang, SI | 1 |
| Chen, JZ; Chen, SL; Du, XF; Hu, XQ; Shao, LY; Wang, J; Wang, JL; Weng, XH; Yu, YQ; Zhang, WH | 1 |
| Chen, L; Hui, S; Li, Z | 1 |
| Bhagani, S; Boum, Y; Calisti, G; Foster, GM; Geretti, AM; Muhindo, R; Wilson, LA | 1 |
| Chang, KC; Chang, MH; Chen, HL; Chiu, YC; Hsu, HY; Ni, YH; Wu, JF | 1 |
| Ahn, SH; Chang, HY; Han, KH; Lee, HW; Lee, MG; Lee, SH | 1 |
| Akarca, US; Brouwer, WP; Guo, S; Hansen, BE; Janssen, HL; Simon, K; Sonneveld, MJ; Streinu-Cercel, A; Tabak, F; Xie, Q; Zeuzem, S; Zhang, N; Zhang, Q | 1 |
| Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| Ding, G; Kang, Y; Li, K; Li, W; Mao, Z; Ning, H; Shang, J; Xiao, E | 1 |
| Hwang, SG; Jang, MK; Jeong, SH; Jung, YK; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Kim, SG; Kim, TY; Kim, YS; Lee, JI; Lee, JW; Lee, SH; Park, H; Park, JW; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ | 1 |
| Kowdley, K; Sundaram, V | 1 |
| Li, P; Lil, K; Liu, B; Pan, Y; Pu, W; Sun, A; Zhang, J; Zhang, R; Zhou, C | 1 |
| Park, JG; Park, SY | 1 |
| Dai, L; Qian, F; Qin, J | 1 |
| Ahn, SH; Cho, M; Han, KH; Heo, J; Kim, CW; Kim, HH; Lee, HJ; Park, JY; Park, SY; Tak, WY; Um, SH; Woo, HY; Yoon, KT | 1 |
| Hiramatsu, N; Takehara, T; Yamada, R | 1 |
| Ao, Y; Chen, S; Chong, Y; Gao, Z; Huang, M; Jie, Y; Li, X; Lin, G; Shi, H; Wu, Y; Yang, F; Zhang, M | 1 |
| Cai, B; Chen, J; Liao, Y; Lu, X; Su, Z; Tao, C; Wang, L; Ying, B; Zhang, Q | 1 |
| Lu, X; Ning, Q; Wang, HL; Yang, X | 1 |
| Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P | 1 |
| Fu, WD; He, LX; Jiang, JN; Li, SH; Liang, P; Liu, ZH; Lu, AL; Mo, YY; Su, MH; Wang, BJ; Wu, XL; Xie, R; Zhong, SH | 1 |
| Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kang, W; Kim, BK; Kim, do Y; Kim, HS; Kim, SU; Park, JY | 1 |
| Imoto, S; Kim, SK; Kim, SR; Otono, Y; Tamura, T; Tohyama, M | 1 |
| Cai, XF; Guo, H; Hu, JL; Huang, AL; Long, QX; Luo, YY; Tao, Y; Zhang, WL | 1 |
| Calica Utku, A; Karabay, O | 1 |
| Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Fujioka, S; Ikeda, F; Kariyama, K; Kobashi, H; Miyatake, H; Morimoto, Y; Moriya, A; Okamoto, R; Seno, T; Takaguchi, K; Takaki, A; Takayama, H; Toshimori, J; Wada, N; Yabushita, K; Yamamoto, K; Yasunaka, T | 1 |
| Fung, J; Lai, CL; Wong, DK; Yuen, MF | 1 |
| An, J; Choi, J; Chung, YH; Kim, KM; Kim, SO; Kim, SW; Lee, D; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Cao, Y; Dai, CY; Hou, W; Jiang, B; Li, XM; Lu, W; Su, R; Xu, J | 1 |
| Anzai, K; Arase, Y; Hirose, S; Kagawa, T; Mine, T; Nagata, N; Shiraishi, K; Tsuruya, K | 1 |
| Liu, Y; Qiu, P; Wang, GL; Wen, JB; Wen, P; Xiao, XZ; Xu, LF; Zhou, SF | 1 |
| Song, J; Sun, M; Tan, G; Wang, J; Wu, X | 1 |
| Chen, B; Chi, J; Liu, M; Song, S; Wang, L; Zhang, Y; Zhao, Z | 1 |
| Chan, SH; Chang, TT; Cheng, PN; Huang, W; Lin, YJ; Su, IJ; Tsai, HW; Wu, HC; Wu, IC; Yen, CJ | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S | 2 |
| Bae, MA; Chung, HS; Jung, SW; Lee, YI; Park, CH; Park, NH; Park, YT; Shin, JW | 1 |
| Aykın, N; Çevik, F; Demirtürk, N; Doğan, N; Koca, B; Köken, T | 1 |
| Cheng, J; Liu, S; Wang, Q; Wang, X; Xing, H; Yang, S | 1 |
| Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, JH; Yang, LH; Yue-Meng, W | 1 |
| Atzeni, F; Sarzi Puttini, P; Talotta, R | 1 |
| Ahn, H; An, H; Choe, WH; Jung, YK; Kim, JH; Kim, SG; Kim, SU; Kim, TY; Kim, YS; Lee, JH; Seo, YS; Suh, SJ; Suk, KT; Um, SH; Yim, HJ; Yim, SY | 1 |
| Atay, K; Canbakan, B; Durcan, E; Gültepe, İ; Hatemi, İ; Köroğlu, E; Özdemir, S; Sonsuz, A; Tuncer, M; Yurttaş, B | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Gededzha, MP; Lukhwareni, A; Mphahlele, MJ; Rakgole, JN; Selabe, SG | 1 |
| Defresne, F; Sokal, E | 1 |
| Choi, MS; Gwak, GY; Kim, H; Kim, JH; Kim, K; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH | 1 |
| Hiraoka, A; Kumada, T; Tada, T; Tanaka, J; Toyoda, H; Tsuji, K | 1 |
| Ahn, SH; Baatarkhuu, O; Han, KH; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Kim, YJ; Park, JW; Park, JY; Song, KJ | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY | 1 |
| Bao, R; Bao, S; Chen, R; Guo, Q; Liu, K; Liu, Y; Wang, H; Xiang, X; Xie, J; Xie, Q | 1 |
| Gaeta, GB; Pontarelli, A; Rizzo, V; Stanzione, M; Stornaiuolo, G | 1 |
| Auh, S; Ghany, MG; Hoofnagle, JH; Koh, C; Lau, DT; Lingala, S | 1 |
| Yim, HJ | 2 |
| Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Giakoustidis, D; Giouleme, O; Goulis, I; Imvrios, G; Papanikolaou, V; Vasiliadis, T | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Jia, J; Kong, Y; Wei, W; Wu, X; You, H; Zhou, J | 1 |
| Chen, B; Ju, JC; Qi, JH; Xu, L; Zhang, NN | 1 |
| Chen, Y; Cheng, KL; Duan, XW; Duan, ZP; Li, Y; Qiu, Q; Wang, L; Xu, MM; Yang, LK | 1 |
| Brahmania, M; Brouwer, WP; Feld, J; Hansen, T; Janssen, HL; Kowgier, M; Mazzulli, T; Wong, D | 1 |
| Cao, LL; Chen, DW; Dong, Y; Gan, Y; Wang, FC; Wang, LM; Wang, P; Xu, ZQ; Yan, JG; Zhang, HF; Zhang, M; Zhu, SS | 1 |
| Ahn, SH; Cho, EY; Hwang, SG; Jeong, SH; Jung, YK; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ | 1 |
| Chao, J; Huo, M; Liu, P; Zhang, H | 1 |
| Cheng, C; Chong, CK; Cullaro, G; Fung, J; Huang, FY; Ip, P; Kopaniszen, M; Lai, CL; Lee, B; Ngai, V; Seto, WK; Wong, D; Wu, R; Yuen, J; Yuen, MF | 1 |
| Andreu, I; Bou, JV; Pereira-Gómez, M; Sanjuán, R | 1 |
| Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T | 1 |
| Cho, YK; Choi, KY; Jeon, WK; Jung, YS; Kim, BI; Kim, HJ; Park, DI; Park, JH; Park, SK; Sohn, CI; Yang, HJ | 1 |
| Gao, F; Geng, M; Jiang, Y; Li, A; Li, X; Li, Y; Liu, H; Liu, Y; Sun, L; Wang, R; Wang, X; Yang, Z; Ye, X; Zeng, H; Zhang, H; Zhou, G | 1 |
| Ahn, SH; Baatarkhuu, O; Han, K; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY | 1 |
| Byun, KS; Jong Eun, Y; Jung, YK; Kang, K; Kang, SH; Kim, JH; Kim, TS; Lee, YS; Seo, YS; Suh, SJ; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| Kim, HY | 1 |
| Arnold, R; Diaz, RS; Duro, RL; Ferreira, MC; Ferreira, PR; Hunter, JR; Komninakis, SV; Leal, É; Mantovani, NP; Santana, LC | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Hu, J; Ji, D; Li, X; Liao, H; Liu, Y; Wu, J; Xin, S; Xu, D; You, S; Zhang, XX; Zhao, J | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Wu, CK; Yen, YH | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Caccamo, L | 1 |
| Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A | 1 |
| Babudieri, S; Garrucciu, G; Madeddu, G; Maida, I; Melis, M; Mura, MS; Muredda, AA; Ortu, S | 1 |
| Adinolfi, LE; Andreana, L; Boemio, A; Guerrera, B; Marrone, A; Pasquale, G; Rainone, I; Rinaldi, L; Ruggiero, G; Zampino, R | 1 |
| Huang, R; Jia, B; Liu, Y; Wang, G; Wu, C | 1 |
| Huang, KW; Kuan, YC; Luo, JC; Tam, KW | 1 |
| Gong, C; Jiang, L; Jiang, W; Liang, G; Liu, Z; Song, E; Zheng, Y | 1 |
| Song, BC | 1 |
| Boyd, A; Lacombe, K; Miailhes, P; Zoulim, F | 1 |
| Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M | 1 |
| Cheng, WS; Gao, YF; Guan, SH; Guan, ZS; Hou, J; Mu, XX; Pan, Y; Sun, BB; Wang, AH; Wu, YY; Yang, K; Zhang, H | 1 |
| Hong, LJ; Wei, L; Ying, H; Zhang, J | 1 |
| Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A | 1 |
| Lim, YS | 1 |
| Bozdayi, AM; Çalışkan, A; Idilman, R; Kabaçam, G; Kalkan, Ç; Karakaya, F; Karatayli, E; Karatayli, S; Keskin, O; Özer, S; Tüzün, EA; Yurdaydin, C | 1 |
| Li, B; Li, XL; Qi, W; Wang, CX; Wei, SF; Wu, LY; Zhang, YD; Zhang, YR; Zhou, N | 1 |
| Cui, RL; Jiang, GR; Shan, JP; Sun, LJ; Yuan, WJ | 1 |
| Banerjee, P; Banerjee, S; Chakrabarti, S; Chakraborty, A; Chowdhury, A; Das, K; Datta, S; Ghosh, S; Khatun, M; Mondal, RK; Mukherjee, S; Pandit, P | 1 |
| Flisiak, R; Jaroszewicz, J | 1 |
| Hindes, R; Kreter, B; Liaw, YF; Rustgi, VK; Sette, H; Sherman, M; Silva, M; Simsek, H; Tenney, DJ; Tsai, N; Vaughan, J; Yurdaydin, C | 1 |
| Imazeki, F; Kage, M; Katano, Y; Kumada, H; Moriyama, M; Omata, M; Sata, M; Seriu, T; Suzuki, F; Toyoda, J | 1 |
| Dong, JH; Guo, T; Liu, Z; Lu, MJ; Lu, YP; Wang, BJ; Yang, DL; Zhu, JF | 1 |
| Chen, JJ; Chen, YP; Guo, YB; Hou, JL; Ma, SW; Peng, J; Wang, ZH | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| Akarca, US; Buster, EH; Cakaloglu, Y; Feinman, SV; Flink, HJ; Hansen, BE; Janssen, HL; Mach, T; Schutten, M; Simon, K; So, TM; Tabak, F; Tielemans, W; Trojan, J; van Vuuren, AJ | 1 |
| Allison, ME; Dillon, R; Hirschfield, GM; Rege, KP | 1 |
| Hikiji, K; Kato, M; Nagaoka, T; Nukui, K; Omura, M; Yuki, N | 1 |
| Cheong, JY | 1 |
| Barraud, L; Carrouée-Durantel, S; Chemin, I; Kay, A; Margeridon, S; Trépo, C; Zoulim, F | 1 |
| Biagini, M; Christensen, PB; Mössner, BK; Pedersen, C | 1 |
| Choi, JH; Hong, SP; Hwang, IJ; Hwang, SG; Kim, KI; Kwon, CI; Park, PW; Rim, KS; Shi, KD; Yoon, JH | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
| Li, SC; Sun, LJ; Yu, JW; Zhao, YH | 1 |
| Jiang, JJ; Wang, YP; Yan, YS | 1 |
| Dan, YJ; Deng, GH; Kuang, XM; Tan, WT; Wang, YM | 1 |
| Fournier, C; Zoulim, F | 1 |
| Barraud, H; Bronowicki, JP; Cadranel, JF; Nani, A | 1 |
| Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Lee, SJ; Park, JJ; Yeon, JE; Yim, HJ | 1 |
| Byun, KS; Choe, WH; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Chen, DS; Chen, PJ; Chou, WP; Liu, CJ; Lu, SF; Shih, YH; Wang, HY; Yeh, SH | 1 |
| Chan, FK; Chan, HL; Chan, HY; Chim, AM; Hui, AY; Sung, JJ; Tsang, SW; Wong, GL; Wong, VW; Yiu, KK | 1 |
| Brett, S; Chokshi, S; Cooksley, H; Evans, A; Naoumov, NV; Nathwani, A; Phillips, S; Puranik, S; Riva, A | 1 |
| Deguchi, M; Hayashi, N; Hikita, H; Ishida, H; Kagita, M; Kato, M; Kohga, K; Miyagi, T; Ohkawa, K; Sakamori, R; Sasakawa, A; Takehara, T; Tatsumi, T; Uemura, A; Yamaguchi, S | 1 |
| Brett-Smith, H; Chao, YC; Goodman, Z; Han, SH; Janssen, HL; Lee, WM; Schiff, E; Sette, H; Simsek, H; Tamez, R; Yang, J | 1 |
| Brandão-Mello, CE; Brett-Smith, H; Cassetti, I; Gazzard, B; Hall, A; Huang, AK; Mendes-Corrêa, MC; Pessôa, MG; Phiri, P; Soriano, V | 1 |
| Benucci, M; Manfredi, M; Mecocci, L | 1 |
| Langlet, P; Lasser, L; Mesquita, M | 1 |
| Bailly, F; Beaugrand, M; Benhamou, Y; Marcellin, P; Maynard, M; Monchecourt, F; Parvaz, P; Trepo, C; Trylesinski, A; Zarski, JP; Zoulim, F | 1 |
| Chan, HL; Lui, YY | 1 |
| Aloe-Spiriti, MA; Angeletti, S; Cipriani, P; Cox, MC; Delle Fave, G; Gallina, S; Leone, F; Marignani, M; Monarca, B; Veggia, B | 1 |
| Bae, SH; Choi, JY; Choi, SW; Han, NI; Jang, JW; Kim, DG; Woo, HY; Yang, JM; Yoon, SK; You, CR | 1 |
| Choi, JW; Eun, JR; Kim, TN; Lee, HJ | 1 |
| Arslan, U; Findik, D; Ural, O | 1 |
| Jeon, WK; Kim, BI; Kim, YJ; Park, H; Woo, HY | 1 |
| Desmond, P; Locarnini, S; Nguyen, T | 1 |
| Feng, T; Guo, JJ; Huang, AL; Li, QL; Shi, XF; Zeng, AZ; Zhang, DZ | 1 |
| Lee, SD; Su, CW; Wu, JC | 1 |
| Bak, YT; Byun, KS; Choi, JH; Joo, MK; Jung, YK; Kim, CH; Kim, JH; Kim, JS; Lee, SJ; Park, JJ; Yeon, JE; Yim, HJ | 1 |
| Andreoni, M; Sarrecchia, C; Sordillo, P; Volpi, A | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, SU; Lee, HW; Lee, KS; Paik, YH; Park, JY | 1 |
| Canbay, A; Gerken, G; Gerlich, WH; Jochum, C; Katsounas, A; Schlaak, J | 1 |
| Canbakan, B; Erdem, L; Mert, A; Ozaras, R; Senturk, H; Tabak, F; Yurdakul, I | 1 |
| Albanis, E; Brown, NA; Bzowej, N; Cakaloglu, Y; Chen, Y; Galil, K; Gane, E; Han, SH; Heathcote, EJ; Hwang, SG; Lai, CL; Leung, N; Liaw, YF; Manns, M; Naoumov, NV; Niu, J; Papatheodoridis, G; Tong, MJ; Wang, Y; Zeuzem, S | 1 |
| Boulos, MI; Guastini, CM; Tuon, FF | 1 |
| Bernassola, M; Cappiello, G; Ceccherini-Silberstein, F; De Sanctis, GM; Gori, C; Gubertini, G; Longo, R; Micheli, V; Niero, F; Perno, CF; Salpini, R; Spanò, A; Svicher, V; Trignetti, M; Visca, M | 1 |
| Brett-Smith, H; Carosi, G; Chang, TT; Cheinquer, H; Han, S; Kaymakoglu, S; Lai, CL; Martin, P; Shouval, D; Tamez, R; Tenney, D; Yang, J | 1 |
| Cheong, JY; Cho, SW; Choi, YW; Kang, CJ; Kim, DH; Kim, MJ; Koh, KH | 1 |
| Colombo, M; Facchetti, F; Lampertico, P; Lunghi, G; Viganò, M | 1 |
| Borup, C; Siboni, A | 1 |
| Andersen, ES; Weis, NM | 1 |
| Beom, SH; Choi, JH; Jung, MK; Kim, JE; Kwon, KH; Lee, KH; Lee, SH; Lee, YJ; Oh, JM; Park, MY | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| García Buey, L; González Mateos, F; Moreno Otero, R | 1 |
| Calleja, JL; Peñas, B | 2 |
| Sarmento E Castro, R; Sheldon, J; Soriano, V | 1 |
| González-Diéguez, ML; Rodríguez, M | 1 |
| Chan, HL; Chan, HY; Kwan, KY; Lai, PB; Limquiaco, JL; Tse, CH; Wong, GL; Wong, J; Wong, VW | 1 |
| Akman, S; Elaldi, A; Köse, S; Tunçbilek, S | 1 |
| Bae, JH; Cho, M; Heo, J; Kang, DH; Kim, GH; Moon, JH; Song, GA; Yoon, KT | 1 |
| Bae, SH; Choi, JY; Hur, WH; Jeong, SW; Woo, HY; Yoon, SK; You, CR | 1 |
| Menting, S; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Takkenberg, RB; Weegink, CJ; Zaaijer, HL | 1 |
| Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD | 1 |
| Locarnini, SA; Yuen, LK | 1 |
| Augustovski, F; Calcagno, JI; Gadano, A; Souto, A; Yuan, Y | 1 |
| McMahon, B; Scott, JD | 1 |
| Bai, SL; Hu, XY; Zhong, S | 1 |
| Cheung, KF; Lau, GK; Lu, L; Luk, JM; Wang, FS; Yueng, YH; Zhang, HY | 1 |
| Chrysagis, DN; Dimitriadis, GT; Goulis, IG; Mimidis, KP; Papadopoulos, VP; Protopapas, AN | 1 |
| Chien, RN; Liaw, YF | 4 |
| Buster, EH; Janssen, HL; Schalm, SW | 1 |
| Chen, JJ; Koay, LB; Kuo, HT; Lee, C; Lin, CY; Sheu, MJ; Tang, LY; Tsai, SL | 1 |
| Choi, DJ; Hwang, YJ; Kim, GH; Kim, JH; Kim, YS; Kwon, OS | 1 |
| Buti, M; Esteban, R; Ferrer-Costa, C; Homs, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D | 1 |
| Chan, HL; Chim, AM; Herrmann, E; Hui, AY; Mihm, U; Sung, JJ; Wong, VW; Zeuzem, S | 1 |
| Han, T; Liang, J; Xiao, SX | 1 |
| Alric, L; Huart, A; Izopet, J; Kamar, N; Rostaing, L; Tack, I | 1 |
| Liaw, YF | 9 |
| Colombo, M; Lampertico, P | 1 |
| Palumbo, E | 1 |
| Araujo, ES; Costa, AM; L 'italien, G; Nita, ME | 1 |
| Cai, T; Lou, GQ; Yang, J | 1 |
| Ahishali, E; Badur, S; Bektas, M; Bozkaya, H; Cakaloglu, Y; Cinar, K; Idilman, R; Karayalcin, S; Kaymakoglu, S; Mithat Bozdayi, A; Oguz Onder, F; Okten, A; Pinarbasi, B; Yurdaydin, C | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 2 |
| de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M | 1 |
| Keeffe, EB; Nguyen, MH | 1 |
| Moreno, V; Valencia, ME | 1 |
| Dan, YJ; Deng, GH; Tan, WT; Tan, ZX; Tang, YZ | 1 |
| Liu, YH; Zhang, YH | 1 |
| Baldick, CJ; Colonno, RJ; Eggers, BJ; Fang, J; Pokornowski, KA; Rose, RE; Tenney, DJ; Wichroski, MJ; Wilber, RB; Xu, D; Yang, J | 1 |
| Bonino, F; Farci, P; Gurel, S; Hadziyannis, S; Jin, R; Lau, GK; Lu, ZM; Marcellin, P; Piratvisuth, T; Popescu, M; Wu, J; Yurdaydin, C | 1 |
| Deguchi, M; Hayashi, N; Hikita, H; Ishida, H; Kagita, M; Kanada, A; Kato, M; Kohga, K; Miyagi, T; Ohkawa, K; Sakamori, R; Sasakawa, A; Takehara, T; Tatsumi, T; Uemura, A; Yamaguchi, S | 1 |
| Chemin, I; Durantel, D; Hantz, O; Lucifora, J; Trepo, C; Vincent, IE; Zoulim, F | 1 |
| Ham, MY; Holt, C; Saab, S; Stone, MA; Tong, M | 1 |
| Dai, YX; Ding, H; Hu, TH; Huang, LH; Jiang, XH; Jiang, YM; Qiu, YW; Zhou, M | 1 |
| Batrla, R; Bonino, F; Brunetto, MR; Farci, P; Hadziyannis, S; Lau, GK; Luo, K; Marcellin, P; McCloud, P; Moriconi, F; Piratvisuth, T; Wang, Y; Wolf, E; Yurdaydin, C | 1 |
| Di Martino, V; Herbein, G; Prati, C; Toussirot, E; Wendling, D | 1 |
| Choe, WH; Choi, HM; Kim, BK; Koo, HW; Kwon, SY; Lee, CH | 1 |
| Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC | 1 |
| Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y | 1 |
| Arnold, E; Cook, G; Iloeje, U; Yuan, Y | 1 |
| Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Nagase, T; Ohkawa, K; Oshita, M; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H | 1 |
| Mimidis, K; Papadopoulos, V; Protopapas, A; Tsianos, E | 1 |
| Cui, ZY; Wang, BE; Yao, GB; Yao, JL; Zeng, MD; Zhu, M | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, CJ; Kim, DH; Park, BR; Park, NH; Shin, JW | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lai, MY; Liu, CJ; Tseng, TC; Wang, CC | 2 |
| Chang, MH; Hsu, CW; Huang, SF; Lai, MW; Liaw, YF; Yeh, CT | 1 |
| Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M | 1 |
| Buffet, C | 2 |
| Chen, YC; Hsu, CW; Liaw, YF; Yeh, CT | 1 |
| Fung, J; Lai, CL; Mizokami, M; Tanaka, Y; Wong, DK; Yuen, J; Yuen, MF | 1 |
| Bessone, F; Brett-Smith, H; Chang, TT; Chao, YC; Cheinquer, H; de Man, R; Gish, RG; Gorbakov, VV; Han, KH; Tamez, R | 1 |
| Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Park, MK; Suh, HJ; Yoo, BC | 1 |
| Kim, JW | 1 |
| Sherman, M | 2 |
| Chen, EQ; Duan, YR; Tang, H; Yang, J; Zhang, YY | 1 |
| Conde-Taboada, A; López-Bran, E; Muñoz, JP; Muñoz, LC | 1 |
| Doi, Y; Fukuda, K; Fukui, H; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Mochizuki, K; Nagase, T; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H | 1 |
| Antonucci, G; Capobianchi, MR; Iacomi, F; Mariano, A; Piselli, P; Puro, V; Solmone, M; Vairo, F; Vincenti, D | 1 |
| Gong, QM; Han, Y; Huang, LH; Jin, GD; Kong, XF; Li, J; Lin, ZM; Liu, CM; Lu, ZM; Yang, S; Yu, DM; Zhang, DH; Zhang, XX | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Liu, JH; Tzeng, CH | 1 |
| LI, H; REN, H; SHI, XF; WANG, ZY; ZHANG, DZ; ZHOU, Z | 1 |
| DING, JG; FU, RQ; HONG, L; SUN, QF; WU, YH | 1 |
| Arrese, E; Basaras, M; Blanco, S; Cisterna, R; Ruiz, P | 1 |
| Cai, GS; Chen, PQ; Chen, Y; Chi, XL; Jiang, JM; Qian, Y; Tian, GJ; Wu, LM; Xiao, HM | 1 |
| Guo, CY; Qin, LY; Wang, C; Wang, YZ; Yu, LJ; Yu, SL | 1 |
| Barraud, L; Durantel, S; Fasano, M; Guastadisegni, A; Heichen, M; Pastore, G; Santantonio, T; Zoulim, F | 1 |
| Lee, KS | 1 |
| Cho, SM; Choe, BH; Chu, MA; Kim, JM | 1 |
| Eun, JR; Hwang, JS; Jang, BK; Kim, BS; Lee, CH; Lee, HJ; Suh, JI | 1 |
| Buster, EH; Buti, M; de Vries, RA; Flink, HJ; Gerken, G; Hansen, BE; Heathcote, EJ; Janssen, HL; Kitis, GE; Sharmila, S; Simsek, H; Verhey, E | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Mohebbi, SR; Sabahi, F; Tacke, F; Trautwein, C; Zali, MR | 1 |
| Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G | 1 |
| Archimandritis, A; Avgerinos, A; Burroughs, AK; Karamanolis, D; Kougioumtzan, A; Manolakopoulos, S; Papatheodoridis, G; Raptis, S; Theodoropoulos, J; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J | 1 |
| Chen, PJ; Cheng, AL; Hsu, C | 1 |
| Brett-Smith, H; Chang, TT; de Man, R; Gadano, A; Gish, RG; Lai, CL; Poordad, F; Tamez, R; Yang, J | 1 |
| Ding, H; Ji, F; Li, F; Ma, S; Zeng, C; Zhou, L | 1 |
| Cong, M; Jia, J; Li, H; Liu, T; Ma, H; Ou, X; Ren, J; Wang, B; Wang, P; Wang, X; You, H | 1 |
| Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Acurcio, Fde A; Almeida, AM; Guerra, AA; Silva, DI; Silva, GD | 1 |
| Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC | 1 |
| Akman, SA; Halicioglu, O; Kose, S | 1 |
| Fleischer, RD; Lok, AS | 1 |
| Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Koh, KH; Lee, MH; Yoo, WD | 1 |
| Lada, O; Marcellin, P; Moucari, R | 1 |
| Kao, JH; Lim, SG; Mohammed, R; Yuen, MF | 1 |
| Brancatelli, S; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Isgrò, G; Maimone, S; Pollicino, T; Raimondo, G; Squadrito, G | 1 |
| Fung, J; Lai, CL; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, HJ; Kim, JK; Lee, CK; Lee, HW; Lee, JM; Lee, KS; Nguyen, T; Paik, YH; Park, JY | 1 |
| Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E | 1 |
| Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ | 1 |
| Chen, W; Hou, JL | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Li, XY; Liu, F; Liu, YD; Wang, JB; Wang, L; Wang, YZ; Zhang, ZH | 2 |
| Chi, NH; Eguchi, K; Hirayama, K; Hoa, PT; Hoang, BH; Huy, NT; Nakao, K; Nga, CN; Thu, le T | 1 |
| Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG | 1 |
| Bae, WK; Kim, HJ; Kim, KA; Kim, MH; Kim, NH; Lee, HW; Lee, JS; Moon, YS; Yun, SG | 1 |
| Cao, XX; Chen, YH; Li, J; Luo, YW; Qiu, LM; Ran, Y | 1 |
| Yang, LQ | 1 |
| Acar, A; Aydin, A; Eken, A; Eyigün, CP; Görenek, L; Pahsa, A; Sayal, A | 1 |
| Akhan, SC; Cekmen, M; Hülagü, S; Meriç, M; Sayan, M; Sentürk, O | 1 |
| Chen, EQ; Lei, J; Tang, H; Wang, LC; Xu, L | 1 |
| Ahn, SH; Chang, HY; Han, KH; Kim, DY; Kim, JK; Lee, CK; Lee, JM; Lee, KS; Park, JY; Park, YK | 1 |
| Lin, Q; Zhang, DZ | 1 |
| Tang, WL; Xie, Q | 1 |
| Chai, YY; Li, JG; Li, JX; Li, SF; Liu, MX; Niu, Q; Qin, HQ; Tian, SW; Wang, XY; Zhang, JQ; Zhao, LF | 1 |
| Ahn, SH; Chon, CY; Han, KH; Han, KJ; Hwang, JS; Jang, JY; Kim, DY; Lee, CK; Lee, HJ; Lee, HW; Lee, KS; Paik, YH; Park, JY; Sohn, JH | 1 |
| Chen, XS; Han, LZ; Luo, Y; Qiu, DK; Shen, CH; Wang, SY; Wang, X; Xi, ZF; Xia, Q; Xin, TY; Zhang, JJ | 1 |
| Gong, ZJ; Hu, DF; Yang, Q | 1 |
| Byun, KS; Choe, WH; Hong, SP; Ji, SI; Jung, YK; Kim, BK; Kim, JH; Kim, KH; Kim, SO; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Keating, GM | 1 |
| Deng, LN; Hou, HB; Li, CP; Liu, FQ; Liu, XR | 1 |
| Kang, P; Li, SC; Sun, LJ; Yu, JW; Zhao, YH | 1 |
| Abreu, L; Calleja, JL; de la Revilla, J; Llop, E; Martínez, JL; Peñas, B; Pons, F | 1 |
| Barros, C; Botecchia, M; de Mendoza, C; Del Romero, J; Madejon, A; Rodriguez, C; Soriano, V; Treviño, A; Tuma, P | 1 |
| Mauss, S | 2 |
| Changchien, CS; Chen, CH; Hung, CH; Kuo, YH; Lee, CM; Lu, SN; Tseng, PL; Wang, JH | 1 |
| Bianchini, M; Critelli, R; Ferretti, I; Gennari, W; Graziosi, A; Lei, B; Luongo, M; Taliani, G; Villa, E | 1 |
| Chen, DS; Chen, PJ; Hsieh, HL; Hsieh, TH; Kao, JH; Lai, MY; Liu, CJ; Tseng, TC | 1 |
| Chen, CW; Jia, JD; Ren, H; Wang, YM; Xu, DZ; Yao, GB; Zhou, XQ | 2 |
| Duong, A; Mousa, SA | 1 |
| Han, KH; Kim, CR; Kim, HR; Kim, J; Lai, CL; Um, SH; Yoon, SK; Yuen, MF | 1 |
| Lau, GK | 3 |
| Bengu, K; Funda, O; Mehmet, K; Nazan, C; Rasit, Y; Savas, K; Serap, A | 1 |
| Feng, H; Zhang, YH | 1 |
| Duan, S; Han, Q; Li, Z; Liu, Z; Lou, S; Lv, Y; Zhang, G; Zhang, N | 1 |
| Chen, XY; Chen, Y; Han, ZH; Li, XY; Si, CW; Xu, JH; Yu, YY | 1 |
| Marcellin, P; Piratvisuth, T; Sung, J | 1 |
| Akuta, N; Arase, Y; Hashimoto, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Buti, M; Deterding, K; Hansen, BE; Janssen, HL; Petersen, J; Reijnders, JG; Santantonio, T; van Bömmel, F; Wedemeyer, H; Zoulim, F | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, WC; Wang, JC; Wang, JH | 1 |
| Ahmed, W; Alam, SE; Arif, A; Qureshi, H | 1 |
| Chan, AW; Chan, HL; Chan, HY; Chim, AM; Choi, PC; Sung, JJ; Tse, CH; Wong, GL; Wong, VW; Yan, KK | 1 |
| Barisik, NO; Bilici, A; Gumus, M; Kefeli, U; Seker, M; Tamer, I; Ustaalioğlu, BB; Yildirim, ME | 1 |
| Topalak, O; Ustundag, Y | 1 |
| Cho, YK; Choi, EK; Cui, XJ; Hyun, S; Jeong, SU; Kim, HU; Park, NH; Shin, JW; Song, BC; Song, HJ | 1 |
| Fukushima, K; Inoue, J; Iwasaki, T; Kakazu, E; Kondo, Y; Niitsuma, H; Obara, N; Shiina, M; Shimosegawa, T; Tamai, K; Ueno, Y; Wakui, Y; Yamagiwa, Y | 1 |
| Abe, M; Akbar, SM; Chen, S; Hiasa, Y; Horiike, N; Matsuura, B; Michitaka, K; Onji, M | 1 |
| Chen, HC; Chen, RH; Li, QG; Pan, C; Xu, LJ; Zhang, QY; Zheng, L | 1 |
| Chan, HL; Han, KH; Hou, JL; Kao, JH; Lui, YY; Mihm, U; Mohamed, R; Piratvisuth, T; Teo, EK; Tsoi, KK; Wong, GL; Wong, VW | 1 |
| Abe, H; Chayama, K; Chen, DS; Hatakeyama, T; Hu, JT; Huang, YW; Kao, JH; Lai, MY; Liu, CJ; Takahashi, S; Tsuge, M; Yang, SS | 1 |
| Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, SO; Lee, JM; Nguyen, T; Park, JY | 1 |
| Choi, CS; Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST | 1 |
| Krämer, A; Prüfer-Krämer, L; Wörmann, T | 1 |
| Chan, HL | 1 |
| Eun, JR; Kim, TN; Lee, HJ; Lee, KS | 1 |
| Apostolopoulou, A; Archimandritis, AI; Hadziyannis, E; Koskinas, J; Manesis, EK; Manolakopoulos, S; Papatheodoridis, GV; Vassilopoulos, D | 1 |
| Lampertico, P; Lok, A; Manolakopoulos, S; Papatheodoridis, GV | 1 |
| Abe, H; Aikata, H; Chayama, K; Hatakeyama, T; Hayes, CN; Hiraga, N; Igarashi, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kimura, T; Kitamura, S; Miki, D; Mitsui, F; Morimoto, K; Saneto, H; Shimizu, M; Takahashi, S; Tsuge, M | 1 |
| Berak, H; Dyda, T; Horban, A; Kołakowska-Rzadzka, A; Stańczak, J | 1 |
| Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Małkowski, P; Pawłowska, M; Simon, K | 1 |
| Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J | 1 |
| Cui, YL; Feng, P; Lei, XZ; Liu, L; Song, XQ; Tang, H; Wang, YB; Yan, F; Zheng, MH | 1 |
| Hu, L; Kong, H; Lu, F; Luo, Y; Pickerill, S; Shi, J; Wang, H; Xu, G; You, P; You, Q; Zhong, H | 1 |
| Cupic, M; Delic, D; Jovanovic, T; Lazarevic, I; Simonovic, J; Svirtlih, NS | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, JK; Lee, KS; Paik, YH; Park, JY | 1 |
| Chien, RN | 2 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S; Yatsuji, H | 1 |
| Colombo, M | 1 |
| Akcan, Y; Altindiş, M; Demirdal, T; Demirtürk, N; Gülamber, G; Kalayci, R | 1 |
| Bock, T; Karlas, T; Krasselt, U; Mössner, J; Schiefke, I; Tillmann, HL; Wiegand, J | 1 |
| Aizawa, M; Baba, M; Fujise, K; Namiki, Y; Ohkusa, T; Sato, K; Tajiri, H; Takamatsu, M; Tsubota, A | 1 |
| Chen, H; Li, T; Shen, J; Wu, B | 1 |
| Chan, TM; Choy, BY; Tang, CS; Yap, DY; Yuen, MF; Yung, S | 1 |
| Ahmed, F; Akbar, SM; Al-Mahtab, M; Karim, F; Khan, SI; Rahman, S; Uddin, H | 1 |
| Lu, HY; Si, CW; Yu, YY; Zhuang, LW | 1 |
| Deng, H; Gao, ZL; Huang, ZL; Lu, CR; Zhang, YF; Zhao, ZX | 1 |
| Einarson, TR; Heathcote, EJ; Kowgier, M; Krahn, M; Nishikawa, Y; Pham, B; Sherman, M; Tomlinson, G; Ungar, WJ; Wong, DK; Woo, G | 1 |
| Chae, HB; Goo, JC; Hong, SP; Jeong, JI; Kim, BU; Kim, SO; Park, BC; Park, SM; Youn, SJ | 1 |
| Alteri, C; Angelico, M; Bernassola, M; Bertoli, A; Cappiello, G; Cassola, G; Ceccherini-Silberstein, F; De Sanctis, GM; Feasi, M; Gallinaro, V; Gori, C; Gubertini, G; Longo, R; Marcuccilli, F; Micheli, V; Parruti, G; Perno, CF; Romano, S; Salpini, R; Spanò, A; Svicher, V; Ursitti, A; Visca, M | 1 |
| Bella, MR; Casas Rodrigo, M; Dalmau Obrador, B; Gil Prades, M; Miquel Planas, M; Puig Domingo, J; Sanchez Delgado, J; Vergara Gómez, M | 1 |
| Bowden, S; Locarnini, S | 1 |
| Schildgen, O; Schildgen, V; Tillmann, RL; Ziegler, S | 1 |
| Chung, YH; Heo, NY; Lee, HC; Lee, YS; Lim, YS; Suh, DJ | 1 |
| Ahn, M; Dunn, SR; Hann, HW; Park, SY | 1 |
| Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI | 1 |
| Chyczewski, L; Kowalczuk, O; Pancewicz, J | 1 |
| He, ZK; Liang, ZG; Xu, QJ | 1 |
| Cheong, JY; Cho, SW; Cho, YJ; Jeon, SJ; Kang, CJ; Lee, MH; Lee, YC; Lim, SG | 1 |
| Chen, L; Dai, X; Fan, X; Tang, L; Zhao, S; Zhou, R | 1 |
| Dakin, H; Fidler, C; Harper, C | 1 |
| Boucher, CA; Hansen, BE; Janssen, HL; Rijckborst, V; Sonneveld, MJ | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Einecke, D | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ | 1 |
| Aung, MO; Dan, YY; Fernandes, M; Koay, E; Lee, GH; Lee, YM; Lim, LG; Lim, SG; Seet, BL; Sutedja, DS; Tan, C | 1 |
| Beggel, B; Kagan, RM; Kaiser, R; Liu, TF; Margeridon-Thermet, S; Nguyen, MH; Rhee, SY; Shafer, RW; Verheyen, J | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Tacke, F; Trautwein, C | 1 |
| Chotiyaputta, W; Ditah, FA; Goodwin, D; Lok, AS; Peterson, C | 1 |
| Block, JM; Haber, BA; Jonas, MM; Karpen, SJ; London, WT; McMahon, BJ; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB | 1 |
| Jiang, Y; Li, W; Liu, J; Niu, J; Sun, P; Xin, G; Xu, D; Yan, H; Yu, L; Zhang, H | 1 |
| Lau, GK; Leung, N | 1 |
| Arai, M; Fukai, K; Imazeki, F; Kanda, T; Wu, S; Yokosuka, O; Yonemitsu, Y | 1 |
| Blin, P; Bregman, B; Cadranel, JF; Fontanges, T; Marcellin, P; Pol, S; Poynard, T; Roudot-Thoraval, F; Schmidely, N; Trepo, C; Zarski, JP | 1 |
| Chan, HL; Chan, HY; Chim, AM; Chu, SH; Sung, JJ; Wong, GL; Wong, VW; Yiu, KK | 1 |
| Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI | 1 |
| Chen, Y; Hwang, SG; Jia, JD; Lopez, P; Safadi, R; Wei, L; Xie, Q; Yin, YK; Zuckerman, E | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Wong, GL; Wong, VW | 1 |
| Bourlière, M; Kahloun, A; Zoulim, F | 1 |
| Benhamou, Y; Pais, R | 1 |
| Marcellin, P | 2 |
| Abbott, WG; Hou, JL; Huang, X; Li, C; Li, YY; Ma, SW; Sun, J; Zhang, GW | 1 |
| Bi, LN; Miao, QL; Zhao, KK | 1 |
| Cornberg, M; Jaroszewicz, J; Manns, MP; Wedemeyer, H | 1 |
| Chang, MH; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Abuduheilili, X; Dong, JP; Hou, CS; Jiao, XJ; Li, T; Li, XG; Liu, BM; Sun, XW; Wang, YH; Xu, J; Yan, CH; Yan, L; Yang, JX; Zhuang, H | 1 |
| Chen, L; Ji, D; Li, X; Liu, Y; Wang, C; Wang, H; Xin, S; Xu, D; Zhong, Y; Zoulim, F | 1 |
| Chen, XY; Chen, Y; Chen, YP; Han, ZH; Li, XY; Si, CW; Xi, HL; Xu, DZ; Xu, JH; Yu, M; Yu, YY; Zhang, WJ | 1 |
| Akimoto, T; Higashizawa, T; Inoue, M; Isoda, N; Kusano, E; Muto, S; Nishino, K; Otake, T; Saito, O; Sugano, K; Takahashi, H; Tanaka, A | 1 |
| Bae, SH; Baek, YH; Han, SY; Lee, SW | 1 |
| Chen, LB; Huang, LF; Zhang, LH | 1 |
| Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z | 1 |
| Bai, HL; Long, H; Luo, HT; Ye, YN; Zhong, RX | 1 |
| Johnson, JR; Kane, RL; MacDonald, R; Shamliyan, TA; Shaukat, A; Wilt, TJ; Yuan, JM | 1 |
| Leung, N | 7 |
| Papatheodoridis, GV | 1 |
| Zoulim, F | 5 |
| Chen, CY; Cheng, QH; Dai, Y; Tu, XL | 1 |
| Demirdag, K; Eser Karlidag, G; Karlidag, T; Keles, E | 1 |
| Jung, SW; Kim, MC; Park, NH; Shin, JW | 1 |
| Angelico, M; Ciotti, M; Di Paolo, D; Lenci, I; Marcuccilli, F; Perno, CF; Svicher, V; Tariciotti, L; Tisone, G | 1 |
| Chung, GE; Hwang, SY; Jeong, JB; Jung, YJ; Kim, BG; Kim, D; Kim, HY; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, KL; Yoon, JH | 1 |
| Goriacheva, LG; Kovalenko, AL; Lin'kova, IuN; Romantsov, MG; Shul'diakov, AA; Sologub, TV | 1 |
| Gogos, C; Ketikoglou, I; Manesis, EK; Manolakopoulos, S; Mimidis, K; Papatheodoridis, GV; Raptopoulou-Gigi, M; Touloumi, G; Vafiadis-Zoumbouli, I; Vasiliadis, T; Vourli, G | 1 |
| Guo, XH; Huang, JF; Jin, R; Li, HW; Liu, Z; Wang, ZB; Xie, YM; Zhang, B | 1 |
| Cornberg, M; Darnedde, M; Jaroszewicz, J; Manns, MP; Mederacke, I; Raupach, R; Wedemeyer, H; Wursthorn, K; Zacher, BJ | 1 |
| Cen, S; Chen, HS; Han, YX; Jiang, JD; Li, YH; Liu, F; Peng, ZG; Ren, G; Wang, YP; Xue, R; Zhao, W; Zhou, ZX | 1 |
| Cao, H; Chen, LB; Chen, N; Li, G; Shu, X; Xu, QH; Zhang, K; Zhang, YF | 1 |
| Chen, L; Chen, R; Deng, L; Gong, QM; Huang, SY; Jiang, Y; Liu, F; Yu, DM; Yu, JL; Zhang, XX | 1 |
| Aoki, J; Kagawa, T; Kojima, S; Koyama, A; Matsuzaki, S; Mine, T; Morino, F; Morizane, T; Nishizaki, Y; Sakuma, K; Shiozawa, H; Watanabe, N | 1 |
| Ikeda, F; Kobashi, H; Yamamoto, K | 1 |
| Akaike, J; Arakawa, T; Karino, Y; Kimura, M; Kuwata, Y; Nakajima, T; Ohmura, T; Ozeki, I; Sato, T; Toyota, J | 1 |
| Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A | 2 |
| Buti, M; Esteban, R; Fernandez-Fernandez, P; Homs, M; Jardi, R; Quer, J; Rodriguez-Frias, F; Schaper, M; Tabernero, D | 1 |
| Ahn, SH; Cho, SW; Choi, SH; Hahn, JS; Han, KH; Hong, SP; Kim, SO; Shin, SK | 1 |
| Cho, HC; Choi, MS; Gwak, GY; Kim, KH; Koh, KC; Lee, JH; Lee, YY; Paik, SW; Sinn, DH; Yoo, BC; Yun, WK | 1 |
| Kojima, S; Mine, T; Motegi, S; Nishizaki, Y; Shiozawa, H; Watanabe, N | 1 |
| Inoue, J; Shimosegawa, T; Ueno, Y | 1 |
| Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S | 1 |
| Alric, L; Basse, G; Daudé, M; Esposito, L; Guitard, J; Izopet, J; Kamar, N; Lavayssière, L; Rostaing, L; Sauné, K | 1 |
| Fung, J; Lai, CL; Yuen, MF | 1 |
| Baranova, IP; Goriacheva, LG; Kovalenko, AL; Lin'kova, IuN; Romantsov, MG; Shul'diakov, AA; Sologub, TV | 1 |
| LI, M; WU, JY; Zhang, H | 1 |
| Basso, M; Fazio, V; Giannini, EG; Picciotto, A; Savarino, V; Torre, F | 1 |
| Akarca, US; Yurdaydin, C | 1 |
| Cheng, C; Fung, J; Hung, IF; Lai, CL; Seto, WK; Wong, DK; Wu, R; Yuen, J; Yuen, MF | 1 |
| Aroldi, A; Colombo, M; Facchetti, F; Invernizzi, F; Lampertico, P; Lunghi, G; Messa, PG; Viganò, M | 1 |
| Aizawa, M; Fujise, K; Hoshina, S; Kono, M; Tajiri, H; Tatsuzawa, K; Tsubota, A | 1 |
| Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N | 1 |
| Brown, A; Thursz, M | 1 |
| Cho, YK; Song, BC | 1 |
| Mickevičienė, A; Padaiga, Z; Vanagas, G | 1 |
| Esmaeilzadeh, M; Fonouni, H; Ganten, TM; Golriz, M; Hafezi, M; Majlesara, A; Mehrabi, A; Rad, MT; Rahbari, NN; Sadeghi, M; Schmidt, J | 1 |
| Devrim, I; Köse, S; Taner, C; Türken, M | 1 |
| Chen, CH; Chiang, LT; Ko, BS; Yao, M | 1 |
| Cong, M; Jia, J; Liu, T; Ma, H; Ou, X; Wang, B; Wang, P; Wang, Q; Wu, X; You, H | 1 |
| Tornai, I | 1 |
| Minami, M; Okanoue, T | 3 |
| Beersma, MF; Boucher, CA; Hansen, BE; Janssen, HL; Rijckborst, V; Sonneveld, MJ; Zwang, L | 1 |
| Kong, LB; Li, WC; Nan, YM; Ren, WG; Wang, MR; Zhang, YG | 1 |
| Chan, HL; Ge, S; Guo, W; Hu, J; Huang, X; Jiang, J; Jiang, Z; Liang, Y; Liu, Z; Su, M; Wong, VW; Xie, R; Zhu, M | 1 |
| Georgiou, A; Giannousis, IP; Hadziyannis, E; Manolakopoulos, SG; Papatheodoridis, GV | 1 |
| Chan, AC; Chan, SC; Chok, KS; Fan, ST; Lo, CM; Poon, RT; Yuen, WK | 1 |
| Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM | 1 |
| Hansen, BE; Janssen, HL; Perquin, M; Reijnders, JG; Zhang, NP | 1 |
| Benetti, S; Cassino, L; Fay, F; Quarleri, J; Tanno, H | 1 |
| Deng, L; Gao, S; Gui, X; Liang, K; Rong, Y; Xiong, Y; Yan, Y; Yang, R; Zhang, Y | 1 |
| Emery, S; Hu, Z; Khabo, P; Maja, P; Manzini, P; Matchaba, G; Matthews, GV; Metcalf, J; Orsega, S; Pool, N; Sangweni, P | 1 |
| Cho, EJ; Hwang, SY; Jang, ES; Kim, CY; Kim, YJ; Kwak, MS; Lee, CH; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH; Yu, SJ | 1 |
| Chen, DY; Chen, YH; Chen, YM; Hsieh, CW; Hsieh, TY; Lan, JL; Yang, SS | 1 |
| Furusyo, N; Hayashi, J; Murata, M; Ogawa, E; Ohnishi, H; Taniai, H; Toyoda, K; Unno, M | 1 |
| Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Cheon, YK; Cho, YD; Jang, JY; Jeon, SR; Jeong, SW; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, JS; Lee, SH; Moon, JH; Park, SH | 1 |
| Jiang, MD; Qin, JP; Wang, Z; Wu, XL; Xu, H; Zeng, WZ; Zhang, Y | 1 |
| Giles, M; Sasadeusz, J; Visvanathan, K | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, SB; Sohn, BS; Son, BH | 1 |
| Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Zhang, DZ | 1 |
| Guo, Y; Liang, P; Liu, Y; Yan, Z; Zhang, J; Zhao, J | 1 |
| Borroto-Esoda, K; Curtis, M; Zhu, Y | 1 |
| Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L | 1 |
| Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW | 1 |
| Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY | 1 |
| Andreone, P; Bernardi, M; Cursaro, C; Fiorino, S; Furlini, G; Galli, C; Galli, S; Gitto, S; Gramenzi, A; Loggi, E; Micco, L | 1 |
| Jang, JS; Jang, MK; Kim, DJ; Kim, HS; Kim, HY; Kim, KH; Lee, JH; Lee, MS; Park, CK; Park, JW; Seo, DD; Shin, WG | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Icardi, G; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D | 1 |
| Chen, T; Chen, TC; Chen, YC; Hsu, CW; Lai, MW; Liang, KH; Yeh, CT | 1 |
| Choi, MS; Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Razonable, RR | 1 |
| Hong, YQ; Mao, QG; Ouyang, LJ; Ruan, QF; Tang, YJ; Yu, HT; Zhao, JF | 1 |
| Li, DJ; Liu, C; Liu, L; Lu, LX; Lu, XJ; Tang, H; Wang, LC; Wang, Y; Xu, KW | 1 |
| Huang, LY; Li, M; Zhou, ZH | 1 |
| Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kim, SS; Lee, D; Lee, MH | 1 |
| Buchanan, C; Tran, TT | 1 |
| Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H | 1 |
| Bagnarelli, P; Biagioni, G; Butini, L; Costantini, A; Ferreri, ML; Manzin, A; Marinelli, K; Monachetti, A; Montroni, M | 1 |
| Lee, SS; Sherman, M | 1 |
| Berr, F; Brosteanu, O; Kullig, U; Maier, M; Schiefke, I; Tillmann, HL; Wiegand, J; Wiese, M | 1 |
| Chen, HH; Hung, HF | 1 |
| Bozdayi, AM; Cinar, K; Gokahmetoglu, S; Güven, K; Idilman, R; Karatayli, E; Karatayli, SC; Yurdaydin, C | 1 |
| Emara, MH; Radwan, MI | 1 |
| Han, KH; Kim, HS; Park, Y | 1 |
| Ağca, H; Akarsu, M; Sayıner, AA; Sengönül, A; Simşek, I | 1 |
| Chuma, M; Hige, S; Nakanishi, M; Sho, T | 1 |
| Miyajima, I; Sata, M | 1 |
| Asahina, Y | 1 |
| Ebinuma, H; Saito, H | 1 |
| Cao, Z; Chen, X; Jin, Y; Liu, Y; Ma, B; Ma, L; Wu, H; Yu, H; Zhang, H; Zhang, Y; Zheng, Y | 1 |
| Buster, EH; Cakaloglu, Y; Chan, HL; Hansen, BE; Janssen, HL; Sonneveld, MJ; Uitterlinden, AG; Woltman, AM; Wong, GL; Wong, VW; Zeuzem, S | 1 |
| Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP | 1 |
| Chen, L; Li, J; Lv, J; Su, H; Xing, X; Zhong, Y; Zhou, X; Zhu, H | 1 |
| Chow, PY; Lee, KK; Lee, VW; Li, H; Wu, DB | 1 |
| Fan, XH; Geng, JZ; Li, J; Lu, HY; Wang, LF; Xu, XY; Zheng, YY | 1 |
| Feng, C; Li, J; Lou, GQ; Wu, LJ; Wu, NP; Yang, J | 1 |
| Chan, HL; Chan, HY; Chim, AM; Chu, SH; Wong, GL; Wong, VW | 1 |
| Choi, JG; Chung, YH; Jin, YJ; Kim, JA; Kim, SE; Kim, SH; Lee, D; Lee, YS; Park, WH; Shim, JH; Yang, SH | 1 |
| Chang, SC; Chang, SY; Chen, MY; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CJ; Sheng, WH | 1 |
| Li, le Q; Wu, LC; Zhong, JH | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 2 |
| Byun, IS; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, SH | 1 |
| Aygen, B; Demirdal, T; Demirtürk, N; Inan, D; Kantürk, A; Tütüncü, E; Yıldırmak, T; Yıldız, O | 1 |
| Wong, GL | 1 |
| Arai, M; Fujiwara, K; Goto, N; Imazeki, F; Kamezaki, H; Kanda, T; Nakamoto, S; Shinozaki, M; Wu, S; Yokosuka, O | 1 |
| Chen, Y; Ju, T | 1 |
| Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Hosui, A; Iio, S; Imai, Y; Inui, Y; Ishida, H; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurokawa, M; Mita, E; Miyagi, T; Miyazaki, M; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Kim, YJ; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH | 1 |
| Fontana, RJ; Singal, AK | 1 |
| Fujimori, M; Kumada, T; Sone, Y; Tada, T; Toyoda, H | 1 |
| Boucher, CA; Cakaloglu, Y; Hansen, BE; Heathcote, EJ; Janssen, HL; Mach, T; Rijckborst, V; Simon, K; Sonneveld, MJ; Tabak, F; Zeuzem, S | 1 |
| Heo, NY; Lee, HC; Lee, TH; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Chen, J; Hou, J; Wang, Y; Wang, Z; Zhou, B | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Bang, SJ; Du Jeong, I; Eum, JB; Jung, SW; Kim, BG; Kim, CJ; Park, BR; Park, NH; Shin, JW | 1 |
| Chang, J; Chen, PJ; Han, SY; Hsiao, CC; Liu, WH; Wu, JY; Yeh, SH | 1 |
| Chang, CY; Hsu, CC; Hsu, CY; Hsu, YC; Huang, SC; Lin, CW; Lin, JT; Lo, GH; Mo, LR; Perng, DS; Tai, CM; Tseng, CH | 1 |
| Hansen, BE; Heathcote, EJ; Janssen, HL; Pas, SD; Rijckborst, V; Senturk, H; Simon, K; Sonneveld, MJ; Zeuzem, S | 1 |
| Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ | 1 |
| Bahar, K; Bozdayi, M; Bozkus, Y; Cinar, K; Elhan, A; Idilman, R; Seven, G; Yurdaydin, C | 1 |
| Tang, JL; Zhou, JK | 1 |
| Angarano, G; Brancaccio, G; Brunetto, MR; Di Marco, V; Fasano, M; Gaeta, GB; Lampertico, P; Marengo, A; Marzano, A; Niro, GA; Rizzetto, M; Santantonio, T; Scotto, G | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mori, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Bacia, V; Baka-Cwierz, B; Bluszcz-Roznowska, A; Boroń-Kaczmarska, A; Brzostek, T; Deroń, Z; Durlik, M; Flisiak, R; Janczewska-Kazek, E; Juszczyk, J; Kalinowska, A; Krygier, R; Mach, T; Olszok, I; Pisula, A; Wawrzynowicz-Syczewska, M | 1 |
| Cooper, C; Shaikh, T | 1 |
| Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J | 1 |
| Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X | 1 |
| Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY | 1 |
| Ali, M; Aslam, MA; Iqbal, F; Qureshi, JA; Rehman, W; Tauseef, I | 1 |
| Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, HY; Ma, XJ | 1 |
| Chen, L; Chen, X; Cui, Q; Ding, K; Gong, Y; Lei, N; Peng, Z; Su, J; Tan, Y; Trinh, X; Yu, R | 1 |
| Wu, F; Wu, MJ; Zhu, B; Zhu, SM; Zhuge, XL | 1 |
| Jiao, JZ; Li, XL; Wei, SF; Wu, LY; Yan, WC; Zhang, T; Zhang, YP; Zhang, YR | 1 |
| Ahn, SH; Baatarkhuu, O; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, JY; Shin, HS | 1 |
| Shi, WQ; Tang, CL; Zhou, Z | 1 |
| Fernandes, CA; Gomes, Sde A; Mello, FC | 1 |
| Chang, KC; Chen, TC; Chen, YT; Chien, YS; Chiu, KW; Hu, TH; Lin, MT; Tsai, MC | 1 |
| Chiba, T; Fujiwara, T; Kou, T; Marusawa, H; Nasu, A; Nishijima, N; Osaki, Y; Shimizu, K; Takahashi, K; Tsuchiya, S; Ueda, Y; Uemoto, S; Yazumi, S | 1 |
| Cha, BK; Chang, HY; Chang, SK; Choi, CH; Do, JH; Hong, SP; Kim, HJ; Kim, JG; Lee, HW | 1 |
| Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ | 1 |
| Hadziyannis, SJ | 3 |
| Anai, H; Honda, K; Maehara, S; Moriuchi, A; Muro, T; Seike, M; Tahara, K | 1 |
| Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V | 1 |
| Cho, MH; Cho, SM; Choe, BH; Chu, M; Kwon, S; Lee, WK | 1 |
| Dybowska, D; Halota, W; Kozielewicz, D | 1 |
| Almasio, PL; Bertino, G; Brandolino, N; Bruno, S; Caroleo, B; Cosco, L; Di Marco, V; Foti, G; Frugiuele, P; Galdieri, A; Madonia, S; Montalto, G; Portelli, V; Russello, M; Sapienza, M; Scifo, G; Siciliano, R; Spadaro, A; Stroffolini, T; Surace, L | 1 |
| Diao, S; Ha, M; Huang, C; Huang, Z; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Wu, J; Zhang, G | 1 |
| Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY | 1 |
| Chen, GM; Chen, J; Li, JH; Li, YQ; Luo, XR; Mo, GY; Rao, GR; Wang, GQ; Yang, FQ; Yu, YY | 1 |
| Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Amemiya, F; Enomoto, N; Inoue, T; Kadokura, M; Kanayama, A; Komase, K; Maekawa, S; Miura, M; Nakayama, Y; Ohmori, T; Sakamoto, M; Shindo, H; Shindo, K; Sueki, R; Uetake, T | 1 |
| Mao, Q; You, JP; Zhang, HY; Zhang, XQ | 2 |
| Huang, Y; Wang, J; Wang, M | 1 |
| Boninsegna, S; Colombo, M; Di Costanzo, GG; Di Marco, V; Facchetti, F; Farci, P; Fargion, S; Fasano, M; Giuberti, T; Iannacone, C; Lampertico, P; Massetto, B; Regep, L; Sagnelli, E; Viganò, M | 1 |
| Ahn, SH; Cho, M; Han, KH; Heo, J; Kim, DY; Lee, HJ; Park, JY; Park, SY; Seo, YS; Tak, WY; Um, SH; Yoon, KT | 1 |
| Bozdayi, AM; Cevik, E; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Seven, G; Yakut, M; Yurdaydin, C | 1 |
| Jiang, H; Wang, J; Zhao, W | 1 |
| Ebata, S; Hashimoto, S; Ishikawa, Y; Ito, M; Koike, T; Maoka, T; Mochizuki, T; Suzuki, A | 1 |
| Baba, N; Fujioka, S; Ikeda, F; Iwasaki, Y; Kobashi, H; Kubota, J; Miyake, Y; Miyoshi, K; Moritou, Y; Takaguchi, K; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T | 1 |
| Chang, CC; Chen, TH; Chen, TY; Lai, HW; Lin, CC; Tsai, MC | 1 |
| Funai, EF; Han, CS; Nayeri, UA; Pettker, CM; Thung, SF; Werner, EF | 1 |
| Fung, J; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Huang, L; Li, T; Wang, C; Xu, D; Zhao, P | 1 |
| Avila, C; Bao, W; Chan, HL; Chen, YC; Choudhuri, G; Chutaputti, A; Gane, EJ; Hwang, SG; Piratvisuth, T; Prabhakar, B; Safadi, R; Sarin, SK; Suh, DJ; Tanwandee, T; Trylesinski, A; Yurdaydin, C | 1 |
| Ooi, M; Teoh, NC | 1 |
| Aung, MO; Dan, YY; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Mak, B; Tan, PS; Thwin, MA | 1 |
| Alberti, A; Campagnolo, D; Erne, EM; Mirandola, S; Romualdi, C; Rossi, C; Sebastiani, G; Tempesta, D; Vario, A; Velo, E | 1 |
| Flink, HJ; Hansen, BE; Janssen, HL; Sonneveld, MJ; Zoutendijk, R; Zwang, L | 1 |
| Qi, JH; Ren, H; Shi, XF; Sun, YC; Xiao, L; Yan, XZ | 1 |
| Li, MY; Yuan, XL; Zhang, DZ | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM | 1 |
| Cai, M; Du, Y; Feng, X; He, Z; Huang, H; Lin, Z; Liu, K; Wang, J | 1 |
| Chung, YH; Jin, YJ; Kim, KM; Lee, HC; Lee, YS; Shim, JH; Suh, DJ; Yoo, DJ | 1 |
| Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kim, SS | 1 |
| Afshar, RM; Mollaie, HR | 1 |
| Babrzadeh, F; Borroto-Esoda, K; Holmes, SP; Liu, TF; Margeridon-Thermet, S; Martin, R; Pacold, M; Reuman, EC; Shafer, RW; Svarovskaia, ES | 1 |
| Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S | 1 |
| Cheng, H; Shen, J; Wu, B | 1 |
| Bae, SH; Choi, JY; Jang, JW; Kwon, JH; Park, CH; Yoo, SH; Yoon, SK | 1 |
| Cho, EJ; Cho, Y; Chung, KH; Jeong, SH; Jin, E; Kim, CY; Kim, JW; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Chen, X; Lu, M; Shi, H; Wang, Y; Wu, C; Xu, Y | 1 |
| Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS | 1 |
| Ahn, SH; Hong, SP; Hwang, SG; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Lee, SJ; Park, SJ; Park, YM; Seo, YS; Yim, HJ; Yoon, EL | 1 |
| Choe, WH; Kim, BK; Kim, JH; Kim, KH; Ko, SY; Kwon, SY; Lee, CH | 1 |
| Deng, X; Liang, J; Tang, YF; Wu, FS | 1 |
| Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM | 1 |
| Bar-Yishay, I; Ben-Yehoyada, M; Burdelova, EO; Fishman, S; Halpern, Z; Mouler Rechtman, M; Shlomai, A | 1 |
| Cai, HD; Liu, M; Yi, W | 1 |
| Buti, M; Petersen, J | 1 |
| Fu, SY; Huang, G; Lau, WY; Pan, ZY; Shen, F; Wu, MC; Yang, Y; Zhou, WP | 1 |
| Lee, SH; Moon, JY | 1 |
| Choi, BS; Choi, SR; Chung, BH; Hong, YA; Kim, YS; Park, CW; Park, HS; Sun, IO; Yang, CW | 1 |
| Colak, Y; Dinler, G; Doganay, L; Enc, FY; Katrinli, S; Ozturk, O; Tuncer, I; Ulasoglu, C | 1 |
| Bae, SH; Choi, JY; Jang, JW; Kim, CW; Kim, HY; Lee, CD; Lee, YS; Park, CH; Yang, JM; Yoon, SK | 1 |
| Wang, H; Yang, J; Zhu, X | 1 |
| Hickey, DP; Raheem, OA | 1 |
| Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL | 1 |
| Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G | 1 |
| An, H; Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ; Yun, TJ | 1 |
| Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP | 1 |
| Han, SS; Hong, G; Kong, SY; Lee, KB; Lee, KW; Park, KU; Park, SJ; Suh, KS; Yi, NJ | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Huang, S; Wu, F; Yu, H | 1 |
| Cheng, CT; Garrido-Lestache, S; Hui, CK; Lai, CL; Lai, YP; Yuen, MF | 1 |
| Alberti, A; Brunetto, MR; Colombo, M; Craxì, A | 1 |
| Kletzmayr, J; Watschinger, B | 1 |
| Colak, H; Demirtürk, N; Dinçer, S; Kartal, ED; Ozgünes, I; Usluer, G | 1 |
| Guptan, RC; Kazim, SN; Sarin, SK; Thakur, V | 1 |
| Bailly, F; Zoulim, F | 1 |
| de Man, RA; Fries, E; Niesters, HG; Osterhaus, AD; Pas, SD | 1 |
| de Man, RA; Hansen, BE; Levi-Drummer, RS; Neumann, AU; Niesters, HG; Schalm, SW; Wolters, LM | 1 |
| Daimon, Y; Itoh, Y; Kirishima, T; Minami, M; Morita, A; Nakamura, H; Okanoue, T; Toyama, T | 1 |
| Dimou, E; Papadimitropoulos, V; Papatheodoridis, GV | 1 |
| Aydogdu, S; Selimoglu, MA; Unal, F; Yagci, RV; Yüce, G; Zeytinoglu, A | 1 |
| Bosnak, M; Dikici, B; Haspolat, K | 1 |
| DE Man, RA; Fries, E; Niesters, HGM; Osterhaus, ADME; Pas, SD | 1 |
| Asahina, Y; Hamano, K; Itakura, J; Izumi, N; Kanazawa, N; Kawamura, S; Miyake, S; Noguchi, O; Sakai, T; Tsuchiya, K; Uchihara, M | 1 |
| Au, WY; Bartholomeusz, A; Fong, DY; He, ML; Lau, GK; Liang, R; Lie, AK; Locarnini, S | 1 |
| Anschuetz, G; Brown, NA; Davis, R; Fontana, RJ; Gardner, SD; Hann, HW; Perrillo, RP; Rakela, J; Vierling, JM; Wright, T | 1 |
| Bosnak, M; Bosnak, V; Dagli, A; Dikici, B; Ece, A; Haspolat, K; Yagci, RV | 1 |
| Berg, T; Jonas, S; Müller, AR; Neuhaus, P; Neuhaus, R; Rayes, N; Seehofer, D; Settmacher, U; Steinmüller, T | 1 |
| Liu, Z; Xie, W; Xu, DZ | 1 |
| Han, QX; Lin, XF; Lin, XY; Wang, JH | 1 |
| Bosnak, M; Bosnak, V; Dagli, A; Davutoglu, M; Dikici, B; Haspolat, K; Yagci, RV | 1 |
| Guptan, RC; Hasnain, SE; Kazim, SN; Khan, LA; Parvez, MK; Raisuddin, S; Sarin, SK; Thakur, V; Wakil, SM | 1 |
| Davis, GL | 1 |
| Guan, R; Kajiji, T; Lim, SG; Rajnakova, A; Wai, CT | 1 |
| Akbar, HO | 1 |
| Keam, SJ; Scott, LJ | 1 |
| Boyacioglu, S; Gür, G; Gürsoy, M; Ozdemir, N | 1 |
| Hasegawa, K; Hashimoto, E; Hayashi, N; Iizuka, A; Ishikawa, K; Joh, R; Kanai, N; Naritomi, T; Ogawa, M; Shizuma, T; Torii, N | 1 |
| de Man, RA; Hansen, BE; Niesters, HG; Wolters, LM | 1 |
| De Vreese, K; Decraemer, H; Hulstaert, F; Locarnini, S; Lok, AS; Maertens, G; Mangia, A; Niro, G; Sablon, E; Zoulim, F | 1 |
| Kaplan, DD; Reddy, KR | 1 |
| Abdurakhmanov, DT; Aprosina, ZG; Kozlovskaia, NL; Milovanova, SIu; Tégaĭ, SV | 1 |
| Hsu, CT; Hu, JT; Lai, YC; Wu, CH; Yang, SS | 1 |
| Kaczmarski, M; Lebensztejn, DM | 1 |
| Cho, SW; Kyun, J; Oh, JM | 1 |
| Koay, E; Kong, HL; Lee, YM; Lim, LL; Lim, R; Lim, SG; Wai, CT | 1 |
| Hong, J; Hu, Y; Liu, P; Wang, H; Zhu, D | 1 |
| Changchien, CS; Chen, TM; Lee, CM; Liao, CA; Lu, SN; Ong, GY; Tung, HD; Wang, JH | 1 |
| Zucker, SD | 1 |
| Lok, AS; Wai, CT | 1 |
| Chan, FK; Chan, HL; Hui, Y; Leung, NW; Sung, JJ; Tsang, SW | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Esteban, R | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Liu, X; Schinazi, RF | 1 |
| Anderson, FH; Dehertogh, D; Lai, CL; Lao, J; Rosmawati, M; Thomas, N; Van Vlierberghe, H | 1 |
| Porst, H | 1 |
| Blum, HE; Moradpour, D | 1 |
| Mano, Y; Shimosegawa, T; Ueno, Y; Yahagi, K | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 2 |
| Pariente, A; Poveda, JD; Tachet, A | 1 |
| Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 2 |
| Koike, K | 1 |
| Bowden, S; Chen, RY; Colledge, D; Delaney, WE; Desmond, P; Edwards, R; Isom, H; Locarnini, SA; Shaw, T | 1 |
| Ahn, SH; Baek, SJ; Bak, JJ; Bak, YT; Byun, KS; Chang, YJ; Choi, CW; Choi, DW; Jeong, WS; Jo, NY; Kim, JS; Kim, KO; Lee, CH; Lee, MS; Oh, SN; Yeon, JE; Yim, HJ | 1 |
| Ahn, SH; Baek, SJ; Byun, KS; Chang, YJ; Cho, NY; Choi, CW; Choi, DW; Kim, JH; Kim, SS; Kwon, OS; Kwon, YD; Lee, CH; Song, JW; Yeon, JE; Yim, JY | 1 |
| Choi, DJ; Chung, MG; Hwang, YJ; Ju, KT; Kim, JH; Kim, SS; Kim, YK; Koo, YS; Kwon, OS; Park, DK | 1 |
| Dienstag, JL; Gardner, S; Goldin, RD; Gray, DF; Hann, HW; Heathcote, EJ; Schiff, ER; Stephenson, SL; Woessner, M | 1 |
| Fisher, DA; Huffam, SE | 1 |
| Khanna, N | 1 |
| Chemello, L; de Man, RA; Fontaine, H; Hansen, BE; Heathcote, J; Janssen, HL; Löhr, HF; Schalm, SW; Song, BC; Suh, DJ; van Nunen, AB | 1 |
| Chien, RN; Liaw, YF; Lin, CH | 1 |
| Chan, FK; Chan, HL; Chui, AK; Lau, WY; Rao, AR; Wong, J | 1 |
| Behboudi, S; Bertoletti, A; Burroughs, AK; Dusheiko, GM; Gotto, J; Malacarne, F; Reignat, S; Webster, GJ; Williams, R | 1 |
| Heathcote, J | 1 |
| Hadziyannis, SJ; Papatheodoridis, GV; Vassilopoulos, D | 1 |
| Cui, Z; Wang, B; Yao, G; Yao, J; Zeng, M | 2 |
| Atkins, M; Boehme, R; Brown, N; Condreay, L; Dienstag, J; Hunt, C; Lai, CL; Leung, NW; Schiff, E; Woessner, M | 1 |
| Benhamou, Y; Bernard-Chabert, B; Poynard, T; Ratziu, V; Thabut, D; Thibault, V | 1 |
| Berkowitz, D; Daudi, N; Eshach-Adiv, O; Hartman, C; Hino, B; Kra-Oz, T; Rimon, N; Satinger, I; Shamir, R; Shouval, D | 1 |
| Cui, ZY; Huang, Y; Ji, NX; Yao, GB; Yao, JL; Zhang, DF | 1 |
| Herrmann, E; Kronenberger, B; Mihm, U; Sarrazin, C; Teuber, G; von Wagner, M; Zeuzem, S | 1 |
| Shi, W; Tang, S; Zhang, W | 1 |
| Ji, D; Li, L; Shao, Q; Zhang, J | 1 |
| Chen, N; Cui, X; Li, X; Ru, H; Tang, Z; Wen, X; Xie, H; Zeng, W | 1 |
| Gładysz, A; Piszko, P; Rotter, K; Simon, K; Zalewska, M | 1 |
| Cianciara, J; Dienstag, JL; Gardner, S; Karayalcin, S; Kowdley, KV; Plisek, S; Schiff, E; Willems, B; Woessner, M | 1 |
| Duan, HY; Lu, H; Ma, LX; Xu, WS; Yu, LJ; Zhang, HY | 1 |
| Guo, SH; Ren, H; Wang, ZY; Zeng, WQ; Zhang, DZ; Zhang, QH; Zhou, Z | 1 |
| Liu, QJ; Liu, W; Liu, XY; Zhang, HR; Zhang, L; Zhao, W; Zhou, ZX | 1 |
| Bogaerts, V; Doutreloigne, J; Fan, ST; Hui, CK; Lai, CL; Li, TM; Sablon, E; Wong, BC; Wong, DK; Yuan, HJ; Yuen, MF | 1 |
| Banina, VB; Bogomolov, PO; Gushchin, AE; Isakov, VA; Kazantseva, IA; Mironova, OS; Pavlova, TV; Seliverstova, TR; Shakhovskiĭ, IuK; Tsodikov, GV | 1 |
| de Man, RA; Geerlings, CJ; Niesters, HG; van Dijk, L; Vulto, AG; Wolters, LM | 1 |
| Ben-Ari, Z; Mor, E; Tur-Kaspa, R | 1 |
| Chen, M; Guo, SH; Guo, Y; Li, YG; Ren, H; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ | 1 |
| Fan, Y; Huang, YP; Lan, L; Wang, YM | 1 |
| Fang, P; Wu, TS | 1 |
| Iino, S | 1 |
| Muñoz Bartolo, G | 1 |
| Ayres, A; Bartholomeusz, A; Lam, KC; Lau, G; Lee, JY; Locarnini, S | 1 |
| Kimura, T; Kiyosawa, K; Maki, N; Matsumoto, A; Rokuhara, A; Tanaka, E; Yagi, S | 1 |
| Bowden, S; Chen, RY; Dean, J; Desmond, PV; Locarnini, SA | 1 |
| Aksu, G; Aydogdu, S; Genel, F; Kutukculer, N; Ozgenc, F; Unal, F; Yagci, RV | 1 |
| Brown, NA; Condreay, LD; Crowther, LM; de Man, RA; Dienstag, JL; Goodman, Z; Grimm, IS; Husa, P; Karayalcin, S; McPhillips, PJ; Perrillo, RP; Schiff, ER; Woessner, MA | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Satoh, J; Someya, T; Suzuki, F; Suzuki, Y; Takagi, K; Tsubota, A | 3 |
| Chrissafidou, A; Malek, M; Musch, E | 1 |
| Liang, WF; Shen, YH; Xie, YJ; Yang, DH; Zhao, NF | 1 |
| Chen, YM; Deng, H; Xu, QH; Yao, JL; Zhao, ZX; Zhou, YP | 1 |
| Chroni, E; Karatza, CL; Papapetropoulos, S; Paschalis, C; Thomopoulos, C | 1 |
| Abete, JF; Garcia, GM; Garcia, JM; Lindeman, ML; Marugan, RB; Terron, SD | 1 |
| Mukherjee, S | 1 |
| Celik, Y; Degertekin, H; Yalcin, K; Yildiz, F | 1 |
| Fontana, RJ | 2 |
| Aslan, N; Bozdayi, AM; Bozdayi, G; Bozkaya, H; Cinar, K; Karayalçin, S; Pai, R; Pai, SB; Sahin, T; Schinazi, RF; Sezgin, O; Türkyilmaz, AR; Uzunalimoğlu, O; Yurdaydin, C | 1 |
| Chang, FY; Chang, TT; Huang, YH; Huo, TI; Lee, PC; Lee, SD; Sheen, IJ; Su, CW; Wang, YJ; Wu, JC | 1 |
| Jeong, Id; Joo, KR; Kim, BC; Kim, DH; Park, JH; Park, NH; Seo, KW | 1 |
| Kong, XJ; Liang, KH; Lin, JS; Song, JW | 1 |
| Yang, Q; Ye, F; Zhang, H; Zhang, SL | 1 |
| Azzaroli, F; Colecchia, A; Fabbri, C; Ferrara, F; Festi, D; Giovanelli, S; Jaboli, MF; Liva, S; Marchetto, S; Mazzella, G; Miracolo, A; Montagnani, M; Nigro, G; Reggiani, LB; Roda, E | 1 |
| Bock, T; Hacker, HJ; Schröder, CH; Tokus, M; Zhang, W | 2 |
| Brook, MG; Dale, AW; Jones, K; Miller, RF | 1 |
| Ji, W; Li, L; Su, HB; Wang, HF | 1 |
| Chen, JJ; Wang, LT; Zhou, F | 1 |
| Jacobson, IM; Purow, DB | 1 |
| Abdurakhmanov, DT; Ibragimova, MM; Ignatova, TM; Krel', PE; Lopatkina, TN; Popova, IV | 1 |
| Bahar, A; Gocmen, I; Iscan, S; Karademir, F | 1 |
| Enomoto, N; Hasegawa, K; Hashimoto, E; Hayashi, N; Joh, R; Tokushige, K; Torii, N; Watanabe, M; Yamashiro, T | 1 |
| Chen, Y; Hu, YY; Jiang, JJ; Li, D; Li, QG; Lin, CW | 1 |
| Ling, Q; Yan, MH; Zhang, C; Zhou, RF | 1 |
| Cui, ZY; Wang, BE; Yao, GB; Yao, JL; Zeng, MD | 2 |
| Csöndes, M; Gervain, J; Nemesánszky, E; Papp, I; Rácz, I; Ribiczey, P; Telegdy, L; Tornai, I; Weisz, G | 1 |
| Han, T; Lu, HM; Yang, YK; Zhang, HZ | 1 |
| Ozden, N; Saruc, M; Yuceyar, H | 1 |
| Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P | 1 |
| Bertoletti, A; Boni, C; Cavalli, A; Cerioni, S; Ferrari, C; Jenkins, J; Lamonaca, V; Missale, G; Panebianco, R; Penna, A; Pilli, M; Rapti, I; Urbani, S | 1 |
| Choi, MH; Chung, YH; Jang, MK; Kim, JA; Lee, HC; Lee, YS; Park, NH; Ryu, SH; Shin, JW; Suh, DJ | 1 |
| Alatrakchi, N; Koziel, MJ | 1 |
| Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Tanaka, E; Tanaka, K | 2 |
| Maier, KP | 2 |
| Terrault, NA; Vyas, G | 1 |
| Keeffe, EB; Yu, AS | 1 |
| Wang, H | 1 |
| Bang, SJ; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW | 3 |
| Lagget, M; Rizzetto, M | 2 |
| De Ridder, RJ; Stronkhorst, A | 1 |
| Guo, XH; Jin, RH; Lang, ZW; Yao, GB | 1 |
| Liu, Z | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Sato, J; Someya, T; Suzuki, F; Suzuki, Y; Takagi, K; Tsubota, A | 1 |
| Arnold, E; Das, K; Delaney, WE; Gibbs, CS; Miller, MD; Westland, CE; Xiong, S; Yang, H | 1 |
| Elefsiniotis, IS; Kafiri, G; Ketikoglou, I; Mavrogiannis, C; Moulakakis, A; Pantazis, KD | 1 |
| De Marino, FA; Di Giacomo Russo, G; Palmentieri, B; Persico, E; Persico, M; Torella, R | 1 |
| Chen, F; Chen, Z; Liang, WF; Liu, KZ; Pan, XP; Wo, JE | 1 |
| He, DM; Mao, Q; Wang, YM | 1 |
| Chien, RN; Chu, CM; Liaw, YF; Tsai, SL; Yeh, CT | 2 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Li, B; Li, XD; Lin, QY; Liu, C; Liu, J; Lu, SC; Ma, YK; Qing, S; Wang, XB; Wen, TF; Yan, LN; Zhang, XH; Zhao, JC; Zhao, LS | 1 |
| Liang, WF; Xie, YJ; Yang, DH; Zhao, NF | 2 |
| Alavian, SM; Einollahi, B; Hajarizadeh, B | 1 |
| Chung, M; Hagmann, S; Jani, M; Neumann, AU; Pollack, H; Rochford, G; Sitnitskaya, Y; Trinh-Shevrin, C | 1 |
| Andriulli, A; Facciorusso, D; Fontana, R; Gioffreda, D; Guastadisegni, A; Insalata, M; Niro, GA; Palmieri, O; Pastore, G; Perri, F; Santantonio, T; Signorile, F | 1 |
| Hou, KY; Li, L; Li, T; Song, SB; Xiu, DR; Yuan, J; Zhang, TL; Zhu, JP; Zhuang, H | 1 |
| Chung, YH; Kim, H; Lee, HC; Lee, YS; Lim, YS; Ryu, SH; Shin, JW; Suh, DJ | 1 |
| Bang, SJ; Joo, KR; Kim, DH; Kim, DY; Park, JH; Park, NH; Shin, JW | 1 |
| Chen, HY; Song, PH; Tian, DY; Xu, D; Zhang, ZG | 1 |
| Chang, AL; Chang, SC; Chen, DS; Chen, MY; Chen, PJ; Fang, CT; Hung, CC | 1 |
| Asahina, Y; Hamano, K; Inoue, K; Itakura, J; Izumi, N; Miyake, S; Nishimura, Y; Noguchi, O; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Brosgart, CL; Durantel, D; Durantel, S; Gibbs, CS; Parvaz, P; Trépo, C; Villeneuve, JP; Werle, B; Westland, C; Xiong, S; Zoulim, F | 1 |
| Balistreri, WF; Hochman, JA | 1 |
| Brosgart, CL; Choy, GS; Colombo, M; Fry, J; Hadziyannis, S; James, C; Lai, CL; Lama, N; Lilly, L; Namini, H; Neuhaus, P; Rendina, M; Samuel, D; Schiff, ER; Terrault, N; Tillmann, HL; Van Doren, S; Villeneuve, JP; Westland, C; Wulfsohn, MS; Xiong, S; Zeuzem, S | 1 |
| Aloman, C; Wands, JR | 1 |
| Aguilera-Guirao, A; Castroagudín, J; Garcia-Riestra, C; Gómez-Tato, A; González-Quintela, A; Regueiro, BJ; Rodríguez-Nóvoa, S | 1 |
| Chan, FK; Chan, HL; Chim, AM; Hui, AY; Hung, LC; Sung, JJ; Tse, AM; Wong, ML | 1 |
| Chan, HL; Leung, WK; Song, W | 1 |
| Avgerinos, A; Economou, M; Elefsiniotis, J; Iliadou, E; Karatapanis, S; Kougioumtzan, A; Manolakopoulos, S; Mathou, N; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J | 1 |
| Suzuki, F | 1 |
| Arinaga, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Tanaka, K | 1 |
| Chayama, K; Ohishi, W | 1 |
| Iino, S; Yasuda, K; Yotsuyanagi, H | 1 |
| Lai, CL; Tanaka, Y; Yuen, MF | 1 |
| Kumada, H | 3 |
| Itoh, Y; Kirishima, T; Kunimoto, K; Minami, M; Mori, K; Okanoue, T; Yasui, K | 1 |
| Dixon, JS; Humphries, JC | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| de Man, RA; Hop, WC; Janssen, HL; Kusters, JG; Kwekkeboom, J; Schalm, SW; Tang, TJ; van der Molen, RG | 1 |
| Cha, JM; Cho, M; Cho, YK; Heo, J; Kim, HP; Kim, KH; Na, IH; Park, SY; Song, CS | 1 |
| Hu, SY; Tan, XY | 1 |
| Wang, YZ; Wu, GX; Zha, YS; Zheng, J; Zhou, GP | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Bourne, E; Brosgart, CL; Gardner, S; Hann, HW; Lee, WM; Leung, N; Moorat, A; Mutimer, D; Perrillo, R; Schiff, E; Willems, B; Woessner, M | 1 |
| Bourliere, M; Brosgart, CL; Buggisch, P; Ebrahimi, R; Gray Df, Df; Hann Hw, Hw; Heathcote, EJ; Kleber, K; Kowdley, K; Martin, P; Peters, MG; Rubin, R; Sullivan, M; Trepo, C; Xiong, S | 1 |
| Bowden, S; Locarnini, S; Shaw, T | 1 |
| Schalm, SW | 2 |
| Lagget, M; Marzano, A; Rizzetto, M | 1 |
| Benhamou, Y; Poynard, T | 1 |
| Bortolotti, F | 1 |
| Castiglia, M; Cui, ZY; Dienstag, JL; Gardner, SD; Griffiths, DA; Heathcote, EJ; Lai, CL; Leung, N; Little, NR; Lok, AS; Schiff, ER; Yao, GB | 1 |
| Dhawan, A; Hinds, R | 1 |
| Arslan, N; Aydogdu, S; Bosnak, M; Buyukgebiz, B; Dikici, B; Doganci, T; Girgin, N; Haspolat, K; Kalayci, AG; Kansu, A; Kasirga, E; Ozgenc, F; Ozkan, T; Selimoglu, A; Targan, S; Tosun, S; Yagci, RV | 1 |
| Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Suzuki, Y; Yokosuka, O; Yoshida, S | 1 |
| Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M | 1 |
| Chiu, MC; Lai, WM; Lau, SC; Tse, KC | 1 |
| Gentilcore, E; Marzano, A; Rizzetto, M; Smedile, A | 1 |
| Selimoğlu, MA; Yağci, RV | 1 |
| Amuca, H; Cakir, B; Dökmeci, G; Karahan, N; Soylu, AR; Tezel, A; Umit, H | 1 |
| Feucht, HH; Fischer, L; Kletzmayr, J; Laufs, R; Petersen, J; Puchhammer-Stöckl, E; Schröter, M; Sterneck, M; Zöllner, B | 1 |
| Ciancio, A; Gerin, J; Korba, B; Lagget, M; Rizzetto, M; Smedile, A | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Gerken, G; Lama, N; Lampertico, P; Malagó, M; Treichel, U; Trippler, M | 1 |
| Hino, T; Hirashima, N; Ide, T; Ito, H; Ito, K; Kato, A; Kumashiro, R; Mizokami, M; Mukaide, M; Nukaya, H; Orito, E; Sakakibara, K; Sata, M; Tanaka, Y; Ueda, R | 1 |
| Dietzel, T; Eucker, J; Fleissner, C; Heider, U; Jakob, C; Ockenga, J; Possinger, K; Sezer, O; Zavrski, I | 1 |
| Cheng, NS; Lei, BJ; Li, B; Li, XD; Liu, C; Liu, J; Lu, SC; Qin, S; Wang, XB; Wen, TF; Yan, LN; Zhang, XH; Zhao, JC; Zhao, LS | 1 |
| Durlik, M; Lao, M; Lewandowska, D; Lewandowski, Z; Pazik, J | 1 |
| Chayama, K; Kamiyasu, M; Kawakami, Y; Kimura, S; Nakanishi, T; Ohishi, W; Shirakawa, H; Tazuma, S | 1 |
| Chan, HL; Leung, NW; Tam, JS; Wong, ML; Wong, VW | 1 |
| Echevarría, JM; León, P; Pozo, F | 1 |
| Lavanchy, D | 1 |
| Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J | 1 |
| Deschênes, M; Laneuville, P | 1 |
| Cicioglu Aridogan, B; Demirci, M; Isler, M; Korkmaz, M; Senol, A | 1 |
| Ganem, D; Prince, AM | 1 |
| Chung, RT; Dienstag, JL; Kuo, A | 1 |
| Fang, SH; Pan, KH; Su, GG; Yang, DH; Zhao, NF; Zhou, Y | 1 |
| Akman, S; Aydogdu, S; Dikici, B; Doganci, T; Ozgenc, F; Targan, S; Yagci, RV | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Sato, J; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Akarca, US; Batur, Y; Ersöz, G; Günşar, F; Karasu, Z | 1 |
| Han, QY; Kang, W; Liu, ZW; Zhang, N | 1 |
| Hamada, K; Muramatsu, A; Nishioji, K; Oda, Y; Okuno, T; Shindo, M | 1 |
| Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H | 1 |
| Thio, CL | 2 |
| Ala, A; Dieterich, DT | 1 |
| Berr, F; Etzrodt, G; Klecker, C; Liebert, UG; Maier, M; Oesen, U; Schiefke, I; Tannapfel, A | 1 |
| Chung, HJ; Han, JH; Hong, SP; Hwang, SG; Kang, MS; Kim, HT; Kim, NK; Kim, S; Kim, SO; Rim, KS; Yoo, W | 1 |
| Concetta Cascioni, M; Di Stefano, R; Giannuoli, G; Madonia, S; Malizia, G; Tinè, F | 1 |
| Arima, J; Horiuchi, T; Imafuku, S; Kohno, H; Sawabe, T; Uenotsuchi, T | 1 |
| Cho, YS; Lee, CK; Park, IS; Suh, JH; Won, SY | 1 |
| Kang, KH; Kweon, YO | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lai, MY; Liao, LY; Lin, CL; Wang, CS | 1 |
| Abdurakhmanov, DT; Ibragimova, MM; Krel', PE | 1 |
| Bozdayi, M; Degertekin, H; Yalcin, K | 1 |
| Chao, TY; Dai, MS; Kao, WY; Shyu, RY | 1 |
| Husa, P | 3 |
| Gardner, SD; Hom, X; Jonas, MM; Little, NR | 1 |
| Demir, H; Koçak, N; Saltik-Temizel, IN | 2 |
| Elefsiniotis, IS; Glynou, I; Kada, H; Mavrogiannis, C; Pantazis, KD; Scarmeas, N | 1 |
| Lai, CL | 2 |
| Lacey, L | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Kagawa, T; Kanai, T; Kanouda, H; Kawazoe, K; Kumaki, N; Matsuzaki, S; Mine, T; Shiba, T; Shimamura, K; Takashimizu, S; Takayama, I; Watanabe, N | 1 |
| Kanemasa, K; Maekawa, K; Minami, M; Mori, K; Okanoue, T; Sumida, Y; Tachibana, S | 1 |
| Del Poggio, P; Jamoletti, C; Zaccanelli, M | 1 |
| Lai, KH; Lo, GH | 1 |
| Perrillo, RP | 3 |
| Tong, MJ; Tu, SS | 1 |
| Wright, TL | 1 |
| Samuel, D | 2 |
| Cooksley, WG | 2 |
| Lok, AS | 5 |
| Chatur, N; Davis, JE; Owen, DA; Ramji, A; Yoshida, EM | 1 |
| Han, BH; Lee, SU; Lim, HJ; Park, CB; Yun, BC | 1 |
| Chan, HL; Chan, JY; Cheng, AS; Go, MY; Leung, WK; Liew, CT; Sung, JJ; To, KF | 1 |
| Dai, J; Gui, M; Lai, W; Li, B; Lin, QY; Liu, J; Lu, SC; Wang, WY; Wen, TF; Yan, LN; Zhang, XH; Zhao, J | 1 |
| Guan, XQ; Xiao, YH; Yang, C; Yuan, Z | 1 |
| Deng, H; Fu, J; Lv, Y | 1 |
| Zhang, TL | 1 |
| Ashur, Y; Ben-Ari, Z; Brown, M; Daudi, N; Klein, A; Mor, E; Shmilovitz-Wiess, H; Shouval, D; Sulkes, J; Tur-Kaspa, R | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Jelev, D; Krastev, Z | 1 |
| Ahmet, D; Atilla, O; Cetin, K; Fatih, B; Güngör, B; Kadir, D; Mürüvvet, B; Sabahattin, K; Selim, B; Yilmaz, C; Zeynel, M; Ziyaettin, D | 1 |
| Akarca, US; Batur, Y; Ersoz, G; Gunsar, F; Karasu, Z; Saritas, E; Yuce, G | 1 |
| Bozkaya, H | 1 |
| Cui, ZY; Lu, WL; Wu, L; Xie, DY; Yao, GB; Yao, JL; Zhang, DF | 1 |
| Abate, ML; Barbon, V; Fadda, M; Gaia, S; Lagget, M; Marzano, A; Niro, G; Olivero, A; Paganin, S; Rizzetto, M; Smedile, A | 1 |
| Chang, J; Earnest-Silveira, L; Gouskos, T; Lewin, SR; Sasadeusz, J; Torresi, J; Wightman, F | 1 |
| Carotenuto, P; De Man, RA; Niesters, HG; Osterhaus, AD; Pontesilli, O; Uytdehaag, FG; van Nunen, AB; van Riel, D | 1 |
| Badsi, E; Bendenoun, M; Bergmann, JF; Caulin, C; Cazals-Hatem, D; Cervoni, J; Clevenbergh, P; Diemer, M; Evans, J; Mazeron, MC; Sellier, P; Vincent, V | 1 |
| Al-Kadasi, H; Flisiak, I; Flisiak, R; Jaroszewicz, J; Prokopowicz, D | 1 |
| Badur, S; Bozaci, M; Cakaloglu, Y; Cevikbas, U; Danalioglu, A; Demir, K; Durakoglu, Z; Karaca, C; Kaymakoglu, S; Okten, A | 1 |
| Chen, XS; Ding, GS; Fu, H; Fu, ZR; Guo, WY; Shi, XM; Wang, ZX; Zhang, JJ | 1 |
| Lau, DT; Membreno, FE | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Lai, CJ; Terrault, NA | 1 |
| Wu, SP; Zhou, JL | 1 |
| He, DM; Mao, Q | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Miyakawa, Y; Saitoh, S; Satoh, J; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Trautwein, C | 3 |
| Changchien, CS; Chen, CH; Chen, WJ; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Barbon, V; Gaia, S; Lagget, M; Marzano, A; Rizzetto, M | 1 |
| Hirashima, N; Ide, T; Ito, K; Mizokami, M; Orito, E; Sata, M; Tanaka, Y; Yeo, AE | 1 |
| Yokosuka, O | 1 |
| Arabe, J; Gomes, SA; Santos, EA; Sucupira, MV | 1 |
| Chen, T; Chen, WH | 1 |
| Ding, JJ; Zhang, LS; Zhang, WS | 1 |
| Fan, HM; Lei, CL; Peng, XM; Tang, XP; Yang, Z; Yuan, XZ | 1 |
| Cheng, YQ; Fu, JL; Lan, Y; Li, HW; Lou, M; Zhao, P | 1 |
| Liu, QJ; Liu, W; Liu, XJ; Zhang, HR; Zhang, L; Zhao, W; Zhou, ZX | 1 |
| Guo, YB; Hao, W; Jin, HY; Li, Z; Lin, ZH; Liu, DG | 1 |
| Fung, SK; Hussain, M; Lok, AS; Wong, F | 1 |
| Corey, L; Engelberg, R; Ferrenberg, J; Holte, S; Huang, ML; Sacks, SL; Shuhart, M; Wang, CC | 1 |
| Nishiguchi, S; Tamori, A | 1 |
| Komorizono, Y; Mawatari, S; Sako, K; Uchida, Y; Uomizu, K; Yamaguchi, H | 1 |
| Asabe, S; Kobayashi, K; Kobayashi, T; Kondo, Y; Niitsuma, H; Shiina, M; Shimosegawa, T; Ueno, Y | 1 |
| Bonino, F; Button, P; Diago, M; Farci, P; Germanidis, G; Gurel, S; Hadziyannis, S; Jin, R; Lai, MY; Lau, GK; Lu, ZM; Marcellin, P; Piratvisuth, T; Pluck, N; Yurdaydin, C | 1 |
| Carreño, N; Moreno, D; Sangro, B | 1 |
| Almasio, PL; Andreone, P; Craxì, A; Di Marco, V; Lampertico, P; Marzano, A; Rizzetto, M; Santantonio, T | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Goto, T; Kato, N; Omata, M | 1 |
| Furusyo, N; Hayashi, J; Nakamuta, M; Shimada, M | 1 |
| Inoue, O; Mawatari, H; Nakagawa, Y | 1 |
| Fujisawa, T; Inui, A; Komatsu, H; Sogo, T | 1 |
| Gunji, T; Omata, M | 1 |
| Daikoku, M; Koga, M | 1 |
| Kawata, S; Saito, T; Togashi, H; Watanabe, H | 1 |
| Ishikawa, T; Kakumu, S | 2 |
| de Gottardi, A; Negro, F | 1 |
| Chow, WC; Dixon, JS; Farrell, G; Gray, DF; Keene, ON; Lee, CZ; Liaw, YF; Sabbat, J; Shue, K; Sung, JJ; Tanwandee, T; Tao, QM; Yuen, H | 1 |
| Wands, JR | 1 |
| Lai, CL; Sum, SM; Wong, DK; Yuan, HJ; Yuen, MF | 1 |
| Fung, SK; Lok, AS | 1 |
| Broderick, A; Jonas, MM | 1 |
| Hadziyannis, SJ; Papatheodoridis, GV | 3 |
| Karayiannis, P | 1 |
| Chang, TT; Chien, RN; Dent, JC; Guan, R; Lai, CL; Lee, CM; Leung, NW; Lim, SG; Ng, KY; Nicholls, GJ | 1 |
| Duffaut, M; Durand, D; Izopet, J; Kamar, N; Ribes, D; Rostaing, L; Sandres-Saune, K; Selves, J | 1 |
| Zhou, YH; Zhuang, H | 1 |
| Lai, CL; Yuen, MF | 5 |
| Jain, M; Malhotra, V; Sandhu, BS; Sarin, SK; Sharma, BC; Singh, J | 1 |
| Zhang, DF | 1 |
| Du, YZ; Li, XY; Wang, JB; Wang, L; Wang, YZ; Yan, J; Zhang, ZH | 1 |
| Lin, JG; Lin, JS; Song, JW; Tang, WX; Zhang, G | 1 |
| Chen, L; Lin, GL; Xiao, JS; Yang, SJ; Zhang, XH; Zhu, JY | 1 |
| Jia, JD; Wang, YC | 1 |
| Hou, JL; Yu, YC | 1 |
| Jia, J; Lin, F | 1 |
| Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG | 1 |
| Fehér, J; Lengyel, G | 1 |
| Kaczmarski, M; Lebensztejn, DM; Skiba, E; Sobaniec-Lotowska, M | 1 |
| Chen, DS; Chen, PJ; Huang, WL; Kao, JH; Lai, MY; Liu, CJ | 1 |
| Chyczewski, L; Kowalczuk, O; Lapinski, TW; Prokopowicz, D | 1 |
| Arikan, C; Aydogdu, S; Nart, D; Ozgenç, F; Sertoz, RY; Yagci, RV | 1 |
| Claro, R; Corpas, R; Jarana, R; Martín-Mazuelos, E; Nogales, MC; Pérez, L; Romero-Gómez, M; Serrano, MC; Suárez, E | 1 |
| Chan, HL; Chui, AK; Hui, AY; Lau, WY; Rao, AR; Wong, J | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Telegdy, L | 1 |
| D'Onofrio, M; Marrone, A; Ricciotti, R; Ruggiero, G; Utili, R; Zampino, R | 1 |
| Boucher, CA; Haverkamp, MH; Hoepelman, IM; Smit, MC; Weersink, AJ | 1 |
| Ferenci, P | 1 |
| Bertoletti, A; Dusheiko, G | 1 |
| Chien, RN; Lee, TH; Liao, SK; Liaw, YF; Lin, CL; Tsai, SL | 1 |
| Kerkar, N; Shneider, BL | 1 |
| Enomoto, M; Habu, D; Kawada, N; Kohmoto, M; Nishiguchi, S; Sakaguchi, H; Seki, S; Shiomi, S; Takeda, T; Tamori, A | 1 |
| Bain, V; Cooper, C; Lowe, C; Martin, S; Myers, RP; Sherman, M; Villeneuve, JP | 1 |
| Chien, RN; Hsieh, SY; Kuo, MC; Liaw, YF; Shih, LY; Wang, PN; Yeh, CT | 1 |
| Chan, PK; Ho, WM; Hui, P; Johnson, PJ; Lam, KC; Lee, JJ; Yeo, W | 1 |
| Choi, MH; Chung, YH; Jang, MK; Kim, IS; Kim, JA; Lee, HC; Lee, YS; Park, NH; Ryu, SH; Shin, JW; Suh, DJ | 2 |
| Durlik, M; Lewandowska, D | 1 |
| Benhamou, Y; Bernard-Chabert, B; Bitker, MO; Di Martino, V; Le Calvez, S; Mouquet, C; Opolon, P; Poynard, T; Thabut, D; Thibault, V | 1 |
| Chen, LY; Jiang, XL; Li, B; Li, LX; Liu, SY; Peng, JF; Wang, M; Wang, ZQ; Zhou, BP | 1 |
| Jia, JD; Zhuang, H | 1 |
| Assy, NN; Hussein, O | 1 |
| Bahar, A; Karademir, F | 1 |
| Grzeszczuk, A; Prokopowicz, D | 1 |
| Flisiak, R; Jaroszewicz, J; Kowalczuk, O; Lapinski, TW; Michalewicz, M | 1 |
| Chen, J; Fan, GR; Fu, XX; Luo, XL; Su, S; Tian, GS; Wang, Y; Wang, YY; Wei, L | 1 |
| Hou, J; Luo, K; Ma, S; Sun, J; Wang, Z; Zeng, G; Zhou, Z | 1 |
| Cheema, FH; Chen, JM; Edwards, NM; Hammond, K; Mancini, D; Pinney, SP | 1 |
| Abe, M; Fazle Akbar, SM; Hiasa, Y; Horiike, N; Joukou, K; Kojima, N; Michitaka, K; Onji, M; Yamamoto, K | 1 |
| de Man, RA; Niesters, HG; Noppornpanth, S; Pas, SD; van der Eijk, AA | 1 |
| Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Lama, N; Miller, MD; Schiff, ER; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H | 1 |
| Bartel, J; Küppers, B; Otto, G; Otto, HF | 1 |
| Dienstag, JL | 1 |
| Esteban, R; Gardner, SD; Goldin, RD; Heathcote, EJ; Lagget, M; Rizzetto, M; Santantonio, T; Taak, NK; Tassopoulos, NC; Woessner, MA | 1 |
| Chevallier, M; Chevallier, P; Durantel, S; Lot, M; Maynard, M; Parvaz, P; Trepo, C; Zoulim, F | 1 |
| Wei, L | 1 |
| Artsen, A; Bruijns, S; Carotenuto, P; De Man, RA; Laman, JD; Osterhaus, AD; Pontesilli, O; Uytdehaag, FG; van Nunen, AB; van Riel, D; Zondervan, PE | 1 |
| He, YZ; Huang, MJ; Huang, QW; Huang, ZM; Qin, HJ; Qin, YQ; Xu, X; Zhou, YN | 1 |
| Ahmed, N; Alam, K; Debnath, CR; Khan, M; Rahman, S; Sarker, CB; Sutradhar, SR | 1 |
| Chan, FK; Chan, HL; Chim, AM; Hui, AY; Hung, LC; Lam, CW; Lee, YT; Leung, NW; Liew, CT; Sung, JJ; Tam, JS; Wong, VW | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y | 1 |
| Trunecka, P | 1 |
| Kuman, M; Mejzlík, V; Ondrásek, J; Pavlík, P; Studeník, P | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Asaka, M; Chuma, M; Hige, S; Nakanishi, M; Natsuizaka, M; Ogawa, K; Ono, Y; Yoshida, S | 1 |
| Durante-Mangoni, E; Grimaldi, M; Mangoni, ED; Marrone, A; Portella, G; Ruggiero, G; Santarpia, L; Utili, R; Zampino, R | 1 |
| Alam, AY; Gill, ML; Khokhar, N | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Davis, R; Hann, HW; Jonsson Funk, ML; Rosenberg, DM | 1 |
| Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zezos, P | 1 |
| Dzwonek, A; Kupś, J; Wiśniewska-Ligier, M; Woźniakowska-Gesicka, T | 1 |
| Alvarez Delgado, A; Carneros Martín, JA; de la Coba Ortiz, D; Fradejas Salazar, P; González San Martín, F; Martínez Núñez, E; Rodrigo Rodriguez, M; Sánchez Martín, F | 1 |
| Ahn, CS; Ha, TY; Hwang, S; Kim, KH; Kim, KK; Lee, SG; Moon, DB | 1 |
| Choi, JY | 1 |
| Dourakis, SP; Elefsiniotis, IS; Katsambas, N; Mpotsi, C; Pantazis, KD; Paparizos, V | 1 |
| Elefsiniotis, IS; Glynou, I; Kada, H; Ketikoglou, I; Moulakakis, A; Pantazis, KD; Tsianos, E; Vezali, E | 1 |
| Chow, DH; Lai, CL; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Dybowska, D; Pilarczyk, M | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Sato, J; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y | 1 |
| Chen, Z | 1 |
| Carenzi, S; Colombo, M; Franchello, A; Lampertico, P; Marzano, A; Mazzaferro, V; Pulvirenti, A; Rizzetto, M; Romito, R; Salizzoni, M; Vigano, M | 1 |
| Chan, AO; Lai, CL; Sum, SS; Wong, BC; Wong, DK; Yuan, HJ; Yuen, JC; Yuen, MF | 1 |
| Bozdayi, AM; Bozkaya, H; Cetinkaya, H; Erden, E; Erkan, O; Heper, AO; Karaoğuz, D; Sahin, T; Törüner, M; Uzunalimoğlu, O; Yurdaydin, C | 1 |
| Li, SG; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ | 1 |
| Asselah, T; Marcellin, P; Ripault, MP | 1 |
| Bozdayi, AM; Bozkaya, H; Cetinkaya, H; Cinar, K; Erden, E; Erkan, O; Idilman, R; Tüzün, A; Uzun, Y; Uzunalimoglu, O; Yurdaydin, C | 1 |
| Balaska, A; Eugenidis, N; Giouleme, O; Grammatikos, N; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Tziomalos, K; Vassiliadis, T | 1 |
| Ertekin, V; Orbak, Z; Selimoğlu, MA | 1 |
| Chan, HL; Chim, AM; Hui, AY; Sung, JJ; Wong, ML; Wong, VW | 1 |
| Han, SH | 1 |
| Au, WY; Cheung, WW; Chim, CS; Hui, CK; Kwong, YL; Lau, GK; Leung, YH; Liang, R; Lie, A; Ma, SY; Sun, J; Zhang, HY | 1 |
| Binda, RS; de Man, RA; Janssen, HL; Kusters, JG; Kwekkeboom, J; Mancham, S; Schalm, SW; Tang, TJ | 1 |
| Chang, ML; Chien, RN; Liaw, YF; Yeh, CT | 1 |
| Dulai, GS; Farid, M; Gralnek, IM; Kanwal, F; Martin, P; Spiegel, BM | 1 |
| von Weizsäcker, F | 1 |
| Ahn, SH; Chang, HY; Chung, HJ; Han, KH; Hong, SP; Kim, EO; Kim, HS; Kim, SO; Moon, MS; Yoo, W | 1 |
| Chen, JX; Chen, Y; Li, CZ; Liang, XS; Song, Y; Wan, MB | 1 |
| Artan, R | 1 |
| de Man, RA; Flink, HJ; Hansen, BE; Janssen, HL; Schalm, SW; Sprengers, D; van Zonneveld, M | 1 |
| Buti, M; Esteban, R; Guardia, J; Jardi, R; Rodriguez-Frias, F; Schaper, M; Valdes, A | 1 |
| Chan, KC; Lee, SS; Wong, KH | 1 |
| Dong, QM; He, ZP; Song, C; Song, SJ; Wei, HS; Xiao, YP; Yan, J; Zhuang, H | 1 |
| Bowden, S; Chan, HL; Hui, AY; Leung, NW; Liew, CT; Locarnini, S; Sung, JJ; Wong, ML; Wong, VW | 1 |
| Fukai, K; Imazeki, F; Kanda, T; Kawai, S; Kurihara, T; Saisho, H; Yokosuka, O | 1 |
| Choi, MS; Koh, KC; Lee, D; Lee, JH; Lee, SY; Paik, SW; Yoo, BC | 1 |
| Chrysagis, D; Haida, C; Hatzakis, A; Mimidis, K; Moulakakis, A; Raptopoulou, M; Sypsa, VA; Tassopoulos, NC; Vassiliadis, T | 1 |
| Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D | 1 |
| Faust, D; Gärtner, BC; Herrmann, E; Hofmann, WP; Mihm, U; Sarrazin, C; Zeuzem, S | 1 |
| Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM | 1 |
| Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO | 1 |
| Chen, Y; Du, SC; Han, JD; Tian, Y; Wei, L; Zhang, R | 1 |
| Bian, Z; Hong, Q; Shen, WS; Xie, HP; Yang, HZ; Zhang, YQ | 1 |
| Beker, T; Bozdayi, AM; Grier, J; Pai, RB; Pai, SB; Sarioglu, M; Schinazi, RF; Turkyilmaz, AR; Yurdaydin, C | 1 |
| Mizokami, M; Orito, E | 1 |
| de Man, RA; Hansen, BE; Janssen, HL; Niesters, HG; Schalm, SW; van de Ende, M; van der Eijk, AA | 1 |
| Bang, SJ; Jeong, ID; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW | 1 |
| Giles, E; Heathcote, EJ; Moskovitz, DN; Osiowy, C; Tomlinson, G | 1 |
| Changchien, CS; Lee, CM; Lu, SN; Tseng, PL; Tung, HD; Wang, JH | 1 |
| Berg, T; Chang, WY; Chow, WC; Cooksley, G; Flisiak, R; Fried, MW; Gane, E; Lau, GK; Luo, KX; Marcellin, P; McCloud, P; Paik, SW; Piratvisuth, T; Pluck, N; Thongsawat, S | 1 |
| Chan, SC; Cheung, CK; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Wong, J; Yuen, MF | 1 |
| Kaczmarski, M; Lebensztejn, DM; Skiba, E; Werpachowska, I | 1 |
| Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Tanaka, K | 1 |
| Bae, SH; Choi, JY; Choi, SW; Chung, KW; Jang, JW; Kim, BS; Kim, CW; Lee, CD; Lee, YS; Sun, HS; Yoon, SK | 1 |
| Asahina, Y; Enomoto, N; Izumi, N; Kitamura, T; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Aguennouz, M; Fodale, V; Mazzeo, A; Praticò, C; Santamaria, LB; Toscano, A; Vita, G | 1 |
| Hou, JL; Sun, J | 1 |
| Dan, YY; Lee, YM; Lim, SG; Seet, BL; Sutedja, DS; Wai, CT | 1 |
| Xu, B; Yao, GB; Zhu, M | 1 |
| Ren, H | 1 |
| Wang, GQ | 1 |
| Blake, MA; Blaszkowsky, LS; Chung, RT; Lauwers, GY; Tanabe, KK | 1 |
| Bosnak, M; Dikici, B; Ece, A | 1 |
| Brown, NA; Chao, G; Han, S; Hann, HW; Lai, CL; Leung, N; Lloyd, D; Myers, M; Poynard, T; Teo, EK; Tong, M; Wong, F | 1 |
| Chang, MH; Chen, HL; Chen, PJ; Hsu, HY; Huang, FC; Jeng, YM; Kong, MS; Ni, YH; Tsuei, DJ; Wu, TC | 1 |
| Ertekin, V; Selimoglu, MA | 1 |
| Liu, KH; Qin, LY; Wang, YZ; Zhang, ZH | 1 |
| Merican, I; Shahidah, KN | 1 |
| Guan, R | 1 |
| Gane, E | 1 |
| Chen, JY; Gong, ZJ; Sun, XM; Wang, LW | 1 |
| Celebi, H; Karabay, O; Tahtaci, M; Tamer, A; Vardi, S | 1 |
| Conzelmann, I; Gerner, P; Radke, R; Wintermeyer, P; Wirth, S | 1 |
| Jones, DB; Katelaris, PH; Le Couteur, DG; Lin, BP; Ngu, MC; Park, GJ; Seow, F | 1 |
| Janssen, HL; ter Borg, MJ | 1 |
| Borowicz, I; Fota-Markowska, H; Kiciak, S; Modrzewska, R | 1 |
| Delaney, WE; Miller, M; Qi, X; Sabogal, A; Xiong, S; Yang, H | 1 |
| Chan, KW; Ho, YW; Kung, NN; Lai, FM; Lai, KN; Leung, JC; Lui, YH; Tang, CS; Tang, S | 1 |
| Alexander, G; Baba, CS; Chetri, K; Choudhuri, G; Negi, TS | 1 |
| Bosnak, M; Dikici, B; Gur, A; Haspolat, K; Nas, K; Sarac, AJ | 1 |
| Bae, SH; Cha, SB; Choi, JY; Chung, KW; Jang, JW; Kim, CW; Lee, CD; Lee, YS; Nam, SW; Yoon, SK | 1 |
| Cho, HJ; Choi, HY; Hong, SP; Hwang, SG; Kim, JK; Kim, NK; Ko, KH; Park, H; Park, PW; Rim, KS | 1 |
| Shen, ZY | 1 |
| Kaptanoglu, AF; Kutluay, L | 1 |
| Gao, DC; Jia, JD; Liu, J; Sun, MC; Wang, BE; Wang, Y; Wu, GC; Wu, P; Zhang, D; Zhang, ZT | 1 |
| Adinolfi, LE; Cesaro, G; Cirillo, G; del Giudice, EM; Guerrera, B; Karayannis, P; Marrone, A; Ricciotti, R; Ruggiero, G; Utili, R; Zampino, R | 1 |
| Chen, G; He, X; Huang, J; Zhu, X | 1 |
| Chen, LY; Geng, YY; Huang, J; Liu, HJ; Qiao, P; Qiu, JM; Wang, SQ; Yang, NM; Zhang, W; Zhang, XP | 1 |
| Su, GG; Ying, MF; Zhao, NF; Zhou, Y | 1 |
| Aroldi, A; Colombo, M; Lampertico, P; Lunghi, G; Manenti, E; Ponticelli, C; Viganò, M | 1 |
| Attanasio, V; Eriksson, T; Finnström, N; Hedrum, A; Marrone, A; Rosario, P; Ruggiero, G; Törmänen, V; Utili, R; Zampino, R | 1 |
| Rajvanshi, P; Song, K | 1 |
| Orlent, H | 1 |
| Bacon, BR; Chang, TT; Cianciara, J; Colonno, RJ; Gish, RG; Hadziyannis, SJ; Hindes, RG; Joshi, S; Klesczewski, KS; Pastore, G; Poynard, T; Rizzetto, M; Rose, RE; Schiff, ER; Thiry, A | 1 |
| Angarano, G; Fazio, V; Palumbo, E; Saracino, A; Scotto, G; Tartaglia, A | 1 |
| Balaska, A; Doukelis, P; Eugenidis, NP; Giouleme, OI; Grammatikos, N; Nikolaidis, NL; Orfanou-Koumerkeridou, E; Patsiaoura, K; Saveriadis, AS; Tziomalos, KA; Vassiliadis, T; Voutsas, AD | 1 |
| Asselah, T; Marcellin, P | 1 |
| Chokshi, S; Mullerova, I; Naoumov, NV; Rice, S; Rigopoulou, EI; Suri, D; Tedder, RS; Williams, R | 1 |
| Cooksley, G | 1 |
| Karayiannis, P; Thomas, HC | 1 |
| Avgerinos, A; Bethanis, S; Economou, M; Filis, S; Manolakopoulos, S; Raptis, S; Trikalinos, TA; Tsianos, EV; Tzourmakliotis, D | 1 |
| Benhamou, Y; Biao, L; Brosgart, C; Calvez, V; Chang, CG; Currie, G; Fievet, MH; Marcelin, AG; Poynard, T; Thibault, V; Vig, P; Xiong, S | 1 |
| Guptan, RC; Kazim, SN; Kumar, M; Kumar, R; Sakhuja, P; Sarin, SK; Sharma, BC | 1 |
| Chen, HS; Chen, XH; Han, YX; Jiang, JD; Li, JN; Li, YH; Wang, YL; Wu, YW; Xue, R; You, XF; Zhao, LX; Zhao, W; Zhou, ZX | 1 |
| Jacobson, I; Weitzman, G | 1 |
| Hasan, M; Miah, AR; Mohammed, S; Rahman, M; Roy, PK; Saha, SK; Sharma, YR | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JC; Wang, JH | 2 |
| Al Amoudi, S; Al-Mashhadani, S; Aleem, A; Siddiqui, N | 1 |
| Rivkin, A | 1 |
| Cirillo, G; Costagliola, L; Karayiannis, P; Marrone, A; Ragone, E; Ruggiero, G; Utili, R; Zampino, R | 1 |
| Akarca, US; Erensoy, S; Niesters, HG; Ozacar, T; Ozgenc, F; Pas, S; Sertoz, RY; Yamazhan, T | 1 |
| Bak, YT; Byun, KS; Chang, YJ; Kim, JH; Kim, JS; Kim, JY; Kwon, OS; Lee, CH; Park, JJ; Yeon, JE; Yim, HJ | 1 |
| Chae, HB; Conjeevaram, H; Fontana, RJ; Fung, SK; Hussain, M; Lok, AS; Marrero, J; Oberhelman, K | 1 |
| Kowdley, KV; Lim, LY | 1 |
| Carpintero Briones, P; Domper Bardají, F; Hernández Albújar, A; Mañas García, MD; Piqueras Alcol, B | 1 |
| Hou, W; Liu, KZ; Ni, Q; Zumbika, E | 1 |
| Castéra, L; Dhumeaux, D; Hézode, C; Nordmann, P; Pallier, C; Pawlotsky, JM; Soulier, A | 1 |
| Morović, M | 1 |
| Qiu, HX; Tu, YY | 1 |
| Brown, RS; Brundage, R; Dickson, RC; Fried, M; Horwith, G; Ishitani, M; Jensen, D; Lok, A; Luketic, V; Reddy, KR; Sheiner, P; Soldevila-Pico, C; Terrault, NA | 1 |
| Baliellas, C; Cañas, C; Casanovas, A; Casanovas, T; Chahri, N; Figueras, J; Gil-Vernet, S; Gornals, JB; Sabidó, M; Serrano, T; Verdura, B | 1 |
| Chen, JJ; Kuo, HT; Lin, CY; Sheu, MJ; Sun, CS; Tang, LY; Tsai, SL; Wang, SL | 1 |
| Hadziyannis, SJ; Manesis, EK; Papatheodoridis, GV | 1 |
| Luo, SQ; Tang, ZR; Wang, FS; Wang, M; Xu, DP; Zhang, LX; Zhu, CL | 1 |
| Cui, SN; Wang, MM | 1 |
| Guan, S; Huang, YX; Lu, M; Roggendorf, M; Wang, XY; Xu, Y; Yin, YK; Zhang, JM | 1 |
| Aguilar, J; Buti, M; Calleja, JL; Casado, MA; Esteban, R; Rueda, M; Salmerón, J | 1 |
| Huang, CH; Huang, QW; Huang, ZM; Lu, CL; Qin, HJ; Qin, YQ; Xu, X; Zhou, YN | 1 |
| Hasnain, SE; Kazim, SN; Khan, LA; Sarin, SK; Sharma, BC | 1 |
| Ikeda, H; Itoh, F; Kimura, K; Koike, J; Kondo, S; Okuse, C; Suzuki, M; Takahashi, H; Yamada, N; Yotsuyanagi, H | 1 |
| Azuma, K; Enjoji, M; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Masumoto, A; Morizono, S; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y | 1 |
| Bae, SH; Chang, UI; Cho, SH; Choi, JY; Han, JY; Jang, JW; Kim, CW; Lee, YS; Yoon, SK | 1 |
| Areias, JA; Badia, IB; Gardener, SD; Jonas, MM; Kelly, DA; Little, NR; Mizerski, J; Schwarz, KB; Sokal, EM; Vegnente, A | 1 |
| Johnson, PJ; Yeo, W | 1 |
| Higuchi, T; Kitazume, K; Kura, Y; Mori, H; Okumura, H; Omine, M; Sawada, U; Shimamoto, K; Takai, K; Tomita, N; Yamanaka, S; Yoshiba, S | 1 |
| Chen, Y; Liang, T; Lu, A; Shen, Y; Wang, W; Zhang, M; Zheng, S | 1 |
| Jacobson, IM | 1 |
| Mateos, ML; Moreira, V; Tato, M | 1 |
| de Man, RA; Flink, HJ; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW | 1 |
| Byun, KS; Chang, YJ; Chung, HJ; Hong, SP; Kim, JH; Kim, SO; Lee, CH; Moon, MS; Seo, YS; Yeon, JE; Yoo, W; Yu, SK | 1 |
| Alberti, A; Buti, M; Cooksley, WG; Fried, MW; Gish, RG; Hadziyannis, SJ; Keeffe, EB; Liaw, YF; Naoumov, NV; Perrillo, RP; Peters, M; Schalm, S; Schiff, ER; Thio, CL; Tsai, N | 1 |
| Chun, S; Zucker, SD | 1 |
| Lai, V; Mirza, D; Mutimer, D; Zhang, WX | 1 |
| Nitschmann, S | 1 |
| Azuma, K; Furusyo, N; Hayashi, J; Kajiwara, E; Maruyama, T; Masumoto, A; Murata, M; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Takeoka, H; Tanabe, Y; Toyoda, K | 1 |
| Atkins, M; Aw, M; D'Antiga, L; Mieli-Vergani, G; Moorat, A; Vergani, D | 1 |
| Asselah, T; Castelnau, C; Marcellin, P | 1 |
| Roche, B; Samuel, D | 1 |
| Bae, SH; Choi, JY; Choi, SW; Chung, KW; Han, JY; Han, NI; Jang, JW; Kim, CW; Sun, HS; Yoon, SK | 1 |
| Andreone, P; Cursaro, C; Fung, S; Hussain, M; Libbrecht, E; Lok, AS; Sablon, E | 1 |
| Chang, TT; Cheinquer, H; Colonno, R; Cross, A; DeHertogh, D; Fernandes, L; Goodman, Z; Lai, CL; Lok, AS; Shouval, D; Wilber, R; Zink, RC | 1 |
| Apelian, D; Chang, TT; Chao, YC; Colonno, R; Cross, A; de Man, R; DeHertogh, D; Gadano, A; Gish, RG; Goodman, Z; Han, KH; Lok, AS; Sollano, J; Wilber, R; Zhu, J | 1 |
| Ambrozaitis, A; Im, SJ; Kharchenko, N; Kim, BM; Kim, CM; Kim, CY; Kim, WB; Kim, YM; Lee, CG; Lee, SH; Park, SH; Son, JM; Song, MK; Sung, YC; Wang, JS; Yang, SH; Yoon, SK; Yun, YD | 1 |
| Han, B; Wang, RS; Yang, ZJ; Zhang, H; Zhu, YF | 1 |
| Chen, ML; Wen, YK | 1 |
| Asselah, T; Boyer, N; Marcellin, P | 1 |
| Avgerinos, A; Bethanis, S; Economou, M; Elefsiniotis, J; Karatapanis, S; Manolakopoulos, S; Sourvinos, G; Spandidos, D; Touloumi, G; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J | 1 |
| Hamada, K; Morikawa, T; Muramatsu, A; Okuno, T; Shindo, M | 1 |
| Angarano, G; Fazio, V; Palumbo, E; Saracino, A; Scotto, G | 1 |
| Krawczuk-Rybak, M; Lebensztejn, DM; Luczyński, W; Muszyńska-Rosłan, K | 1 |
| Awi, D; Kaye, S; McConkey, SJ; Mendy, ME; Rayco-Solon, P; Shipton, D; Snell, P; van der Sande, M; Waight, PA; Whittle, H | 1 |
| Lok, AS; Osborn, MK | 1 |
| Albert, C; Breuil, V; Brocq, O; Euller-Ziegler, L; Roux, CH | 1 |
| Chien, RN; Lee, CM; Liaw, YF; Yeh, CT | 1 |
| Blin, P; Degos, F; Deny, P; El Hasnaoui, A; Landais, P; Mercier, F; Parvaz, P; Poynard, T; Slama, A; Trepo, C; Zoulim, F | 1 |
| Byun, KS; Hong, SP; Kim, EO; Kim, SO; Lee, CH; Moon, MS; Yeon, JE; Yoo, W | 1 |
| Akarca, US; Cakaloglu, Y; de Man, RA; Flink, HJ; Janssen, HL; Schalm, SW; Simon, C; So, TM; van Zonneveld, M; Zondervan, PE | 1 |
| Cui, JJ; Dai, W; Zhou, BP | 1 |
| Akman, SA; Artan, R; Aydoğdu, S; Boşnak, M; Dalgiç, B; Dikici, B; Doğanci, T; Ertekin, V; Girgin, N; Haspolat, K; Kalayci, AG; Kansu, A; Kasirga, E; Kuloğlu, Z; Kuyucu, N; Ozkan, TB; Selimoğlu, A; Tanir, G; Yağci, RV | 1 |
| Funk, A; Gerlich, WH; Hartmann, H; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Wend, UC; Will, H; Willems, WR | 1 |
| Gong, ZJ; Jiang, XL; Mizokami, M; Xu, LM; Yuan, J; Zhou, BP | 1 |
| Duan, XZ; Jin, B; Li, HW; Wang, FS; Wang, HF | 1 |
| Montazeri, G | 1 |
| Bonzel, KE; Gerken, G; Hoyer, PF; Kranz, B; Paul, A; Vester, U | 1 |
| Bako, W; Czerwionka-Szaflarska, M; Góra-Gebka, M; Korzon, M; Liberek, A; Szaflarska-Popławska, A; Łoś-Rycharska, E; Łuczak, G | 1 |
| Eugenidis, N; Giouleme, O; Gkiourtzis, T; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Rizopoulou, D; Tziomalos, K; Vassiliadis, T | 1 |
| Jung, JO; Kim, BG; Kim, YJ; Lee, HS; Yoon, JH | 1 |
| Kakizaki, S; Mori, M; Sato, K; Sohara, N; Takagi, H | 1 |
| Itoh, Y; Kirishima, T; Kunimoto, K; Makiyama, A; Minami, M; Mori, K; Nakajima, T; Nakayama, M; Okanoue, T; Okita, M; Yamaoka, J; Yasui, K | 1 |
| Basir, SF; Jameel, S; Parvez, MK; Sarin, SK; Sehgal, D | 1 |
| Chang, ML; Hsu, CW; Lin, SM; Lin, WP; Sheen, IS; Yeh, CT | 1 |
| Buster, EH; Janssen, HL; Ter Borg, MJ; Vingerling, JR | 1 |
| Chung, YH; Jung, SW; Kim, KM; Kim, SO; Lee, HC; Lee, YS; Lim, YS; Suh, DJ; Yoo, W | 1 |
| Chen, M; Feng, B; Han, FZ; Wang, LP; Wei, L | 1 |
| Feng, B; Wei, L | 1 |
| Hou, JL; Zeng, GB | 1 |
| Halota, W; Pawłowska, M | 1 |
| Nozić, D | 1 |
| Boron-Kaczmarska, A; Cianciara, J; Colonno, R; Cross, A; Denisky, G; Goodman, Z; Hindes, R; Kreter, B; Liaw, YF; Martin, P; Sherman, M; Silva, M; Sollano, J; Yurdaydin, C | 1 |
| Brotman, B; Lee, DH; Murthy, K; Pfahler, W; Prince, AM; Shata, MT; Tricoche, N | 1 |
| Buster, EH; Janssen, HL | 1 |
| Domagała, M; Gładysz, A; Simon, K; Zalewska, M | 1 |
| Zhuang, H | 1 |
| Cho, M; Heo, J; Kang, DH; Kim, GH; Lee, DH; Park, HS; Song, GA | 1 |
| Eun, JR | 1 |
| Du, ZL; Duan, WJ; Wan, XX; Wang, R; Zeng, FL; Zhang, X | 1 |
| Chen, Y; Gong, ZJ; Ke, CZ; Liu, L; Meng, ZJ; Ren, ZJ; Zhou, ZH | 1 |
| Jin, LJ; Lin, QY; Shi, M; Wang, RS; Xu, YP; Yang, ZJ; Zhang, H; Zhu, YF | 1 |
| Chan, HL; Chim, AM; Hui, AY; Sung, JJ; Tse, AM; Wong, VW; Zhang, MD | 1 |
| García-Buey, L; Gisbert, JP; Gómez-Domínguez, E; Moreno-Otero, R | 1 |
| Jonas, MM | 1 |
| Hannoun, C; Lindberg, J; Lindh, M; Malmström, S; Norkrans, G | 1 |
| Hatami, S; Karimi, B; Mohammad Alizadeh, AH; Ranjbar, M | 1 |
| Chen, DS; Chen, PJ; Chen, TC; Kao, JH; Lai, MY; Lin, FY; Liu, CJ | 1 |
| Bertoletti, A; Brown, D; Dusheiko, GM; Gotto, J; Jenkins, J; Webster, GJ | 1 |
| Chang, TT; Lai, CL | 1 |
| Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, SO; Lee, HW; Lee, KS; Moon, YM; Paik, YH; Shin, JE | 1 |
| Chan, HL; Chan, HY; Chan, JL; Hui, AY; Sung, JJ; Tsang, SW; Wong, GL; Wong, VW | 1 |
| Wang, XW; Yang, X; Yi, LX | 1 |
| Chen, JJ; Koay, LB; Kuo, HT; Lee, C; Lin, CY; Sheu, MJ; Sun, CS; Tang, LY; Tsai, SL | 1 |
| Hissar, S; Kumar, M; Sarin, SK; Sharma, BC | 1 |
| Dixit, V; Fabrizi, F; Martin, P | 1 |
| Haché, C; Villeneuve, JP | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Iwasaki, S; Kobayashi, M; Kumada, H; Miyakawa, Y; Sato, J; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Chauhan, R; Das, BC; Kazim, SN; Sarin, SK | 1 |
| Fujioka, S; Iwasaki, Y; Kobashi, H; Matsumura, M; Sakaguchi, K; Shiraha, H; Shiratori, Y; Takaki, A; Tatsukawa, M; Umeoka, F | 1 |
| Müller, C | 1 |
| Ali, JA; Harrigan, PR; Law, JK; Savage, KJ; Sherlock, CH; Yoshida, EM | 1 |
| Akarca, US; de Man, RA; Haagmans, BL; Hansen, BE; Janssen, HL; Schalm, SW; Senturk, H; Simon, C; ter Borg, MJ; van Zonneveld, M; Zeuzem, S | 1 |
| Fukushima, K; Kakazu, E; Kanno, N; Kido, O; Kikuchi, K; Kogure, T; Matsuda, Y; Nagasaki, F; Nakagomi, Y; Niitsuma, H; Shimosegawa, T; Ueno, Y; Yamagiwa, Y; Yamamoto, T | 1 |
| Chieochansin, T; Chutinimitkul, S; Komolmit, P; Payungporn, S; Poovorawan, Y; Tangkijvanich, P; Theamboonlers, A | 1 |
| Alavian, SM; Amini-Bavil-Olyaee, S; Hosseini, SY; Merat, S; Sabahi, F | 1 |
| Berak, H; Cybula, A; Horban, A; Stańczak, JJ; Wasilewski, M | 2 |
| Flisiak, R; Maxwell, PR | 1 |
| Keeffe, EB; Kohrt, HE; Ouyang, DL | 2 |
| Han, B; Jin, LJ; Shi, M; Wang, RS; Xu, YP; Yang, ZJ; Zhang, H; Zhang, Y; Zhu, YF | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Kimura, T; Kiyosawa, K; Maki, N; Matsumoto, A; Rokuhara, A; Tanaka, E; Umemura, T; Yoshizawa, K | 1 |
| Blum, HE; Thimme, R | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| de Man, RA; Feinman, SV; Flink, HJ; Hansen, BE; Heathcote, EJ; Janssen, HL; Karayalcin, S; Leemans, WF; Mach, T; Schalm, SW; Simsek, H; Verhey, E | 1 |
| Pichoud, C; Trépo, C; Villeneuve, JP; Villet, S; Zoulim, F | 1 |
| Berkowitz, D; Eshach-Adiv, O; Hartman, C; Hino, B; Kra-Oz, T; Rimon, N; Satinger, I; Shamir, R | 1 |
| Li, J; Yang, HY; Yi, M | 1 |
| Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H | 1 |
| Huang, XL; Shen, WS; Wang, FL; Wang, YZ; Xu, GL; Yang, HZ; Yang, YW | 1 |
| Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY | 1 |
| Tsubota, A | 1 |
| Abacioglu, YH; Akarsu, M; Akpinar, H; Sayiner, AA; Sengonul, A; Tankurt, E; Topalak, O | 1 |
| Zarski, JP | 1 |
| Benhamou, Y | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BC; Kim, DH; Kwon, SH; Park, JS; Park, NH; Shin, JW | 1 |
| Chen, XY; Huang, YL; Ma, LN; Shen, CL; Si, CW; Xu, DZ; Yu, YY; Zhang, WJ | 1 |
| Eisenbach, C; Encke, J; Mehrabi, A; Sauer, P; Stremmel, W | 1 |
| Demir, H; Gürakan, F; Ozen, H; Saltik-Temizel, IN; Usta, Y; Yüce, A | 1 |
| Sims, KA; Woodland, AM | 1 |
| Chen, YK; Lei, BJ; Lu, ZM; Wang, YM; Yin, YK; Yu, YS; Zhang, DZ | 1 |
| Bonino, F; Brunetto, MR; Diago, M; Farci, P; Germanidis, G; Gurel, S; Hadziyannis, S; Jin, R; Lai, MY; Lau, GK; Marcellin, P; McCloud, P; Piratvisuth, T; Popescu, M; Yurdaydin, C | 1 |
| Angarano, G; Cibelli, DC; Fazio, V; Palumbo, E; Saracino, A; Scotto, G | 1 |
| Arús Soler, E; Dávila González, Y; Grá Oramas, B; Ruenes Domech, C; Vilar Gómez, E | 1 |
| Jin, HZ; Liu, J; Tu, MZ; Wang, XL; Yang, ZJ | 1 |
| Baldick, CJ; Colonno, RJ; Eggers, B; Fang, J; Hsu, M; Klesczewski, K; Levine, S; Mazzucco, C; Plym, M; Pokornowski, K; Rose, R; Tenney, DJ; Walsh, A; Yu, CF; Zhang, S | 1 |
| Dienstag, JL; Kreter, B; Wei, LJ; Xu, D | 1 |
| Wang, H; Xu, KC; Zhao, YL | 1 |
| Guo, CX; He, YW; Li, SL; Pan, YF; Wang, H | 1 |
| Dumas, L; Mieli-Vergani, G; Vergani, D | 1 |
| Choe, BH; Hyun, MC; Jang, CH; Jang, YC; Ko, CW; Kwon, S; Lee, JH; Lee, KS; Lee, WK; Oh, KW | 1 |
| Antonov, K; Jelev, DT; Krastev, Z | 1 |
| Beier, C; Gille, J; Kaufmann, R; Meissner, M | 1 |
| Bourne, EJ; Condreay, LD; Dienstag, JL; Hall, JG; Kwiatkowski, RW; Lai, CL; Longlet, JM; Lopez, VA; Sander, TJ; Wright, T | 1 |
| Keeffe, EB; Marcellin, P | 1 |
| Barreiro, P; García-Samaniego, J; Labarga, P; Martín-Carbonero, L; Núñez, M; Ramos, B; Rios, P; Romero, M; Sheldon, J; Soriano, V | 1 |
| Allice, T; Cerutti, F; Colucci, G; Franchello, A; Gabella, S; Ghisetti, V; Marzano, A; Pittaluga, F; Varetto, S | 1 |
| Barraud, L; Ollivet, A; Pichoud, C; Trépo, C; Villeneuve, JP; Villet, S; Zoulim, F | 1 |
| Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A | 1 |
| Huang, YX; Mao, RC; Qin, YL; Weng, XH; Wu, XH; Yin, YK; Zhang, JM; Zhang, QB; Zhang, WQ | 1 |
| Ren, H; Shi, XF; Wang, ZY; Zhang, DZ; Zhou, Z | 1 |
| Dimou, E; Hadziyannis, SJ; Mitsoula, P; Rapti, I | 1 |
| Chang, ML; Hsu, CW; Liaw, YF; Yeh, CT | 1 |
| Amrapurkar, D; Arora, A; Chawla, YK; Hissar, S; Jain, RK; Konar, A; Kumar, A; Kumar, M; Lahoti, D; Lavate, P; Nanda, V; Sarin, SK; Sharma, BC; Sood, A | 1 |
| Chan, SC; Fan, ST; Lau, GK; Lo, CM; Wong, J | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Tsai, JF; Wang, LY; Yu, ML | 1 |
| Fung, J; Lai, CL; Ngai, VW; Wong, DK; Yuen, MF | 1 |
| Chan, HL; Chan, HY; Chow, KC; Ding, C; Hui, AY; Lo, YM; Sung, JJ; Wong, GL; Wong, VW | 1 |
| Locarnini, SL; Macdonald, G; Sasadeusz, JJ | 1 |
| Fung, J; Lai, CL; Libbrecht, E; Sablon, E; Van De Velde, H; Wong, BC; Wong, DK; Yuen, MF | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Takeda, Y; Toyoda, H; Yano, M; Yoshioka, K | 1 |
| Chen, DS; Kao, JH; Lai, MY; Liu, CJ; Wang, CC | 1 |
| Chen, CW; Hou, JL; Tan, DM; Wang, YM; Xu, DZ; Yao, GB; Zhu, M | 1 |
| Chen, M; Feng, B; Wang, L; Wei, L | 1 |
| Bouvier-Alias, M; Brillet, R; Chevaliez, S; Dhumeaux, D; Hézode, C; Pawlotsky, JM; Roudot-Thoraval, F; Zafrani, ES | 1 |
| Gish, RG | 1 |
| Berger, A; Faust, D; Stuermer, M; Teuber, G; Trojan, J | 1 |
| Abe, M; Hino, T; Ide, T; Kage, M; Kumashiro, R; Kuromatsu, R; Kuwahara, R; Saitsu, H; Sata, M; Takata, A; Tanaka, K; Tanikawa, K | 1 |
| Enomoto, M; Habu, D; Hayashi, T; Jomura, H; Kawada, N; Koh, N; Kohmoto, MT; Nishiguchi, S; Sakaguchi, H; Seki, S; Shiomi, S; Takeda, T; Tamori, A | 1 |
| Chng, HH; Chow, WC; Koh, ET; Thong, BY | 1 |
| Brunetto, MR | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Tsai, JF; Wang, LY; Yu, ML | 2 |
| Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, CH; Wong, GL; Wong, VW | 1 |
| Aoyagi, T; Aoyagi, Y; Ichida, T; Nomoto, M; Ohkoshi, S; Osaki, A; Takamura, M; Terada, H; Tsubata, S; Uehara, K | 1 |
| Colak, T; Haberal, M; Savas, N; Selcuk, H; Yilmaz, U | 1 |
| Chen, XC; Deng, X; Zhong, XH; Zhou, BP | 1 |
| Akarca, U; Akyildiz, M; Batur, Y; Ersoz, G; Gunsar, F; Ilter, T; Karasu, Z | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S; Yatsuji, H | 1 |
| Bloom, A; Blum, S; Loganathan, RS; Remy, P; Singu, BS; Widjaja, D; Yarlagadda, S | 1 |
| Abe, H; Aimitsu, S; Aisaka, Y; Chayama, K; Fujimoto, Y; Hatakeyama, T; Hiraga, N; Imamura, M; Kawakami, H; Kawakami, Y; Kohno, H; Maekawa, T; Mori, N; Noguchi, C; Ochi, H; Takahashi, S; Tsuge, M; Yatsuji, H | 1 |
| Pár, A; Szalay, F; Tornai, I | 1 |
| Kowdley, KV; Lim, CY | 1 |
| Ali, S; Cheema, HA; Memon, I; Mirza, R; Shah, U; Thobani, S | 1 |
| Cho, YK; Jeon, WK; Kim, BI; Kim, YJ; Park, H; Woo, HY | 1 |
| Fung, J; Lai, CL; Mizokami, M; Tanaka, Y; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Angelopoulou, OP; Hadziyannis, ES; Hadziyannis, SJ; Manesis, EK | 1 |
| Bouzas, MB; Cahn, P; Carrillo, MG; Giuliano, SF; Laufer, N; Moretti, F; Pérez, H; Quarleri, J; Salomon, H | 1 |
| Duong, TN; Hiasa, Y; Horiike, N; Joko, K; Konishi, I; Michitaka, K; Onji, M; Yano, M | 1 |
| Bae, SH; Chang, UI; Choi, JY; Jang, JW; Lee, YC; Sun, HS; Wie, SH; Yang, JM; Yoon, SK | 1 |
| Cakaloglu, Y; Ersöz, G; Gur, G; Gurel, S; Kalayci, C; Kaymakoglu, S; Oguz, D; Okten, A; Ozenirler, S; Poturoglu, S; Tankurt, E | 1 |
| Agnelli, F; Caccamo, L; Donato, MF; Gatti, S; Maggi, U; Melada, E; Paone, G; Reggiani, P; Rossi, G | 1 |
| Bakulin, I; Balakirev, E; Baranova, F; Chervinko, V; Kovalchuk, A; Novozhenov, V; Stahanova, V; Stanke, A; Stenina, I; Zolotarevsky, V; Zubkin, M | 1 |
| Chen, CW; Chen, YG; He, YW; Hou, JL; Jia, JD; Ma, H; Niu, JQ; Ren, H; Tan, DM; Wan, MB; Wang, QH; Wang, YM; Wei, L; Wu, SM; Xu, DZ; Xu, JZ; Yin, YK; Zhou, XQ; Zhu, LM | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kawaoka, T; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE; Yim, HJ; Yu, SK | 1 |
| Bethanis, S; Christidou, A; Katsanika, A; Liapi, C; Manolakopoulos, S; Margeli, A; Sklavos, P; Stripeli, F; Theocharis, S; Tzourmakliotis, D; Vogiatzakis, E | 1 |
| Bonovas, S; Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Schapper, M; Vargas, V | 1 |
| Funk, A; Gerlich, W; Schildgen, O; Sirma, H | 1 |
| Chen, XY; Chen, Y; Han, ZH; Hou, DM; Ivan, H; Li, J; Lu, HY; Si, CW; Yu, YY; Zeng, Z; Zhuang, LW | 1 |
| Fasano, M; Palattella, S; Pastore, G; Santantonio, T | 1 |
| Bang, SJ; Han, DH; Hwang, YT; Jeong, ID; Jung, SW; Kim, DH; Kim, HS; Park, NH; Shin, JW | 1 |
| Cho, BM; Cho, M; Heo, J; Kang, DH; Kim, GH; Kim, TO; Lee, SM; Song, GA | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Chan, HL; Chim, AM; Niu, J; Sung, JJ; Wang, H | 1 |
| Li, H; Li, J; Liang, SR; Lu, CZ; Zhao, GM; Zhu, LM; Zou, HB | 1 |
| Alison, T; Larry, L; Lu, XZ | 1 |
| Arora, G; Keeffe, EB | 1 |
| Bae, SH; Cha, SB; Choi, JY; Jang, JW; Kim, CW; Kim, MS; Lee, SY; Yoon, SK | 1 |
| Aledort, JE; Dusheiko, GM; Jacobs, M; Lewis, G; Patel, KK; Sullivan, SD; Veenstra, DL | 1 |
| Chen, XY; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H | 1 |
| Arici, ZS; Berberoğlu, M; Demirçeken, F; Girgin, N; Kansu, A; Kuloğlu, Z; Ocal, G | 1 |
| Accadia, L; Andriulli, A; Caruso, N; Conoscitore, P; Fiorella, S; Fontana, R; Gioffreda, D; Iacobellis, A; Niro, GA | 1 |
| Jia, JD; Li, HY; Liang, L; Ma, H; Ren, JB; Sun, SJ; Wang, RL; Wang, Y | 1 |
| Li, MH; Wu, YZ; Xie, Y; Zhang, CZ; Zhao, FL | 1 |
| Gish, RG; Lau, DT; Perrillo, R; Schmid, P | 1 |
| Erensoy, S; Pullukçu, H; Sertöz, R; Taşbakan, M; Ulusoy, S; Yamazhan, T | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Chevallier, M; Chevallier, P; Lebouché, B; Miailhes, P; Pradat, P; Trabaud, MA; Trepo, C; Zoulim, F | 1 |
| Tillmann, HL | 1 |
| Khoo, TL; Lee, AU; McCaughan, GW; Ngu, MC; Prakoso, E; Strasser, SI; van der Poorten, D | 1 |
| Balaska, A; Dona, K; Eugenidis, N; Giouleme, O; Grammatikos, N; Mpoumponaris, A; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Soufleris, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zagris, T; Zezos, P | 1 |
| Ayres, A; Bartholomeusz, A; Colledge, D; Dore, GJ; Lewin, SR; Littlejohn, M; Locarnini, SA; Matthews, GV; Revill, PA; Sasaduesz, J; Thio, CL; Yuen, L | 1 |
| Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE | 1 |
| Chae, HB; Hann, HW | 1 |
| Piao, DM; Piao, XX; Ren, FY | 1 |
| Fukai, K; Imazeki, F; Kurihara, T; Mikata, R; Yokosuka, O; Zhang, KY | 1 |
| Craxì, A; Di Marco, V | 1 |
| Alavian, SM; Amini-Bavil-Olyaee, S; Hosseini, SY; Sabahi, F | 1 |
| Gish, RG; Jacobson, IM; Perrillo, RP | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Iwasaki, S; Kobayashi, M; Kumada, H; Miyakawa, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S; Yatsuji, H | 1 |
| Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C | 1 |
| Chan, HL; Chan, HY; Chim, AM; Choi, PC; Hui, AY; Sung, JJ; Wong, GL; Wong, VW | 1 |
| Brandão, CE; Carrilho, FJ; Coelho, HS; França, PH; Gouvea, VS; Mattos, AA; Ono-Nita, S; Quintaes, RF; Sablon, E; Segadas, JA; Tovo, C; Vanderborght, BO | 1 |
| Dan, YY; Lim, SG | 1 |
| Chang, TT; Chen, PJ; Chuang, WL; Patel, K; Sullivan, SD; Tsai, C; Veenstra, DL | 1 |
| Lu, GF; Qi, YM; Wang, BS; Yang, PC; Zhang, DY; Zheng, PY | 1 |
| Buti, M; Elefsiniotis, I; Esteban, R; Gimferrer, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D | 1 |
| Enomoto, M; Habu, D; Kawada, N; Kohmoto, MT; Morikawa, H; Nishiguchi, S; Sakaguchi, H; Seki, S; Shiomi, S; Takeda, T; Tamori, A | 1 |
| Burnett, RJ; Leeuw, YG; Lukhwareni, A; Mphahlele, MJ; Selabe, SG; Song, E | 1 |
| Buster, EH; Cianciara, J; de Vries, RA; Flink, HJ; Hansen, BE; Janssen, HL; Kitis, G; Merican, I; Nevens, F; Schalm, SW | 1 |
| Binda, R; de Man, RA; Janssen, HL; Kusters, JG; Niesters, HG; Schalm, SW; Sprengers, D; van der Molen, RG | 1 |
| Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, SO; Lee, ST; Shin, KD | 1 |
| Boxall, EH; Price, N | 1 |
| Doutreloigne, J; Lai, CL; Libbrecht, E; Sablon, E; Shapiro, F; Van De Velde, H; Yuen, MF | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Toyoda, H | 1 |
| Okanoue, T | 2 |
| Abiru, S; Nagaoka, S; Yatsuhashi, H | 1 |
| Orito, E | 1 |
| Shiryu, H; Suzuki, F; Tanaka, E; Tanaka, Y | 1 |
| Fukushima, K; Inoue, J; Kogure, T; Nagasaki, F; Niitsuma, H; Shimosegawa, T; Ueno, Y | 1 |
| Auguet, T; Barragan, P; Quer, JC; Ramírez, R; Richart, C; Sirvent, JJ | 1 |
| Bai, XF; Fang, Y; Huang, CX; Lei, YF; Ma, HH; Nie, OH; Ren, GL; Sun, YT; Wang, D; Wang, PZ; Xu, MC | 1 |
| Gane, E; Lacey, LF | 1 |
| Cao, HC; Du, WB; Li, LJ; Li, MW; Pan, XP; Sheng, JF | 1 |
| Felaco, FM; Leone, S; Stanzione, M | 1 |
| Fung, J; Lai, CL; Mizokami, M; Tanaka, Y; Wong, DK; Yuen, MF | 1 |
| Brancaccio, G; Cuomo, G; Di Biase, S; Felaco, FM; Gaeta, GB; Piccinino, F; Precone, V; Stanzione, M; Stornaiuolo, G | 1 |
| Aghakhani, A; Banifazl, M; Gachkar, L; Keyvani, H; Ramezani, A; Roshan, MR; Velayati, AA | 1 |
| Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL | 1 |
| D'Onofrio, M; Orlando, R; Piazza, M; Portella, G; Tosone, G; Veropalumbo, E | 1 |
| Chuang, TW; Huang, SC; Hung, CH; Lee, CM | 1 |
| Chen, JL; Fan, XL; Wang, L; Yan, J; Yu, H; Zhang, L | 1 |
| Bzowej, NH; Han, SH; Ishitani, MB; Lok, AS; Osborn, MK; Regev, A; Tran, TT | 1 |
| Brett-Smith, H; Chang, TT; Chao, YC; Colonno, R; de Man, RA; Gadano, A; Gish, RG; Han, KH; Harris, M; Lee, SD; Lok, AS; Sollano, J; Yang, J | 1 |
| Keeffe, EB | 2 |
| Bethanis, S; Christias, E; Christidou, A; Goulis, J; Karamanolis, D; Koutsounas, S; Manolakopoulos, S; Papatheodoridis, G; Pavlidis, C; Saveriadis, A; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J | 1 |
| Buti, M; Calleja, JL; Carnicer, F; Casanovas, T; Crespo, J; Enríquez, J; Esteban, R; García Bengoechea, M; García Samaniego, J; Jardí, R; Miras, M; Pérez Roldán, F; Pons, F; Prieto, M; Rodríguez Frías, F; Romero, M; Rueda, M | 1 |
| Fong, DY; Fung, J; Lai, CL; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Cooksley, G; Ferrari, C; Gane, E; Horsmans, Y; Lau, GK; Leroux-Roels, G; Merican, MI; Tawandee, T; Trepo, C; Vandepapelière, P; Wettendorff, M; Win, KM | 1 |
| Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Wu, CM; Yen, YH | 1 |
| Borentain, P; Colson, P; Gérolami, A; Gérolami, R; Norguet, E; Tamalet, C | 1 |
| Akman, SA; Anil, M; Bakiler, AR; Halicioğlu, O; Kizilgunesler, A; Okcu, SC; Sutcuoglu, S | 1 |
| Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, AM; Tse, CH; Wong, GL; Wong, VW | 1 |
| Flisiak, R; Pogorzelska, J | 1 |
| Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Ruiz, G; Schaper, M | 1 |
| Brown, NA; Chao, G; Chen, C; Chen, Y; Constance, BF; Harb, G; He, Y; Hou, J; Jia, J; Niu, J; Ren, H; Tan, D; Wan, M; Wang, Q; Wang, Y; Wei, L; Wu, S; Xu, D; Xu, J; Yin, YK; Zhou, X; Zhu, L | 1 |
| de Man, RA; Leemans, WF; Ter Borg, MJ | 1 |
| Ando, M; Araki, Y; Fujio, K; Fujioka, S; Higashi, T; Ikeda, H; Iwasaki, Y; Kawaguchi, M; Kobashi, H; Nishida, T; Sakaguchi, K; Shiratori, Y; Shoji, B; Takaguchi, K; Takaki, A; Yamamoto, K | 1 |
| Gardner, SD; Jonas, MM; Little, NR | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; ter Borg, MJ | 1 |
| Brown, NA; Bzowej, N; Chao, G; Chen, Y; Constance, BF; Di Bisceglie, AM; Gane, E; Goodman, Z; Heathcote, EJ; Hsu, CW; Lai, CL; Liaw, YF; Moon, YM; Naoumov, NV; Rasenack, J; Thongsawat, S; Wang, Y; Zeuzem, S | 1 |
| Ahn, SH; Cho, M; Choi, HS; Han, JY; Hwang, SG; Kim, BS; Kim, DJ; Kim, YS; Moon, YM; Rim, KS | 1 |
| Cho, JY; Choi, JH; Han, JM; Jin, MI; Jung, JK; Jung, JT; Kim, BS; Kim, EY; Lee, CH; Shin, IH | 1 |
| Baek, SY; Chung, KS; Koh, H | 1 |
| Anaky, MF; Blanche, S; Chaix, ML; Fassinou, P; Inwoley, A; Kpozehouen, A; Msellati, P; Rouet, F; Rouzioux, C | 1 |
| Jin, HZ; Wang, X; Wang, XL; Xie, SG; Yang, WX; Zhang, L | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG | 1 |
| Janssen, HL; Reijnders, JG | 1 |
| Dalmi, L; Gervain, J; Horváth, G; Hunyady, B; Ibrányi, E; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Amendola, M; Bottecchia, M; Brandão, CE; Gomes, SA; Niel, C; O, KM; Souto, FJ | 1 |
| Button, P; Chow, WC; Cooksley, G; Fried, MW; Lau, GK; Liaw, YF; Luo, KX; Marcellin, P; Paik, SW; Piratvisuth, T; Popescu, M | 1 |
| Kansu, A | 1 |
| Bond, MI; Carroll, MB | 1 |
| Cakaloglu, Y; de Man, RA; Flisiak, R; Haagmans, BL; Hansen, BE; Herrmann, E; Janssen, HL; Karayalcin, S; Schalm, SW; ter Borg, MJ; van' t Veen, A; Zeuzem, S | 1 |
| Chow, DH; Fung, J; Lai, CL; Ngai, VW; Seto, WK; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Bayan, K; Canoruç, F; Dursun, M; Paşa, S; Saka, G; Yilmaz, S | 1 |
| Asaka, M; Chiba, H; Chuma, M; Fujisawa, S; Hige, S; Kitamura, T; Nishimura, M; Sato, K; Yamashita, N; Yoshida, M; Yoshida, S | 1 |
| Alessandria, C; Barbon, V; Carenzi, S; Gaia, S; Lagget, M; Marzano, A; Olivero, A; Rizzetto, M; Smedile, A | 1 |
| Chun, JY; Kim, JK; Kim, MH; Ko, SY; Lee, HJ; Lee, IK; Lee, YJ; Lim, YS; Oh, HB; Suh, DJ | 1 |
| Hann, HW | 1 |
| Byun, KS; Choe, WH; Kim, BK; Kim, GH; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Brosgart, CL; Chow, WC; Gardner, SD; Gray, DF; Heathcote, EJ; Lai, JY; Perrillo, RP; Scott, SA; Sung, JJ; Woessner, MA; Zeuzem, S | 1 |
| Lv, WL; Wang, SL; Yao, NL | 1 |
| Brosa, M; Buti, M; Esteban, R; Idris, BI; Richardus, JH; Schalm, SW | 1 |
| Sánchez-Tapias, JM | 1 |
| Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R | 1 |
| Bae, SH; Cho, SH; Choi, JY; Han, JY; Kang, SB; Kim, YS; Lee, SW; Lee, YS; Nam, SW; Yang, JM; Yoon, SK | 1 |
| Ikeda, K | 1 |
| Li, J; Lu, HY; Si, CW; Yu, YY; Zhuang, LW | 1 |
| Chao, KC; Chen, CY; Chu, CJ; Hung, JH; Hung, SC; Sung, PL; Yang, MJ | 1 |
| Cheong, JY; Cho, JH; Cho, SW; Hong, SP; Kang, JK; Kim, SO; Lee, MH; Lim, NK; Park, JS; Yoo, WD | 1 |
| Bisceglie, A; Di Bisceglie, A; Gish, RG; Kowdley, KV; Spackman, DE; Veenstra, DL | 1 |
| Csako, G; Hoofnagle, JH; Liang, TJ; Loomba, R; Pucino, F; Rowley, A; Wesley, R | 1 |
| McHutchison, JG; Tillmann, HL | 1 |
| Chien, RN; Chuang, WL; Lacey, L; Pwu, RF | 1 |
| Butí, MA | 1 |
| Jia, JD | 1 |
| Ahn, SH; Chang, HY; Han, KH; Hong, SP; Lee, HW; Lee, JI; Moon, YM; Park, YK; Um, SH | 1 |
| Hsu, EK; Murray, KF | 1 |
| Chen, XY; Chen, Y; Han, ZH; Lu, HY; Si, CW; Yu, YY; Zheng, JJ; Zhuang, LW | 1 |
| Ye, YA | 1 |
| Li, J | 1 |
| Badiale, R; Caltran, G; Galli, C; Gessoni, G; Orlandini, E; Penzo, L; Valverde, S | 1 |
| Chandrasekhar, J; Dusheiko, G; Jacobs, M; Jacobs, R; Kennedy, PT; Phillips, N | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Iwasaki, S; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S; Yatsuji, H | 1 |
| Allice, T; Cerutti, F; Franchello, A; Gabella, S; Ghisetti, V; Marzano, A; Pittaluga, F; Varetto, S | 1 |
| Audsley, J; Baden, R; Caro, J; Hunter, H; Lewin, SR; Matthews, G; McMahon, MA; Mijch, A; Olender, SA; Sasadeusz, J; Siliciano, RF; Thio, CL | 1 |
| Arnold, C; Dervisevic, S; Ijaz, S; Mechurova, J; Naoumov, NV; Tatman, N; Tedder, RS | 1 |
| Ayoub, WS; Keeffe, EB | 1 |
| Chen, JJ; Hou, JL; Sun, J; Wang, C; Wang, ZH | 1 |
| de Man, RA; Honkoop, P; Roth, WK; Schalm, SW; Schmidt, JM; Zeuzem, S | 1 |
| Heijtink, RA; Honkoop, P; Hop, WC; Kruining, J; Kuhns, MC; Osterhaus, AD; Schalm, SW | 1 |
| Crespo, J; Pons-Romero, F | 1 |
| Atkins, M; Gray, DF | 1 |
| Buti, M; Cotrina, M; Esteban, R; Guardia, J; Jardi, R; Rodriguez-Frias, F | 1 |
| Tassopoulos, NC | 1 |
| Bassendine, MF; Bennett, MK; Brind, AM | 1 |
| Aldrich, CE; Averett, D; Condreay, LD; Cullen, J; Frick, L; Jilbert, AR; Mason, WS; Miller, DS; Moraleda, G; Saputelli, J; Tennant, B | 1 |
| Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V | 1 |
| de Man, RA; Honkoop, P; Niesters, HG; Wolters, LM | 1 |
| Barber, J; Chang, TT; Chien, RN; Dent, JC; Gray, DF; Guan, R; Lai, CL; Leung, NW; Ng, KY; Stephenson, SL; Tai, DI; Wu, PC | 1 |
| Omata, M | 1 |
| Ahmed, M; de Man, R; Elias, E; Honkoop, P; Johnson, M; Marinos, G; McPhillips, P; Mutimer, D; Naoumov, N; Schalm, S; Williams, R | 1 |
| Jaeckel, E; Manns, MP | 1 |
| de Man, RA; Honkoop, P; Niesters, HG; Schalm, SW | 1 |
| Han, DJ; Jung, YO; Lee, YS; Park, JS; Park, SK; Yang, WS | 1 |
| de Man, RA; Fevery, J; Honkoop, P; Main, J; Nevens, F; Niesters, HG; Schalm, SW; Thomas, HC; Tyrrell, DL | 1 |
| Lavanchy, D; Renner, EL | 1 |
| Main, J; McCarron, B; Thomas, HC | 1 |
| Battegay, M; Bernasconi, E | 1 |
| Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R | 1 |
| Barber, J; Buti, M; Condreay, L; Goldin, RD; Gray, DF; Hawley, S; Heathcote, J; Pastore, G; Tassopoulos, NC; Volpes, R | 1 |
| Koziel, MJ | 1 |
| Dusheiko, G | 1 |
| Hosaka, H; Kubo, S; Nagai, K; Nakamura, N; Nonaka, H; Shinohara, M | 1 |
| Buti, M; Cotrina, M; Cruz de Castro, E; Esteban, R; Guardia, J; Jardí, R; Rodríguez, F | 1 |
| de Man, RA; Niesters, HG; Schalm, SW; Wolters, LM | 1 |
| Kowdley, KV | 1 |
| Arase, Y; Chayama, K; Ikeda, K; Kobayashi, M; Koike, M; Kumada, H; Ogawa, N; Saitoh, S; Suzuki, Y; Tanikawa, K; Tsubota, A | 1 |
| Asensi, V; Carton, JA; Maradona, JA; Martínez, A; Rodríguez, M | 1 |
| Pessoa, MG; Wright, TL | 1 |
| Lee, WM; Malik, AH | 2 |
| Faulds, D; Jarvis, B | 1 |
| Bessesen, M; Condreay, L; Ives, D; Lawrence, S; Sherman, KE | 1 |
| Bechstein, WO; Budde, K; Hocher, B; Krüger, DH; Meisel, H; Neuhaus, P; Neumayer, HH; Preikschat, P; Reinke, P | 1 |
| Atkins, M; Chien, RN; Liaw, YF | 1 |
| Farrell, GC | 2 |
| Clouston, AD; Crawford, DH; Hourigan, LF; Maguire, CM; Powell, EE; Walpole, ET | 1 |
| Cui, Z; Wang, B; Yao, G | 1 |
| Brown, N; Casey, DE; Condreay, L; Crowther, L; Dienstag, JL; Gelb, LD; Gitlin, N; Lissoos, T; Mitchell, M; Rubin, M; Schiff, ER | 1 |
| Chan, PK; Johnson, PJ; Lam, KC; Leung, NW; Mok, TS; Steinberg, JL; Tam, JS; Yeo, W | 1 |
| Asakura, H; Fujii, K; Ichida, T; Nomoto, M; Ogata, N; Takigawa, S | 1 |
| Trepo, C; Zoulim, F | 1 |
| de Man, RA; Honkoop, P; Janssen, HL; Schalm, SW | 1 |
| Brown, NA; Condreay, LD; Crowther, L; Dienstag, JL; Goodman, Z; Hann, HW; Perrillo, RP; Rubin, M; Schiff, ER; Woessner, M; Wright, TL | 1 |
| Hagmeyer, KO; Pan, YY | 1 |
| Chung, SW; Eggen, HJ; Erb, SR; Frighetto, L; Partovi, N; Scudamore, CH; Steinbrecher, UP; Yoshida, EM | 1 |
| di Gennaro, G; Donada, C; Donadon, V; Nasti, G; Tirelli, U | 1 |
| Brown, NA; Hunt, CM; Rubin, M | 1 |
| Bourne, EJ; Brown, NA; Condreay, LD; Crowther, LM; Dienstag, JL; Gauthier, J; Lutz, MW | 1 |
| Musher, DR; Saggi, SJ; Wasser, WG | 1 |
| Yao, FY | 1 |
| Hultgren, C; Milich, DR; Sällberg, M; Weiland, O | 1 |
| Rizzetto, M; Saracco, G | 1 |
| Bilodeau, M; Condreay, LD; Fenyves, D; Heathcote, EJ; Leduc, R; Margulies, M; Peltekian, K; Pomier-Layrargues, G; Villeneuve, JP; Willems, B; Wong, F | 1 |
| Hamid, S | 1 |
| Burroughs, NJ; Mutimer, D; Pillay, D | 1 |
| Barber, J; Boxall, E; Dallow, N; Johnson, M; Kelly, D; McPhillips, P; Mieli-Vergani, G; Roberts, EA; Sokal, EM | 1 |
| Mutimer, D | 3 |
| Gordon, SC | 2 |
| Erhardt, A; Häussinger, D; Heintges, T; Petry, W | 1 |
| Gürakan, F; Koçak, N; Ozen, H; Saltik, IN | 1 |
| Goffin, E; Verhelst, D | 1 |
| Guastadisegni, A; Iacovazzi, T; Mazzola, M; Miglietta, A; Pastore, G; Santantonio, T | 1 |
| Berby, F; Petit, MA; Pichoud, C; Stuyver, L; Trépo, C; Zoulim, F | 1 |
| Antoine, C; Duboust, A; Duong, JP; Glotz, D; Landau, A; Menoyo, V | 1 |
| Doo, E; Hoofnagle, JH | 1 |
| Barber, J; Cianciara, J; Dhillon, A; Farrell, G; Gray, DF; Heathcote, J; Moorat, A; Schalm, SW; Sherman, M; Willems, B | 1 |
| Freiman, JS; McCaughan, GW | 1 |
| Cote, P; Gerin, JL; Hornbuckle, W; Korba, BE; Schinazi, R; Tennant, BC | 1 |
| Airoldi, A; Pinzello, G; Zavaglia, C | 1 |
| Chien, RN; Chu, CM; Liaw, YF; Yeh, CT | 1 |
| Fen, X; Hou, J; Nie, Z | 1 |
| Farrell, G | 1 |
| Yao, GB | 1 |
| Rizzetto, M; Smedile, A; Volpes, R | 1 |
| Gutfreund, K; Hirsch, K; Lamy, P; Murray, A; Perrillo, R; Schiff, E; Statler, A; Wright, T; Yoshida, E | 1 |
| de Man, RA; Heijtink, RA; Niesters, HG; Schalm, SW; van Nunen, AB | 1 |
| Carman, WF; Gibbs, CS; Hou, J; Lam, S; Lau, GK; Tsiang, M; Yuen, S; Zhang, L | 1 |
| Locarnini, S; Shaw, T | 1 |
| Cheung, ST; Fan, ST; Lo, CM | 1 |
| Bass, NM; Yao, FY | 1 |
| Agarwal, SR; Guptan, RC; Hasnain, SE; Kapoor, D; Kaul, R; Kazim, SN; Raisuddin, S; Sarin, SK; Wakil, SM | 1 |
| Fontana, RJ; Lok, AS | 1 |
| Böcher, WO; Galle, PR; Ibe, M; Kanzler, S; Löhr, HF; Lohse, AW; Schlaak, JF | 1 |
| de Man, RA; Honkoop, P; Niesters, HG; Schalm, SW; Zondervan, PE | 1 |
| Dodson, SF | 1 |
| Cote, P; Gangemi, JD; Gerin, JL; Hornbuckle, W; Korba, BE; Schinazi, R; Tennant, BC | 1 |
| Crowley, SJ; Desmond, PV; Lees, M; Tognarini, D | 1 |
| Terrault, NA | 1 |
| Ciecierski, R; Cieciura, T; Durlik, M; Kukuła, K; Lao, M; Lewandowska, D; Rowiński, W; Szmidt, J; Walewska-Zielecka, B | 1 |
| Feucht, H; Laufs, R; Plettenberg, A; Schäfer, P; Schröter, M; Stoehr, A; Zöllner, B | 1 |
| Huang, J; Rosenthal, P | 1 |
| Chung, YH; Lee, HC; Lee, YS; Song, BC; Suh, DJ | 1 |
| Condreay, LD; Doo, E; Gauthier, J; Ghany, MG; Herion, D; Hoofnagle, JH; Khokhar, MF; Kleiner, DE; Kuhns, MC; Lau, DT; Liang, TJ; Park, Y; Schmid, P | 1 |
| Dimou, E; Hadziyannis, SJ; Laras, A; Papaioannou, C; Papatheodoridis, GV | 1 |
| Richman, DD | 1 |
| Gerken, G | 1 |
| Dubois, F; Dutronc, H; Fleury, HJ; Neau, D; Ragnaud, JM; Robert, D; Schvoerer, E | 1 |
| Aoki, M; Haga, H; Miyano, S; Saito, T; Shinzawa, H; Takahashi, T; Terui, Y; Watanabe, H | 1 |
| Abidi, H; Ahmed, S; Berby, F; Johnson, M; Merle, P; Nafa, S; Pichoud, C; Stuyver, L; Tavan, D; Trépo, C; Zoulim, F | 1 |
| Andreone, P; Benardi, M; Cursano, C; Gramenzi, A; Grazi, GL; Hussain, M; Jovine, E; Lok, AS; Margotti, M | 1 |
| Cho, SW; Hahm, KB; Kim, JH | 1 |
| Gürakan, F; Koçak, N; Ozen, H; Saltik, IN; Yüce, A | 1 |
| Busuttil, RW; Han, SH; Kim, M; Martin, P; Saab, S; Wright, TL | 1 |
| Chan, PK; Ho, WM; Hui, P; Johnson, PJ; Leung, NW; Steinberg, JL; Tam, JS; Yeo, W; Zee, B; Zhong, S | 1 |
| Bechstein, WO; Berg, T; Hopf, U; Langrehr, JM; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Platz, KP; Rayes, N; Seehofer, D; Steinmüller, T | 1 |
| Kellner, H; Zoller, WG | 1 |
| Bacon, BR; Di Bisceglie, AM; Sponseller, CA | 1 |
| Aldrich, CE; Condreay, LD; Guo, JT; Litwin, S; Mason, WS; Molnar-Kimber, KL; Nunes, FA; Saputelli, J; Seeger, C; Wilson, JM; Zhou, T | 1 |
| McCaughan, GW; Strasser, SI | 1 |
| Bechstein, WO; Berg, T; Müller, AR; Neuhaus, P; Neuhaus, R; Rayes, N; Seehofer, D | 1 |
| de Man, RA; Honkoop, P; Niesters, HG; van Nunen, AB; Vossen, AC; Wolters, LM; Zondervan, PE | 1 |
| Bernard, B; Bitker, MO; Coriat, P; Mouquet, C; Opolon, P; Poynard, T; Thibault, V | 1 |
| Cane, P; Dowling, D; Elias, E; Mutimer, D; O'Donnell, K; Pillay, D; Ratcliffe, D; Shaw, J; Tang, H | 1 |
| Regev, A; Schiff, ER | 1 |
| Ben-Ari, Z; Broida, E; Chagnac, A; Kittai, Y; Tur-Kaspa, R | 1 |
| Keeffe, EB; Lin, OS | 1 |
| de Man, RA; Osterhaus, AD; Pontesilli, O; Uytdehaag, F; van Nunen, AB | 1 |
| Adams, P; Anschuetz, G; Bell, S; Brown, N; Condreay, L; Dickson, R; Dienstag, J; Gish, R; Levy, G; Martin, P; Perrillo, RP; Rakela, J; Schiff, E; Wright, T | 1 |
| Benzaken, S; Doglio, A; Longo, F; Rampal, P; Saint-Paul, MC; Tran, A | 1 |
| Lacaille, F | 1 |
| Bruno, R; Filice, C; Filice, G; Sacchi, P | 1 |
| Lim, SG; Tan, KC; Wai, CT | 2 |
| Maddrey, WC | 1 |
| Berg, T; Kallinowski, B; Löhr, HF; Müller, R; Teuber, G; Zeuzem, S | 1 |
| Buffet, C; Perlemuter, G | 1 |
| Arase, Y; Chayama, K; Ikeda, K; Kobayashi, M; Kumada, H; Murashima, N; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Kiyosawa, K; Tanaka, E | 1 |
| de Man, RA; Niesters, HG; van Nunen, AB; Wolters, LM | 1 |
| Arase, Y; Chayama, K; Ikeda, K; Kobayashi, M; Kumada, H; Murashima, N; Saitoh, S; Suzuki, F; Suzuki, Y; Tsubota, A | 1 |
| Bani-Sadr, F; Gassin, M; Hoff, J; Raffi, F | 1 |
| Allegra, CJ; Hamilton, JM; Little, RF; Saif, MW; Wilson, WH | 1 |
| Cheng, YC; Chevallier, M; Guerret, S; Hantz, O; Jamard, C; King, I; Le Guerhier, F; Peyrol, S; Pichoud, C; Trépo, C; Zoulim, F | 1 |
| Buti, M; Cotrina, M; Esteban, R; Guardia, J; Jardi, R; Rodríguez, F; Sánchez, F | 1 |
| Grande Santamaría, L; Romero Gómez, M; Suárez García, E | 1 |
| Forns, X; Sánchez-Tapias, JM | 1 |
| Bertoletti, A; Boehme, R; Boni, C; Cavalli, A; Cavallo, C; Ferrari, C; Fiaccadori, F; Ogg, GS; Panebianco, R; Penna, A; Pilli, M; Urbani, S | 1 |
| Feucht, HH; Laufs, R; Petersen, J; Schoder, V; Schröter, M; Zöllner, B | 1 |
| Agarwal, S; Sarin, SK | 1 |
| Hayashi, N | 1 |
| Fried, MW; Sommadossi, JP | 1 |
| Aberle, SW; Kletzmayr, J; Puchhammer-Stöckl, E; Schmied, B; Vetter, N; Watschinger, B | 1 |
| Arnold, JC; Stremmel, W | 1 |
| Matthews, GV; Nelson, MR | 1 |
| Batty, DS; Colonna, JO; Goodman, ZD; Holtzmuller, KC; Ormseth, EJ; Sjogren, MH | 1 |
| Chang, TT; Chien, RN; Condreay, LD; Dent, JC; Edmundson, S; Guan, R; Lai, CL; Lee, CM; Leung, NW; Lim, SG; Ng, KY; Wu, PC | 1 |
| Ma, H; Yin, S; You, H | 1 |
| Blendis, L; Wong, F | 1 |
| Chi, JG; Jang, JJ; Kim, CY; Kim, JW; Lee, HS; Woo, GH; Yoon, JH | 1 |
| Anschuetz, G; Baker, A; Brown, N; Everson, G; Fontana, RJ; Hann, HW; Riely, C; Riker-Hopkins, M; Schiff, ER; Wright, T | 1 |
| Werle, B; Zoulim, F | 1 |
| Buti, M; Cotrina, M; de Castro, EC; Esteban, R; Guardia, J; Jardi, R; Rodriguez-Frias, F; Sánchez-Avila, F | 1 |
| Brooks, EA; Lacey, LF; Miller, DW; Payne, SL | 1 |
| Krawczuk, G; Lyczak, A; Modrzewska, R; Tomasiewicz, K | 1 |
| de Man, RA; Heijtink, RA; Ostberg, L; Osterhaus, AD; van Bergen, P; van Nunen, AB | 1 |
| Aydogdu, S; Selimoglu, MA; Unal, F; Yagci, RV; Yüce, G | 1 |
| Bar-Nathan, N; Ben-Ari, Z; Dinari, G; Mor, E; Shapira, R; Sokal, EM; Tur-Kaspa, R | 1 |
| Carrilho, FJ; Da Fonseca, LE; Da Silva, LC; Pinho, JR; Sitnik, R | 1 |
| Yoshida, EM | 1 |
| Alexander, GJ; Bloor, S; Lamy, P; Walsh, KM; Wight, DG; Woodall, T | 1 |
| Fischer, KP; Gutfreund, KS; Tyrrell, DL | 1 |
| Andreani, T; Carbonell, N; Chazouillères, O; Loria, A; Poupon, R; Serfaty, L; Thabut, D; Zoulim, F | 1 |
| Chen, RW; Koskela, P; Lappalainen, M; Piiparinen, H; Sarna, S; Seppänen, M | 1 |
| Filer, A; Hughes, A; Jobanputra, P; Kane, K; Mutimer, D | 1 |
| Lee, SS; Myers, RP; Swain, MG; Urbanski, SJ | 1 |
| Hadziyannis, SJ; Vassilopoulos, D | 1 |
| Decraemer, H; Hui, CK; Lai, CL; Sablon, E; Yuan, HJ; Yuen, MF | 1 |
| Annese, M; Babudieri, S; Bacca, D; Barbarini, G; Barbaro, G; Bruno, M; Di Stefano, G; Francavilla, R; Matarazzo, F; Pellicelli, AM; Scotto, G; Zechini, F | 1 |
| Bosnak, M; Dagli, A; Dikici, B; Dogru, O; Gürkan, F; Haspolat, K; Kara, IH | 1 |
| de Man, RA; Janssen, HL; Niesters, HG; Schalm, SW; van Nunen, AB; Wolters, LM | 1 |
| Mazumdar, TN | 1 |
| Chan, FK; Chan, HL; Chau, TN; Lai, ST; Leung, NW; Sung, JJ; Tsang, SW | 1 |
| Fabrizi, F; Lunghi, G; Martin, P | 1 |
| Merle, P; Trepo, C | 1 |
| Gow, PJ; Mutimer, D | 1 |
| Hussain, KB | 1 |
| Brenner, DA; Brown, NA; Burchardt, E; Burkhardt, E; Dienstag, JL; Fried, MW; Goodman, ZD; Kweon, YO; Schiff, ER; Schoonhoven, R | 1 |
| Amoruso, A; Francavilla, A; Francavilla, R; Ierardi, E; Panella, C; Rizzo, GL; Tatulli, I; Vinciguerra, V | 1 |
| Di Bisceglie, AM; Lyra, AC | 1 |
| de Man, RA; Niesters, HG; Wolters, LM | 1 |
| Feucht, HH; Laufs, R; Petersen, J; Schäfer, P; Schröter, M; Zöllner, B | 1 |
| Dussaix, E; Emile, JF; Feray, C; Gigou, M; Roche, B; Roque-Afonso, AM; Samuel, D; Shouval, D; Simoneau, D | 1 |
| Cai, Y; Han, Y; Lu, Z; Zhang, D; Zhang, X | 1 |
| Cabello Tapia, MJ; López, FN; Martínez, RM; Redondo-Cerezo, E | 1 |
| Dodson, FS; Rakela, J; Vargas, HE | 1 |
| De Marino, F; De Renzo, A; Morante, A; Persico, M; Rotoli, B; Russo, GD; Torella, R | 1 |
| Andriani, A; Barlattani, A; Bibas, M; Stroffolini, T | 1 |
| Krogsgaard, K; Münster, T; Weis, NM | 1 |
| Bourikas, G; Kartalis, G; Kotsiou, S; Margaritis, D; Martinis, G; Mimidis, K; Spanoudakis, E; Tsatalas, C | 1 |
| Eng, HL; Lee, CM; Liao, CA; Lu, SN; Wang, MC; Wu, HC | 1 |
| Devecioglu, C; Dikici, B; Ece, A; Haspolat, K; Söker, M | 1 |
| Brinkman, K; de Man, RA; Hansen, BE; Kroon, FP; Meenhorst, PL; Niesters, HG; Richter, C; van der Ende, ME; Wolters, LM | 1 |
| Rizzetto, M | 1 |
| Böcher, WO; Dahmen, A; Galle, PR; Herzog-Hauff, S; Löhr, HF | 1 |
| Kawata, S; Okumoto, K; Saito, T; Shinzawa, H; Sugahara, K; Togashi, H; Watanabe, H | 1 |
| Sokal, E | 2 |
| Di Bisceglie, AM | 1 |
| Chizuka, A; Hori, A; Kanda, Y; Kobayashi, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Saito, T; Takaue, Y; Takeuchi, T; Tanosaki, R; Tobinai, K; Watanabe, T; Won Kim, S | 1 |
| Changchien, CS; Chen, CH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Chou, YP; Lee, CM; Lee, JF; Lu, SN; Wang, JH | 1 |
| Andreani, T; Calmus, Y; Chazouillères, O; Poupon, R | 1 |
| Ben-Ari, Z; Delpré, G; Niv, Y | 1 |
| Feucht, HH; Laufs, R; Petersen, J; Schäfer, P; Schröter, M; Sterneck, M; Zöllner, B | 1 |
| Kronenberger, B; Trojan, J; von Wagner, M; Zeuzem, S | 1 |
| Andreani, T; Chazouillères, O; Poupon, R; Serfaty, L | 1 |
| Adamek, J; Bolewska, B; Cianciara, J; Czajka, B; Gonciarz, Z; Gładysz, A; Juszczyk, J; Król, F; Kryczka, W; Mazur, W; Nazzal, K; Swietek, K | 1 |
| Benhamou, Y; Bochet, MV; Bombled, T; Calvez, V; Delaugerre, C; Katlama, C; Marcelin, AG; Peytavin, G; Thibault, V | 1 |
| Crowley, S; Desmond, P; Lees, M; Saal, G; Tognarini, D | 1 |
| Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H | 1 |
| Matsushima, T | 1 |
| Anselmo, DM; Baquerizo, A; Busuttil, RW; Cao, C; Chen, PW; Farmer, DG; Geevarghese, S; Ghobrial, RM; Goldstein, L; Gornbein, JA; Han, SH; Holt, CD; Jung, LC; Kunder, G; Saab, S; Weaver, M; Yersiz, H | 1 |
| Chen, G; Tang, Y; Zheng, R | 1 |
| Du, KF; Liu, H; Lu, ZG; Wu, L; Xue, P | 1 |
| Pramoolsinsup, C | 1 |
| Crewe, E; Farrell, GC; George, J; Hui, JM; Liddle, C; Lin, R; Samarasinghe, D | 1 |
| Carey, W; Fontana, RJ; Fried, M; Keeffe, EB; Kowdley, KV; Lok, AS; McClure, LA; Reddy, R; Soldevila-Pico, C | 1 |
| Cho, SW; Hahm, KB; Kim, HJ; Kim, JH; Kim, SW; Lee, KM | 1 |
| de Man, RA; Heijtink, RA; Schalm, SW; van Nunen, AB; Vossen, AC | 1 |
| de Man, RA; Hansen, BE; Niesters, HG; Schalm, SW; Wolters, LM; Zeuzem, S | 1 |
| Areias, JA; Badia, IB; Bell, MS; Gardner, SD; Greensmith, MJ; Jonas, MM; Kelley, DA; Little, NR; Mizerski, J; Schwarz, KB; Sokal, EM | 1 |
| Chen, WN; Lim, GK; Oon, CJ | 1 |
| Andriulli, A; Facciorusso, D; Gravinese, E; Guastadisegni, A; Insalata, M; Leandro, G; Niro, GA; Pastore, G; Santantonio, T; Sinisi, E | 1 |
| Cianciara, J; Cybula, A; Jabłońska, J; Nazzal, K; Walencik, G; Łoch, T | 1 |
| Atkins, M; Brown, NA; Dienstag, JL; Gardner, SD; Heathcote, EJ; Lai, CL; Liaw, YF; Perrillo, RP; Schalm, SW; Schiff, ER; Woessner, M | 1 |
| Dimou, E; Hadziyannis, SJ; Laras, A; Papadimitropoulos, V; Papatheodoridis, GV | 1 |
| de Man, RA; Doorduijn, JK; Janssen, HL; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
345 review(s) available for lamivudine and Chronic Hepatitis B
| Article | Year |
|---|---|
Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
Topics: Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Randomized Controlled Trials as Topic; Seroconversion; Tenofovir; Treatment Outcome | 2020 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viral Load | 2017 |
Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reproducibility of Results; Rheumatic Diseases; Risk; Sensitivity and Specificity; Virus Activation | 2018 |
Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Treatment Outcome | 2019 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network Meta-Analysis; Organophosphonates; Prospective Studies; Telbivudine; Tenofovir | 2019 |
Lamivudine therapy for chronic hepatitis B in children: a meta-analysis.
Topics: Antiviral Agents; Child; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Odds Ratio | 2019 |
Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bilirubin; China; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Prothrombin Time; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Phyllanthus; Phytotherapy; Randomized Controlled Trials as Topic; Thymalfasin; Thymosin | 2013 |
The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.
Topics: Animals; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine | 2013 |
Hepatitis B viral factors and treatment responses in chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2013 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastroenterology; Guanine; Hematology; Hepatitis B, Chronic; Humans; Hungary; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Interdisciplinary Communication; Interferons; Lamivudine; Medical Oncology; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rheumatology; Tenofovir | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Lamivudine; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2013 |
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Salvage Therapy | 2013 |
Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Treatment Outcome | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine | 2014 |
HBV genotype B/C and response to lamivudine therapy: a systematic review.
Topics: Antiviral Agents; DNA Replication; DNA, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2013 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2014 |
Lamivudine treatment for hepatitis B in dialysis population : case reports and literature review.
Topics: Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Lamivudine; Male; Renal Dialysis; Viral Load; Young Adult | 2013 |
Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Treatment Outcome | 2014 |
What physicians should know about the management of chronic hepatitis B in children: East side story.
Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Child; Child, Preschool; Diagnostic Errors; Drug Resistance, Viral; Education, Medical, Continuing; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Pediatrics; Treatment Outcome | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Mutation; Nucleic Acid Hybridization; Organophosphonates; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2014 |
Optimization therapy for the treatment of chronic hepatitis B.
Topics: Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferons; Lamivudine; Precision Medicine; Treatment Outcome; Viral Load | 2014 |
Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Treatment Outcome | 2014 |
Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Animal; Reverse Transcriptase Inhibitors; Virus Replication | 2014 |
Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Drug Resistance, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2014 |
Hepatitis B and C in pregnancy: a review and recommendations for care.
Topics: Antiviral Agents; Breast Feeding; Cesarean Section; Contraindications; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mass Screening; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Telbivudine; Thymidine; Viremia | 2014 |
Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; China; Cross-Sectional Studies; Databases, Bibliographic; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Male; Mutation; Sex Factors | 2015 |
Advances in treating drug-resistant hepatitis B virus in HIV-infected patients.
Topics: Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2015 |
Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Hepatitis B, Chronic; Humans; Lamivudine; Telbivudine; Thymidine; Treatment Outcome | 2015 |
How to achieve immune control in chronic hepatitis B?
Topics: Antiviral Agents; Biomarkers; DNA, Circular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukins; Lamivudine; Polyethylene Glycols; Pteridines; Telbivudine; Thymidine | 2015 |
Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Treatment Outcome; Viral Load | 2016 |
[Intervention efficacy of lamivudine on liver dysfunction in patients undergoing anti-tuberculosis treatment for pulmonary tuberculosis complicated with
chronic hepatitis B: a Meta-analysis].
Topics: Antitubercular Agents; Antiviral Agents; China; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load | 2015 |
Monotherapy for hepatitis B infection: a review of treatment options.
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Organophosphonates; Telbivudine; Thymidine; Treatment Outcome | 2015 |
Management of chronic hepatitis B infection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunization Programs; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Viral Load | 2015 |
The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Topics: Adult; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Interferons; Lamivudine; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Randomized Controlled Trials as Topic; Risk Factors | 2016 |
Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Tenofovir | 2016 |
HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Seroconversion | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-alpha; Lamivudine; Molecular Targeted Therapy; Organophosphonates; Practice Guidelines as Topic; Seroconversion; Telbivudine; Tenofovir; Thymidine; Viral Envelope Proteins | 2017 |
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Odds Ratio; Organophosphonates; Treatment Outcome | 2016 |
Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic | 2017 |
Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.
Topics: Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Chemoprevention; China; Drug Therapy; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Treatment Outcome; Virus Activation | 2017 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2017 |
[Treatment recommendations of chronic hepatitis B. Did the world escape us?].
Topics: Adenine; Antiviral Agents; Disease Management; Drug Therapy, Combination; Guanine; Health Planning Guidelines; Health Services Accessibility; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; National Health Programs; Organophosphonates; Poland; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2008 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
[Management of chronic hepatitis B in treatment-naive patients].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Lamivudine; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins | 2008 |
[Management of antiviral-resistant chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome | 2008 |
[Combination therapy in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2008 |
[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?].
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Recurrence | 2008 |
A review of telbivudine for the management of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Thymidine | 2008 |
[Interferon in hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Thymidine; Treatment Outcome | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Liver Transplantation; Male; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Role of combination therapy in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Salvage Therapy; Treatment Outcome | 2009 |
[Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine].
Topics: Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Medicine, Chinese Traditional; Phytotherapy; Randomized Controlled Trials as Topic; Serologic Tests; Time Factors; Treatment Outcome | 2008 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Treatment Outcome; Virus Replication | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2008 |
Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
Topics: Age Factors; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome | 2009 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2009 |
Lamivudine for chronic hepatitis B: a brief review.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2008 |
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Liver; Male; Middle Aged; Mutation; Recurrence; Time Factors; Treatment Outcome | 2009 |
Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Time Factors; Treatment Outcome | 2009 |
On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Medication Adherence; Nucleosides; Organophosphonates; Polyethylene Glycols; Prognosis; Pyrimidinones; Recombinant Proteins; Telbivudine; Thymidine; Time Factors; Treatment Outcome | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.
Topics: Alanine Transaminase; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Reverse Transcriptase Inhibitors; Risk Assessment; Viral Load | 2009 |
Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Thymalfasin; Thymosin; Treatment Outcome | 2009 |
[Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review].
Topics: Antiviral Agents; Clinical Protocols; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Meta-Analysis as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Creatine Kinase; Drug Discovery; Early Termination of Clinical Trials; Hepatitis B, Chronic; Humans; Lamivudine; Mitochondrial Myopathies; Muscular Diseases; Nervous System Diseases; Nucleosides; Nucleotides; Pyrimidinones; Republic of Korea; Telbivudine; Thymidine | 2009 |
Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Topics: Adolescent; Adult; Antiviral Agents; Asia; Carcinoma, Hepatocellular; Child; Child, Preschool; Disease Progression; DNA, Viral; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization Programs; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Treatment Outcome | 2009 |
Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Interactions; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Patient Selection; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2009 |
Therapy of chronic hepatitis B: new goals and new treatments.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferons; Lamivudine; Virus Replication | 2009 |
Current status of nucleoside antivirals in chronic hepatitis B.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2009 |
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Assessment; Serologic Tests; Severity of Illness Index; Tenofovir; Treatment Outcome | 2010 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Drug Administration Schedule; Hepatitis B, Chronic; Humans; Immunophenotyping; Lamivudine; Lymphoma, B-Cell, Marginal Zone; Male; Remission Induction; Reverse Transcriptase Inhibitors; Rituximab; Skin Neoplasms | 2010 |
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cytosine; Female; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Nucleosides; Risk Factors | 2010 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2010 |
[Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature].
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Doxorubicin; Fatal Outcome; Hepatectomy; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Magnetic Resonance Imaging; Male; Ultrasonography; Viral Load | 2010 |
Drug resistance in antiviral therapy.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.
Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Factual; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Treatment of chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2010 |
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.
Topics: Adenine; Animals; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2011 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Internalization; Virus Replication | 2011 |
[Treatment of patients with lamivudine-resistant chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2011 |
[Sequential therapy with a nucleos(t)ide analogue and interferon in patients with chronic hepatitis B: efficacy and limitations].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male | 2011 |
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.
Topics: Antiviral Agents; Combined Modality Therapy; Female; Graft Rejection; Graft Survival; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Failure; Liver Transplantation; Male; Postoperative Care; Prognosis; Risk Assessment; Secondary Prevention; Survival Analysis; Treatment Outcome | 2012 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
[Progress and perspectives in treatment of chronic hepatitis B].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2011 |
Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
Topics: Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Salvage Therapy; Time Factors; Treatment Outcome; Viral Load | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Current status of liver transplantation for hepatitis B virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunosuppressive Agents; Interferons; Lamivudine; Liver Transplantation; Male; Secondary Prevention; Treatment Outcome; Viral Load | 2011 |
Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.
Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Health Care Costs; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Primary Prevention; Quality-Adjusted Life Years; Taiwan | 2011 |
[The past, present and future treatment for chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Practice Guidelines as Topic | 2011 |
[Interferon therapy for chronic hepatitis B].
Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2011 |
[Lamivudine, adefovir dipivoxil].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2011 |
[Sequential therapy for chronic hepatitis B].
Topics: Antiviral Agents; Drug Administration Schedule; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Practice Guidelines as Topic | 2011 |
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates | 2011 |
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Postoperative Care | 2011 |
Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic | 2012 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2012 |
The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.
Topics: Amino Acid Motifs; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Viral Proteins | 2012 |
[Forecasting of efficacy of chronic hepatitis B therapy].
Topics: Alanine Transaminase; Disease Management; DNA, Circular; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic | 2012 |
Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Randomized Controlled Trials as Topic; Telbivudine; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2013 |
[Comparison of peg-interferon monotherapy to peg-interferon and nucleoside analogue combination therapy for hepatitis B: a meta-analysis of randomized controlled trials].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review.
Topics: Alanine Transaminase; Antiviral Agents; Data Interpretation, Statistical; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Life Style; Organophosphonates; Severity of Illness Index; Telbivudine; Tenofovir; Thymidine; Time Factors | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Nucleotides; Organophosphonates; Prognosis; Tenofovir; Viral Load | 2012 |
Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Nucleosides; Nucleotides | 2013 |
Chronic hepatitis B virus infection in renal transplant recipients.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Practice Guidelines as Topic; Risk Factors | 2002 |
[Chronic hepatitis B: natural history and treatments].
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunotherapy; Interferon-alpha; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2002 |
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Topics: 2-Aminopurine; Antiviral Agents; Cross Reactions; Drug Resistance, Viral; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors; Virus Replication | 2002 |
Update on the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2002 |
Lamivudine: in children and adolescents with chronic hepatitis B virus infection.
Topics: Adolescent; Antiviral Agents; Child; Hepatitis B, Chronic; Humans; Lamivudine | 2002 |
One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Tandem Repeat Sequences; Treatment Failure | 2002 |
Treatment of hepatitis B.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2002 |
Management of chronic hepatitis B: an overview.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2002 |
Clinical experience with lamivudine.
Topics: Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2002 |
Advances in therapy for chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors | 2002 |
Hepatitis B virus resistance to lamivudine and its clinical implications.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2002 |
Antiviral treatment of patients with HBV-related cirrhosis.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis | 2002 |
Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Topics: Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2002 |
Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers.
Topics: Adenine; Adolescent; Adult; Algorithms; Antiviral Agents; Australia; Carcinoma, Hepatocellular; Child; Child, Preschool; Clinical Protocols; Endemic Diseases; Female; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Interferon-alpha; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Native Hawaiian or Other Pacific Islander; Organophosphonates; Primary Health Care; Rural Health Services | 2003 |
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
Topics: Adult; Alanine Transaminase; Antiviral Agents; D-Alanine Transaminase; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Multivariate Analysis | 2003 |
Treatment of HBe antigen-positive chronic hepatitis B.
Topics: Alanine Transaminase; Anti-Inflammatory Agents; Antiviral Agents; Drug Resistance; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Prednisone; Reverse Transcriptase Inhibitors; Risk Factors | 2003 |
Treatment of HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Inflammation; Interferon-alpha; Lamivudine; Liver Cirrhosis; Organophosphonates; Patient Care Planning; Prognosis; Reverse Transcriptase Inhibitors; Virus Replication | 2003 |
Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Treatment Outcome; Virus Replication | 2003 |
[Antiviral therapy for chronic viral hepatitis B and C].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Renal transplantation in HBsAg+ patients: is lamivudine your "final answer"?
Topics: Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C; Humans; Kidney Transplantation; Lamivudine; Postoperative Care; Renal Dialysis | 2003 |
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications.
Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Child; Disease Progression; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Thymosin in the treatment of HBeAg-negative chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Thymosin | 2003 |
Antiviral T-cell responses and therapy in chronic hepatitis B.
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; T-Lymphocytes; T-Lymphocytes, Cytotoxic | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2003 |
Hepatitis B immune globulin preparations and use in liver transplantation.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Treatment Failure | 2003 |
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Nucleosides; Organophosphonates; Preoperative Care; Recurrence; Virus Replication | 2003 |
Current pharmacotherapy for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Organophosphonates | 2003 |
Chronic viral hepatitis: always be current!
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunization Schedule; Infant, Newborn; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prevalence; Risk Factors; Serologic Tests; Treatment Outcome; United States; Viral Hepatitis Vaccines | 2003 |
Viral breakthrough during lamivudine therapy for chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Practice Guidelines as Topic | 2003 |
Viral hepatitis B.
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Viral Load | 2003 |
Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy | 2004 |
Results of lamivudine trials in Asia.
Topics: Asia; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
Combination therapy for chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Nucleosides; Organophosphonates; Reverse Transcriptase Inhibitors; Viral Vaccines | 2003 |
Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine.
Topics: Drug Administration Schedule; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2003 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Treatment of chronic hepatitis B in children.
Topics: Antiviral Agents; Child, Preschool; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferons; Lamivudine; Prognosis; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Treatment of chronic hepatitis B--a paediatric perspective.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Pediatrics; Prednisolone | 2003 |
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins | 2004 |
Hepatitis B virus infection--natural history and clinical consequences.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Viremia; Virus Replication | 2004 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
[HBeAg-negative chronic hepatitis].
Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Mutation | 2004 |
Therapeutic advances in chronic hepatitis B.
Topics: Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors | 2004 |
Review of economic benefits of treating chronic hepatitis B with lamivudine.
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Quality of Life; Reverse Transcriptase Inhibitors | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
Overview of treatment of hepatitis B: key approaches and clinical challenges.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2004 |
Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Clinical trial results and treatment resistance with lamivudine in hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Patient Selection; Treatment Outcome | 2004 |
Management of hepatitis B in liver transplantation patients.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Reoperation; Secondary Prevention; Virus Replication | 2004 |
Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2004 |
Antiviral therapy for treatment-naïve hepatitis B virus patients.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Organophosphonates | 2004 |
Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation.
Topics: Antiviral Agents; Genome, Viral; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Recurrence; Treatment Failure | 2004 |
[Advances of combined treatment for chronic hepatitis B with lamivudine].
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Vidarabine Phosphate | 2003 |
[Prevalence and clinical course in HBV and HCV dual chronic infection].
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Male; Prevalence; Ribavirin; Superinfection | 2004 |
[Treatment of chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates | 2004 |
[Hepatitis B (acute and chronic)].
Topics: Acute Disease; Adenine; Adolescent; Adult; Antiviral Agents; Child; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors | 2004 |
[YMDD motif and its significance].
Topics: Amino Acid Motifs; Asparagine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Methionine; Mutation; Reverse Transcriptase Inhibitors; Reverse Transcription; RNA-Directed DNA Polymerase; Tyrosine | 2004 |
[Mechanism of hepatitis B surface antigen disappearance from and reappearance in the serum of patients with chronic HBV infection].
Topics: Antiviral Agents; Biomarkers; Carrier State; DNA, Viral; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation | 2004 |
[Introduction to chronic hepatitis type B].
Topics: Age Factors; Amino Acid Motifs; Antiviral Agents; Disease Progression; Genotype; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver; Liver Cirrhosis; Mutation | 2004 |
[Long-term history of chronic hepatitis B virus infection in children].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Genotype; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Neoplasms; Mutation; Risk; Seroepidemiologic Studies | 2004 |
[Treatment and selection criteria for chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation; Patient Selection | 2004 |
[Lamivudine therapy for chronic hepatitis B].
Topics: Amino Acid Motifs; Anti-HIV Agents; Biomarkers; Deoxycytosine Nucleotides; Depression, Chemical; DNA Replication; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication | 2004 |
[Efficacy and problems in combination therapy using lamivudine and interferon for chronic hepatitis B].
Topics: Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation; RNA-Directed DNA Polymerase | 2004 |
[Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Combined Modality Therapy; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[Management of hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; Child; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Interferon-alpha; Lamivudine; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors | 2004 |
Treatment of chronic hepatitis B: who to treat, what to use, and for how long?
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors | 2004 |
Treatment of hepatitis B with interferon and combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Recurrence | 2004 |
Management of hepatitis B in children.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Interferon-alpha; Lamivudine | 2004 |
Lamivudine for chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppression Therapy; Infectious Disease Transmission, Vertical; Lamivudine; Liver Transplantation; Point Mutation; Practice Guidelines as Topic; Pregnancy | 2004 |
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
Current therapies for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates | 2004 |
Adefovir dipivoxil in chronic hepatitis B infection.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2004 |
[Treatment of chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2004 |
Emerging treatments in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Therapy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Recombinant Proteins; Vaccines | 2004 |
[Treatment of hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Nucleosides; Viral Load | 2004 |
Treatment of chronic viral hepatitis.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates | 2004 |
Resistance to lamivudine therapy: is there more than meets the eye?
Topics: CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2005 |
The management of chronic viral hepatitis: a Canadian consensus conference 2004.
Topics: Adenine; Adult; Antiviral Agents; Canada; Child; Child, Preschool; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Infant, Newborn; Interferon-alpha; Lamivudine; Male; Organophosphonates; Polymerase Chain Reaction; Practice Guidelines as Topic; Pregnancy; RNA, Viral; Viral Hepatitis Vaccines | 2004 |
The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine | 2005 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
[The efficacy of lamivudine in Korean patients with chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Treatment Outcome | 2005 |
Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?
Topics: Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors | 2005 |
[Chronic hepatitis B: which patients should be treated and how?].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Patient Care Planning; Patient Selection; Polyethylene Glycols; Prognosis; Recombinant Proteins | 2005 |
Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine | 2005 |
[Management of chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Mutation; Organophosphonates; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Recurrence; Time Factors; Virus Replication | 2005 |
[Clinical and virologic characteristics and treatment for chronic hepatitis B: relation with HBV genotypes].
Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Prognosis | 2005 |
Chronic hepatitis B and herbal therapy.
Topics: Antiviral Agents; Drugs, Chinese Herbal; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Phyllanthus; Phytotherapy | 2005 |
Treatment of chronic hepatitis B in HIV co-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Comorbidity; Disease Progression; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Recurrence; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
Treatment of immunosuppressed chronic hepatitis B patients.
Topics: Hepatitis B, Chronic; Humans; Immunosuppression Therapy; Lamivudine; Recurrence; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
Liver transplantation in chronic hepatitis B.
Topics: Chemoprevention; Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors; Secondary Prevention | 2005 |
[Evidence based antiviral therapy for chronic hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged | 2005 |
A review of entecavir in the treatment of chronic hepatitis B infection.
Topics: Animals; Clinical Trials as Topic; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Sclerosing; Chronic Disease; Drug Therapy, Combination; Fatty Liver; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Hepatolenticular Degeneration; Humans; Immunosuppression Therapy; Interferons; Lamivudine; Liver Cirrhosis, Biliary; Liver Diseases; Organophosphonates; Prednisolone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors | 2005 |
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; DNA, Viral; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Recurrence; Risk Factors; Rituximab; Virus Activation | 2006 |
Therapeutic options for chronic hepatitis B: considerations and controversies.
Topics: Adenine; Antiviral Agents; Decision Making; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
[New virologic tests and their application in management of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Research; Reverse Transcriptase Inhibitors; Viral Load; Virology; Virus Replication | 2006 |
[Treatment of chronic hepatitis B].
Topics: Adenine; Administration, Oral; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Drug Tolerance; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver; Mutation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Time Factors; Virus Replication | 2006 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vaccination; Viral Load; Virus Replication | 2006 |
Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Tenofovir | 2006 |
Current treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Forecasting; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleocapsid; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2006 |
[Entecavir--close perspective for using it].
Topics: Animals; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine | 2006 |
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Neoplasms; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2006 |
Treatment of chronic hepatitis B in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Hepatitis B, Chronic; Humans; Infant; Interferon-alpha; Lamivudine | 2006 |
New developments in the treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Patient Selection; Polyethylene Glycols; Recombinant Proteins | 2006 |
Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Female; Glomerulonephritis; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Nephrotic Syndrome; Patient Dropouts; Treatment Outcome | 2006 |
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Topics: Disease Progression; Drug-Related Side Effects and Adverse Reactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2006 |
Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
Topics: Adenine; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2006 |
Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Topics: Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2006 |
[Therapy of hepatitis B].
Topics: Adenine; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2006 |
[Therapy of hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Forecasting; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Organophosphonates; Polyethylene Glycols; Prognosis; Recombinant Proteins; Reverse Transcriptase Inhibitors; Time Factors | 2006 |
[Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
[Managing lamivudine resistance in liver transplantation for hepatitis B liver disease].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Secondary Prevention; Treatment Outcome | 2006 |
Prevention of hepatitis B virus recurrence after liver transplantation.
Topics: Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Postoperative Complications; Reverse Transcriptase Inhibitors; Secondary Prevention | 2006 |
Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Topics: Animals; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2006 |
Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
Topics: Adenine; Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Hepatitis B virus: something old, something new.
Topics: Adolescent; Adult; Antiviral Agents; Carrier State; Child; Child, Preschool; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Interferon-alpha; Lamivudine | 2007 |
New and emerging treatment of chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2007 |
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; England; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Wales | 2007 |
Improving outcomes for patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Thymidine; Treatment Outcome; Viral Load | 2007 |
[Entecavir: a new hope for the treatment of chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Viremia | 2007 |
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Thymidine | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Organophosphonates | 2007 |
Customizing the management of chronic hepatitis B virus infection.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides | 2007 |
Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression.
Topics: Antiviral Agents; Child; Child, Preschool; DNA Replication; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Interferon-alpha; Lamivudine; Treatment Outcome | 2007 |
[Indications for antiviral therapy for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Biomarkers; Carrier State; Consensus Development Conferences as Topic; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Japan; Lamivudine; Organophosphonates; Societies, Medical | 2007 |
[Natural course and recommendation of therapy for HBV infection].
Topics: Antiviral Agents; Biomarkers; Carrier State; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Risk Factors | 2007 |
[Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2007 |
[Therapeutic options in chronic HBV infection].
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors | 2007 |
Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Virus Activation | 2007 |
[Long-term effects of HBV treatment Peg-IFN alfa-2a alone or combined with lamivudine].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Virus Replication | 2007 |
Treatment of chronic hepatitis B in children.
Topics: Child; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Virus Replication | 2008 |
Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Topics: Aged; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; DNA, Viral; Drug Therapy, Combination; Etanercept; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Lamivudine; Male; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2008 |
Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2008 |
[Advances in studies on effect superiorities of traditional Chinese medicine on chronic hepatitis B].
Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis B, Chronic; Humans; Lamivudine; Medicine, Chinese Traditional; Phytotherapy | 2007 |
Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
Topics: Adult; Aged; Antiviral Agents; Cost of Illness; Drug Resistance, Viral; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Models, Statistical; Spain | 2008 |
[Pharmacological agents for the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Time Factors; Treatment Outcome | 2008 |
[Anti-viral therapy of type B chronic hepatitis. 1. Selection of evidence-based therapeutic policy].
Topics: Antiviral Agents; Evidence-Based Medicine; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Middle Aged | 2008 |
Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Epidemiologic Methods; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2008 |
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Liver Failure, Acute; Neoplasms; Virus Activation | 2008 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2007 |
[Telbivudine in the treatment of the chronic B hepatitis].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers, Pharmacological; Biotransformation; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Muscular Diseases; Nucleosides; Phosphorylation; Prodrugs; Pyrimidinones; Randomized Controlled Trials as Topic; Telbivudine; Thymidine; Virus Replication | 2008 |
Hepatitis B and C in children.
Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Ribavirin; Treatment Outcome | 2008 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 1998 |
Nucleoside analogue therapy in fibrosing cholestatic hepatitis--a case report in an HBsAg positive renal transplant recipient.
Topics: Cholestasis, Intrahepatic; DNA, Viral; Fatal Outcome; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunohistochemistry; Kidney Transplantation; Lamivudine; Liver; Liver Function Tests; Middle Aged; Reverse Transcriptase Inhibitors | 1998 |
[New antiviral agents in the treatment of chronic hepatitis B and C].
Topics: 2-Aminopurine; Antimetabolites; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Prodrugs; Reverse Transcriptase Inhibitors; Ribavirin | 1998 |
Experience with lamivudine against hepatitis B virus.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Famciclovir; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Reverse Transcriptase Inhibitors | 1997 |
Treatment of chronic viral hepatitis.
Topics: 2-Aminopurine; Animals; Antimetabolites; Antiviral Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Drug Therapy, Combination; Ducks; Famciclovir; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Animal; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Marmota; Poultry Diseases; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured | 1998 |
Update on clinical trials in the treatment of hepatitis B.
Topics: Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors | 1999 |
Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
Topics: Animals; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 1999 |
New antiviral agents for the therapy of chronic hepatitis B virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Famciclovir; Hepatitis B, Chronic; Humans; Lamivudine; Virus Replication | 1999 |
[Chronic hepatitis-b-virus infections: new options for antiviral therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon Type I; Lamivudine; Recombinant Proteins; Reverse Transcriptase Inhibitors; Virus Replication | 1999 |
Role of lamivudine in the treatment of chronic hepatitis B virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 1999 |
Lamivudine therapy of chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Lamivudine | 1999 |
[Chronic viral hepatitis caused by B and C virus: diagnostic and therapeutic trends].
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral | 1999 |
Hepatitis B virus antiviral drug resistance: from the laboratory to the patient.
Topics: Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 1998 |
Antiviral therapy for chronic hepatitis B and C. Which patients are likely to benefit from which agents?
Topics: Antiviral Agents; Contraindications; Drug Combinations; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Ribavirin | 2000 |
[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Transplantation; Long-Term Care; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors | 2000 |
Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Organophosphonates; Treatment Outcome | 2000 |
Antiviral therapy of HBV- and HCV-induced liver cirrhosis.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Prognosis; Reverse Transcriptase Inhibitors; Survival Rate; Thymalfasin; Thymosin; Treatment Outcome | 2000 |
Chronic hepatitis B virus infection: treatment strategies for the next millennium.
Topics: Adjuvants, Immunologic; Amino Acid Motifs; Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Mutation; Recombinant Proteins; RNA-Directed DNA Polymerase; Virus Replication | 2000 |
Profound suppression of hepatitis B virus replication with lamivudine.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Virus Replication | 2000 |
Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2000 |
Liver disease-significant improvement with lamivudine.
Topics: Antiviral Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Treatment Outcome | 2000 |
End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Liver Transplantation; Treatment Outcome | 2000 |
Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better?
Topics: Antiviral Agents; Drug Administration Schedule; Hepatitis B, Chronic; Humans; Lamivudine | 2000 |
Nucleoside analogues in the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Deoxycytidine; Emtricitabine; Famciclovir; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2000 |
Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors | 2000 |
Short-term corticosteroid therapy in combination with lamivudine: A case of déjà vu?
Topics: Adrenal Cortex Hormones; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors | 2000 |
Clinical potential of emerging new agents in hepatitis B.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Virus Replication | 2000 |
Drug therapy for hepatitis B.
Topics: Adenine; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Male; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors | 2001 |
Current treatment strategies for chronic hepatitis B and C.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Life Style; Recombinant Proteins; Ribavirin; Treatment Outcome; Vaccination | 2001 |
Hepatitis B--an important public health issue.
Topics: Antiviral Agents; Carrier State; Endemic Diseases; Hepatitis B; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Diseases; Public Health | 2001 |
[Treatment of chronic viral hepatitis B with lamivudine].
Topics: Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2001 |
Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Liver; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Management protocols for hepatitis B.
Topics: Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
Symposium on clinical aspects in hepatitis virus infection. 3. Update of liver disease related to chronic hepatitis B virus infection.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Antiviral Agents; Genome, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Interleukin-12; Lamivudine; Mutation | 2001 |
[Chronic viral liver dysfunction].
Topics: Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine | 2001 |
Nucleoside analogues and other investigational modalities for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Combined Modality Therapy; Dideoxynucleosides; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors; Ribavirin; Vidarabine | 1996 |
[Chronic hepatitis--new therapeutic options].
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Lamivudine; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2001 |
The management of chronic hepatitis B infection.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Sexually Transmitted Diseases, Viral; Treatment Outcome | 2001 |
Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity.
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Failure; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2001 |
Hepatitis B infection in China.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; China; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Drugs, Chinese Herbal; Emtricitabine; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Thymosin | 2001 |
Hepatitis B virus infection: resistance to antiviral agents.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis Viruses; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
[Chronic hepatitis B].
Topics: Amino Acid Sequence; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2001 |
Lamivudine for hepatitis B after liver transplantation.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation | 2001 |
[Current knowledge on chronic hepatitis B therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors | 2001 |
Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
Topics: Animals; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
Diagnosis and management of pre-core mutant chronic hepatitis B.
Topics: Antiviral Agents; Diagnosis, Differential; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Lamivudine | 2001 |
Hepatitis B e antigen-negative chronic hepatitis B.
Topics: Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Terminology as Topic | 2001 |
Treatment of viral hepatitis--2001.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2001 |
Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Treatment Outcome | 2001 |
Management of chronic hepatitis B infection: an update.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; India; Interferon-alpha; Lamivudine; Patient Selection; Thymosin | 2001 |
Treatment of HBV-related liver disease in the dialysis population: reality and promises.
Topics: Antiviral Agents; Genome, Viral; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompetence; Interferon-alpha; Kidney Diseases; Lamivudine; Renal Dialysis; Virus Replication | 2001 |
Therapeutic management of hepatitis B-related cirrhosis.
Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Recombinant Proteins | 2001 |
Treatment of chronic hepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Ribavirin | 2001 |
What is the optimal therapy for chronic hepatitis B?
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
Nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Ganciclovir; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors | 2001 |
A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.
Topics: DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Recurrence | 2002 |
How will we use the new antiviral agents for hepatitis B?
Topics: 2-Aminopurine; Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Famciclovir; Ganciclovir; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic | 2002 |
Interferon-alpha treatment as a possible cause of relapse in a child with precursor B acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Fatal Outcome; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Sepsis | 2001 |
Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
Lamivudine for the treatment of chronic hepatitis B.
Topics: Antiviral Agents; Child; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Transplantation | 2002 |
Treatment of chronic hepatitis B.
Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
[Treatment of chronic hepatitis B].
Topics: Antiviral Agents; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Prognosis | 2002 |
[Antiviral therapy for liver cirrhosis type B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Japan; Lamivudine; Liver Cirrhosis | 2002 |
[Risks and precautions for the use of lamivudine in patients with chronic hepatitis B virus infection].
Topics: DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine | 2002 |
Treatment of chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Nucleosides | 2002 |
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin | 2002 |
[Treatment strategies for viral hepatitis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin | 2002 |
Management of patients with chronic hepatitis B.
Topics: Antiviral Agents; Drug Administration Schedule; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Patient Selection; Reverse Transcriptase Inhibitors | 2002 |
Management of viral hepatitis B.
Topics: Adjuvants, Immunologic; Antiviral Agents; Forecasting; Genetic Variation; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors | 2002 |
Drug treatment of pediatric chronic hepatitis B.
Topics: Antiviral Agents; Child; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Pediatrics | 2002 |
A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Transplantation; Pregnancy; Risk Assessment | 2002 |
[Therapy of chronic hepatitis B infection].
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Pregnancy | 2002 |
439 trial(s) available for lamivudine and Chronic Hepatitis B
| Article | Year |
|---|---|
Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2022 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; RNA, Mitochondrial; Tenofovir | 2020 |
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Circular; DNA, Viral; Female; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Mutation; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2021 |
Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination.
Topics: Adult; Aged; Antiviral Agents; Creatinine; Early Termination of Clinical Trials; Female; Glomerular Filtration Rate; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Male; Middle Aged; Myalgia; Prospective Studies; Telbivudine; Time Factors | 2020 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Sustained Virologic Response; Telbivudine; Tenofovir | 2020 |
Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2021 |
Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Topics: Absorptiometry, Photon; Adult; Anti-Retroviral Agents; Body Composition; Bone Density; Bone Resorption; Cross-Sectional Studies; Female; Femur Neck; Fibroblast Growth Factor-23; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hip; Humans; Lamivudine; Lumbar Vertebrae; Male; Middle Aged; Osteoclasts; Tenofovir | 2021 |
The ultra-short virological dynamics in response to entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation.
Topics: Adult; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Viral Load | 2018 |
[Clinical analysis of modified Chaiping decoction in treating HBeAg-negative chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drugs, Chinese Herbal; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2016 |
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Republic of Korea; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Tenofovir
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospital Costs; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2017 |
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Phosphorous Acids; Prospective Studies | 2018 |
Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immune Tolerance; Infant; Interferon-alpha; Lamivudine; Male; Pilot Projects; Seroconversion | 2018 |
Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Splenomegaly; Thrombocytopenia; Viral Load | 2019 |
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Telbivudine; Thymidine; Treatment Outcome | 2013 |
[Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, Third; Treatment Outcome; Young Adult | 2012 |
Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies | 2013 |
Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Viral Load; Young Adult | 2013 |
Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2013 |
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2013 |
Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Expression Regulation, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Viral Proteins; Young Adult | 2013 |
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Treatment Outcome; Viral Load; Young Adult | 2013 |
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Evolution, Molecular; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phylogeny; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Failure; Young Adult | 2013 |
Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Antiviral Agents; Carrier State; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, IGA; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Prednisolone; Prospective Studies; Proteinuria; Recurrence; Treatment Outcome; Virus Activation | 2014 |
Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Telbivudine; Thymidine; Treatment Outcome; Viral Load; Young Adult | 2013 |
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Topics: Adenine; Adult; Aged; Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Telbivudine; Thymidine; Treatment Outcome | 2014 |
Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Topics: Adenine; Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Young Adult | 2013 |
Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase | 2013 |
Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossover study in healthy Chinese male subjects.
Topics: Administration, Oral; Adolescent; Adult; Asian People; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Healthy Volunteers; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Tablets; Therapeutic Equivalency; Young Adult | 2013 |
De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Disease Transmission, Infectious; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Treatment Outcome; Viral Load; Young Adult | 2014 |
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Organophosphonates; Polymerase Chain Reaction; Treatment Outcome; Ultrasonography; Viral Load | 2014 |
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; New Zealand; North America; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Mutation; Organophosphonates; Real-Time Polymerase Chain Reaction; Recombinant Proteins | 2013 |
Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Patient Selection; Prospective Studies; Republic of Korea; Telbivudine; Thymidine; Time Factors; Treatment Failure; Viral Load; Young Adult | 2013 |
[A clinical study on lamivudine treatment for advanced schistosomisis with chronic B hepatits].
Topics: Adult; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Schistosomiasis | 2013 |
Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; Drug Resistance, Viral; End Stage Liver Disease; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Polymorphism, Restriction Fragment Length; Predictive Value of Tests; Prognosis; Severity of Illness Index | 2014 |
Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Female; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2014 |
[Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Young Adult | 2013 |
[Investigation of entecavir treatment in patients with LAM-refractory chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
[Comparative efficacy of etiotropic therapy of patients with HBeAg-positive chronic hepatitis B (by the data of the international comparative placebo-controlled study)].
Topics: Acridines; Adult; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatocytes; Humans; Interferon Inducers; Lamivudine; Male; Reverse Transcriptase Inhibitors; Time Factors | 2013 |
Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients kohort.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Poland; Practice Guidelines as Topic; Retrospective Studies; Socioeconomic Factors; Treatment Outcome | 2013 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Point Mutation; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir | 2014 |
Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; CD8-Positive T-Lymphocytes; China; Cytokines; DNA, Viral; Female; Forkhead Transcription Factors; Hepacivirus; Hepatitis B e Antigens; Hepatitis B, Chronic; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation Mediators; Lamivudine; Male; Middle Aged; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Telbivudine; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2014 |
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2014 |
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Young Adult | 2015 |
Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Young Adult | 2014 |
Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Topics: DNA, Viral; End Stage Liver Disease; Evolution, Molecular; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors; Secondary Prevention; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Neoplasms; Organophosphonates; Virus Activation; Young Adult | 2015 |
Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; China; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Young Adult | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Telbivudine; Thymidine | 2015 |
A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Substitution; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Young Adult | 2016 |
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Telbivudine; Thymidine; Treatment Outcome | 2016 |
Long-term lamivudine therapy in chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Treatment Outcome; Young Adult | 2016 |
Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study.
Topics: Adult; Case-Control Studies; Demography; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors | 2016 |
Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Th17 Cells; Treatment Outcome | 2017 |
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Gene Dosage; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Retreatment; Treatment Outcome; Viral Load | 2008 |
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Time Factors; Treatment Failure; Viral Load; Young Adult | 2008 |
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Canada; China; DNA, Viral; Drug Therapy, Combination; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Polyethylene Glycols; Promoter Regions, Genetic; Proportional Hazards Models; Recombinant Proteins; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Core Proteins | 2008 |
Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Viral Core Proteins | 2008 |
Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.
Topics: Acute Disease; Adult; Antiviral Agents; Female; Forecasting; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Models, Biological; Plasma Exchange; Predictive Value of Tests; Prognosis; Severity of Illness Index | 2008 |
Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2008 |
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Single-Blind Method; Virus Replication | 2008 |
Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection.
Topics: Adolescent; Adult; Combined Modality Therapy; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Protein Precursors; Reverse Transcriptase Inhibitors; Young Adult | 2009 |
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Global Health; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Prospective Studies; Pyrimidinones; Regression Analysis; Telbivudine; Thymidine; Treatment Outcome; Virus Replication; Young Adult | 2009 |
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Recurrence; Viral Load | 2009 |
Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine.
Topics: Adenine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Treatment Outcome | 2008 |
Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis | 2009 |
Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hepatitis A virus; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Remission Induction; Young Adult | 2009 |
Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Viral Load | 2008 |
[Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome; Virus Replication | 2009 |
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Liver; Male; Middle Aged; Mutation; Recurrence; Time Factors; Treatment Outcome | 2009 |
Influence of TCM therapy for supplementing Pi and nourishing Shen on dendritic cell function in patients with chronic hepatitis B treated by lamivudine.
Topics: Adult; Alanine Transaminase; Dendritic Cells; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interleukin-12; Lamivudine; Male; Medicine, Chinese Traditional; Middle Aged; Phenotype; Young Adult | 2009 |
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Topics: Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Education, Medical, Continuing; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Probability; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Treatment Outcome | 2009 |
[A study on the treatment of chronic hepatitis B with YMDD mutation].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Young Adult | 2009 |
A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2009 |
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Time Factors; Treatment Outcome | 2009 |
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Sequence Analysis, DNA | 2009 |
[Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Time Factors; Treatment Outcome; Virus Replication; Young Adult | 2009 |
[Evaluation of Chai Shao Liu Jun Tang for the treatment of chronic hepatitis B].
Topics: Adult; Alanine Transaminase; DNA, Viral; Drug Combinations; Drug Resistance, Viral; Drugs, Chinese Herbal; Female; Genes, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Medicine, Chinese Traditional; Mutation; Phytotherapy; Treatment Outcome; Virus Replication | 2009 |
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Cell Line; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; RNA-Directed DNA Polymerase | 2009 |
[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase | 2009 |
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Area Under Curve; Chi-Square Distribution; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Polyethylene Glycols; Recombinant Proteins; Statistics, Nonparametric | 2009 |
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2010 |
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Treatment Outcome | 2009 |
Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Topics: Adult; Aged; Drug Resistance, Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Treatment Outcome | 2009 |
Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Topics: Adolescent; Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome; Young Adult | 2009 |
Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome | 2009 |
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Reverse Transcriptase Inhibitors; Secondary Prevention | 2009 |
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Collagen; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome | 2009 |
[Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Young Adult | 2009 |
Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.
Topics: Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2009 |
[Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease.
Topics: Adult; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Young Adult | 2010 |
Effect of Chinese medicine therapy for strengthening-Pi and nourishing-Shen in preventing lamivudine induced YMDD mutation and its immunologic mechanism.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Male; Medicine, Chinese Traditional; Middle Aged; Mutation; Palliative Care; Secondary Prevention; Young Adult | 2010 |
[A clinical study of viral dynamic change in patients with hepatitis B e antigen positive chronic hepatitis B by lamivudine treatment].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; Viral Load; Young Adult | 2009 |
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2010 |
Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome | 2010 |
Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Drug Resistance, Viral; Female; Hepatitis B Antibodies; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Spondylarthropathies; Tumor Necrosis Factor-alpha; Virus Activation | 2010 |
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Time Factors; Treatment Outcome | 2010 |
Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study.
Topics: Adenine; Adult; Aged; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects | 2010 |
Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Method; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Viral Load; Young Adult | 2010 |
[A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2010 |
Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009).
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2010 |
[Effect of adefovir and lamivudine combination therapy on lamivudine resistance chronic hepatitis B patients for 48 weeks].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2010 |
[Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2010 |
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Treatment Outcome | 2010 |
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome; Young Adult | 2010 |
Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2010 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Substitution; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Complementarity Determining Regions; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphocyte Activation; Male; Nucleosides; Polymerase Chain Reaction; Pyrimidinones; Receptors, Antigen, T-Cell, alpha-beta; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2011 |
[Comparison of lamivudine or interferon monotherapy and sequential therapy in chronic hepatitis B: a random controlled trial].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Treatment Outcome | 2010 |
[Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2010 |
[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Young Adult | 2010 |
[Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Watchful Waiting | 2010 |
[Efficacy of adefovir treatment in the lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Treatment Failure; Young Adult | 2010 |
The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Auditory Threshold; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Earache; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Postural Balance; Recombinant Proteins; Tinnitus; Vestibular Function Tests; Young Adult | 2011 |
[Chemotherapy of chronic viral hepatitis B: randomized multicenter investigation results].
Topics: Acridines; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon Inducers; Lamivudine; Male; Remission Induction | 2010 |
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece c
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors | 2011 |
[A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Young Adult | 2011 |
[Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load].
Topics: Adult; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Viral Load | 2010 |
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inflammation; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Young Adult | 2011 |
[Cycloferon efficacy of therapy of chronic hepatitis B (results of randomized multicentre study)].
Topics: Acridines; Administration, Oral; Adult; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Intramuscular; Interferon Inducers; Lamivudine; Reverse Transcriptase Inhibitors; Russia; Treatment Outcome | 2010 |
[Effect of glucocorticoid treatment on the clinical outcome of patients with early-stage liver failure].
Topics: Adult; Female; Glucocorticoids; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Treatment Outcome; Young Adult | 2011 |
Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.
Topics: Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Viral Load | 2011 |
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Topics: Adenine; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Organophosphonates; Survival Rate; Treatment Outcome | 2011 |
Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; Young Adult | 2011 |
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
Topics: Adult; Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Didanosine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Stavudine; Treatment Outcome | 2011 |
Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; Recurrence; Salvage Therapy; Treatment Outcome; Withholding Treatment | 2011 |
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome | 2011 |
[Effect of Lamivudine on chronic hepatitis B patients with chemotherapy or immunosuppressive agents therapy and research the drug resistance].
Topics: Adult; Antineoplastic Agents; Drug Resistance; Female; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Neoplasms; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Young Adult | 2011 |
[Study of xiaozhang recipe combined with lamivudine in treatment of 84 chronic viral hepatitis B patients with compensated liver cirrhosis].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Integrative Medicine; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Phytotherapy; Prospective Studies; Young Adult | 2011 |
Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2011 |
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Japan; Lamivudine; Liver Neoplasms; Male; Middle Aged; Risk Factors; Treatment Outcome; Viral Load | 2012 |
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Viral Load | 2012 |
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adult; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Polyethylene Glycols; Promoter Regions, Genetic; Recombinant Proteins; Severity of Illness Index; Treatment Outcome; Virus Replication; Young Adult | 2012 |
[Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)].
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Poland; Treatment Outcome; Viral Load | 2011 |
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2012 |
[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2011 |
Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2012 |
[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients].
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Treatment Outcome | 2012 |
[Effects of Fuzheng Huayu Capsule on the ratio of TGF-beta1/BMP-7 of chronic viral hepatitis B fibrosis patients of Gan-Shen insufficiency blood-stasis obstruction syndrome].
Topics: Adult; Antiviral Agents; Bone Morphogenetic Protein 7; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Transforming Growth Factor beta1 | 2012 |
A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged | 2012 |
Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Treatment Outcome; Viral Load | 2012 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Time Factors | 2012 |
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Nucleosides; Organophosphonates; Prospective Studies; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2012 |
A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy; Electroporation; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunotherapy; Interferon-gamma; Lamivudine; Male; Middle Aged; Placebos; Plasmids; T-Lymphocytes; Treatment Outcome; Vaccines, DNA; Viral Load; Young Adult | 2012 |
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome | 2013 |
A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; ROC Curve; Treatment Outcome; Viral Load; Young Adult | 2012 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Multicenter Studies as Topic; Nucleosides; Prospective Studies; Pyrimidinones; Severity of Illness Index; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2012 |
Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chi-Square Distribution; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2013 |
Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors | 2012 |
Safety of lamivudine treatment for chronic hepatitis B in early pregnancy.
Topics: Abortion, Spontaneous; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Maternal Exposure; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, First; Reverse Transcriptase Inhibitors | 2012 |
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates | 2012 |
Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Immunoassay; Lamivudine; Male; Middle Aged; Oligonucleotides; Organophosphonates; Prospective Studies; Republic of Korea; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Famciclovir; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2002 |
Comparison of different treatment combinations for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Famciclovir; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Intramuscular; Injections, Subcutaneous; Interferon-alpha; Lamivudine; Male; Middle Aged; Treatment Outcome | 2002 |
Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine.
Topics: Adolescent; Adult; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Linear Models; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Female; Hematopoietic Stem Cell Transplantation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Survival Analysis; Transplantation, Homologous | 2002 |
Combination therapy for children with chronic hepatitis B virus infection.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors | 2002 |
[Ara-Amp and thymus peptide with lamivudine for the treatment of chronic hepatitis B].
Topics: Drug Therapy, Combination; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Thymus Hormones; Vidarabine Phosphate | 2002 |
[Effects of lamivudine on cirrhotic patients following chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2002 |
Lamivudine in chronic hepatitis B virus.
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2002 |
Lamivudine in renal transplant candidates with chronic hepatitis B infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Safety | 2002 |
Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; Ganciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Theoretical; Reverse Transcriptase Inhibitors; Virus Replication | 2002 |
Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Asian People; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Time Factors | 2002 |
Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation.
Topics: Acute Disease; Adolescent; Adult; Alanine Transaminase; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Recurrence; Reverse Transcriptase Inhibitors | 2002 |
The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.
Topics: Adult; Bilirubin; DNA, Viral; Female; Hepatitis Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Jaundice; Lamivudine; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Survival Analysis | 2002 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Topics: Adolescent; Adult; Alanine Transaminase; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2002 |
Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Mutation; Recurrence; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2002 |
Histological outcome during long-term lamivudine therapy.
Topics: Adult; Alanine Transaminase; Disease Progression; DNA, Viral; Drug Administration Schedule; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Necrosis; Reverse Transcriptase Inhibitors; Safety | 2003 |
An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Double-Blind Method; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged | 2002 |
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Prevalence | 2003 |
Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
Topics: Adolescent; Chi-Square Distribution; Child; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Function Tests; Male; Prognosis; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2003 |
[Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Middle Aged; Quality of Life | 2003 |
[Therapeutic effects of Lamivudine in combination with Thymopentin on chronic hepatitis B].
Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Thymopentin; Treatment Outcome | 2002 |
[Famciclovir treatment of patients with chronic hepatitis B virus infection].
Topics: 2-Aminopurine; Adolescent; Aged; Antiviral Agents; Famciclovir; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Treatment Outcome | 2002 |
[Observation on the therapeutic effect of Lamivudin on chronic hepatitis B].
Topics: Administration, Oral; Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Virus Replication | 2002 |
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Retreatment; Reverse Transcriptase Inhibitors; Safety; Time Factors | 2003 |
[Effectiveness of lamivudine in the treatment of chronic HBeAg-negative viral hepatitis B: results of continuous therapy for 18 months].
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Treatment Outcome | 2003 |
Lamivudine plasma levels in chronic hepatitis B patients.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2003 |
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Prospective Studies; Recombinant Proteins | 2003 |
YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Pharmacogenetics; Polymerase Chain Reaction; Reference Values; Sensitivity and Specificity | 2003 |
[Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Point Mutation; Polymerase Chain Reaction | 2003 |
Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; RNA, Viral | 2003 |
Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop.
Topics: Adult; Aged; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2003 |
Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
Topics: Adult; Aged; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Multivariate Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome | 2003 |
[The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Virus Replication | 2003 |
Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report.
Topics: Adult; Aged; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Reverse Transcriptase Inhibitors; Virus Replication | 2003 |
Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Evaluation; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Recurrence; Retreatment; Reverse Transcriptase Inhibitors | 2003 |
Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Base Sequence; Child; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reference Values; Time Factors | 2003 |
Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Topics: Adolescent; Antiviral Agents; CD8-Positive T-Lymphocytes; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Predictive Value of Tests; Treatment Outcome | 2004 |
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Viral Proteins | 2004 |
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies | 2003 |
Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins | 2004 |
Use of prophylactic lamivudine and mycophenolate mofetil in renal transplant recipients with chronic hepatitis B infection.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibiotic Prophylaxis; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Male; Mycophenolic Acid; Treatment Outcome | 2003 |
Ineffectiveness of hepatitis B vaccination in lamivudine-treated cirrhotics.
Topics: Adult; Combined Modality Therapy; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; Treatment Failure | 2004 |
Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
Topics: Adult; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Reference Values; Secondary Prevention; Transplantation, Homologous; Treatment Outcome | 2004 |
[The influence of lamivudine therapy on the course of chronic hepatitis B in renal allograft recipients].
Topics: Adult; Alanine Transaminase; Female; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors | 2003 |
Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.
Topics: Adult; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2004 |
Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
Topics: Administration, Oral; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins; Time Factors; Treatment Outcome | 2004 |
Interferon re-treatment for resistance to lamivudine plus interferon treatment.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Retreatment; Treatment Outcome; Young Adult | 2003 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Famciclovir; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Pilot Projects; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Topics: 2-Aminopurine; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclovir; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Recombinant Proteins; Treatment Outcome; Viral Load; Viremia | 2004 |
[Adequacy of immediate Lamivudine trial for chronic hepatitis B patients with acute exacerbation].
Topics: Acute Disease; Adolescent; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2004 |
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Double-Blind Method; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Predictive Value of Tests; Treatment Outcome | 2004 |
Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Treatment Failure; Treatment Outcome | 2004 |
A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Virus Replication | 2004 |
Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrosis; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Necrosis; Remission Induction; Reverse Transcriptase Inhibitors; Time Factors | 2004 |
[Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Safety; Treatment Outcome | 2004 |
Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; T-Lymphocytes; Viral Load; Virus Replication | 2004 |
Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Matrix Metalloproteinase 1; Middle Aged; Reverse Transcriptase Inhibitors; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.
Topics: Adult; Aged; Alanine Transaminase; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Treatment Outcome | 2004 |
[Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China].
Topics: Adjuvants, Immunologic; Antiviral Agents; China; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Thymalfasin; Thymosin; Treatment Outcome | 2004 |
[IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B].
Topics: Adult; Alkaloids; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Quinolizines; Recombinant Proteins; Treatment Outcome | 2004 |
Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily.
Topics: Adult; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Models, Biological; Mutation; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins | 2004 |
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Drug Resistance; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Severity of Illness Index | 2004 |
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.
Topics: Adolescent; Adult; Alanine Transaminase; Asian People; DNA, Viral; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2004 |
Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; Single-Blind Method; Treatment Outcome | 2004 |
[Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Prospective Studies; Virus Replication | 2004 |
[The HBeAg/antiHBe seroconversion as a result of lamivudine treatment in children with chronic hepatitis B unresponsive to previous interferon alpha therapy].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Time Factors; Treatment Outcome | 2004 |
End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.
Topics: Adult; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2005 |
Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Reverse Transcriptase Inhibitors; Time Factors | 2004 |
Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation.
Topics: Adult; Aged; Female; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Renal Dialysis; Treatment Outcome | 2005 |
In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Topics: Adult; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.
Topics: DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.
Topics: Adolescent; Adult; Aged; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Viral Load | 2005 |
Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Topics: Adult; Aged; Amino Acid Motifs; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
[Results of 12-month lamivudine therapy of chronic hepatitis B in children].
Topics: Adolescent; Child; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2004 |
Clinical outcome of long-term lamivudine treated chronic HBV infected and HIV/HBV coinfected patients.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy.
Topics: Adolescent; Adult; Asian People; Biopsy; China; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2005 |
[Treatment of chronic hepatitis B].
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Costs; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2004 |
Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.
Topics: Adolescent; Adult; Amino Acid Motifs; Anti-HIV Agents; Aspartic Acid; DNA, Circular; DNA, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Isoleucine; Lamivudine; Male; Methionine; Middle Aged; Mutation; Placebos; Reverse Transcriptase Inhibitors; Tyrosine; Valine; Viral Load | 2005 |
Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2005 |
Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia | 2005 |
Effects of lamivudine therapy on the glucose metabolism in children with chronic hepatitis B: first year follow-up results.
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Hepatitis B, Chronic; Humans; Insulin; Interferon-alpha; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2005 |
Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Dosage; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Recurrence; Reverse Transcriptase Inhibitors; Viral Load | 2005 |
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Treatment Outcome | 2005 |
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
Topics: Adult; Antiviral Agents; DNA, Circular; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Sensitivity and Specificity; Treatment Outcome | 2005 |
Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT level.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Two-year observation of the clinical efficacy in treating chronic hepatitis B Patients with Ganxian recipe and lamivudine.
Topics: Adolescent; Adult; Female; Gene Frequency; Genes, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Medicine, Chinese Traditional; Middle Aged; Mutation; Phytotherapy; Plant Preparations; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Recurrence; Retreatment | 2005 |
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatic Encephalopathy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Organophosphonates; Survival Analysis; Taiwan | 2005 |
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins | 2005 |
Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics.
Topics: Adult; Aged; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
[Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Virus Replication | 2005 |
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adolescent; Adult; Age Factors; Aged; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Long-Term Care; Male; Maximum Tolerated Dose; Middle Aged; Nucleosides; Pyrimidinones; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Telbivudine; Thymidine; Treatment Outcome | 2005 |
Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Polymerase Chain Reaction | 2005 |
Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged | 2005 |
Lamivudine in hepatitis B-associated membranous nephropathy.
Topics: Adult; Blood Pressure; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome | 2005 |
High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Child; Child, Preschool; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; India; Lamivudine; Male; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors | 2005 |
Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
Topics: Adolescent; Antiviral Agents; Bone Density; Child; Child, Preschool; Collagen; Collagen Type I; Cytokines; Drug Therapy, Combination; Female; Femur; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Lamivudine; Male; Osteoporosis; Parathyroid Hormone; Peptides; Receptors, Interleukin-2; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2005 |
Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Topics: Adult; Antigens, Viral; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2005 |
Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Viremia | 2005 |
Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Mutation; Recurrence; Reverse Transcriptase Inhibitors; Time Factors | 2005 |
Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Topics: Adjuvants, Immunologic; Adult; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-12; Lamivudine; Male; Pilot Projects; Recombinant Proteins; Reverse Transcriptase Inhibitors; T-Lymphocytes; Viremia; Virus Replication | 2005 |
Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?
Topics: Biopsy; Disease Progression; Double-Blind Method; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Ultrasonography | 2005 |
Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Treatment Outcome | 2005 |
Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection.
Topics: Adult; Aged; Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Female; Foscarnet; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2005 |
A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors | 2004 |
Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B.
Topics: DNA Probes; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genes, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Sequence Analysis, DNA | 2005 |
Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Pregnancy; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Immunoglobulins; Infusions, Intravenous; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Risk Assessment; Secondary Prevention; Transplantation Immunology; Treatment Outcome | 2006 |
[Antiviral therapy of chronic hepatitis B patients resistant to lamivudine].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Thymosin; Treatment Outcome | 2005 |
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Secondary Prevention; Treatment Outcome; Viral Load; Virus Activation | 2006 |
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA Mutational Analysis; DNA, Viral; Female; Gene Products, pol; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Time Factors; Treatment Outcome | 2006 |
[Evaluation of prophylactic use of lamivudine in HBV-positive patients with malignant lymphoma undergoing chemotherapy].
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carrier State; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Lymphoma; Male; Middle Aged; Prospective Studies | 2005 |
[Treatment options in chronic hepatitis B].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Function Tests; Male; Polyethylene Glycols; Recombinant Proteins | 2006 |
Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Child; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Immunocompetence; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Male; Pilot Projects; Treatment Outcome | 2006 |
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Molecular Sequence Data; Treatment Outcome | 2006 |
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Molecular Sequence Data; Treatment Outcome | 2006 |
Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins | 2006 |
[Lamivudine administration prevents fulminant hepatic failure in patients with severe chronic hepatitis B].
Topics: Adult; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2006 |
Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins; Sex Hormone-Binding Globulin; Viral Load | 2006 |
High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Bilirubin; Biomarkers; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Liver Failure; Male; Middle Aged; Multivariate Analysis; Mutation; Platelet Count; Predictive Value of Tests; Prospective Studies; Prothrombin Time; Reverse Transcriptase Inhibitors; Risk Factors; Serum Albumin | 2006 |
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2006 |
Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment.
Topics: Adolescent; Adult; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2006 |
Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese.
Topics: Adult; Antiviral Agents; Asian People; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-1; Lamivudine; Male; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Treatment Outcome | 2006 |
Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2006 |
The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Time Factors; Treatment Outcome | 2006 |
Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
Topics: Administration, Oral; Adolescent; Adult; Aged; Disease Progression; Female; Genetic Markers; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Hospitals, Urban; Humans; Lamivudine; Male; Middle Aged; Mutation; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Time Factors; Tokyo; Treatment Outcome | 2006 |
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Viral Load | 2006 |
[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Viral Load | 2006 |
[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (+)].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Viral Load | 2006 |
Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
Topics: Adult; Antiviral Agents; China; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins | 2006 |
[Study on chronical hepatitis B with treatment of integrative traditional Chinese and Western medicine].
Topics: Adolescent; Adult; Aged; Albumins; Anti-HIV Agents; Astragalus propinquus; DNA, Viral; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Plants, Medicinal | 2006 |
[The clinical study on chronic hepatitis B treated by the four-step therapeutics of Traditional Chinese Medicine].
Topics: Adolescent; Adult; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Phytotherapy; Plants, Medicinal; Treatment Outcome | 2006 |
[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2006 |
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Sex Factors; Treatment Outcome | 2007 |
Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation | 2006 |
[Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Prednisone; Recombinant Proteins | 2006 |
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Treatment Outcome | 2006 |
[Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B].
Topics: Adult; Capsules; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Phytotherapy; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
[Optimal lamivudine treatment duration and the relationship between its early response and long term effect].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Young Adult | 2006 |
Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Topics: Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; Biopsy, Fine-Needle; DNA Probes; DNA, Circular; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Mutation; Pilot Projects; Virus Replication | 2007 |
[Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Treatment Failure; Virus Replication; Young Adult | 2007 |
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Salvage Therapy; Treatment Outcome; Virus Replication | 2007 |
Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Topics: Adult; Antibody Formation; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Protein Precursors; Protein S | 2007 |
One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Topics: Adult; Antiviral Agents; China; DNA, Circular; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2006 |
Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Taiwan; Treatment Outcome | 2006 |
Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Precursors; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2006 |
[A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Double-Blind Method; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Viral Load | 2006 |
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.
Topics: Adult; Age Factors; Female; France; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-beta; Lamivudine; Male; Middle Aged; Remission Induction; Retrospective Studies; Reverse Transcriptase Inhibitors | 2007 |
Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Bilirubin; Creatinine; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2007 |
[Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B].
Topics: Anti-HIV Agents; Child; Child, Preschool; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Treatment Outcome | 2007 |
Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2007 |
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2007 |
Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2007 |
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Biopsy, Needle; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Lamivudine; Leptin; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome | 2007 |
Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Predictive Value of Tests; Treatment Outcome; Virus Replication | 2007 |
Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alanine Transaminase; China; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Endpoint Determination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2007 |
[The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
Topics: Adolescent; Adult; Antiviral Agents; Female; Genome, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Young Adult | 2007 |
Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Health Care Costs; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Sensitivity and Specificity; United Kingdom | 2007 |
[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection.
Topics: Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth Disorders; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male | 2007 |
Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Viral Load | 2007 |
[Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Evaluation; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Failure; Young Adult | 2007 |
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2007 |
A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Virus Replication | 2007 |
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tokyo; Treatment Outcome; Viral Load | 2007 |
Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Recurrence; Risk Factors | 2007 |
In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Treatment Outcome; Viral Load | 2007 |
The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2007 |
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Quality of Life; Salvage Therapy | 2007 |
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2007 |
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Spain | 2007 |
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Combined Modality Therapy; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunity, Cellular; Immunotherapy; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Topics: Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors | 2007 |
Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Child; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Treatment Outcome; Viral Load | 2007 |
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Topics: Adult; Antiviral Agents; Biopsy; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Treatment Outcome | 2007 |
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Double-Blind Method; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2008 |
A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Time Factors | 2008 |
Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Retrospective Studies | 2008 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2007 |
[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome | 2007 |
[Change of HBV DNA level as a predictor of HBeAg loss after lamivudine treatment].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Treatment Outcome | 2007 |
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Topics: Adult; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2007 |
Long-term conventional interferon alpha in combination with lamivudine for chronic hepatitis B: data from Turkey.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins; Reverse Transcriptase Inhibitors; Turkey | 2007 |
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates | 2008 |
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Viral Load | 2008 |
[Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; DNA, Circular; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Young Adult | 2008 |
Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Thymalfasin; Thymosin | 2008 |
[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Time Factors | 2008 |
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2008 |
Dynamics of hepatitis B virus infection in vivo.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Least-Squares Analysis; Middle Aged; Reverse Transcriptase Inhibitors; Virus Replication | 1997 |
Lamivudine resistance in chronic hepatitis B.
Topics: Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors | 1998 |
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 1998 |
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.
Topics: Adult; Aged; Alanine Transaminase; Amylases; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Pilot Projects; Recombinant Proteins; Time Factors | 1998 |
Clinical impact of lamivudine resistance in chronic hepatitis B.
Topics: Anti-HIV Agents; Drug Resistance; Hepatitis B, Chronic; Humans; Lamivudine | 1998 |
Treatment of chronic hepatitis B with lamivudine in renal transplant recipients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Creatinine; Cyclosporine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Reverse Transcriptase Inhibitors; Virus Replication | 1998 |
Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; DNA, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Single-Blind Method; Time Factors | 1998 |
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Topics: Adolescent; Adult; Aged; DNA, Viral; Double-Blind Method; Female; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Protein Precursors; Reverse Transcriptase Inhibitors; Treatment Outcome | 1999 |
[One year treatment with lamivudine in different hepatitis B virus related hepatic diseases].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors | 1999 |
Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Biopsy; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inflammation; Lamivudine; Liver; Male; Necrosis; Observer Variation; Time Factors | 1999 |
Lamivudine for chronic hepatitis B and HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine | 1999 |
[Long-term effect of lamivudine treatment in chronic hepatitis B virus infection].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 1999 |
Lamivudine as initial treatment for chronic hepatitis B in the United States.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; United States | 1999 |
Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.
Topics: Antiviral Agents; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Genetic Variation; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors; Viremia | 1999 |
A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Dose-Response Relationship, Drug; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2000 |
Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Safety | 2000 |
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Treatment Outcome | 2000 |
Management of hepatitis B in China.
Topics: Adult; Alanine Transaminase; Antiviral Agents; China; DNA, Viral; Double-Blind Method; Female; Genetic Variation; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2000 |
Response of pre-core mutant chronic hepatitis B infection to lamivudine.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Protein Precursors; Treatment Outcome; Viral Core Proteins | 2000 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclovir; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2000 |
Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Drug Evaluation; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2000 |
Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2000 |
Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2000 |
Treatment of chronic hepatitis B with lamivudine in renal allograft recipients.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Postoperative Complications | 2000 |
[Successful primary therapy of chronic hepatitis B with lamivudine].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2000 |
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lamivudine; Male; RNA, Viral | 2000 |
Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection.
Topics: Antiviral Agents; DNA, Viral; Drug Synergism; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome; Viral Load | 2000 |
An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
Topics: Adult; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; Virus Replication | 2000 |
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Topics: Adult; Aged; DNA-Directed DNA Polymerase; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Mutation; Postoperative Care; Preoperative Care; Reverse Transcriptase Inhibitors; Safety; Secondary Prevention; Survival Analysis | 2001 |
[Long-term lamivudine therapy for interferon-alpha- and/or adenine arabinoside monophosphate-resistant chronic hepatitis B infection. Results of a pilot study].
Topics: Adult; Antiviral Agents; Drug Resistance, Microbial; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Long-Term Care; Male; Middle Aged; Pilot Projects; Treatment Outcome; Vidarabine Phosphate | 2000 |
Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Biopsy; Cohort Studies; DNA Primers; DNA, Viral; Female; Fluorescent Antibody Technique; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Prognosis; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Virus Replication | 2000 |
Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Genetic Variation; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Luminescent Measurements; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Time Factors; Viral Load | 2001 |
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
Topics: Adult; Antiviral Agents; Drug Resistance, Microbial; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Statistics as Topic | 2001 |
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Delayed-Action Preparations; DNA, Viral; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Safety; Time Factors | 2001 |
[Clinical efficacy of lamivudine in the treatment of chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation | 2001 |
Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
Topics: Antiviral Agents; Budgets; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; United States | 2001 |
Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes.
Topics: Antibodies, Monoclonal; Antigen-Antibody Complex; Cohort Studies; Dose-Response Relationship, Drug; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Injections, Intravenous; Lamivudine; Neutralization Tests; Reverse Transcriptase Inhibitors | 2001 |
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Topics: Adolescent; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2001 |
Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Recombinant Proteins | 2001 |
A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Virus Replication | 1999 |
Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection.
Topics: Administration, Oral; Adult; Aged; Comorbidity; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Failure; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
Topics: Actins; Adult; Biopsy; Collagen Type III; Female; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lamivudine; Liver; Male; Middle Aged; Muscle, Smooth; Procollagen; Reverse Transcriptase Inhibitors | 2001 |
Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Genetic Variation; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Mutation; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis | 2001 |
Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Viral Load | 2001 |
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Intradermal; Interleukin-2; Lamivudine; Lymphocyte Activation; Reverse Transcriptase Inhibitors; Treatment Outcome; Vaccination; Vaccines, Synthetic | 2002 |
Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Treatment Outcome | 2002 |
A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Topics: Abdominal Pain; Adult; Aged; Alanine Transaminase; Angina Pectoris; Antiviral Agents; Biomarkers; Bronchopneumonia; Colitis, Ulcerative; DNA, Viral; Female; Gastrointestinal Diseases; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Poland; Reverse Transcriptase Inhibitors; Safety; Urinary Tract Infections; Viral Load; Viremia; Virus Replication | 2002 |
Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
Topics: Adult; Combined Modality Therapy; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Male; Middle Aged; Neutralization Tests; Reverse Transcriptase Inhibitors | 2002 |
Viral dynamics in chronic hepatitis B patients during lamivudine therapy.
Topics: DNA, Viral; Half-Life; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Biological; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viral Load; Virus Replication | 2002 |
Clinical trial of lamivudine in children with chronic hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Double-Blind Method; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Logistic Models; Reverse Transcriptase Inhibitors | 2002 |
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
[Lamivudine in patients with chronic HBV infection and therapeutic difficulties].
Topics: Adult; Aged; Contraindications; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon Type I; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Virus Replication | 2002 |
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Ethnicity; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Placebos; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
1319 other study(ies) available for lamivudine and Chronic Hepatitis B
| Article | Year |
|---|---|
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2007 |
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Dioxolanes; DNA, Viral; Dose-Response Relationship, Drug; Guanine; Half-Life; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Injections, Intravenous; Marmota; Prodrugs; Purines; Tissue Distribution | 2007 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Marmota; Organophosphonates; RNA, Viral; Rodent Diseases; Tenofovir; Virus Replication | 2008 |
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2010 |
Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Treatment Outcome; Viral Load | 2021 |
[Analysis of risk factors for drug resistant mutations in the reverse transcriptase region in chronic hepatitis B virus-infected patients].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Pharmaceutical Preparations; Retrospective Studies; Risk Factors; RNA-Directed DNA Polymerase | 2021 |
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Topics: Adult; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; RNA | 2022 |
Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients.
Topics: Antiviral Agents; Child, Preschool; Coinfection; DNA, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; Romania | 2022 |
A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase | 2022 |
Association of Pre-S/S and Polymerase Mutations with Acute and Chronic Hepatitis B Virus Infections in Patients from Rio de Janeiro, Brazil.
Topics: Brazil; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nucleotides; Phylogeny; Protein S | 2022 |
A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
[Analysis of characteristics of drug resistance gene mutation in HBV RT region of hepatitis B infected patients].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Retrospective Studies | 2023 |
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Topics: Aldo-Keto Reductase Family 1 member B10; Aldo-Keto Reductases; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Tenofovir | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukin-10; Interleukin-12; Lamivudine; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Nucleosides; Organophosphonates; Proto-Oncogene Proteins c-akt; Tenofovir | 2020 |
Effects of lamivudine on cell proliferation of liver cancer and expressions of HBsAg, HBeAg, and MMP-9 in patients.
Topics: Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Matrix Metalloproteinase 9; Time Factors; Virus Replication | 2019 |
Serum Vitamin D Levels in Chronic Hepatitis B Patients Before and During Treatment.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Prospective Studies; Vitamin D | 2020 |
Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis.
Topics: Antiviral Agents; Bibliometrics; China; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2020 |
Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; RNA-Directed DNA Polymerase | 2019 |
Long term follow-up of children with chronic hepatitis B: a single center experience.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Infant; Interferons; Lamivudine; Male; Retrospective Studies; Seroconversion | 2019 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
Topics: Antigens, Surface; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation | 2020 |
Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nanopore Sequencing; Pharmaceutical Preparations; Polymerase Chain Reaction | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir | 2020 |
Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Treatment Outcome | 2021 |
Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.
Topics: Antiviral Agents; DNA, Circular; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Mutation; Trans-Activators; Viral Regulatory and Accessory Proteins; Virus Replication | 2020 |
Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
Topics: DNA; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; RNA | 2021 |
De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis.
Topics: Antiviral Agents; Child; DNA, Viral; Female; Fibrosis; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Interferon-alpha; Lamivudine; Male; Treatment Outcome | 2020 |
Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation | 2020 |
Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy.
Topics: Antiviral Agents; Glomerulonephritis, Membranous; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Treatment Outcome | 2020 |
Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Nucleotides; Prospective Studies; Treatment Outcome | 2020 |
Management of Hepatitis-B Virus Infection in Immunocompromised Children: A Single Center Experience.
Topics: Antiviral Agents; Child; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Herpesviridae Infections; Humans; Lamivudine; Retrospective Studies; Symptom Flare Up; Virus Activation | 2021 |
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Treatment Outcome | 2021 |
Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mutation; Nucleosides; Nucleotides; Organophosphonates; Phylogeny; Telbivudine; Viral Load; Virus Replication | 2021 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes.
Topics: Adult; Antiviral Agents; Child; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Real-Time Polymerase Chain Reaction | 2021 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis; Tenofovir; Treatment Failure | 2017 |
Telbivudine attenuates gentamicin-induced kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Cystatin C; Gentamicins; Glomerular Filtration Rate; Hepatitis B, Chronic; Kidney; Lamivudine; Male; Pilot Projects; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Telbivudine; Thymidine | 2017 |
Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; DNA, Viral; Elasticity Imaging Techniques; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Severity of Illness Index | 2017 |
Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
Topics: Animals; Cell Division; Cell Proliferation; Chimera; Disease Models, Animal; DNA, Circular; DNA, Viral; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Keratin-18; Lamivudine; Lipopeptides; Mice; Primary Cell Culture; Recurrence; Reverse Transcriptase Inhibitors; Viral Load; Virus Integration; Virus Replication | 2018 |
Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Brazil; Coinfection; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates | 2017 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Guidelines as Topic; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B?
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Recurrence | 2017 |
Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B.
Topics: Adolescent; Anthropometry; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Malnutrition; Nutritional Status; Obesity; Weight Loss | 2017 |
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; ROC Curve; Tenofovir; Treatment Outcome | 2017 |
Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Mutation; Nucleosides; Nucleotides; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lactic Acid; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Sex Factors; Tenofovir; Time Factors; Treatment Outcome; Up-Regulation; Young Adult | 2017 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Child; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy Complications, Infectious; Tenofovir | 2017 |
Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Polymerase Chain Reaction; Sensitivity and Specificity; Seroconversion; Tenofovir; Viral Load; Virus Replication | 2017 |
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2017 |
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Virus Activation; Young Adult | 2018 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Lamivudine: fading into the mists of time.
Topics: Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2017 |
Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Topics: Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Mutation | 2017 |
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Remission Induction; Retrospective Studies; Tenofovir | 2018 |
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray.
Topics: Adenine; Dendrimers; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microarray Analysis; Mutation; Nucleic Acid Amplification Techniques; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction | 2018 |
Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Male; Middle Aged; Treatment Outcome | 2018 |
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2018 |
Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Patient Safety; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, First; Retrospective Studies; Telbivudine; Thymidine; Treatment Outcome; Viral Load | 2018 |
Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Sustained Virologic Response | 2018 |
A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Child; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Medication Adherence; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tacrolimus | 2018 |
Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; China; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Telbivudine; Thymidine; Virus Activation; Virus Replication | 2018 |
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.
Topics: Adenine; Adult; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Organophosphonates; Reverse Transcriptase Inhibitors; Sustained Virologic Response; Telbivudine; Thymidine | 2018 |
48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Nucleosides; Organophosphonates; Outpatients; Prognosis; Prospective Studies; Recurrence; Risk Factors; RNA, Viral; Telbivudine; Time Factors; Treatment Outcome; Withholding Treatment | 2018 |
Monitoring and treatment results of 88 HBsAg-positive pregnant women.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Tenofovir; Young Adult | 2016 |
[Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Organophosphonates; Telbivudine; Treatment Outcome | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2019 |
Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
Topics: Antiviral Agents; Cell Line; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; RNA, Viral; Viral Load; Virus Replication | 2018 |
Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues.
Topics: Antiviral Agents; Child; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2018 |
Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Nucleosides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Seroconversion; Tenofovir | 2018 |
Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Virus Activation; Young Adult | 2018 |
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Tenofovir; Virus Activation; Young Adult | 2019 |
High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Early Detection of Cancer; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Retrospective Studies; Risk Factors; Telbivudine | 2019 |
Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Germany; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load; Young Adult | 2019 |
Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study.
Topics: Adenine; Administration, Oral; Aged; Antiviral Agents; DNA, Mitochondrial; Female; Gene Deletion; Hepatitis B, Chronic; Humans; Lamivudine; Mitochondrial Myopathies; Muscle, Skeletal; Organophosphonates | 2019 |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load | 2019 |
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Middle Aged; Nucleosides; Organophosphonates; Prognosis | 2019 |
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Nucleotides; Viral Envelope Proteins; Young Adult | 2019 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Epithelial Cells; Female; Glomerular Filtration Rate; Heat-Shock Proteins; Hepatitis A Virus Cellular Receptor 1; Hepatitis B, Chronic; Humans; In Vitro Techniques; Interleukin-18; Kidney Tubules; Lamivudine; Lipocalin-2; Male; Middle Aged; Organophosphonates; Prospective Studies; Protective Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Telbivudine; Tenofovir | 2019 |
Long-term data on entecavir treatment for treatment-naive or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Retrospective Studies; Transplant Recipients | 2019 |
A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus.
Topics: Anti-HIV Agents; Blotting, Southern; Cell Line, Tumor; Drug Resistance, Viral; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Phenotype; Plasmids; Real-Time Polymerase Chain Reaction; Transfection; Virus Replication | 2013 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Phosphorous Acids; Viremia | 2013 |
Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach.
Topics: Alleles; Antiviral Agents; DNA Primers; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Mutation; Oligonucleotide Probes; Sensitivity and Specificity | 2013 |
Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Nucleosides; Point Mutation; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Thymidine; Treatment Outcome | 2013 |
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.
Topics: Adenine; Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2013 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Topics: Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Guanine; Hematologic Diseases; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Patient Selection; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Virus Activation | 2013 |
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Hypophosphatemia; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Risk Factors; Time Factors | 2014 |
Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies | 2013 |
Choice of drugs in the treatment of chronic hepatitis B in pregnancy.
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious | 2013 |
Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon?
Topics: Antiviral Agents; Biomarkers; Case-Control Studies; Child; Child, Preschool; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Retrospective Studies; Treatment Outcome | 2013 |
Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2013 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Europe; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.
Topics: Adult; Asian People; China; DNA, Viral; Female; Fibrosis; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Rural Population; Treatment Outcome | 2013 |
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Recurrence; Telbivudine; Thymidine; Treatment Outcome | 2013 |
[Low prevalence of hepatitis B virus primary drug resistance in Southern Spain].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Gene Products, pol; Genes, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Point Mutation; Prevalence; Prospective Studies; Reverse Transcriptase Inhibitors; Spain; Young Adult | 2013 |
[Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Genetic Drift; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2012 |
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Care; Proportional Hazards Models; Secondary Prevention; Survival Rate; Viral Load; Young Adult | 2013 |
[Anti-HBV effect of nucleotide analogues on mouse model of chronic HBV infection mediated by recombinant adeno-associated virus 8].
Topics: Animals; Antiviral Agents; Dependovirus; Disease Models, Animal; Genetic Vectors; Genome, Viral; Guanine; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Lamivudine; Mice; Mice, Inbred C57BL; Nucleotides; Transduction, Genetic; Virus Replication | 2013 |
Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; ROC Curve; Treatment Outcome | 2013 |
Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Topics: Adenine; Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Organophosphonates; Prospective Studies; Recurrence; Treatment Outcome | 2013 |
Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Organophosphonates | 2013 |
Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Recurrence; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Viral Load; Young Adult | 2013 |
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2013 |
Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study.
Topics: Adult; Antiviral Agents; Asian People; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2013 |
The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Plasma; Prevalence; Prognosis; Serbia; Survival Analysis; Time Factors; Treatment Outcome; Viral Load | 2013 |
Hepatitis B prevalence and influence on HIV treatment outcome and mortality in the Chilean AIDS Cohort.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Chile; Coinfection; Cyclopropanes; Female; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Prevalence; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues.
Topics: Adenine; Alanine Transaminase; Genotype; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Homozygote; Humans; India; Lamivudine; Liver Function Tests; Mutation; Nucleosides; Nucleotides; Organophosphonates; Pilot Projects; Polymorphism, Genetic; Receptors, CCR5; Telbivudine; Thymidine | 2013 |
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
Topics: Adenine; Adult; Aged; Asian People; DNA, Viral; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Treatment Outcome | 2014 |
Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Clinical Competence; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Practice Patterns, Physicians' | 2013 |
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
Topics: Animals; Antiviral Agents; Cell Line; DNA, Viral; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Lamivudine; Male; Mice; Mice, Nude; Microbial Sensitivity Tests; Primary Cell Culture; Pyridines; Pyrimidines; Thiazoles; Viral Core Proteins; Viremia; Virion; Virus Replication | 2013 |
[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Young Adult | 2013 |
Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2014 |
Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Treatment Outcome; Young Adult | 2013 |
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Aspartate Aminotransferases; Bilirubin; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects | 2013 |
[Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2013 |
Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; France; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Mutation; Phenotype; Prospective Studies; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2014 |
Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genetic Markers; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Treatment Outcome | 2014 |
Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Diagnostic Techniques; Mutation; Nucleosides; Nucleotides; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sensitivity and Specificity; Sequence Analysis, DNA | 2013 |
Strategic use of lamivudine in the management of chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine | 2013 |
Hepatitis B virus complications of pregnancy after kidney transplantation.
Topics: Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2013 |
Successful pregnancy in a kidney transplant recipient with chronic hepatitis B virus infection.
Topics: Adult; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2013 |
[Outcome of chronic hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive drugs and anti-TNF agents].
Topics: Adalimumab; Adenine; Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azathioprine; Crohn Disease; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Organophosphonates; Tumor Necrosis Factor-alpha; Viral Load; Viremia; Virus Activation | 2014 |
Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.
Topics: Adenine; Adult; Aged; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2013 |
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2013 |
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Time Factors | 2014 |
Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.
Topics: Adult; Antiviral Agents; Brazil; Diagnostic Errors; DNA, Viral; Drug Resistance, Viral; False Negative Reactions; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Male; Mutation, Missense; Polymerase Chain Reaction; Sequence Analysis, DNA | 2013 |
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Case-Control Studies; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Methionine; Middle Aged; Mutation; Organophosphonates; Prognosis; Retrospective Studies; Turkey; Tyrosine | 2013 |
What evidence exists to support antiviral treatment in children with chronic hepatitis B?
Topics: Alanine Transaminase; Antiviral Agents; Child; Disease Management; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous | 2014 |
Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; China; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Codon, Nonsense; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Young Adult | 2014 |
Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Telbivudine; Thymidine; Time Factors; Treatment Outcome | 2014 |
Restoration of albumin production by nucleoside analogue therapy in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression; Guanine; Hepatitis B, Chronic; Hepatocyte Growth Factor; Humans; Lamivudine; Liver; Male; Middle Aged; Serum Albumin; Transforming Growth Factor beta1; Young Adult | 2014 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hospitalization; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Monitoring, Ambulatory; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Lamivudine treatment failure risks in chronic hepatitis B patients with low viral load.
Topics: Adult; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Treatment Failure; Viral Load | 2013 |
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunohistochemistry; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Phosphorylation; Protein Isoforms; Signal Transduction; Smad3 Protein; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2014 |
Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Viral Load | 2014 |
Early entecavir treatment for chronic hepatitis B with severe acute exacerbation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Time Factors; Treatment Outcome; Viral Load | 2014 |
HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2013 |
Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Multiplex Polymerase Chain Reaction; Mutation; Organophosphonates; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Time | 2014 |
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Serum HBsAg level and its clinical significance in lamivudine treatment for patients with HBeAg-negative acute-on-chronic liver failure.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2014 |
Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Prospective Studies; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity; Viral Load; Young Adult | 2014 |
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Host-Derived Cellular Factors; Humans; Interleukin-10; Lamivudine; Middle Aged; Mutation; Nucleosides; Organophosphonates; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Sex Factors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tenofovir; Viral Load | 2014 |
Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients.
Topics: Adult; Aged; Biomarkers; Female; Forecasting; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
[Loss of hbs antigen after treatment with analogues: infrequent but stable and beneficial].
Topics: Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2013 |
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
Topics: Adult; Antiviral Agents; Cell Line, Tumor; China; DNA, Viral; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Virus Replication | 2014 |
Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application.
Topics: Adenine; Adult; Alleles; Antiviral Agents; DNA Primers; DNA, Viral; Drug Resistance, Viral; Early Diagnosis; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Isoleucine; Lamivudine; Limit of Detection; Male; Middle Aged; Molecular Sequence Data; Mutation; Nucleotide Motifs; Oligonucleotides; Organophosphonates; Real-Time Polymerase Chain Reaction | 2014 |
Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Protein Domains | 2014 |
Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Kaplan-Meier Estimate; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Patient Acuity; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time | 2014 |
Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Thymidine; Time Factors; Virus Activation; Withholding Treatment | 2014 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B.
Topics: Acute-On-Chronic Liver Failure; End Stage Liver Disease; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2014 |
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Severity of Illness Index; Tenofovir; Time Factors; Young Adult | 2014 |
Ending vertical transmission of hepatitis B: the third trimester intervention.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Telbivudine; Thymidine | 2014 |
Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Arabinofuranosyluracil; Biomarkers; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Time Factors | 2014 |
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services Research; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; Thailand; Treatment Outcome | 2014 |
On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
HBV mutations associated with lamivudine therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cross Reactions; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Gene Products, pol; Genetic Variation; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Point Mutation; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2013 |
HLA-DQ polymorphisms with HBV infection: different outcomes upon infection and prognosis to lamivudine therapy.
Topics: Adult; Aged; Asian People; Female; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hepatitis B, Chronic; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2014 |
Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2014 |
Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Topics: Acute-On-Chronic Liver Failure; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; China; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2014 |
Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Republic of Korea; Retrospective Studies; RNA-Directed DNA Polymerase | 2014 |
The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Recurrence; Regression Analysis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Withholding Treatment | 2014 |
Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman.
Topics: Adolescent; Adult; Amino Acid Sequence; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Molecular Sequence Data; Mutation; Oman; Reverse Transcriptase Inhibitors; Young Adult | 2014 |
Expression and clinical significance of myeloid derived suppressor cells in chronic hepatitis B patients.
Topics: Adult; Alanine Transaminase; Albumins; Aspartate Aminotransferases; Bilirubin; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Myeloid Cells | 2014 |
Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Topics: Adenine; Adult; Antiviral Agents; China; Clone Cells; Drug Resistance, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Organophosphonates; Phenotype; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Viral Proteins | 2015 |
Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Serum; Treatment Outcome; Viral Load | 2014 |
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Telbivudine; Thymidine; Treatment Outcome; Viral Load; Young Adult | 2014 |
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2015 |
Reducing the risk of infection in a 74-year-old man who is to receive prednisone.
Topics: Aged; Glucocorticoids; Hepatitis B, Chronic; Humans; Lamivudine; Latent Tuberculosis; Male; Pemphigoid, Bullous; Pneumonia, Pneumocystis; Prednisone; Reverse Transcriptase Inhibitors; Risk Factors; Risk Reduction Behavior; Strongyloidiasis | 2014 |
Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; China; Cohort Studies; DNA Replication; Drug Resistance, Viral; Female; Genes, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Virus Replication; Young Adult | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Professional-to-Patient; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Viral Load; Viremia | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Tenofovir; Thymidine | 2014 |
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Greece; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Risk Assessment; Treatment Outcome | 2015 |
[Hepatitis B infection transmission by anti-HBc-positive grafts].
Topics: Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Immunoglobulin G; Lamivudine; Liver Transplantation; Tissue Donors | 2014 |
HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy.
Topics: Adult; Antiviral Agents; Asian People; Biomarkers; Down-Regulation; Female; Gene Frequency; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HLA-DP Antigens; Humans; Japan; Lamivudine; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Time Factors; Treatment Outcome; Viral Load | 2015 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Withholding Treatment; Young Adult | 2014 |
Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Treatment Outcome | 2014 |
Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Disease Progression; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors | 2015 |
Safety and efficacy of entecavir in adefovir-experienced patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Substitution; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Time Factors; Treatment Outcome; Viral Load | 2015 |
[Antiviral therapy in children with chronic hepatitis B and children with chronic hepatitis C].
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Polyethylene Glycols | 2014 |
Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function.
Topics: Adult; Antiviral Agents; Creatinine; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Recurrence; Telbivudine; Thymidine | 2014 |
The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Feasibility Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.
Topics: Adolescent; Antiviral Agents; Biomarkers; Child; Child, Preschool; DNA, Viral; Drug Monitoring; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Lamivudine; Liver; Male; Plasma; Prognosis; Treatment Outcome | 2015 |
[Viral relapse and genetic resistance after a nearly 8-year cessation of lamivudine therapy in a patient with chronic hepatitis B: a case report].
Topics: Adult; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Recurrence | 2014 |
Pretreatment and on-treatment indicators of virologic breakthrough of lamivudine therapy in chronic hepatitis B patients: an Egyptian study.
Topics: Adult; Egypt; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2014 |
Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome; Viral Load; Young Adult | 2015 |
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation Rate; Mutation, Missense; Organophosphonates; Point Mutation; Retrospective Studies; RNA-Directed DNA Polymerase; Selection, Genetic; Young Adult | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2014 |
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphates; ROC Curve; Treatment Outcome | 2014 |
Lamivudine treatment and outcome in pregnant women with high hepatitis B viral loads.
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Retrospective Studies; Withholding Treatment; Young Adult | 2015 |
Discovering novel direct acting antiviral agents for HBV using in silico screening.
Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Protein; Drug Design; Drug Discovery; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligands; Liver; Mice; Middle Aged; Molecular Docking Simulation; Organophosphonates; Protein Binding; Real-Time Polymerase Chain Reaction; Tenofovir | 2015 |
Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates | 2015 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Treatment Outcome | 2014 |
Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Disease-Free Survival; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Young Adult | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hematuria; Hepatitis B, Chronic; Humans; Hypophosphatemia; Kidney Diseases; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Proteinuria; Vitamin D Deficiency | 2015 |
[Effects of oral antiviral agents on long-term outcomes of treatment-naive patients with HBV-related decompensated cirrhosis: a retrospective cohort study].
Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Retrospective Studies; Treatment Outcome | 2014 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report.
Topics: Adult; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Glomerulus; Lamivudine; Male; Methylprednisolone; Nephrosis, Lipoid; Telbivudine; Thymidine; Treatment Outcome | 2015 |
Clinical significance of periodic detection of hepatitis B virus YVDD mutation by ultrasensitive real-time amplification refractory mutation system quantitative PCR during lamivudine treatment in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; DNA Primers; DNA, Viral; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sensitivity and Specificity | 2015 |
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Time Factors; Treatment Outcome; Viral Load | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Organophosphonates; Retrospective Studies; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2015 |
Role of lamivudine in the therapy of Nigerian patients with Chronic HBV infection.
Topics: Adolescent; Adult; Biopsy; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver; Male; Middle Aged; Nigeria; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2014 |
Thymosin alpha-1 treatment in chronic hepatitis B.
Topics: Adjuvants, Immunologic; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Thymalfasin; Thymosin; Virus Replication | 2015 |
High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; India; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors; Viral Load | 2015 |
High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Treatment Failure; Treatment Outcome; Viremia; Young Adult | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; ROC Curve; Tenofovir; Treatment Failure; Treatment Outcome | 2015 |
Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; Biomarkers; China; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Time Factors; Treatment Outcome; Viral Load | 2015 |
New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Young Adult | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Female; Genotype; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Live Birth; Male; Middle Aged; Mutation; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Vaccination; Viral Load; Young Adult | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viral Matrix Proteins; Young Adult | 2015 |
[Nucleoside analogues for acute-on-chronic liver failure associated with hepatitis B virus infection: a 24-month survival analysis].
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Prospective Studies; Survival Analysis; Survival Rate; Telbivudine; Thymidine; Time Factors | 2015 |
[Pharmacoeconomic evaluation of treatments based on antiretrovirals for HBeAg-negative chronic hepatitis B].
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Economics, Pharmaceutical; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins | 2015 |
[The possibility of tenofovir monotherapy as a rescue therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2015 |
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Medical Records; Middle Aged; Organophosphonates; Phosphorous Acids; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Hepatitis B e antigen and hepatitis B surface antigen seroclearance with the emergence of lamivudine-associated and core mutations following CD4 elevation in a patient with hepatitis B and HIV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation | 2015 |
Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2015 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Nucleotides; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Viral Load | 2015 |
Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Telbivudine; Thymidine | 2015 |
Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation sequencing.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Prognosis; Retrospective Studies; RNA-Directed DNA Polymerase; ROC Curve; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2015 |
Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-beta; Lamivudine; Liver Function Tests; Male; Middle Aged; Time Factors; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2015 |
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retreatment; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variation; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Prevalence; RNA-Directed DNA Polymerase; Telbivudine; Thymidine; Time Factors; Young Adult | 2015 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Nucleosides; Reproducibility of Results; Tandem Mass Spectrometry; Telbivudine; Tenofovir; Thymidine | 2015 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Follow-Up Studies; Forecasting; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Italy; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Tenofovir | 2015 |
Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Liver Function Tests; Male; Middle Aged; Treatment Outcome | 2015 |
Viral mutant discovery in hepatitis B virus quasi-species in patients undergoing long-term lamivudine treatment.
Topics: DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; RNA, Viral; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Remission Induction; Retrospective Studies; Young Adult | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Blood; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Treatment Outcome; Viral Load; Young Adult | 2016 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Viral Load; Young Adult | 2015 |
Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; ROC Curve; Time Factors; Treatment Outcome | 2016 |
Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Feasibility Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Retrospective Studies; Telbivudine; Thymidine; Young Adult | 2015 |
The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medicine, Chinese Traditional; Middle Aged; Mortality; Plant Preparations; Population Surveillance; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Organophosphonates; Tenofovir; Virus Replication | 2015 |
Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; China; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2015 |
Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Uganda | 2015 |
Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Cohort Studies; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Prospective Studies; Risk Factors; Seroconversion; Young Adult | 2016 |
The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Deoxycytidine Kinase; DNA, Viral; Female; Gene Frequency; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Single Nucleotide; Republic of Korea; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Young Adult | 2016 |
Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Seroconversion; Treatment Outcome; Young Adult | 2016 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
[Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B].
Topics: Adenine; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Organophosphonates; Phosphorus | 2015 |
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Viral Load; Young Adult | 2015 |
A Nanoscale Mutation-Sensitive On/Off Switch Based Assays for the Detection of Hepatitis B Virus Lamivudine-Resistant Mutations.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotyping Techniques; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nanomedicine; Polymerase Chain Reaction; Virology | 2015 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Organophosphonates; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load | 2015 |
[Variability of Reverse Transcriptase Gene and S Gene in Lamivudine-treated Chronic Hepatitis B Patients].
Topics: Adolescent; Adult; Antigens, Surface; Antigens, Viral; DNA Mutational Analysis; Female; Genetic Variation; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; RNA-Directed DNA Polymerase; Young Adult | 2015 |
Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Hospitalization; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; Telbivudine; Thymidine; Treatment Outcome | 2016 |
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Ethnicity; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Mutation; Organophosphonates; Prevalence | 2015 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Hospitals; Humans; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Nephrons; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Telbivudine; Tenofovir; Thailand; Thymidine; Tropical Medicine | 2015 |
Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovir.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Medication Adherence; Middle Aged; Organophosphonates; Rhabdomyolysis | 2015 |
A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
Topics: Antiviral Agents; Cell Line; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genetic Complementation Test; Genetic Predisposition to Disease; Guanine; HEK293 Cells; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inhibitory Concentration 50; Lamivudine; Lentivirus; Mutation; Nucleotides; Real-Time Polymerase Chain Reaction; RNA Viruses; Transduction, Genetic; Virus Replication | 2016 |
Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations.
Topics: Amino Acid Motifs; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation | 2016 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
Topics: Age Factors; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2016 |
COLD-PCR for early detection of hepatitis B virus antiviral drug resistance mutations.
Topics: Antiviral Agents; Cold Temperature; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sensitivity and Specificity; Telbivudine; Thymidine | 2015 |
Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
Topics: Adult; Alanine Transaminase; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Assessment; Viral Load; Virus Activation | 2016 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine | 2016 |
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2016 |
Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Viral Load; Young Adult | 2016 |
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; DNA, Circular; Drug Resistance, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Lamivudine; Liver; Liver Neoplasms; Male; Middle Aged; Necrosis; Organophosphonates; Protein Precursors; Sequence Deletion; Viral Load; Young Adult | 2016 |
Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
Topics: Adenine; Adult; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2016 |
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Tenofovir; Treatment Outcome | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Real-Time Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine; Turkey | 2016 |
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Viral Proteins | 2016 |
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Retrospective Studies; Seroconversion; Telbivudine; Thymidine; Treatment Outcome; Viral Load | 2017 |
Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
Topics: Abatacept; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Asymptomatic Infections; Biomarkers; DNA, Viral; Drug Monitoring; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infusions, Intravenous; Lamivudine; Male; Methotrexate; Treatment Outcome; Virus Activation | 2016 |
Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals.
Topics: Adult; Antiviral Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Prothrombin Time; Retrospective Studies; Serum Albumin | 2016 |
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; DNA, Viral; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; South Africa; Viral Load | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Risk Factors; Treatment Outcome | 2016 |
Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Phosphorous Acids; Platelet Count; Proportional Hazards Models; Risk Factors; ROC Curve; Time Factors | 2017 |
Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Retrospective Studies; Treatment Outcome | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Recurrence; Sustained Virologic Response; Time Factors; Withholding Treatment | 2017 |
A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; Asian People; China; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Viral Load | 2016 |
HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lamivudine; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Seroconversion; Viremia | 2016 |
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Proportional Hazards Models; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
[Efficacy of tenofovir monotherapy or lamivudineadefovir dipivoxil combination therapy in treatment of lamivudine-resistant chronic hepatitis B].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2016 |
[HBsAg clearance rate in patients with HBeAg-positive chronic hepatitis B: a comparative effect analysis based on the real world].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Retrospective Studies; Telbivudine; Thymidine; Treatment Outcome | 2016 |
Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
[A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with heptitis B e antigen negative chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Child; Child, Preschool; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Male; Retrospective Studies | 2016 |
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Arabinofuranosyluracil; Cohort Studies; Disease Management; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Viral Load | 2017 |
Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Bayes Theorem; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Monte Carlo Method; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Nucleosides; Organophosphonates; Outcome Assessment, Health Care; Telbivudine; Thymidine; Time; Virus Replication | 2017 |
Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.
Topics: Adenine; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Mutation; Organophosphonates; Polymorphism, Single Nucleotide | 2016 |
Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Azathioprine; Cyclophosphamide; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Infliximab; Lamivudine; Male; Methylprednisolone; Middle Aged; Pilot Projects; Rheumatic Diseases | 2016 |
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2016 |
Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; Decision Support Techniques; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Viral Load; Withholding Treatment; Young Adult | 2017 |
Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Treatment Outcome | 2016 |
Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Mutation; Organophosphonates; Phylogeny; Reassortant Viruses; Recombination, Genetic; Retrospective Studies | 2017 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
Topics: Adenine; Adult; Antiviral Agents; China; Cohort Studies; Drug Resistance, Multiple, Viral; Female; Gene Expression; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Mutation Rate; Organophosphonates; Phylogeny; Viral Proteins | 2017 |
Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
Topics: Adenine; Adult; Biomarkers; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Thymidine; Treatment Outcome | 2016 |
Long-term nucleos(t)ide analog(s) monoprophylaxis in Delta coinfected liver transplant recipients.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation | 2017 |
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2017 |
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
Topics: Adenine; Aged; Antiviral Agents; Cross-Sectional Studies; Cytosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; DNA, Mitochondrial; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nucleosides; Organophosphonates; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine | 2017 |
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Letter: is body-mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B?
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2017 |
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2016 |
Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Lamivudine; Liver Transplantation; Mutation | 2017 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Tenofovir | 2016 |
The Study of Immune Response in PBMC of CHB Patients treated with IFN-α and 3-TC in vitro.
Topics: Antiviral Agents; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferon-Stimulated Gene Factor 3, gamma Subunit; Janus Kinases; Lamivudine; Leukocytes, Mononuclear; Myxovirus Resistance Proteins; Signal Transduction; STAT1 Transcription Factor; STAT2 Transcription Factor; Up-Regulation | 2016 |
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Kaplan-Meier Estimate; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2017 |
Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Pilot Projects; Time Factors; Treatment Outcome; Viral Load | 2017 |
Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Sustained Virologic Response; T-Lymphocytes, Regulatory; Time Factors | 2017 |
Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Topics: Adult; Aged; Alanine Transaminase; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Glomerulonephritis; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proteinuria; Retrospective Studies; Reverse Transcriptase Inhibitors | 2017 |
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Topics: Adult; Amino Acid Substitution; Clonal Evolution; Demography; Epitopes, B-Lymphocyte; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hydrophobic and Hydrophilic Interactions; Lamivudine; Mutation; Protein Domains; Quasispecies; RNA-Directed DNA Polymerase; Tenofovir; Treatment Outcome; Viral Proteins | 2017 |
Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genetic Vectors; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleic Acid Amplification Techniques; Organophosphonates; Plasmids; Replicon; Transfection; Virus Replication | 2008 |
[Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2008 |
Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Lymphoma, B-Cell; Prednisone; Rituximab; Vincristine; Virus Activation | 2008 |
Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.
Topics: Antiviral Agents; Carrier State; Cell Line, Tumor; DNA, Circular; DNA, Viral; Drug Resistance, Viral; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Sequence Analysis, DNA; Transfection; Virus Replication | 2008 |
Regression of cirrhosis of the liver detected by elastiometry.
Topics: Adult; Antiviral Agents; Biopsy, Needle; Elasticity Imaging Techniques; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Remission Induction; Reverse Transcriptase Inhibitors; Severity of Illness Index; Treatment Outcome | 2008 |
[Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Viral Load | 2008 |
[RtL164V, a mutation possibly associated with lamivudine resistant HBV].
Topics: DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation | 2008 |
[The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Young Adult | 2008 |
Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Failure; Male; Middle Aged | 2008 |
Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Mutation; Organophosphonates; Time Factors | 2008 |
Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
Topics: Adult; Amino Acid Motifs; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Sensitivity and Specificity; Transition Temperature | 2008 |
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Topics: Adult; Alanine Transaminase; Antigens, CD; Antiviral Agents; Apoptosis Regulatory Proteins; Biopsy; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-10; Lamivudine; Liver; Longitudinal Studies; Male; Middle Aged; Nucleosides; Programmed Cell Death 1 Receptor; Pyrimidinones; Telbivudine; Thymidine; Treatment Outcome; Viral Load; Viremia | 2008 |
Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Genome, Viral; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Precursors; Sequence Analysis, DNA; Virus Replication | 2008 |
Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Hepatitis B, Chronic; Humans; Immunoglobulin G; Lamivudine; Middle Aged; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Inhibitors; Tumor Necrosis Factor-alpha | 2008 |
Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis.
Topics: Adult; Drug Administration Schedule; Glomerulonephritis; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2008 |
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Cohort Studies; Drug Resistance; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies | 2009 |
Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
Topics: Choice Behavior; Disease Management; Follow-Up Studies; Hematologic Diseases; Hepatitis B, Chronic; Humans; Lamivudine | 2009 |
Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Secondary Prevention; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Tomography, X-Ray Computed | 2008 |
[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Topics: Adenine; Amino Acid Motifs; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2008 |
Evaluation of dual priming oligonucleotide-based multiplex PCR for detection of HBV YMDD mutants.
Topics: Adult; Aged; DNA Primers; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Oligonucleotides; Polymerase Chain Reaction | 2008 |
Changing landscape of antiviral resistance management in chronic hepatitis B.
Topics: Administration, Oral; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Polymerase Chain Reaction; Predictive Value of Tests; Time Factors; Treatment Failure; Viral Load | 2008 |
Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
Topics: Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation, Missense; Sequence Analysis, DNA | 2009 |
Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Retreatment; Treatment Outcome | 2008 |
Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoradiometric Assay; Lamivudine; Male; Middle Aged; Multivariate Analysis; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load; Virus Replication | 2009 |
Multidrug resistance after lamivudine therapy for chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2009 |
Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Viral Load | 2008 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mutation; Organophosphonates; Promoter Regions, Genetic; Tenofovir | 2008 |
Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis.
Topics: Acute Disease; Hepatitis B, Chronic; Humans; Hyperamylasemia; Lamivudine; Male; Middle Aged; Pancreatitis; Reverse Transcriptase Inhibitors | 2008 |
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Topics: Adult; Alanine Transaminase; Amino Acid Substitution; Antiviral Agents; Aspartate Aminotransferases; Cluster Analysis; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Polymerase Chain Reaction; RNA-Directed DNA Polymerase | 2009 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2008 |
[Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B].
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Base Sequence; DNA, Viral; Drug Resistance, Multiple, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors | 2008 |
[Lamivudine treatment of a HBs antigen positive man with reactive arthritis].
Topics: Antiviral Agents; Arthritis, Reactive; DNA, Viral; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
[New treatment of chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine | 2008 |
[Clinical outcomes of lamivudine therapy and HLA alleles in chronic hepatitis B patients].
Topics: Adult; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Genetic Predisposition to Disease; Hepatitis B virus; Hepatitis B, Chronic; HLA Antigens; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Treatment Outcome | 2008 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
Topics: Adenine; Adult; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Lamivudine resistance in untreated chronic hepatitis B patients in Turkey.
Topics: Adolescent; Adult; Amino Acid Motifs; Child; Child, Preschool; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Turkey; Viral Load; Young Adult | 2008 |
[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA | 2008 |
[A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection].
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Polyethylene Glycols; Recombinant Proteins | 2008 |
Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation, Missense; Organophosphonates; Sequence Analysis, DNA; Viral Load | 2009 |
Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Polymorphism, Restriction Fragment Length; Sequence Analysis, DNA; Serum; Viral Load | 2009 |
Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Open Reading Frames; Virus Replication | 2009 |
[Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B].
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Making; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2008 |
Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Viral Load; Young Adult | 2009 |
Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Sequence Analysis, DNA | 2009 |
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
Topics: Adenine; Antiviral Agents; Biomarkers; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Predictive Value of Tests; Retrospective Studies; RNA-Directed DNA Polymerase | 2008 |
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.
Topics: Acid-Base Equilibrium; Adenine; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Transplantation; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies | 2009 |
Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Viral Load; Virus Replication | 2008 |
Anti-hepatitis B virus treatment guided by long-term virus kinetics stepwise tracing.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Mutation; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2009 |
A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Salvage Therapy; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2009 |
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2008 |
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
[Analysis of the correlation between the pre-S1 antigen, pre-S2 antigen and DNA of hepatitis B virus in the serum of chronic hepatitis B patients undergoing nucleoside analogue therapy.].
Topics: DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Real-Time Polymerase Chain Reaction | 2009 |
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Population Surveillance; Randomized Controlled Trials as Topic; Time Factors | 2009 |
Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Topics: Cell Line; DNA, Viral; Dose-Response Relationship, Drug; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferon-gamma; Lamivudine; Oligodeoxyribonucleotides; Reverse Transcriptase Inhibitors; RNA, Viral; Toll-Like Receptor 9; Tumor Necrosis Factor-alpha; Virus Replication | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Markov Chains; Models, Economic; Organophosphonates; Retrospective Studies; Salvage Therapy; Secondary Prevention; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2009 |
Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.
Topics: Adenine; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combination; Etanercept; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunoglobulin G; Infliximab; Lamivudine; Male; Methotrexate; Organophosphonates; Receptors, Tumor Necrosis Factor; Spondylarthropathies; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load; Virus Activation | 2009 |
[Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Korea; Lamivudine; Models, Statistical; Organophosphonates; Quality of Life; Severity of Illness Index | 2009 |
[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Recurrence; Retrospective Studies; Risk Factors | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2009 |
Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Topics: Absenteeism; Analysis of Variance; Anti-HIV Agents; Australia; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Forecasting; Guanine; Health Care Costs; Health Services Research; Hepatitis B, Chronic; Humans; Lamivudine; Life Expectancy; Models, Econometric; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Treatment Outcome; Value of Life | 2008 |
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Viral Load | 2009 |
Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates | 2009 |
Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Codon, Nonsense; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Viral Load | 2009 |
Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.
Topics: Adult; Animals; Carcinoma, Hepatocellular; Codon, Nonsense; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Transplantation; NIH 3T3 Cells; Reverse Transcriptase Inhibitors; Viral Envelope Proteins | 2009 |
Current trends in chronic hepatitis B management: results of a questionnaire.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Clinical Competence; Drug Administration Schedule; Family Health; Guanine; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver; Male; Middle Aged; Organophosphonates; Practice Patterns, Physicians'; Spain; Surveys and Questionnaires | 2009 |
Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Recurrence; Treatment Outcome; Withholding Treatment; Young Adult | 2009 |
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Topics: Adult; China; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors; Young Adult | 2009 |
[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors | 2009 |
[Treatment of hepatitis B virus resistant to lamivudine and adefovir].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2009 |
Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection.
Topics: Adult; Antibodies, Monoclonal; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Infliximab; Lamivudine; Male; Psoriasis | 2009 |
Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, env; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Sequence Analysis, DNA | 2009 |
Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.
Topics: Adenine; Adult; Antiviral Agents; Asian People; Base Composition; China; Computational Biology; Databases, Genetic; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Phylogeny; RNA-Directed DNA Polymerase; Treatment Failure; Virus Replication; Young Adult | 2009 |
Hepatitis B infection in haematopoietic stem cell transplantation: still unresolved.
Topics: Endemic Diseases; Hematopoietic Stem Cell Transplantation; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Taiwan; Virus Activation | 2009 |
[The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome; Young Adult | 2009 |
Monitoring of therapy in patients with chronic hepatitis B virus.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Point Mutation; Sequence Analysis, DNA | 2010 |
[A reduction study of seroconversion of HBsAg in chronic hepatitis B patients with HBeAg positive by combination treatment with interferon and lamivudine].
Topics: Adolescent; Adult; Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
[Clevudine therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Practice Guidelines as Topic | 2009 |
[Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Retrospective Studies | 2009 |
Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Base Sequence; Child; Cohort Studies; DNA Primers; Drug Resistance, Viral; Female; Gene Products, pol; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Male; Middle Aged; Organophosphonates; Point Mutation; Virus Replication; Young Adult | 2009 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Viremia | 2009 |
Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Biomarkers; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Hypertension, Portal; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Prognosis; Prospective Studies; Treatment Outcome | 2009 |
Lamivudine and hepatitis B reactivation.
Topics: Antineoplastic Agents; Antiviral Agents; Data Interpretation, Statistical; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Virus Activation | 2009 |
Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient.
Topics: Adenine; Antiviral Agents; Cluster Analysis; DNA, Viral; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; Phylogeny; Sequence Analysis, DNA; Sequence Deletion; Sequence Homology; Viral Proteins | 2009 |
Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Prognosis; Pyrimidinones; Retrospective Studies; Telbivudine; Thymidine; Young Adult | 2009 |
Therapeutic strategies for chronic hepatitis B virus infection in 2008-optimum dosing lamivudine challenged for HIV-1 infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine | 2009 |
Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzymes; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Organophosphonates; Treatment Outcome; Viral Load; Young Adult | 2010 |
Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
Topics: Adenine; Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors; Young Adult | 2010 |
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome; Viral Load | 2010 |
Chronic hepatitis B: back to the future with HBsAg.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Multicenter Studies as Topic; Nucleosides; Polyethylene Glycols; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2009 |
[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2009 |
[Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B].
Topics: Adult; Antifungal Agents; China; Cost-Benefit Analysis; DNA, Viral; Drug Costs; Economics, Pharmaceutical; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Insurance, Long-Term Care; Lamivudine; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Models, Economic; Nucleosides; Prescription Drugs; Pyrimidinones; Quality-Adjusted Life Years; Telbivudine; Thymidine | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients.
Topics: Adolescent; Adult; Antiviral Agents; Asian People; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Prospective Studies; Recurrence; Treatment Outcome; Withholding Treatment; Young Adult | 2010 |
[Efficacy of 48-week clevudine therapy for chronic hepatitis B].
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2009 |
[Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; China; DNA Mutational Analysis; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction | 2009 |
[Discussions the therapy strategy of chronic hepatitis B by analyzing the therapeutics course of a chronic hepatitis B patient].
Topics: Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Virus Replication | 2009 |
[Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress].
Topics: Acute Disease; Adult; Alanine Transaminase; Antioxidants; Antiviral Agents; Aspartate Aminotransferases; Carrier State; Case-Control Studies; Drug Therapy, Combination; Female; Glutathione Peroxidase; Hepatitis B; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Malondialdehyde; Oxidative Stress; Superoxide Dismutase | 2009 |
[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Young Adult | 2009 |
Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.
Topics: Adult; Analysis of Variance; Case-Control Studies; Confidence Intervals; Disease Progression; Female; Follow-Up Studies; Gene Expression Regulation; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polymorphism, Genetic; Probability; Promoter Regions, Genetic; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2009 |
[Interferon therapy for chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Time Factors; Treatment Outcome; Virus Replication | 2009 |
[Early prediction of lamivudine response in e antigen-negative chronic hepatitis B patients].
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.
Topics: Adult; Aged; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Time Factors; Young Adult | 2010 |
Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Treatment Outcome | 2009 |
Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
Topics: Acute Disease; Adult; Antiviral Agents; China; Cohort Studies; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Viral Load | 2010 |
Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48.
Topics: Adenine; Adult; Antiviral Agents; Female; Forecasting; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Viral Load | 2009 |
Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation | 2009 |
Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion.
Topics: Adult; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Taiwan; Time Factors; Treatment Outcome | 2010 |
Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Multivariate Analysis; Reverse Transcriptase Inhibitors; Taiwan; Time Factors | 2009 |
Sustained seroconversion of chronic hepatitis B infection after stem cell transplantation.
Topics: Adaptive Immunity; Adolescent; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Immunotherapy; Lamivudine; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Stem Cell Transplantation; Treatment Outcome; Viral Load | 2011 |
Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Laminin; Lamivudine; Male; Prognosis; Serum | 2010 |
Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; RNA-Directed DNA Polymerase; Treatment Outcome; Viral Load; Viral Proteins; Young Adult | 2010 |
Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Evolution, Molecular; Female; Gene Products, pol; Genome, Viral; Genotype; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Phylogeny; Reverse Transcriptase Inhibitors; Young Adult | 2010 |
YMDD mutation in Pakistani patients. The comparison of Eastern response with the Western response.
Topics: Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Pakistan; Virus Replication | 2009 |
Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Young Adult | 2010 |
Think twice if you consider entecavir treatment in cases with lamivudine refractoriness.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Practice Guidelines as Topic | 2010 |
Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Promoter Regions, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2010 |
Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
Topics: Adenine; Adolescent; Adult; Aged; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Young Adult | 2011 |
Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells.
Topics: Adult; Aged; Antigen Presentation; Cell Growth Processes; Dendritic Cells; DNA, Viral; Female; Flow Cytometry; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Innate; Immunophenotyping; Lamivudine; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Young Adult | 2011 |
[Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Viral Load; Viral Proteins; Young Adult | 2010 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Germany; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Nucleosides; Organophosphonates; Pyrimidinones; Salvage Therapy; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; United States | 2010 |
[Serological and sociodemographic differences in HBV-patients with and without migration background].
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Cross-Sectional Studies; Educational Status; Emigrants and Immigrants; Female; Germany; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Seropositivity; Humans; Incidence; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Outpatient Clinics, Hospital; Socioeconomic Factors; Unemployment; Viral Load; Young Adult | 2010 |
Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late?
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Liver Transplantation | 2010 |
Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; Risk Assessment; Time Factors; Young Adult | 2010 |
Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Poland; Treatment Outcome; Viral Load | 2010 |
[Therapeutic recommendations for year 2010: antiviral treatment of chronic HBV infection].
Topics: Antiviral Agents; Disease Management; Health Services Accessibility; Hepatitis B; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Poland; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Recombinant Proteins | 2010 |
Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligase Chain Reaction; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Reagent Strips; Reverse Transcriptase Inhibitors; Sensitivity and Specificity | 2010 |
Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Female; Gene Frequency; Genes, Viral; Genetic Variation; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Serbia; Viral Load | 2010 |
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Asian People; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Logistic Models; Male; Middle Aged; Mutation; Odds Ratio; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoprevention; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Nucleotides; Polyethylene Glycols; Recombinant Proteins | 2010 |
Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoprevention; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Nucleosides; Nucleotides; Polyethylene Glycols; Primary Prevention; Recombinant Proteins; Selection Bias; Tertiary Prevention | 2010 |
[Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Young Adult | 2010 |
Resistance management in chronic hepatitis B complicated by renal failure.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Contraindications; Drug Resistance; Guanine; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Male | 2010 |
Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Models, Economic; Models, Statistical; Monte Carlo Method; Nucleosides; Organophosphonates; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Serologic Tests; Telbivudine; Thymidine | 2010 |
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Transplantation; Lamivudine; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2010 |
Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers at Bangladesh.
Topics: Alanine Transaminase; Antiviral Agents; Bangladesh; Carrier State; DNA, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunization, Secondary; Injections, Intramuscular; Lamivudine; Liver; Viral Load | 2010 |
Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Blood; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Recombinant Proteins; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
[Genotypic resistance to entecavir in chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymorphism, Restriction Fragment Length; Retrospective Studies; RNA-Directed DNA Polymerase | 2010 |
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Viral Load; Viremia | 2010 |
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.
Topics: Adenine; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Child; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Sequence Alignment | 2010 |
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genes, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Viral Load | 2010 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Evaluation of distant results after lamivudine discontinuation in children with chronic hepatitis B.
Topics: Amino Acid Motifs; Child; Gene Products, pol; Genetic Variation; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free Survival; Female; Guanine; Hepatectomy; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organophosphonates; Proportional Hazards Models; Risk Assessment; Risk Factors; RNA, Viral; Survival Rate; Time Factors; Treatment Outcome | 2010 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Organophosphonates; Patient Care Team; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2010 |
Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; Biomarkers; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity | 2010 |
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
Topics: Adenine; Base Sequence; Databases, Genetic; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Genetic Association Studies; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Multilocus Sequence Typing; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Viral Load; Viral Proteins; Virus Replication | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2011 |
Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Patient Selection; Recombinant Proteins | 2010 |
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Case-Control Studies; Cytokines; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Lamivudine; Male; Middle Aged; Organophosphonates; T-Lymphocytes, Regulatory; Th1-Th2 Balance | 2011 |
Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Treatment Outcome | 2011 |
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drug Utilization; Female; France; Health Care Surveys; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Patterns, Physicians'; Registries; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2010 |
Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Virus Activation | 2011 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; ROC Curve; Time Factors; Treatment Outcome; Young Adult | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
[Loss or seroconversion of HBsAg in patients with chronic hepatitis B after treatment with lamivudine: 2 cases report].
Topics: Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2010 |
Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cloning, Molecular; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; Sequence Analysis, DNA; Time Factors | 2011 |
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Typing; Mutation, Missense; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Young Adult | 2010 |
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Evolution, Molecular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Organophosphonates; Phylogeny; Recombinant Proteins; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2010 |
Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases.
Topics: Aged; Female; Glomerulonephritis, Membranous; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Prednisolone; Ribonucleosides; Treatment Outcome | 2011 |
[Key points of nursing HbeAg negative cirrhotic patients with nucleot (s) ide analogues antiviral therapy].
Topics: Adult; Aged; Antiviral Agents; Breast Feeding; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Middle Aged; Mortality; Nucleosides; Nursing Care; Weights and Measures | 2010 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome | 2011 |
The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Treatment Outcome | 2011 |
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; DNA, Circular; DNA, Viral; Female; Follow-Up Studies; Hepacivirus; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunologic Factors; Lamivudine; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Secondary Prevention | 2011 |
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
Topics: Clinical Laboratory Techniques; Drug Resistance, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoassay; Lamivudine; Longitudinal Studies; Mutation; Nucleosides; Pyrimidinones; Reagent Kits, Diagnostic; Telbivudine; Thymidine | 2011 |
Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance.
Topics: Administration, Oral; Adult; Alkaloids; Antiviral Agents; Biopsy; China; DNA, Viral; Down-Regulation; Drug Resistance; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HSC70 Heat-Shock Proteins; Humans; Lamivudine; Liver; Male; Middle Aged; Quinolizines; Treatment Outcome; Viral Load | 2011 |
Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Genetic Variation; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Phylogeny; Retrospective Studies; RNA-Directed DNA Polymerase; Selection, Genetic; Sequence Analysis, DNA; Treatment Outcome; Young Adult | 2011 |
Predictive factors for the response to lamivudine in HBV-infected patients with chronic hepatitis and cirrhosis.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
[Efficacy of entecavir and adefovir combination therapy in patients with chronic hepatitis B refractory to lamivudine and adefovir combination therapy].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2011 |
HBV core region variability: effect of antiviral treatments on main epitopic regions.
Topics: Adenine; Adult; Amino Acid Sequence; Antigenic Variation; Antiviral Agents; B-Lymphocytes; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunodominant Epitopes; Interferons; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Polymorphism, Genetic; T-Lymphocytes | 2011 |
Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mass Spectrometry; Mutation; Organophosphonates; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Sequence Analysis, DNA; Viral Load | 2011 |
Defining virologic relapse in chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Recurrence; Retrospective Studies; Treatment Outcome; Viral Load | 2011 |
Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Treatment Failure; Viral Load | 2010 |
Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Virus Replication | 2011 |
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes; Female; France; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organ Transplantation; Organophosphonates; Pilot Projects; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2011 |
To stop or not to stop: the quest for long-term viral suppression.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Monitoring; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Predictive Value of Tests; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2011 |
Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients.
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2011 |
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2011 |
Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited.
Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Endemic Diseases; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2011 |
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Organophosphonates; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Aged; Amino Acid Substitution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Young Adult | 2011 |
Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male | 2011 |
[New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2011 |
Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Topics: Adult; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Lithuania; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Survival Analysis | 2010 |
Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Liver Function Tests; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Viral Load | 2011 |
Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.
Topics: Adenine; Adoptive Transfer; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Middle Aged; Organophosphonates; Peripheral Blood Stem Cell Transplantation; Taiwan; Treatment Outcome; Unrelated Donors | 2011 |
Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepacivirus; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-gamma; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Predictive Value of Tests; Pyrimidinones; T-Lymphocytes; Telbivudine; Thymidine; Treatment Outcome; Up-Regulation; Young Adult | 2011 |
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.
Topics: Drug Monitoring; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome; Viral Load | 2011 |
Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Recurrence; Time Factors | 2011 |
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy.
Topics: Adenine; Administration, Oral; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Keratin-18; Lamivudine; Organophosphonates | 2011 |
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Guanine; Hepatectomy; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2011 |
Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2011 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2011 |
Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Retrospective Studies; Risk Factors; RNA, Viral; Young Adult | 2011 |
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Etanercept; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulin G; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Retrospective Studies; Tumor Necrosis Factor-alpha; Viral Load; Virus Activation | 2011 |
Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.
Topics: Adult; Aged; Asian People; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Time | 2011 |
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Incidence; Kaplan-Meier Estimate; Kidney; Kidney Diseases; Lamivudine; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Organophosphonates; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
HBV DNA loss within 24 weeks predicts late viral breakthrough in chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Retrospective Studies | 2011 |
Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.
Topics: Acute Disease; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Logistic Models; Longitudinal Studies; Medical Records; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Risk Factors; Secondary Prevention; Taxoids; Treatment Outcome | 2011 |
The natural YMDD mutations of hepatitis B virus in Western China.
Topics: Adolescent; Adult; Child; China; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2012 |
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2011 |
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Virus Replication | 2012 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome; Viral Load | 2011 |
Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Retrospective Studies; Serum; Treatment Outcome | 2011 |
Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Salvage Therapy; Treatment Outcome | 2011 |
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Treatment Failure; Viral Load; Viremia | 2011 |
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Nucleic Acid Amplification Techniques; Retrospective Studies; Risk Factors | 2011 |
Virological response to adefovir monotherapy and the risk of adefovir resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies | 2011 |
[Multivariate analysis on virologic breakthrough in HBeAg positive patients treated with lamivudine].
Topics: Adult; Anti-Retroviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Viral Load | 2011 |
Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome; Viral Load | 2012 |
[Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy].
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2011 |
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Evolution, Molecular; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA | 2011 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis B, Chronic; Humans; Insurance Coverage; Lamivudine; Liver Cirrhosis; National Health Programs; Organophosphonates; Tenofovir | 2011 |
Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
Topics: Adenine; Adult; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Fatal Outcome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Mutation; Organophosphonates; Virus Replication | 2012 |
Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Virus Activation; Young Adult | 2011 |
Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cytokines; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2011 |
[A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Nucleotide Motifs; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Sensitivity and Specificity | 2011 |
Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Guanine; Hepatectomy; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male | 2011 |
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors; Young Adult | 2012 |
Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asia; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Therapy, Combination; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Kaplan-Meier Estimate; Lamivudine; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Genetic; Proportional Hazards Models; Recombinant Proteins; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Asian People; Child; Child, Preschool; China; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Mutation Rate; Organophosphonates; RNA-Directed DNA Polymerase; Virus Replication; Young Adult | 2012 |
Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; DNA, Viral; Drug Costs; Drug Resistance, Viral; Guanine; Health Care Costs; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Hospitals, Public; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Quality-Adjusted Life Years; Viral Load | 2012 |
De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2011 |
Rapid identification of YVDD mutants of hepatitis B virus using smart amplification process with competition probe.
Topics: Antiviral Agents; Codon; DNA Primers; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleic Acid Amplification Techniques; Point Mutation; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors | 2011 |
Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2011 |
HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA Primers; DNA, Viral; Female; Gene Frequency; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HLA-DRB1 Chains; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Retrospective Studies; Young Adult | 2011 |
Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2012 |
Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2012 |
Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Topics: Adult; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Selection, Genetic; Viral Load; Young Adult | 2012 |
Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D.
Topics: Adult; Aged; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Young Adult | 2011 |
How does hepatitis B virus infection react to hepatocellular carcinoma treatment?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Virus Activation | 2012 |
Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors | 2012 |
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Treatment Outcome; Viral Load | 2012 |
Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Disease-Free Survival; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nucleosides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Treatment Failure; Viral Load | 2012 |
Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Multivariate Analysis; Sex Factors; Treatment Outcome; Viral Load | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Treatment Outcome; Viral Load | 2012 |
High-resolution melting and real-time PCR for quantification and detection of drug-resistant HBV mutants in a single amplicon.
Topics: Adenine; Antiviral Agents; DNA, Complementary; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Nucleic Acid Denaturation; Organophosphonates; Pilot Projects; Polymerase Chain Reaction; Viral Load | 2012 |
Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Recurrence; Risk Factors | 2011 |
Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Topics: Adult; Aged; Antibodies, Viral; Antiviral Agents; DNA, Viral; Female; Fibrosis; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |
[The mutation patterns of HBV P gene and genotyping in patients with lanivudine-resistant chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Young Adult | 2011 |
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Time Factors | 2012 |
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.
Topics: Adult; Alanine Transaminase; Bilirubin; Disease Progression; Disseminated Intravascular Coagulation; DNA, Viral; Female; Glucocorticoids; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Jaundice; Lamivudine; Male; Middle Aged; Prognosis; Prospective Studies; Prothrombin; Treatment Outcome; Viral Load; Young Adult | 2012 |
Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: to switch or not to switch?
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2012 |
Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prognosis; Retrospective Studies; Treatment Failure | 2012 |
A PCR-RFLP based protocol for the detection of hepatitis B virus variants in some lamivudine-untreated chronic hepatitis B virus carriers in Pakistan.
Topics: Adult; Antiviral Agents; Carrier State; DNA-Directed DNA Polymerase; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Pakistan; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length | 2012 |
Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Antiviral Agents; Aspartic Acid; China; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Isoleucine; Lamivudine; Logistic Models; Male; Methionine; Middle Aged; Mutation; Retrospective Studies; Tyrosine; Valine | 2012 |
[Clinical prognosis of drug-susceptible chronic hepatitis B virus patients at year 5 of lamivudine monotherapy].
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2012 |
Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Retrospective Studies; Severity of Illness Index | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Young Adult | 2012 |
Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Liver; Male; Middle Aged | 2012 |
Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
Topics: Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense | 2012 |
Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Topics: Administration, Oral; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nucleotides; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Reverse Transcriptase Inhibitors | 2012 |
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Italy; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Patterns, Physicians'; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Young Adult | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-1; Lamivudine; Organophosphonates; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.
Topics: Adult; Aged; Alanine Transaminase; Amino Acid Sequence; Amino Acid Substitution; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Open Reading Frames; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Statistics, Nonparametric | 2012 |
Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antiviral Agents; Early Medical Intervention; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Liver Failure; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2012 |
Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Histocytochemistry; Humans; Lamivudine; Liver Failure, Acute; Liver Transplantation; Male; Medication Adherence; Necrosis; Organophosphonates; Telbivudine; Thymidine | 2013 |
A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease.
Topics: Adenine; Adolescent; Adult; Child, Preschool; Cholestasis, Intrahepatic; Drug Resistance, Viral; Female; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Organophosphonates | 2012 |
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome; Viral Load | 2012 |
Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2012 |
Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Decision Support Techniques; Disease Transmission, Infectious; Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Reverse Transcriptase Inhibitors | 2012 |
Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Statistics, Nonparametric; Time Factors; Treatment Outcome; Viremia; Young Adult | 2012 |
Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Salvage Therapy; Treatment Outcome | 2012 |
Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications?
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Nucleotides | 2012 |
Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Topics: Adult; Antiviral Agents; Asia; Blood Chemical Analysis; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Function Tests; Male; Middle Aged; Mutation Rate; Mutation, Missense; RNA-Directed DNA Polymerase; Treatment Outcome; Viral Load | 2013 |
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Topics: Adenine; Administration, Oral; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genes, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Mutation Rate; Organophosphonates; Prevalence; Virus Replication | 2012 |
[Efficacy of lamivudine on acute-on-chronic liver failure in patients with chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Netherlands; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Telbivudine; Tenofovir; Thymidine | 2012 |
Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Treatment Outcome; Viral Load; Withholding Treatment; Young Adult | 2012 |
Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; RNA-Directed DNA Polymerase | 2013 |
Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using Zip nucleic acid probes in Kerman, southeast of Iran.
Topics: Adult; Aged; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Male; Middle Aged; Mutation; Nucleic Acid Probes; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors | 2012 |
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Molecular Typing; Mutation; Retrospective Studies; Time Factors; Viral Load | 2013 |
Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Guanine; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Proportional Hazards Models | 2013 |
Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Topics: Adult; Antiviral Agents; China; Cohort Studies; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Emergency Treatment; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Patient Simulation; Predictive Value of Tests; Quality-Adjusted Life Years; Sensitivity and Specificity; Viral Load | 2012 |
Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Recurrence; Time Factors; Treatment Outcome; Viral Load | 2013 |
The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Failure | 2013 |
A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation, Missense | 2012 |
The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2013 |
Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Treatment Outcome; Viral Load | 2013 |
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.
Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; Drug Combinations; Drug Resistance, Viral; Drug Substitution; Gene Products, pol; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphates; Organophosphonates; Phenotype; Time Factors; Treatment Outcome | 2012 |
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Topics: Adult; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2013 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
The metabolic regulator PGC-1α links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus.
Topics: Acetylcysteine; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cyclophosphamide; Dexamethasone; DNA Damage; Etoposide; Gene Expression Regulation, Viral; Heat-Shock Proteins; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mitochondria; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Transcription Factors; Transcriptional Activation; Up-Regulation; Virus Activation | 2013 |
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organophosphonates; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Viral Load | 2013 |
Treatment of hepatitis B virus-associated membranous nephropathy: lamivudine era versus post-lamivudine era.
Topics: Antiviral Agents; Female; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2012 |
Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
Topics: Adenine; Adult; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Female; Glomerulonephritis, Membranous; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Young Adult | 2012 |
The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs.
Topics: Adenine; Adult; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HLA-DQ beta-Chains; Humans; Lamivudine; Male; Organophosphonates; RNA, Viral | 2013 |
Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir.
Topics: Adolescent; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Virus Activation | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2013 |
Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Mutation; Organophosphonates; Probability; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2012 |
Outcome of various treatments for posttransplant hepatitis B virus recurrence.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
[Effects of lamivudine and thymosin alpha1 combination therapy on patients with chronic hepatitis B].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Thymalfasin; Thymosin | 2002 |
Recent progress and new trends in the treatment of hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms | 2002 |
The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.
Topics: Amino Acid Motifs; Antiviral Agents; Codon; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Sequence Analysis, DNA | 2002 |
Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.
Topics: Adult; Aged; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors; Sensitivity and Specificity | 2002 |
Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2002 |
The effect of thymosine 1 alpha and Lamivudine combination therapy in chronic hepatitis B patients.
Topics: Adjuvants, Immunologic; Child; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Thymalfasin; Thymosin | 2002 |
Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.
Topics: Alanine Transaminase; Base Sequence; DNA-Directed DNA Polymerase; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors; Selection, Genetic; Sequence Analysis, DNA | 2002 |
[Ulcerative colitis developed after acute exacerbation of chronic hepatitis B].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Colectomy; Colitis, Ulcerative; Hepatitis B, Chronic; Humans; Lamivudine; Male; Prednisolone | 2002 |
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Hepatitis Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Prognosis; Survival Analysis | 2002 |
Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
Topics: Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Reverse Transcriptase Inhibitors; Virus Replication | 2002 |
Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone.
Topics: Antiviral Agents; Case-Control Studies; Child; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins; Retrospective Studies | 2002 |
Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Lamivudine; Mutation; Polymerase Chain Reaction; Prevalence; Prospective Studies; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2002 |
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance, Viral; Famciclovir; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Recurrence; Virus Activation | 2002 |
Repeated jaundice due to YMDD mutant in a patient with prolonged lamivudine therapy for chronic hepatitis B under prednisolone treatment for Still's disease.
Topics: Amino Acid Sequence; DNA, Viral; Drug Resistance, Viral; Female; Glucocorticoids; Hepatitis B, Chronic; Hepatitis Viruses; Humans; Jaundice; Lamivudine; Middle Aged; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Prednisolone; Recurrence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Still's Disease, Adult-Onset; Virus Replication | 2002 |
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Mutation | 2002 |
[Expression of extrahepatic symptoms in patients with chronic hepatitis B with low activity].
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Prednisolone | 2002 |
Lamivudine-associated thrombocytopenia.
Topics: Antiviral Agents; Child; Hepatitis B, Chronic; Humans; Lamivudine; Male; Thrombocytopenia | 2002 |
Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carrier State; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Virus Activation | 2002 |
[Effects of lamivudine on cirrhotic patients following chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2002 |
All kidding aside with the use of lamivudine in children with chronic hepatitis B.
Topics: Child, Preschool; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2002 |
Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.
Topics: Adult; Alanine Transaminase; Base Sequence; DNA-Directed DNA Polymerase; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Viral Core Proteins | 2002 |
[Therapy of viral hepatitis].
Topics: Antiviral Agents; Critical Pathways; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Liver Function Tests; Liver Transplantation; Virus Replication | 2002 |
Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis.
Topics: Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors; Rhabdomyolysis; Waiting Lists | 2002 |
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.
Topics: Adult; Amino Acid Motifs; Amino Acid Substitution; Cohort Studies; DNA-Directed DNA Polymerase; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Isoleucine; Lamivudine; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk; Severity of Illness Index; Valine | 2003 |
[Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2002 |
Remission of breakthrough hepatitis in chronic hepatitis B patients on lamivudine.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Recurrence; Remission Induction; Reverse Transcriptase Inhibitors | 2002 |
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Topics: Adenine; Baculoviridae; Carcinoma, Hepatocellular; Drug Resistance, Viral; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; In Vitro Techniques; Lamivudine; Liver Neoplasms; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured; Virus Replication | 2003 |
[Clinical outcome in cases of viral breakthrough during lamivudine therapy in chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2002 |
[Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
Topics: Adult; Amino Acid Motifs; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2002 |
[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].
Topics: Adult; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2002 |
[Exacerbation of chronic hepatitis B after discontinuing of antiretroviral therapy in HIV infection].
Topics: Adult; Anti-HIV Agents; Diagnosis, Differential; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Time Factors; Virus Replication | 2002 |
The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.
Topics: Adult; Bilirubin; Drug Administration Schedule; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Odds Ratio; Reverse Transcriptase Inhibitors; Survival Analysis | 2003 |
Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor.
Topics: Adult; Antiviral Agents; Cadaver; Carcinoma, Hepatocellular; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Tissue Donors | 2003 |
Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment.
Topics: CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Flow Cytometry; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymph Nodes; Species Specificity | 2003 |
Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Middle Aged; Organophosphonates; Salvage Therapy | 2003 |
[Factors predicting the disappearance of virus B replication markers following treatment with lamivudine].
Topics: Antiviral Agents; Clinical Enzyme Tests; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Placebos; Prognosis; Randomized Controlled Trials as Topic; Time Factors; Transaminases; Virus Replication | 2003 |
Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Male; Middle Aged; Prognosis; Retrospective Studies; Virus Replication | 2003 |
[Possibility of persistent replication of HBV in patients with serological evidence of virus elimination].
Topics: Adult; Antiviral Agents; Biomarkers; Biopsy, Needle; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Treatment Outcome | 2002 |
[Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Treatment Outcome; Viral Load; Virus Replication | 2003 |
[One year and half treatment with lamivudine in active cirrhosis resulting from chronic hepatitis B].
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome; Virus Replication | 2003 |
[Detection and identification of HBV DNA YMDD motif mutation during lamivudine treatment using oligonucleotide array].
Topics: Antiviral Agents; DNA, Viral; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Oligonucleotide Array Sequence Analysis; Point Mutation; Sequence Analysis, DNA | 2003 |
Prognostic factors in severe exacerbation of chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Ascites; Biomarkers; DNA, Viral; Female; Fibrosis; Hepatic Encephalopathy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Prognosis; Promoter Regions, Genetic; Serologic Tests | 2003 |
[Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antiviral Agents; Cells, Cultured; Dendritic Cells; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interleukin-4; Lamivudine; Male; Middle Aged; Virus Replication | 2003 |
[Quasispecies and mutation of hepatitis B virus polymerase gene in lamivudine- treated patients].
Topics: Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Point Mutation | 2003 |
[Therapy effects of short-term lamivudine treatment on 22 hepatitis B patients with HBeAg-negative].
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2003 |
[Hepatitis B. Chronic hepatitis. Outcome and treatment].
Topics: Antiviral Agents; Child; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome | 2003 |
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Famciclovir; Fatal Outcome; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Reverse Transcriptase Inhibitors | 2003 |
New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.
Topics: Antibodies, Monoclonal; Antiviral Agents; Centrifugation, Density Gradient; DNA, Viral; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Lamivudine; Reproducibility of Results | 2003 |
Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Australia; Base Sequence; Catalytic Domain; Codon, Terminator; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genome, Viral; Genotype; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Promoter Regions, Genetic; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics as Topic; Treatment Outcome; Viral Core Proteins; Viral Load | 2003 |
Decreased ratio of CD4/CD8 lymphocytes might be predictive for successful interferon alpha and lamivudine combined therapy in childhood chronic hepatitis B infection: A preliminary study.
Topics: Adolescent; Alanine Transaminase; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Child; Child Welfare; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunoglobulin A; Immunoglobulin G; Infant; Infant Welfare; Interferon-alpha; Lamivudine; Male; Predictive Value of Tests; Prospective Studies; Reverse Transcriptase Inhibitors; T-Lymphocyte Subsets; Treatment Outcome | 2003 |
HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Codon, Terminator; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Viral Core Proteins; Viral Load | 2003 |
[Severe exacerbation of chronic hepatitis B during therapy with corticosteroids and lamivudine therapy and successful short-term combination therapy with interferon-beta and interferon-gamma].
Topics: Anti-Inflammatory Agents; Antiviral Agents; Connective Tissue Diseases; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon Type I; Interferon-gamma; Lamivudine; Liver Function Tests; Lupus Erythematosus, Systemic; Middle Aged; Prednisolone; Recombinant Proteins; Recurrence; Reverse Transcriptase Inhibitors; Virus Activation | 2003 |
[Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Topics: Adolescent; Adult; Aged; Amino Acid Motifs; Child; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Time Factors | 2003 |
[Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Mutation | 2003 |
A case of relapsing Guillain-Barré syndrome associated with exacerbation of chronic hepatitis B virus hepatitis.
Topics: Aged; Antigen-Antibody Complex; DNA, Viral; Guillain-Barre Syndrome; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lamivudine; Liver Function Tests; Male; Prednisolone; Recurrence; Time Factors; Viremia; Virus Replication | 2003 |
TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine.
Topics: Adult; Aged; DNA Virus Infections; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prevalence; Reverse Transcriptase Inhibitors; Torque teno virus; Virus Replication | 2003 |
Adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Placebos; Research Design | 2003 |
Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.
Topics: Adult; Aged; Base Sequence; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Polymerase Chain Reaction; Probability; Prospective Studies; Recurrence; Reverse Transcriptase Inhibitors; Risk Assessment; Serologic Tests; Severity of Illness Index; Statistics, Nonparametric; Taiwan; Treatment Outcome; Viral Core Proteins; Viral Load | 2003 |
[Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence | 2003 |
[Detection and clinical significance of serum HBeAg and HBeAg/IC during the treatment of chronic hepatitis B patients with lamivudine].
Topics: Adolescent; Adult; Antigen-Antibody Complex; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2003 |
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Transplantation; Organophosphonates; Placebos; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
Management of HIV and hepatitis B or C co-infection in 15 HIV treatment centres. Disparity between protocols and practice.
Topics: Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Clinical Protocols; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lamivudine; Male; Mass Screening; Medical Audit; Polymerase Chain Reaction; Practice Guidelines as Topic; Retrospective Studies; Surveys and Questionnaires; United Kingdom | 2003 |
[Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Famciclovir; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2003 |
[Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif].
Topics: Adolescent; Adult; Amino Acid Motifs; Antiviral Agents; Conserved Sequence; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Phytotherapy | 2003 |
[Efficacy of lamivudine in HBeAg-negative chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Female; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Efficacy of interferon alpha-2b and lamivudine therapy for chronic hepatitis B in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Recombinant Proteins | 2003 |
Chronic hepatitis B with flare due to co-infection of hepatitis delta virus during lamivudine therapy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Lamivudine; Male; RNA, Viral | 2003 |
[Evaluation of different methods in monitoring YMDD motif mutations associated with lamivudine resistance].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Sensitivity and Specificity | 2003 |
[Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Amino Acid Motifs; Antiviral Agents; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2003 |
[Determination of the lamivudine-resistant mutants of hepatitis B virus].
Topics: Adult; Aged; Antiviral Agents; Codon; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors | 2003 |
[Lamivudine treatment consensus from relative experts in 2003].
Topics: Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Lamivudine; Polymerase Chain Reaction; Virus Replication | 2003 |
[Short-term therapeutic effect of lamivudine on patients with severe chronic hepatitis B].
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Safety; Treatment Outcome | 2003 |
Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Patient Selection; Recurrence; Treatment Failure; Viremia | 2003 |
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mitogens; Phytohemagglutinins; Reverse Transcriptase Inhibitors; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Tetanus Toxoid; Time Factors | 2003 |
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
Topics: Adult; Aging; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Recurrence; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Viral Core Proteins | 2003 |
A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
Topics: Adult; Base Sequence; Cohort Studies; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Probability; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Statistics, Nonparametric | 2003 |
[Aspects for long-term anti-viral therapy in treatment of chronic hepatitis B].
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation | 2003 |
[Efficacy of lamivudine re-treatment and relapse patterns after initial lamivudine treatment for chronic hepatitis B infection].
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Recurrence; Retreatment | 2003 |
Effect of long-term lamivudine therapy on histological outcome in chronic hepatitis B.
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
[Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive].
Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male | 2003 |
[Individual therapy for the patients with YMDD mutation in HBV by lamivudine].
Topics: Adult; Antiviral Agents; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2003 |
Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
Topics: Adult; Aged; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Female; Gene Products, pol; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Recurrence; Time Factors | 2003 |
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Virus Replication | 2003 |
Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment.
Topics: Adult; Antiviral Agents; Biomarkers; Case-Control Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Neuropeptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Radioimmunoassay; Viral Load | 2003 |
Lamivudine 'as needed': a novel therapeutic approach for HBe-minus chronic hepatitis.
Topics: Adult; Drug Administration Schedule; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2003 |
[Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Topics: Adult; Amino Acid Motifs; Antiviral Agents; Cloning, Molecular; DNA Primers; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Point Mutation | 2003 |
[Changes of IL-12 in the sera of chronic hepatitis B patients before and after lamivudine treatment].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interleukin-12; Lamivudine; Male; Mutation | 2003 |
Determinants for sustained HBeAg response to lamivudine therapy.
Topics: Adult; Aging; Drug Administration Schedule; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Logistic Models; Male; Recurrence; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Natural infection of HBV DNA YMDD variant strains in a chronic hepatitis B patient before treatment with lamivudine.
Topics: DNA, Viral; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2002 |
Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients.
Topics: Adult; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Liver Function Tests; Male; Middle Aged; Postoperative Complications; Reverse Transcriptase Inhibitors; Safety | 2003 |
Response to lamivudine treatment in children with chronic hepatitis B virus infection.
Topics: Adolescent; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load; Virus Replication | 2003 |
Prevention and treatment of hepatitis B recurrence after liver transplantation.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Assessment; Sampling Studies; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2003 |
Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Prospective Studies; Recurrence | 2003 |
[Predictive factors and efficacy of lamivudine treatment in chronic hepatitis B infection].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2003 |
Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Topics: Adult; Aged; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Precursors; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2004 |
[Influence of SEN virus infection on their response to lamivudine in patients with chronic hepatitis B].
Topics: Anti-HIV Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Respirovirus Infections; Sendai virus | 2003 |
Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies | 2003 |
Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.
Topics: Adult; Case-Control Studies; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors | 2003 |
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
Topics: Adenine; Amino Acid Sequence; Combined Modality Therapy; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; Reverse Transcriptase Inhibitors | 2003 |
Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Organophosphonates | 2003 |
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates | 2003 |
Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Lamivudine; Mutation; Organophosphonates | 2003 |
Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance.
Topics: Amino Acid Motifs; Base Sequence; Cluster Analysis; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2004 |
Icteric flare of chronic hepatitis B in a 95-year old patient.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Fatal Outcome; Hepatitis B, Chronic; Humans; Jaundice; Lamivudine; Male | 2003 |
Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome | 2004 |
Management of decompensated HBV cirrhosis: lamivudine and beyond.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Survival Rate | 2004 |
Influence of the hepatitis B e antigen/anti-HBe status on the response to lamivudine.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Promoter Regions, Genetic; Viral Core Proteins | 2003 |
Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
Topics: Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Treatment Outcome | 2003 |
Rare quasispecies in the YMDD motif of hepatitis B virus detected by polymerase chain reaction with peptide nucleic acid clamping.
Topics: Amino Acid Motifs; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Peptide Nucleic Acids; Polymerase Chain Reaction | 2003 |
Short-term lamivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2003 |
Short-term lamivudine for the treatment of chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Safety; Treatment Outcome | 2003 |
Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.
Topics: Adult; Alanine Transaminase; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2003 |
Continued lamivudine therapy in patients with chronic hepatitis B.
Topics: Adult; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Treatment Outcome | 2003 |
Lamivudine therapy for Japanese patients with cirrhosis B.
Topics: Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Microbial; Fibrosis; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2003 |
Antivirals for the treatment of chronic hepatitis B: current and future options.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Survival Analysis; Viral Load | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
[Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B].
Topics: Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2003 |
[Predictive factors and clinical outcome of viral breakthrough during lamivudine treatment for chronic hepatitis B infection].
Topics: Adolescent; Adult; Aged; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; Reverse Transcriptase Inhibitors | 2003 |
[Therapeutic effect of lamivudine on liver fibrosis resulted from chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2003 |
[Effect of interferon combined with lamivudine in treatment of chronic hepatitis B patients infected with HBV with mutation of YMDD].
Topics: Antiviral Agents; Drug Therapy, Combination; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation | 2003 |
Corticosteroids and lamivudine combined to treat acute severe flare-up in a chronic hepatitis B and C patient.
Topics: Acute Disease; Aged; Antiviral Agents; Betamethasone; Drug Therapy, Combination; Glucocorticoids; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Male; Prednisolone | 2004 |
[Update in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Evaluation; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2004 |
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B, Chronic; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Maximum Tolerated Dose; Middle Aged; Organophosphonates; Prospective Studies; Risk Assessment; Treatment Outcome | 2004 |
Plasma and liver carnitine levels of children with chronic hepatitis B.
Topics: Adolescent; Antiviral Agents; Carnitine; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Infant; Interferon-alpha; Lamivudine; Male; Regression Analysis | 2004 |
Lamivudine-induced acute pancreatitis in a patient with decompensated Hbv-related chronic liver disease.
Topics: Acute Disease; Aged; Amylases; Fatal Outcome; Hepatitis B, Chronic; Humans; Lamivudine; Male; Pancreatitis; Reverse Transcriptase Inhibitors | 2004 |
Viral features of lamivudine resistant hepatitis B genotypes A and D.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Inhibitors | 2004 |
Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
Topics: Adult; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors | 2004 |
Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates | 2003 |
Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection.
Topics: Adult; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Recurrence; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase | 2004 |
Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Time Factors; Treatment Outcome | 2004 |
[New antiviral agent. Hepatitis B therapy with slight resistance risk].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors | 2003 |
Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Topics: Adult; Amino Acid Sequence; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2004 |
Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Diagnostic Tests, Routine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Multiple, Viral; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Retrospective Studies; RNA-Directed DNA Polymerase; Spain | 2004 |
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure; Liver Transplantation; Living Donors; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors | 2004 |
Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection.
Topics: Bone Marrow Transplantation; Female; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Preoperative Care; Reverse Transcriptase Inhibitors; Tissue Donors | 2004 |
Coinfection of chronic hepatitis B and fasciolosis.
Topics: Adult; Animals; Drug Therapy, Combination; Fascioliasis; Follow-Up Studies; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Function Tests; Male; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Sampling Studies; Severity of Illness Index; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.
Topics: Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Topics: Acute Disease; Adult; Aged; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors | 2004 |
Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B.
Topics: Adolescent; Adult; Alanine Transaminase; Female; Ferritins; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2004 |
Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Approval; Drug Resistance, Viral; European Union; France; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; United States | 2004 |
The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartic Acid; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Methionine; Middle Aged; Mutation; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Tyrosine | 2004 |
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.
Topics: Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2004 |
Sustained response after lamivudine treatment in HBe minus chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2004 |
Remission of hepatitis B virus-related vasculitis with lamivudine.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Vasculitis | 2004 |
[Pretreatment ALT level and histologic activity as predictors of HBeAg loss in lamivudine treatment for chronic hepatitis B].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged | 2004 |
Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
Topics: Adult; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Virus Replication | 2004 |
Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Vaccines, Synthetic | 2004 |
Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antiviral Agents; Carrier State; Cyclosporine; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Recurrence | 2004 |
[Adefovir dipivoxil--a further step in the control of chronic viral hepatitis B. There is still a long way to go].
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates | 2004 |
Serum beta2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: relationship with virological breakthrough.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Proportional Hazards Models | 2004 |
Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.
Topics: Drug Resistance, Viral; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Recurrence; Reverse Transcriptase Inhibitors | 2004 |
[A case of liver cirrhosis B resistant to lamivudine showing the clinical effect of adefovir dipivoxil].
Topics: Adenine; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Preemptive lamivudine in hepatitis B patients undergoing chemotherapy.
Topics: Antineoplastic Agents; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma; Reverse Transcriptase Inhibitors; Secondary Prevention | 2004 |
Is it meaningful to pursue the safety of long-term lamivudine treatment in patients with chronic hepatitis B?
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2004 |
Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy.
Topics: Adult; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Long-Term Care; Male; Reverse Transcriptase Inhibitors | 2004 |
[The clinical meaning of the emergence of viral breakthrough during lamivudine treatment in patients with hepatitis B virus related chronic liver disease].
Topics: Acute Disease; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2004 |
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
Topics: Anti-HIV Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Green Fluorescent Proteins; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferons; Isoenzymes; Lamivudine; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Plasmids; Prostaglandin-Endoperoxide Synthases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins | 2004 |
[Investigation on the alteration of hepatitis B virus (HBV) markers in liver allograft of HBV related recipients in perioperative period].
Topics: Adolescent; Adult; Aged; Biomarkers; Child; DNA, Viral; Female; Hepatitis B Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Preoperative Care; Secondary Prevention | 2004 |
[A study on the clinical and pathological efficacy of lamivudine in the treatment of chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Biopsy, Needle; Child; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
[Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
Topics: Adolescent; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation | 2004 |
[Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Immunization, Passive; Lamivudine; Liver Transplantation; Male; Postoperative Complications; Secondary Prevention | 2004 |
Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Topics: Adult; Codon, Terminator; DNA, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Male; Middle Aged; Mutation; Postoperative Period; Recurrence; Reverse Transcriptase Inhibitors; Seroepidemiologic Studies; Viral Load; Virus Replication | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
Lamivudine induced stable reversal in HBV liver cirrhosis Child C: a case report.
Topics: Adult; Alanine Transaminase; Female; Hepatitis B, Chronic; Humans; Hyperbilirubinemia; Lamivudine; Liver Cirrhosis; Prothrombin Time; Reverse Transcriptase Inhibitors; Serum Albumin | 2003 |
Lamivudine treatment in patients with hepatitis B virus induced liver cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Reverse Transcriptase Inhibitors; Serum Albumin; Treatment Outcome | 2003 |
Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nucleic Acids; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Time Factors; Virus Replication | 2004 |
Breaking the tolerance or the virus?
Topics: Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Immunocompetence; Lamivudine; Male; Prognosis; Prospective Studies; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Evaluation; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient.
Topics: Adult; Antiretroviral Therapy, Highly Active; Base Sequence; CD8-Positive T-Lymphocytes; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Virus Replication | 2004 |
Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Virus Activation | 2004 |
Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Mutation; Treatment Outcome | 2004 |
Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
Topics: Adenine; Adult; Combined Modality Therapy; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Reverse Transcriptase Inhibitors; Secondary Prevention | 2004 |
[Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Gene Products, pol; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation | 2004 |
[Influence of Th1/Th2 balance of chronic hepatitis B patients and its significance after lamivudine therapy].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Th1 Cells; Th2 Cells | 2004 |
[Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
Topics: Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2004 |
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Topics: Adult; Aged; Amino Acid Motifs; Amino Acid Sequence; Anti-HIV Agents; DNA, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors | 2004 |
Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Recurrence; Viremia | 2004 |
Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Chromosome Deletion; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Precursors; Regression Analysis | 2004 |
Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Mutation; Recurrence; Virus Replication | 2004 |
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Topics: Adult; Anti-HIV Agents; Cloning, Molecular; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Fatal Outcome; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Phylogeny; Polymerase Chain Reaction | 2004 |
[A study on detection method of lamivudine related mutations in hepatitis B virus polymerase gene].
Topics: Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length | 2004 |
[Detection and identification of emergence of HBV YMDD motif mutation during lamivudine treatment by hybridization to an oligonucleotide array].
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction | 2003 |
[Detection of the mutation in HBV polymerase gene by RFLP PCR method in hepatitis B patients treated with lamivudine].
Topics: Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors | 2003 |
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adult; Asian People; Canada; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Recurrence; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Successful treatment by lamivudine and regular hemodialysis in a patient with decompensated hepatitis B virus-related cirrhosis complicated by terminal renal impairment.
Topics: Anti-HIV Agents; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Treatment Outcome | 2004 |
Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Epitopes; Female; Hepatitis B Core Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; HLA-A Antigens; HLA-A24 Antigen; Humans; In Vitro Techniques; Interferon-gamma; Lamivudine; Male; Middle Aged; T-Lymphocytes, Cytotoxic; Th1 Cells | 2004 |
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome | 2004 |
Prevention of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Mutation; Virus Replication | 2004 |
HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.
Topics: Adult; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome | 2004 |
[Lamivudine treatment for hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Effects of long-term lamivudine therapy in renal-transplant patients.
Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Middle Aged | 2004 |
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
[An attempt to approach an optional therapeutic regimen for chronic hepatitis B].
Topics: Adenine; Animals; Antiviral Agents; Combined Modality Therapy; Genetic Therapy; Hepatitis B Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Recombinant Proteins | 2004 |
[Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
Topics: Adolescent; Adult; Aged; Amino Acid Motifs; Antiviral Agents; Child; Child, Preschool; DNA-Directed DNA Polymerase; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation | 2004 |
[Clinical characteristics of and the related factors to the relapse of chronic hepatitis B after lamivudine withdrawal].
Topics: Adolescent; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Recurrence | 2004 |
[Therapeutic strategies for chronic hepatitis B recommended by the American Association for the Study of Liver Diseases].
Topics: American Medical Association; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; United States | 2004 |
[Several important issues in the antiviral therapy of hepatitis B].
Topics: Antiviral Agents; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Secondary Prevention | 2004 |
[Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma; Male; Middle Aged; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Secondary Prevention; Stomach Neoplasms | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome | 2004 |
Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.
Topics: Adolescent; Adult; Aged; Apoptosis; Biomarkers; Carrier State; DNA, Viral; Fas Ligand Protein; fas Receptor; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Male; Membrane Glycoproteins; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Solubility | 2004 |
[Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations].
Topics: Adult; DNA, Viral; Drug Resistance, Viral; Female; Genetic Techniques; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B.
Topics: Drug Resistance; Fatty Liver; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tissue Donors; Treatment Outcome | 2004 |
Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection.
Topics: Acute Disease; Adult; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2004 |
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2004 |
[Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
Topics: Adult; Amino Acid Sequence; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytotoxicity, Immunologic; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Epitopes, T-Lymphocyte; Female; Hepatitis B virus; Hepatitis B, Chronic; HLA-A2 Antigen; Humans; Immunity, Cellular; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic | 2005 |
Evolving approaches to the treatment of chronic hepatitis B virus infection in children.
Topics: Antiviral Agents; Child; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2005 |
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Topics: Adult; Antiviral Agents; Carrier State; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoassay; Lamivudine; Luminescent Measurements; Male; Middle Aged; Time Factors; Viral Load | 2005 |
Acute leukaemia in chronic hepatitis B patients with lamivudine therapy.
Topics: Acute Disease; Adult; Female; Hepatitis B, Chronic; Humans; Lamivudine; Leukemia, Myeloid; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2004 |
Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Secondary Prevention; Treatment Outcome | 2004 |
Lamivudine therapy for chronic hepatitis B in renal transplant recipients.
Topics: Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Postoperative Care; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Amino Acid Sequence; DNA, Viral; Drug Resistance, Viral; Female; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Long-Term Care; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors | 2004 |
[High-flux detection of HBV lamivudine resistant strains by genechip and analysis of mutant hotspots in those strains].
Topics: Amino Acid Motifs; Antiviral Agents; Codon; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Oligonucleotide Array Sequence Analysis; Point Mutation | 2004 |
[The overview of the seminar on chronic hepatitis B].
Topics: Adjuvants, Immunologic; Antiviral Agents; China; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2004 |
Peginterferon and lamivudine for hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Mutation; Polyethylene Glycols; Recombinant Proteins | 2004 |
[Treatment of chronic hepatitis B in children].
Topics: Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Pregnancy; Prognosis; Risk Assessment | 2004 |
Serum hyaluronic acid during lamivudine treatment in chronic hepatitis B.
Topics: Adult; Biomarkers; Female; Hepatitis B, Chronic; Humans; Hyaluronic Acid; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
[Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation].
Topics: Adolescent; Adult; Child; Combined Modality Therapy; Dipyridamole; DNA, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunotherapy; Lamivudine; Levamisole; Middle Aged; Mutation | 2004 |
Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amino Acid Sequence; Amino Acid Substitution; Child; China; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Virus Replication | 2005 |
Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies.
Topics: Adult; Aged; Female; Heart Transplantation; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; New York; Postoperative Complications; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome | 2005 |
Quantification of the newly detected lamivudine resistant YSDD variants of Hepatitis B virus using molecular beacons.
Topics: Amino Acid Motifs; Asian People; Diseases in Twins; Drug Resistance, Viral; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Probes; Molecular Sequence Data; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Twins | 2005 |
Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prothrombin Time; Serum Albumin; Viral Load | 2005 |
[Ambulatory management of hepatitis B before and after liver transplantation].
Topics: Ambulatory Care; Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunization, Passive; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Care; Premedication; Preoperative Care; Secondary Prevention | 2005 |
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.
Topics: Adenine; Adult; DNA, Viral; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Polymerase Chain Reaction; Treatment Failure | 2005 |
[Lamivudine treatment of patients with decompensated HBV cirrhosis and mutation in YMDD motif].
Topics: Amino Acid Motifs; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2005 |
Antiviral treatment with alpha interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferon Type I; Interleukin-10; Lamivudine; Lipopolysaccharide Receptors; Liver; Macrophages; Phenotype; Recombinant Proteins; Up-Regulation | 2005 |
A comparative study on effect of lamivudine in wild and precore mutant variety of chronic hepatitis B virus infected patients.
Topics: Antiviral Agents; Chi-Square Distribution; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Prospective Studies; Treatment Outcome | 2005 |
Summaries for patients. Combination therapy for chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Viral Load | 2005 |
[Liver transplantation finally available also for our patients with chronic hepatitis B virus infection].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Recurrence | 2004 |
[Liver transplantation for chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Recurrence | 2004 |
[Liver transplantation for hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Secondary Prevention | 2004 |
Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Topics: Adult; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Markers; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Probability; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Treatment Outcome; Virus Replication | 2005 |
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B.
Topics: Adolescent; Adult; Age Factors; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Function Tests; Male; Probability; Prospective Studies; Recombinant Proteins; Risk Assessment; Sampling Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2005 |
Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B.
Topics: Adolescent; Adult; Age Factors; Aged; Biomarkers; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Sex Factors; Treatment Outcome | 2005 |
Treatment of chronic hepatitis B with lamivudine.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Pakistan; Reverse Transcriptase Inhibitors | 2005 |
Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.
Topics: Acute Disease; Administration, Oral; Adult; Bilirubin; Biomarkers; Disease Progression; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Failure, Acute; Male; Middle Aged; Prognosis; Radiography; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Transaminases; Treatment Outcome; Ultrasonography | 2005 |
Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Biomarkers; CD13 Antigens; DNA, Viral; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospitals, University; Humans; Lamivudine; Magnetic Resonance Imaging; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2005 |
[Lamivudine for the treatment of patients with chronic hepatitis with negative hepatitis B AgHbe].
Topics: Adult; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2005 |
[Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors | 2005 |
Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Recurrence; Retrospective Studies; Risk Factors; Treatment Outcome | 2005 |
[Advances in treatment of chronic hepatitis B].
Topics: Adenine; Animals; Antiviral Agents; Drug Therapy, Combination; Genetic Therapy; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Phytotherapy | 2005 |
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Topics: Adenine; Adult; Antibodies, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Phenotype; Retrospective Studies; Reverse Transcriptase Inhibitors; Secondary Prevention | 2005 |
[A long-term observation and follow-up for patients with HBeAg/Anti-HBe seroconversion after lamivudine treatment].
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2005 |
Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
Topics: Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2005 |
Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.
Topics: Adult; Antibiotic Prophylaxis; Female; Hematopoietic Stem Cell Transplantation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2005 |
Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; CD56 Antigen; CD8-Positive T-Lymphocytes; Cell Count; Drug Therapy, Combination; Female; Granzymes; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lamivudine; Liver; Longitudinal Studies; Lymphocyte Count; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Serine Endopeptidases; Viral Load | 2005 |
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Amino Acid Motifs; DNA-Directed DNA Polymerase; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2005 |
Summaries for patients. Antiviral regimens for chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Markov Chains; Organophosphonates; Recombinant Proteins; Salvage Therapy; Sensitivity and Specificity; Transaminases | 2005 |
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Markov Chains; Organophosphonates; Recombinant Proteins; Salvage Therapy; Sensitivity and Specificity; Transaminases | 2005 |
Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.
Topics: Antiviral Agents; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Polymorphism, Restriction Fragment Length; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2005 |
[Therapeutic and preventive activities of lamivudine on HBV re-activation in HBV carriers with immunodeficiency].
Topics: Adult; Carrier State; Female; Hepatitis B, Chronic; Humans; Immunologic Deficiency Syndromes; Lamivudine; Male; Middle Aged; Secondary Prevention | 2005 |
Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus.
Topics: Adolescent; Child; Child, Preschool; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immune Tolerance; Lamivudine; Liver Function Tests; Male; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
Topics: Adult; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors | 2005 |
Screen for underlying HIV before antiviral treatment for HBV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Contraindications; Drug Resistance, Viral; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Treatment Failure | 2005 |
[Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
Topics: China; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Topics: Adult; Codon, Terminator; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Time Factors; Treatment Outcome; Viral Load | 2005 |
Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.
Topics: Adult; Amino Acid Sequence; Anti-HIV Agents; Base Sequence; DNA Mutational Analysis; DNA-Directed DNA Polymerase; DNA, Viral; Gene Deletion; Genes, Overlapping; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation; Protein Precursors; Sequence Alignment; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Viral Proteins | 2005 |
A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
Topics: Adult; Antiviral Agents; Biomechanical Phenomena; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Viral Load | 2005 |
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Failure; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Theoretical; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome; Virus Replication | 2005 |
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Topics: Adolescent; Adult; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Injections, Intramuscular; Lamivudine; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Secondary Prevention; Treatment Failure; Vaccination | 2005 |
[YVDD is the primary symbol of gene mutation in hepatitis B patients treated with lamivudine].
Topics: Antiviral Agents; Base Sequence; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Mutation | 2005 |
Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.
Topics: Aged; Amino Acid Sequence; Base Sequence; Cell Line, Tumor; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors | 2005 |
Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Topics: Alanine Transaminase; Amino Acid Substitution; Antiviral Agents; Canada; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome | 2005 |
The maze of treatments for hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins | 2005 |
Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Preoperative Care; Reverse Transcriptase Inhibitors; Secondary Prevention; Treatment Outcome | 2005 |
[The evaluation of hyaluronic acid and laminin concentration in serum in children with chronic hepatitis B treated with lamivudine, unresponsive to previous interferon-alpha therapy].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B, Chronic; Humans; Hyaluronic Acid; Interferon-alpha; Laminin; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment.
Topics: Administration, Oral; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2005 |
Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Mutation, Missense; Predictive Value of Tests; Protein Structure, Tertiary; Recurrence; RNA-Directed DNA Polymerase | 2005 |
Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage.
Topics: Fatal Outcome; Heart Arrest; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Male; Middle Aged; Mitochondrial Diseases; Peripheral Nervous System Diseases; Respiratory Insufficiency; Reverse Transcriptase Inhibitors | 2005 |
[Influence of nucleoside analogues resistance on anti-HBV treatment].
Topics: Adenine; Antiviral Agents; Dideoxynucleosides; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2005 |
[Some strategies for the long-term treatment of chronic hepatitis B].
Topics: Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male | 2005 |
[Antiviral treatment of HBeAg positive chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins | 2005 |
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Ultrasonography; Virus Replication | 2005 |
Which combination should be preferred in the management of children with chronic hepatitis B infection?
Topics: Antiviral Agents; Child; Decision Making; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Is leptin a predictive factor in the end of therapy response in chronic hepatitis B?
Topics: Child; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Leptin; Male; Treatment Outcome | 2005 |
[A preliminary study on the serum HBsAg level in patients with chronic hepatitis B and hepatitis cirrhosis during lamivudine therapy].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged | 2005 |
Chronic hepatitis B--treatment with nucleoside analogues.
Topics: Adenine; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Nucleosides; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors | 2005 |
Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Disease Progression; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Severity of Illness Index | 2005 |
Complete hepatitis B virus genome analysis in chronically infected children before and during lamivudine treatment.
Topics: Amino Acid Substitution; Antiviral Agents; Carrier State; Child; Drug Administration Schedule; Female; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation, Missense | 2005 |
The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy.
Topics: Adult; Breath Tests; Caffeine; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
[Adefovir dipivoxil-a new effective treatment for chronic infection with hepatitits B virus.].
Topics: Antiviral Agents; Drug Interactions; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Lamivudine; Treatment Outcome | 2005 |
Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2005 |
Pregnancy during lamivudine therapy in chronic hepatitis B--case report.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious | 2004 |
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
Topics: Cell Line, Tumor; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Reverse Transcriptase Inhibitors; Transfection | 2005 |
[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
[Comprehensive prophylaxis and treatment of hepatitis B recurrence after liver transplantation].
Topics: Combined Modality Therapy; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Postoperative Complications; Secondary Prevention | 2005 |
Ichthyosiform eruption associated with lamivudine in a patient with chronic hepatitis-B infection.
Topics: Adult; Drug Eruptions; Female; Hepatitis B, Chronic; Humans; Ichthyosis; Lamivudine; Reverse Transcriptase Inhibitors | 2005 |
[Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Topics: Administration, Oral; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulin G; Injections, Intramuscular; Lamivudine; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Secondary Prevention | 2005 |
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Topics: Adult; Amino Acid Sequence; Codon, Terminator; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Virus Activation | 2005 |
Liver transplantation for patients with hepatitis B virus-related diseases.
Topics: Antiviral Agents; Combined Modality Therapy; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure, Acute; Liver Neoplasms; Liver Transplantation; Male; Secondary Prevention; Survival Rate | 2001 |
Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance.
Topics: Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Oligonucleotide Array Sequence Analysis; Sensitivity and Specificity | 2005 |
[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
Topics: Adenine; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepatic Encephalopathy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Organophosphonates; Protein Structure, Tertiary; Recurrence; Reverse Transcription | 2005 |
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays.
Topics: Adolescent; Adult; Antiviral Agents; Child; Computer Systems; DNA Mutational Analysis; DNA-Directed DNA Polymerase; DNA, Viral; Female; Genes, Viral; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Mutation, Missense; Point Mutation; Polymerase Chain Reaction; Promoter Regions, Genetic; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Load | 2005 |
Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2005 |
Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
Topics: Antiviral Agents; Drug Administration Schedule; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2005 |
Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2005 |
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Polymerase Chain Reaction; Prospective Studies; RNA, Viral; Treatment Outcome | 2006 |
Cost-effectiveness in hepatitis B.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Recombinant Proteins | 2005 |
Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Antibodies; Humans; Lamivudine; Organophosphonates; Treatment Outcome | 2006 |
Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Topics: Adolescent; Adult; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Core Proteins | 2006 |
Haemophagocytic syndrome associated with hepatitis-B virus infection responding to etoposide.
Topics: Etoposide; Fatal Outcome; Hepatitis B, Chronic; Humans; Lamivudine; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Remission Induction | 2005 |
Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment.
Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Heart Diseases; Heart Transplantation; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Postoperative Period; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Virus Activation | 2005 |
Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Liver Function Tests; Male; Proportional Hazards Models; Recurrence; Retreatment; Risk Factors | 2005 |
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome | 2006 |
[Treatment response to lamivudine in chronic hepatitis B patients].
Topics: Adult; Aged; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2005 |
Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; DNA Mutational Analysis; Female; Gene Products, pol; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Treatment Outcome | 2005 |
Dynamics of hepatitis B virus resistance to lamivudine.
Topics: Adult; Amino Acid Sequence; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Alignment; Time Factors; Viral Proteins | 2006 |
[Treatment of chronic hepatitis B].
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon Type I; Lamivudine; Recombinant Proteins | 2005 |
[Effect of a Chinese herbal compound and lamivudine combination therapy on patients with chronic hepatitis B and its influence on YMDD motif mutation].
Topics: Adolescent; Adult; Drugs, Chinese Herbal; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Phytotherapy | 2005 |
Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Renal Dialysis; Treatment Failure; Virus Replication | 2005 |
Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Immunoglobulin M; Lamivudine; Male; Middle Aged; Treatment Failure | 2006 |
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins | 2006 |
[Sequential analyses of circulating HBV specific T helper cell response in chronic hepatitis B patients receiving antiviral treatment].
Topics: Adult; Antiviral Agents; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; T-Lymphocytes, Helper-Inducer | 2005 |
Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Fatal Outcome; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Molecular Sequence Data; Mutation | 2006 |
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Spain | 2006 |
Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population.
Topics: Adolescent; Adult; Aged; China; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2005 |
Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Female; Genes, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Sequence Alignment; Sequence Analysis, Protein; Treatment Outcome; Viral Load | 2006 |
Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine.
Topics: Adult; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Proteinuria; Reverse Transcriptase Inhibitors | 2006 |
Relationship between body surface area and ALT normalization after long-term lamivudine treatment.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Body Surface Area; Data Interpretation, Statistical; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors | 2005 |
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Probability; Retrospective Studies; Risk Assessment; Secondary Prevention; Statistics, Nonparametric; Treatment Outcome | 2006 |
[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Viral Load | 2006 |
The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2006 |
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Retrospective Studies; Reverse Transcriptase Inhibitors | 2006 |
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Competence; Disease Progression; DNA, Viral; Drug Therapy, Combination; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver; Organophosphonates; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Societies, Medical; Virus Replication | 2006 |
Combination therapy for chronic hepatitis B: a one-two knockout punch, or a swing and a miss?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2006 |
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis, Autoimmune; Humans; Lamivudine; Liver Transplantation; Male; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors | 2006 |
Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2006 |
Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
Topics: Adult; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
Topics: Adenine; Antiviral Agents; Base Sequence; DNA Probes; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; In Vitro Techniques; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Sensitivity and Specificity; Virology | 2006 |
Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Female; Genetic Engineering; Genetic Therapy; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Heterozygote; Humans; Immunologic Memory; Interferon-gamma; Interleukin-12; Lamivudine; Male; Middle Aged; Recurrence; T-Lymphocytes; Vaccines, DNA; Virus Replication | 2006 |
Detection of YMDD mutants using universal template real-time PCR.
Topics: Antiviral Agents; Aspartic Acid; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Methionine; Mutation; Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Tyrosine | 2006 |
Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
Topics: Administration, Oral; Adult; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Remission Induction; Reverse Transcriptase Inhibitors; RNA, Viral | 2006 |
Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Long-Term Care; Male; Middle Aged; Mutation; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2006 |
Early reduction of infected hepatocytes by activated immunity at the time of interferon withdrawal hepatitis followed by lamivudine administration resulted in higher seroconversion in hepatitis Be antigen-positive patients with chronic hepatitis B.
Topics: Adult; Drug Resistance; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Interferons; Lamivudine; Male; Mutation; Recurrence; Substance Withdrawal Syndrome | 2006 |
Extended lamivudine treatment in patients affected by chronic active anti-Hbe positive hepatitis.
Topics: Administration, Oral; Adult; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Polymerase Chain Reaction; Time Factors; Virus Replication | 2006 |
[Immunotherapy in aplastic anaemia as a cause of reactivation of hepatitis B virus-immunologic aspects].
Topics: Anemia, Aplastic; Antigens, CD; Antiviral Agents; Child; Combined Modality Therapy; Cyclosporine; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Immunotherapy; Interferon-alpha; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2005 |
Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Carrier State; Child; Child, Preschool; DNA Primers; DNA, Viral; Gambia; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Viral Load | 2006 |
Antiviral options for the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates | 2006 |
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Immunoglobulin G; Infliximab; Lamivudine; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Retrospective Studies; Spondylarthropathies; Transaminases; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2006 |
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Serum Albumin; Statistics, Nonparametric | 2006 |
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; France; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Statistics, Nonparametric | 2006 |
Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
Topics: DNA, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Prognosis; Retrospective Studies; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Viral Load | 2006 |
Variant of hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2006 |
[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Treatment Outcome; Viral Core Proteins; Young Adult | 2006 |
[Clinical profiles of circulating dendritic cell phenotype and lymphocyte subsets in patients chronically infected with HBV during lamivudine treatment].
Topics: Adolescent; Adult; Antigens, CD; Antiviral Agents; CD4 Lymphocyte Count; Dendritic Cells; Female; Flow Cytometry; Hepatitis B, Chronic; HLA-DR Antigens; Humans; Immunophenotyping; Lamivudine; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Young Adult | 2006 |
Antiviral treatment of chronic hepatitis B with lamivudine in pediatric renal transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Nephrotic Syndrome; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
Lamivudine therapy for children with chronic hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon Type I; Lamivudine; Male; Recombinant Proteins; Treatment Failure | 2006 |
Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins | 2006 |
Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Organophosphonates; Time Factors; Treatment Outcome | 2006 |
Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
Topics: Adult; Aged; DNA Mutational Analysis; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Time Factors | 2006 |
Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Topics: Antiviral Agents; Baculoviridae; Cell Line; DNA Replication; DNA, Viral; Drug Combinations; Drug Therapy, Combination; Gene Expression Regulation, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Lamivudine; Recombinant Proteins; Reverse Transcriptase Inhibitors; Time Factors; Virus Replication | 2006 |
Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy.
Topics: Adult; Antiviral Agents; Base Sequence; Codon, Nonsense; DNA, Viral; Female; Genes, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Promoter Regions, Genetic | 2006 |
Low incidence of retinopathy during peginterferon alpha-2b and lamivudine therapy for chronic hepatitis B.
Topics: Antiviral Agents; Evoked Potentials, Visual; Hepatitis B, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Risk Factors | 2006 |
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Case-Control Studies; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Pharmacogenetics; Probability; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2006 |
[Dynamic variations of hepatitis B virus polymerase gene in lamivudine-treated hepatitis B patients].
Topics: Amino Acid Sequence; Base Sequence; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Reverse Transcriptase Inhibitors | 2006 |
[The use of nucleotide analogues in treating patients with chronic hepatitis B].
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2006 |
[Problems of and strategies in nucleotide analogues therapy for chronic hepatitis B].
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates | 2006 |
[Successful lamivudine therapy for chronic hepatitis B in the family].
Topics: Adult; Aged; Antiviral Agents; Family Health; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2006 |
Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load.
Topics: Animals; Antibody Affinity; Antiviral Agents; Ape Diseases; DNA, Viral; Female; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Immunization; Interferon-gamma; Lamivudine; Pan troglodytes; Protein Precursors; RNA, Viral; Vaccines, DNA; Viral Load | 2006 |
[Hepatitis B virus genotypes and the response to lamivudine therapy].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Viral Load | 2005 |
[To evaluate treatments of chronic hepatitis B].
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates | 2006 |
[Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged | 2006 |
[Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B].
Topics: Acute Disease; Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2006 |
Antiviral treatment of hepatitis B virus-transgenic mice by a marine organism, Styela plicata.
Topics: Animals; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Interleukin-2; Interleukin-6; Lamivudine; Mice; Mice, Transgenic; Tissue Extracts; Urochordata | 2006 |
Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection.
Topics: Child, Preschool; China; Cost-Benefit Analysis; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Lamivudine; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors | 2006 |
Lamivudine response of IgM anti-HBc chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Immunoglobulin M; Lamivudine; Male; Middle Aged | 2006 |
Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
Topics: Antiviral Agents; Base Sequence; DNA Probes; DNA, Viral; Drug Resistance, Viral; False Negative Reactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Reagent Kits, Diagnostic; Sequence Analysis, DNA; Viral Load | 2006 |
Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Child; DNA, Viral; Dose-Response Relationship, Drug; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors | 2006 |
The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Topics: Adult; Amino Acid Sequence; CD8-Positive T-Lymphocytes; DNA, Viral; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Female; Glucocorticoids; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Peptides; Prednisolone; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
Hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Viral Load | 2006 |
[Effect of lamivudine treatment on the quality of life of chronic hepatitis B].
Topics: Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Quality of Life; Reverse Transcriptase Inhibitors; Surveys and Questionnaires | 2006 |
Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation.
Topics: Acute Disease; Antiviral Agents; DNA, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine | 2006 |
Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Treatment Outcome; Viral Load | 2006 |
Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Topics: Adult; DNA, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Nucleic Acid Amplification Techniques; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Time Factors; Viral Load | 2006 |
Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients.
Topics: Adult; Antiviral Agents; DNA Probes; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Fluorometry; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Nucleic Acid Hybridization; Sensitivity and Specificity; Transition Temperature | 2006 |
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Fatal Outcome; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Lymphoma, Follicular; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Virus Activation | 2006 |
Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.
Topics: Anti-HIV Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Middle Aged; Treatment Outcome; Viral Load | 2006 |
Rapid detection of lamivudine-resistant hepatitis B virus mutations by PCR-based methods.
Topics: Amino Acid Motifs; DNA Mutational Analysis; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Sequence Data; Mutation; Polymerase Chain Reaction | 2006 |
A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
Topics: Adult; Aged; Antiviral Agents; Deoxyribonucleases, Type II Site-Specific; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Reference Standards; Reproducibility of Results; Sequence Analysis, DNA | 2006 |
Evaluation of alpha-glutathione-S-transferase as a biomarker of lamivudine therapy for chronic hepatitis B.
Topics: Adult; Biomarkers; Case-Control Studies; Female; Glutathione Transferase; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Reverse Transcriptase Inhibitors; ROC Curve; Treatment Outcome | 2006 |
Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.
Topics: Adult; Aged; Centrifugation, Density Gradient; DNA, Viral; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
Topics: Adenine; Adult; Antiviral Agents; Biological Evolution; Cells, Cultured; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Virus Replication | 2006 |
Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Prospective Studies; Time Factors; Treatment Failure; Treatment Outcome; Treatment Refusal; Viral Load | 2006 |
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Famciclovir; Female; Heart Transplantation; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Liver Neoplasms; Male; Middle Aged | 2006 |
[A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Eruptions; Female; Hepatitis B, Chronic; Humans; Ichthyosis; Lamivudine; Middle Aged; Organophosphonates | 2006 |
How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
Topics: Amino Acid Motifs; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Virus Replication | 2006 |
YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Topics: Adult; Aged; Amino Acid Motifs; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral | 2006 |
Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.
Topics: Adult; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2006 |
[Effects of antiviral effects of agents and prognosis of chronic hepatitis B.].
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Prognosis; Retrospective Studies | 2006 |
Five-year results of chronic hepatitis B infection treatment in children with cured cancer.
Topics: Adolescent; Adult; Alanine Transaminase; Child; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Neoplasms | 2006 |
Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B.
Topics: Drug Resistance, Viral; Genetic Techniques; Hepacivirus; Hepatitis B, Chronic; Humans; Lamivudine; Plasmids; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Time Factors | 2006 |
Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B, Chronic; Humans; Infant; Interferon-alpha; Lamivudine; Male; Treatment Outcome | 2007 |
The prevention of an expected hepatic flare in HBe negative patients after lamivudine discontinuation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inosine Pranobex; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Secondary Prevention; Time Factors; Treatment Outcome; Viral Load | 2006 |
Annular leukocytoclastic vasculitis in association with chronic hepatitis B.
Topics: Aged; Antiviral Agents; Dapsone; Hepatitis B, Chronic; Humans; Lamivudine; Male; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation | 2007 |
COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.
Topics: Adenine; Antiviral Agents; Automation; Biopsy; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Nucleic Acid Amplification Techniques; Organophosphonates; Polymerase Chain Reaction; Sensitivity and Specificity; Taq Polymerase; Viremia | 2007 |
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation | 2007 |
[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates | 2007 |
Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Salvage Therapy | 2007 |
Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
Topics: Adult; Amino Acid Substitution; Cell Line; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Lamivudine; Male; Middle Aged; Mutagenesis, Site-Directed; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Protein Precursors; Radioimmunoassay; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Time Factors; Transfection; Treatment Outcome; Viremia | 2007 |
Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chi-Square Distribution; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Viral Load | 2007 |
Combination therapy for chronic hepatitis B: simultaneous or sequential?
Topics: Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Viral Load | 2007 |
Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Models, Theoretical; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Severity of Illness Index; Survival Analysis; Taiwan; Virus Replication | 2006 |
Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
Topics: Adult; Aged; Amino Acid Motifs; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Point Mutation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Viral Load | 2006 |
Why do we not yet have combination chemotherapy for chronic hepatitis B?
Topics: Adenine; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Synergism; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2007 |
Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan.
Topics: Acute Disease; Adolescent; Adult; Aged; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Mutation; Odds Ratio; Reverse Transcriptase Inhibitors; Species Specificity; Viral Proteins | 2007 |
Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Linear Models; Logistic Models; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2007 |
Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Mutation, Missense; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Sequence Analysis, DNA; Viral Proteins | 2008 |
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Successful treatment with corticosteroid and lamivudine for autoimmune hepatitis in a patient with asymptomatic HBV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis B, Chronic; Hepatitis, Autoimmune; Humans; Lamivudine; Middle Aged; Prednisolone | 2007 |
Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Asian People; Comorbidity; Female; Glucocorticoids; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Lupus Erythematosus, Systemic; Male; Middle Aged; Prednisolone; Retrospective Studies; Rheumatic Diseases; Treatment Outcome; Virus Activation | 2007 |
Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance.
Topics: Adenine; Contraindications; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2007 |
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Hong Kong; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2007 |
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Viral; Follow-Up Studies; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lamivudine; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
Clinical course of hepatitis B virus infection in renal allograft recipients.
Topics: Adolescent; Adult; Biopsy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Liver; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Virus Activation | 2007 |
Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
Topics: Adult; Drug Resistance; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2007 |
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.
Topics: Adenine; Adolescent; Adult; Black or African American; Contraindications; Female; Hepatitis B, Chronic; Hispanic or Latino; Hospitals, Urban; Humans; Insurance Coverage; Interferons; Lamivudine; Liver Cirrhosis; Male; Mass Screening; Middle Aged; New York City; Organophosphonates; Patient Compliance; Pilot Projects; Refusal to Treat; Risk Factors; Urban Health; Utilization Review | 2007 |
Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
Topics: Adult; Amino Acid Motifs; Amino Acid Substitution; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Probe Techniques; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Directed DNA Polymerase; RNA, Viral; Time Factors | 2007 |
[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2007 |
Optimal duration of therapy in HBV-related cirrhosis.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Health Planning Guidelines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins | 2007 |
Recommendations for the treatment of chronic hepatitis B infection in children.
Topics: Adenine; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Male; Organophosphonates; Pakistan; Practice Guidelines as Topic | 2007 |
Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Topics: Adult; Aged; Amino Acid Motifs; Codon; DNA Mutational Analysis; DNA-Directed DNA Polymerase; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymorphism, Restriction Fragment Length; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Viral Load | 2007 |
Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Asian People; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2007 |
Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2007 |
Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
Topics: Adult; Aged; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny | 2007 |
Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Female; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Time Factors | 2007 |
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Base Sequence; DNA Mutational Analysis; DNA Primers; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Gene Products, pol; Genes, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Promoter Regions, Genetic; Viral Core Proteins; Viremia | 2007 |
Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection.
Topics: Adult; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Hepatitis D; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Reoperation; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis | 2007 |
Treatment of chronic hepatitis B with lamivudine in renal transplant recipients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunosuppression Therapy; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Remission Induction; Renal Dialysis; Reverse Transcriptase Inhibitors; Time Factors; Viremia | 2007 |
Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.
Topics: Adult; Age Factors; Alanine Transaminase; DNA, Viral; Female; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Gene Dosage; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates | 2007 |
Hepatitis B surface antigen clearance in lamivudine-treated patients: main therapeutic goal?
Topics: Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2007 |
[Clinical outcomes of lamivudine therapy in HBeAg positive chronic hepatitis B with minimally elevated ALT].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; Treatment Outcome | 2007 |
[Predictors of lamivudine resistance in patients with chronic hepatitis B virus infection].
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prognosis; Retrospective Studies | 2007 |
[An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Quality-Adjusted Life Years; Treatment Outcome | 2007 |
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferon-beta; Japan; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2007 |
Prediction of treatment outcomes for lamivudine.
Topics: Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Treatment Outcome | 2007 |
Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Predictive Value of Tests; Reverse Transcriptase Inhibitors | 2007 |
[Factors related to the outcome of patients with chronic severe hepatitis B and effectiveness of antivirus therapy].
Topics: Adult; Age Factors; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prothrombin; Treatment Outcome; Viral Load | 2007 |
[A case of chronic hepatitis B with primary adefovir resistance].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Organophosphonates | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Follow-Up Studies; France; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged | 2007 |
Screening for and treating hepatitis B virus in patients with HIV infection.
Topics: Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mass Screening; Practice Guidelines as Topic | 2007 |
Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies | 2007 |
Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Statistics, Nonparametric; Treatment Outcome | 2007 |
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Gene Deletion; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Polymerase Chain Reaction; Prospective Studies; Sequence Analysis, DNA; Viral Core Proteins | 2007 |
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2007 |
Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Mutation; Predictive Value of Tests; Retrospective Studies; Viral Core Proteins; Viral Load | 2007 |
Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2007 |
Adefovir for lamivudine resistant HBV: more than meets the eye.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Organophosphonates | 2007 |
Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
Topics: Adult; Aged; Amino Acid Motifs; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phylogeny; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2008 |
[New first line therapy of chronic hepatitis B. Primary therapy goal: effective virus suppression].
Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Virus Replication | 2007 |
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2007 |
The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.
Topics: Adult; Aged; Alanine Transaminase; Amino Acid Motifs; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors | 2007 |
Applicability of cost-effectiveness analysis to management of chronic hepatitis B.
Topics: Antiviral Agents; Asia; Cost-Benefit Analysis; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins | 2007 |
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
Topics: Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Markov Chains; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Taiwan | 2007 |
Chronic hepatitis B: a wider range of therapeutic options.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection.
Topics: Antigens, CD; Asia; Cell Shape; Cells, Cultured; Dendritic Cells; Dose-Response Relationship, Drug; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunophenotyping; Interleukin-12; Interleukin-6; Lamivudine; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Reverse Transcriptase Inhibitors; T-Lymphocytes; Time Factors; Virus Replication | 2007 |
Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors | 2007 |
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Topics: Adult; Aged; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Female; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Topics: Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; South Africa | 2007 |
[Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Retrospective Studies | 2007 |
Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome | 2007 |
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
Topics: Adenine; Amino Acid Substitution; Drug Resistance, Viral; Evolution, Molecular; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation, Missense; Nucleic Acid Hybridization; Organophosphonates; Sequence Analysis, DNA; Time Factors | 2007 |
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; DNA, Viral; Female; Follow-Up Studies; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Mutation; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2007 |
[Recent therapies for hepatitis B (discussion)].
Topics: Adenine; Antiviral Agents; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates | 2007 |
Lamivudine in the treatment of hepatitis B virus-related polyarteritis nodosa.
Topics: Anti-HIV Agents; Cyclophosphamide; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Methylprednisolone; Middle Aged; Polyarteritis Nodosa | 2007 |
The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; DNA, Viral; Drug Resistance, Viral; Gene Expression Regulation, Viral; Genetic Vectors; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Mice; Mice, Inbred BALB C; Mice, Transgenic; RNA Interference; RNA Polymerase II; RNA, Messenger; RNA, Small Interfering | 2007 |
Entecavir: new drug. Chronic hepatitis B: a last resort.
Topics: Adult; Antiviral Agents; Europe; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Topics: Adenine; Antiviral Agents; Asian People; Cost-Benefit Analysis; Drug Costs; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Markov Chains; Models, Economic; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Singapore | 2007 |
Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Topics: Adult; Aged; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Alignment | 2007 |
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.
Topics: Adult; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Luminescent Measurements; Male; Middle Aged; Necrosis; Statistics as Topic | 2007 |
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors | 2007 |
Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
Topics: Adolescent; Adult; Amino Acid Motifs; Child; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Iran; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors | 2008 |
Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mutation; Withholding Treatment | 2008 |
Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy.
Topics: Adult; Antiviral Agents; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Nephrotic Syndrome; Remission Induction | 2007 |
[Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
Topics: Adult; DNA, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Proportional Hazards Models; Random Amplified Polymorphic DNA Technique; Treatment Outcome; Young Adult | 2007 |
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list.
Topics: Disease Progression; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; United States; Waiting Lists | 2007 |
Hepatitis B: explosion of new knowledge.
Topics: Adenine; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Lamivudine; Organophosphonates | 2007 |
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric | 2008 |
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.
Topics: Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Treatment Outcome; Viral Load | 2007 |
Efficacy of hepatitis B virus (HBV) vaccination in treating lamivudine-resistant HBV reactivation following hepatitis B surface antigen seroconversion.
Topics: Adult; Combined Modality Therapy; Drug Resistance, Viral; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2007 |
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Retrospective Studies; RNA-Directed DNA Polymerase | 2007 |
Exacerbation of chronic hepatitis B infection after delivery.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2008 |
Lamivudine therapy for korean children with chronic hepatitis B.
Topics: Adolescent; Adult; Age Factors; Alanine Transaminase; Anti-HIV Agents; Asian People; Child; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Male; Sex Factors; Treatment Outcome | 2007 |
Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
Topics: Adolescent; Africa, Western; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cote d'Ivoire; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Longitudinal Studies; Male; Prevalence; Retrospective Studies | 2008 |
Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B.
Topics: Drug Resistance, Viral; Genetic Testing; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligase Chain Reaction; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load; Virus Replication | 2008 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[Protocol for the treatment of chronic viral hepatitis].
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Protocols; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.
Topics: Adult; Aged; Brazil; Child; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hospitals; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors | 2008 |
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Monitoring; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Treatment Outcome | 2008 |
Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B.
Topics: Base Sequence; DNA Probes; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reproducibility of Results; Sensitivity and Specificity; Taq Polymerase | 2008 |
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2008 |
Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.
Topics: Antiviral Agents; DNA Primers; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sensitivity and Specificity | 2008 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load | 2008 |
Telbivudine: new drug. Chronic hepatitis B: similar to lamivudine.
Topics: Clinical Trials as Topic; Europe; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Pyrimidinones; United States | 2008 |
Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious | 2008 |
[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymorphism, Restriction Fragment Length | 2008 |
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Viral Load | 2008 |
Economic evaluation of chronic hepatitis B treatments in Taiwan.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Taiwan; Time Factors | 2008 |
Antiviral therapy for various stages of HBV-related diseases: lamivudine and beyond.
Topics: Antiviral Agents; Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine | 2008 |
[Treatment of chronic hepatitis B with integrative medicine].
Topics: Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Phytotherapy | 2008 |
[Paying attention to TCM and integrative medicine in treating YMDD mutation of chronic hepatitis B].
Topics: Amino Acid Motifs; Amino Acid Sequence; Drug Resistance, Viral; Drug Therapy, Combination; Drugs, Chinese Herbal; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Phytotherapy; RNA-Directed DNA Polymerase | 2008 |
What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?
Topics: Anti-HIV Agents; Biomarkers; DNA, Viral; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoassay; Immunoglobulin G; Immunoglobulin M; Lamivudine; Molecular Biology; Serologic Tests; Serology | 2008 |
Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
Topics: Adult; Aged; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Phenotype; Reverse Transcriptase Inhibitors; Treatment Outcome; Virus Replication | 2008 |
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Mutation; Organophosphonates; Risk Factors; Treatment Outcome; Virus Replication | 2008 |
Comparison of the Cobas Ampliprep/Cobas TaqMan HBV Test versus the Cobas Amplicor HBV monitor for HBV-DNA detection and quantification during antiviral therapy.
Topics: Adenine; Antiviral Agents; Automation; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Polymerase Chain Reaction; Taq Polymerase | 2008 |
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Evaluation; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral | 2008 |
A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Young Adult | 2008 |
[Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
Topics: Anti-HIV Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation | 2008 |
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Interferons; Lamivudine; Predictive Value of Tests; Reproducibility of Results; Sensitivity and Specificity | 1997 |
[Lamivudine treatment: realities and expectations].
Topics: Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferons; Lamivudine; Polymerase Chain Reaction | 1997 |
Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.
Topics: Adult; Amino Acid Sequence; Conserved Sequence; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance; Genetic Variation; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Point Mutation; Time Factors | 1998 |
Lamivudine therapy of WHV-infected woodchucks.
Topics: Amino Acid Sequence; Animals; DNA Replication; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Lamivudine; Marmota; Molecular Sequence Data; Reverse Transcriptase Inhibitors; Virus Replication | 1998 |
Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Point Mutation; Prodrugs | 1998 |
Treatment of chronic hepatitis B infection.
Topics: Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Reverse Transcriptase Inhibitors | 1998 |
[Drug therapy of chronic hepatitis B].
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Virus Replication | 1998 |
Lamivudine for chronic hepatitis B.
Topics: Drug Administration Schedule; Half-Life; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors | 1998 |
Treatment of chronic hepatitis B: a need for consensus.
Topics: Adjuvants, Immunologic; Decision Making; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Thymalfasin; Thymosin | 1999 |
Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective.
Topics: 2-Aminopurine; Adjuvants, Immunologic; Animals; Antiviral Agents; Asia; Drug Therapy, Combination; Famciclovir; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Pacific Islands; Vaccines, DNA | 1999 |
What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B.
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Immunity, Cellular; Interferon-alpha; Lamivudine; Virus Replication | 1999 |
A pill a day, or two, for hepatitis B?
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 1999 |
Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections.
Topics: Adult; Anti-HIV Agents; Biopsy, Needle; Drug Therapy, Combination; Gene Products, pol; Hepatitis B Antibodies; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Liver; Male; Zidovudine | 1999 |
Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal?
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Microbial; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Recurrence | 1999 |
Lamivudine for chronic hepatitis B: the magic bullet or just another bright prospect?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors | 1999 |
HBV resistance in HIV patients.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 1999 |
Antiviral therapy for hepatitis B and C in Asians.
Topics: Asian People; China; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 1999 |
Hepatitis B therapy: the plot thickens.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Lamivudine; Mutation | 1999 |
Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Resistance; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Treatment Failure | 1999 |
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Follow-Up Studies; Genetic Variation; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mutation; Renal Dialysis; Sequence Deletion | 1999 |
Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Lamivudine; Recurrence; Reverse Transcriptase Inhibitors; Virus Activation | 1999 |
Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Middle Aged; Necrosis; Reverse Transcriptase Inhibitors; Virus Activation | 1999 |
Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Glucocorticoids; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Prednisolone; Reverse Transcriptase Inhibitors | 1999 |
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Topics: Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Microbial; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retreatment; Reverse Transcriptase Inhibitors; Salvage Therapy | 1999 |
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Treatment Outcome; Virus Activation | 1999 |
Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Base Sequence; DNA, Viral; Drug Resistance, Microbial; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Sequence Deletion | 1999 |
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.
Topics: Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors; Time Factors | 1999 |
Combination therapy with alpha interferon and lamivudine in patients with chronic hepatitis B and HIV infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 1999 |
High dose lamivudine and hepatitis B.
Topics: Anti-HIV Agents; Antiviral Agents; DNA, Viral; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nephritis, Interstitial; Substance-Related Disorders | 1999 |
Elevated alpha-fetoprotein levels in hepatocellular carcinoma.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Anti-HIV Agents; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carcinoma, Hepatocellular; Diagnosis, Differential; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male | 1999 |
Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Topics: 2-Aminopurine; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclovir; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Cellular; Lamivudine; Male; Treatment Outcome; Virus Replication | 1999 |
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Topics: Bilirubin; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome; Virus Replication | 2000 |
Lamivudine for chronic hepatitis B: uses and abuses.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine | 1999 |
Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus.
Topics: Antiviral Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Markov Chains; Models, Theoretical; Monte Carlo Method; Mutation; Time Factors; Viremia; Virus Replication | 1999 |
Lamivudine treatment for children with interferon refractory chronic hepatitis B.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Recombinant Proteins; Retreatment; Reverse Transcriptase Inhibitors | 2000 |
Lamivudine for the treatment of chronic hepatitis B.
Topics: DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver | 2000 |
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.
Topics: Adult; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Antibodies, Viral; DNA-Directed DNA Polymerase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulin M; Lamivudine; Liver; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data | 2000 |
Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B.
Topics: 2-Aminopurine; Antibodies, Viral; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Famciclovir; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Virus Replication | 2000 |
Combination therapy of hepatitis B.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Randomized Controlled Trials as Topic; Research Design | 2000 |
Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Carrier State; Disease Models, Animal; Drug Therapy, Combination; Famciclovir; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Lamivudine; Marmota; Prodrugs; Reverse Transcriptase Inhibitors; Viremia; Virus Replication | 2000 |
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
Topics: Adult; Amino Acid Motifs; Amino Acid Sequence; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Time Factors | 2000 |
[Dynamic changes of hepatitis B virus during treatment with lamivudine versus lamivudine plus famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Virus Replication | 2000 |
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates | 2000 |
Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Reverse Transcriptase Inhibitors; Viremia | 2000 |
Combination chemotherapy for hepatitis B virus: the final solution?
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Famciclovir; Hepatitis B, Chronic; Humans; Lamivudine | 2000 |
Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma.
Topics: Antiviral Agents; Asia; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Recurrence | 2000 |
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
Topics: Administration, Oral; Adult; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2000 |
How long to treat chronic hepatitis B virus infection with lamivudine?
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2000 |
Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.
Topics: Adolescent; Adult; Alanine Transaminase; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prednisolone; Reverse Transcriptase Inhibitors; Th1 Cells | 2000 |
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.
Topics: Adult; Drug Administration Schedule; Hepatitis B, Chronic; Humans; Jaundice; Lamivudine; Liver Failure; Male; Retreatment; Reverse Transcriptase Inhibitors; Time Factors | 2000 |
Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors.
Topics: Antiviral Agents; Disease Susceptibility; Graft Survival; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Probability; Survival Rate; Tissue Donors; Transplantation, Homologous | 2000 |
Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks.
Topics: Animals; Antiviral Agents; Carrier State; Drug Therapy, Combination; Female; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Interferon Type I; Interferon-alpha; Lamivudine; Marmota; Recombinant Proteins; RNA, Viral; Viremia; Virus Replication | 2000 |
In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note.
Topics: Base Sequence; Drug Resistance, Microbial; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Time Factors | 2000 |
Is interferon therapy in pediatric chronic hepatitis B infection warranted?
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies | 2000 |
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors | 2000 |
Long-term therapy of chronic hepatitis B with lamivudine.
Topics: Adult; Aged; Alanine Transaminase; DNA, Viral; Drug Resistance; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2000 |
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2000 |
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.
Topics: Drug Resistance; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2000 |
[Standard hepatitis B therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2000 |
Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Mutation | 2000 |
Lamivudine as an alternative therapy for interferon-resistant chronic hepatitis B and the characteristics of hepatitis B virus: a case report.
Topics: Adult; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA Primers; Drug Resistance; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Point Mutation; Viremia | 2000 |
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Famciclovir; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Recombinant Proteins; Retreatment; Reverse Transcriptase Inhibitors | 2000 |
Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Topics: Adult; Aged; Cohort Studies; Drug Resistance, Microbial; Female; Gene Products, pol; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Viral Core Proteins | 2000 |
Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Topics: Adult; Female; Gene Deletion; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Reverse Transcriptase Inhibitors; Viral Core Proteins | 2000 |
Lamivudine for children with chronic hepatitis B.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2000 |
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.
Topics: Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2000 |
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
Topics: Adult; Age Factors; Alanine Transaminase; Female; Hepatitis Antibodies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunosuppressive Agents; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Factors; Sex Factors; Virus Activation | 2000 |
[Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Famciclovir; Female; Hepatitis B, Chronic; Humans; Immunization, Passive; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2000 |
Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Topics: Aged; Antiviral Agents; Biopsy; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Severity of Illness Index; Virus Replication | 2000 |
Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections.
Topics: Adenoviridae; Animals; Drug Therapy, Combination; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Immunotherapy; Lamivudine; Marmota; Reverse Transcriptase Inhibitors; Virus Replication | 2000 |
[Chronic hepatitis B. Is long-term healing possible?].
Topics: Disease-Free Survival; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine | 2000 |
Therapies for chronic hepatitis B: emerging roles for nucleoside analogues.
Topics: Anti-HIV Agents; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2000 |
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Famciclovir; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Transplantation; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Time Factors; Virus Replication | 2000 |
Chronic hepatitis B treatment with lamivudine in kidney transplant patients.
Topics: Adult; Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Liver Function Tests; Postoperative Complications; Retrospective Studies | 2000 |
Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production.
Topics: Acute Disease; Antiviral Agents; Cells, Cultured; DNA, Viral; Hepatitis A; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatovirus; Humans; Interferon-gamma; Lamivudine; Lymphocyte Activation; Male; Superinfection; Viral Interference; Virus Replication | 2001 |
[Long-term treatment with lamivudine for chronic hepatitis B].
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Survival Analysis; Time Factors; Treatment Outcome | 2000 |
Lamivudine treatment for children with interferon refractory chronic hepatitis B.
Topics: Antiviral Agents; Child; Drug Resistance; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Retreatment | 2000 |
Acute liver failure during lamivudine treatment in a hepatitis B cirrhotic patient.
Topics: Drug Administration Schedule; Fatal Outcome; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure, Acute; Long-Term Care; Male; Middle Aged; Recurrence; Treatment Failure | 2001 |
Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore.
Topics: Antiviral Agents; Drug Resistance, Microbial; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Postoperative Complications; Treatment Outcome | 2000 |
[Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B].
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Europe; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Retrospective Studies; Viral Load | 2001 |
Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant.
Topics: Amino Acid Motifs; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors | 2001 |
Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B.
Topics: Antiviral Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2001 |
Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study.
Topics: Acute Disease; Adult; Alanine Transaminase; Bilirubin; DNA, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prothrombin Time; Reverse Transcriptase Inhibitors | 2001 |
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Viral Load | 2001 |
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Topics: Animals; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, Viral; Drug Administration Schedule; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Lamivudine; Liver; Marmota; Skin Pigmentation; Viremia; Virus Replication; Zalcitabine | 2001 |
[Current treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Forecasting; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Prednisone; Prognosis; Reverse Transcriptase Inhibitors; Time Factors; Virus Replication | 2001 |
[Laboratory diagnosis of hepatitis B].
Topics: 2-Aminopurine; Acute Disease; Antiviral Agents; DNA Replication; DNA, Viral; Drug Resistance; Famciclovir; Genetic Variation; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lamivudine; Virus Replication | 2001 |
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HLA-A2 Antigen; Humans; Immunotherapy; Lamivudine; Longitudinal Studies; Male; T-Lymphocytes, Cytotoxic; Viral Load | 2001 |
Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore.
Topics: Antiviral Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Postoperative Complications; Treatment Outcome | 2001 |
Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.
Topics: Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Mutation; Sequence Analysis, DNA | 2001 |
Lamivudine for hepatitis B: the end of the beginning?
Topics: DNA, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Topics: Amino Acid Motifs; Antiviral Agents; Drug Resistance, Microbial; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompetence; Lamivudine; Male; Middle Aged; Mutation; Necrosis; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Inhibitors | 2001 |
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Safety | 2001 |
Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Virus Replication | 2001 |
Lamivudine therapy for chronic hepatitis B virus infection and pregnancy: a case report.
Topics: Administration, Oral; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Serum zinc status in chronic hepatitis B and its relationship to liver histology and treatment results.
Topics: Alanine Transaminase; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Interferon-alpha; Lamivudine; Liver; Reverse Transcriptase Inhibitors; Zinc | 2001 |
Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
Topics: 2-Aminopurine; Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Cystic Fibrosis; DNA, Viral; Famciclovir; Female; Hepatitis A; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hyperoxaluria; Lamivudine; Liver Failure; Liver Transplantation; Living Donors; Male; Postoperative Complications; Retrospective Studies; Time Factors | 2001 |
Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viremia | 2001 |
Efficacy of lamivudine in decompensated cirrhosis secondary to hepatitis B: cautious optimism in the war not yet won.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis | 2001 |
Treatment of chronic hepatitis B: interferon alfa first.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Occupational Diseases; Organophosphonates; Treatment Outcome | 2001 |
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver; Male; Middle Aged; Pilot Projects; Retreatment | 2001 |
Real-time PCR for detection and quantitation of hepatitis B virus DNA.
Topics: Acute Disease; Antiviral Agents; Computers; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Polymerase Chain Reaction; Predictive Value of Tests; Sensitivity and Specificity | 2001 |
Successful treatment of hepatitis B-associated vasculitis using lamivudine as the sole therapeutic agent.
Topics: Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Vasculitis, Leukocytoclastic, Cutaneous | 2001 |
Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal.
Topics: Adult; Bone Marrow Transplantation; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Risk Assessment; Secondary Prevention | 2001 |
Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins | 2001 |
Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Virus Replication | 2001 |
Treatment option for chronic hepatitis B.
Topics: Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Immunoglobulins, Intravenous; Lamivudine; Liver Transplantation; Polymerase Chain Reaction; Treatment Outcome; Virus Activation | 2002 |
Detection of hepatitis B virus polymerase variations resistant to lamivudine therapy.
Topics: Antiviral Agents; Drug Resistance, Microbial; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Polymerase Chain Reaction | 2000 |
Lamivudine therapy for chronic hepatitis B in a Mediterranean population.
Topics: Adult; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mediterranean Region; Reverse Transcriptase Inhibitors | 2002 |
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Comorbidity; Drug Evaluation; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunocompromised Host; Lamivudine; Liver Function Tests; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prevalence; Reverse Transcriptase Inhibitors; Treatment Outcome; Virus Activation; Virus Replication | 2002 |
Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Recurrence; Reverse Transcriptase Inhibitors | 2002 |
[Polyarteritis nodosa and hepatitis B infection treated with lamivudine].
Topics: Adult; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Polyarteritis Nodosa; Reverse Transcriptase Inhibitors | 2002 |
Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; DNA, Viral; False Negative Reactions; Female; Hematologic Neoplasms; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Therapeutic Equivalency | 2002 |
Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Recurrence; Virus Activation | 2002 |
Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutagenesis; Netherlands; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors | 2002 |
Lamivudine and rapid regeneration of the atrophic liver in decompensated cirrhosis due to hepatitis B.
Topics: Atrophy; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Function Tests; Liver Regeneration; Male; Middle Aged; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Combination therapy for hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Forecasting; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine | 2002 |
Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients.
Topics: Adult; Antiviral Agents; Bone Marrow; DNA, Viral; Female; Hematopoietic Stem Cell Transplantation; Hepatitis B, Chronic; Humans; Lamivudine; Transplantation, Homologous | 2002 |
Lamivudine treatment for recurrent pancreatitis associated with reactivation of chronic B hepatitis.
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Male; Pancreatitis; Recurrence; Tomography, X-Ray Computed | 2002 |
Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis.
Topics: Base Sequence; DNA, Viral; Drug Resistance, Microbial; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors | 2002 |
[Combined interferon-lamivudine as a first line therapy for chronic hepatitis B].
Topics: Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lamivudine | 2002 |
Lack of birth defects after paternal exposure to lamivudine.
Topics: Abnormalities, Drug-Induced; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Paternal Exposure; Reverse Transcriptase Inhibitors | 2002 |
Combination therapy of chronic viral hepatitis B with lamivudine and interferon: better than what?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2002 |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors | 2002 |
Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
Topics: Antiviral Agents; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Health Care Costs; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Markov Chains; Models, Economic; Models, Statistical | 2002 |
New era of liver transplantation for hepatitis B: a 17-year single-center experience.
Topics: Antiviral Agents; Cause of Death; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2002 |
[Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
Topics: Adult; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Time Factors; Treatment Outcome | 2002 |
[Influence of a triplex superimposed treatment on HBV replication and mutation during treating chronic hepatitis B].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Astragalus Plant; Astragalus propinquus; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Phytotherapy; Recombinant Proteins; Virus Replication | 2001 |
Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Male; Middle Aged; Serum Albumin; Time Factors; Treatment Outcome | 2002 |
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure; Waiting Lists | 2002 |
Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Reagent Kits, Diagnostic; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Sensitivity and Specificity | 2002 |
Chronic hepatitis B.
Topics: Antiviral Agents; Child; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2002 |
Hepatitis B virus surface antigen mutants persist in chronic carriers receiving lamivudine therapy in Singapore.
Topics: Carrier State; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Singapore | 2002 |
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
Topics: Adult; Aged; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Liver; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Recurrence; Remission Induction; Viremia | 2002 |
[Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Reverse Transcriptase Inhibitors; Virus Activation | 2002 |